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by Michael Vaclav Holmes
Background
Genetic epidemiology is at the interface of translational and basic research and the
pace of progress has been unprecedented, with findings representing some of the most
robust available in the Scientific literature. However, how we can translate this high-
fidelity genomic information into improvements in health of the population? Two dis-
tinct translational opportunities include personalized medicine (pharmacogenetics) and
using Mendelian randomization to investigate disease aetiology to inform public health
policy and develop new therapies.
Objectives
In this PhD thesis, I investigated the evidence base underlying the well-publicized use
of the pharmacogenetic biomarker CYP2C19 genotype to predict the response to clopi-
dogrel, a widely prescribed antiplatelet drug. Second, I used Mendelian randomization
to investigate the role of an endogenous biomarker, secretory phospholipase A2-IIA
(sPLA2-IIA), thought to be a pro-atherogenic enzyme and a potential drug target for
the prevention of cardiovascular disease (CVD). Third, I used Mendelian randomization
to investigate the relationship between alcohol, an exogenous exposure, and cardiovas-
cular traits and disease events.
Results
CYP2C19 and cardiovascular disease
I identified 32 studies of 42,016 patients reporting 3545 CVD events. Only 6 studies
were set within randomized trials (“effect-modification” design) and the remaining 26
reported individuals exposed to clopidogrel (“treatment-only” design). In treatment-
only studies, possession of one or more ?2-?8 CYP2C19 alleles was associated with
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lower cytochrome P450 C19 (CYP2C19) enzyme activity and a higher risk of CVD
events (RR 1.18; 95%CI:1.09, 1.28), however, there was strong evidence of small-study
bias (Harbord test P=0.001) and, when restricted to large studies (≥200 events), the
association of CYP2C19 ?2-?8 carrier status with CVD was null (RR 0.97; 95%CI: 0.86,
1.09). In the effect-modification studies, CYP2C19 genotype did not modify the effect
of clopidogrel on CVD end-points. These findings cast doubt on whether information
on CYP2C19 genotype would be helpful to guide selection of the dose of clopidogrel or
use of an alternative antiplatelet agent.
The role of secretory phospholipase A2-IIA (sPLA2-IIA) in CVD
I used Mendelian randomization to make causal inference on the role of sPLA2-IIA in
CVD. I identified a single nucleotide polymorphism (SNP) in PLA2G2A (rs11573156)
that was specific for and had a very strong impact on circulating levels of the sPLA2-IIA
isoform. Using data from 36 studies and over 100,000 participants, instrumental variable
analysis found no association between sPLA2-IIA with incident, prevalent or recurrent
CVD events. These findings suggest sPLA2-IIA is not a valid therapeutic target for
CVD prevention, which was in keeping with a phase III randomized clinical trial that
was halted for futility in 2012 (during this thesis).
Alcohol and CVD
I used a SNP in ADH1B to investigate the relationship between alcohol and coronary
heart disease (CHD) in >260,000 participants. The genetic variant (ADH1B rs1229984
A-allele) showed very strong association with reduced alcohol consumption when evalu-
ated as volume of alcohol consumed, binge drinking and abstaining from alcohol. The
A-allele of rs1229984 showed associations with SBP, CRP, IL-6, BMI and waist circum-
ference that were all directionally concordant with a reduced risk of CHD. Indeed, when
the clinical outcome CHD was investigated, individuals carrying the A-allele (who con-
sumed less alcohol than non-carriers) had a reduced risk of CHD at all levels of alcohol
consumption. No evidence of a cardioprotective association of alcohol with CHD was
identified.
Conclusions My investigation into use of CYP2C19 genotype as a pharmacogenetic
biomarker for clopidogrel response did not identify evidence to support its clinical use
and limitations were identified that could apply to other pharmacogenetic tests. Use
of Mendelian randomization revealed no evidence to support a causal role of sPLA2-
IIA in CVD, which paralleled findings from a phase III randomized clinical trial, and
provides support for the use of Mendelian randomization studies more widely to in-
form drug development. Finally, using the ADH1B gene to interrogate the relationship
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of alcohol yielded findings that argue against a cardioprotective effect of alcohol con-
sumption. These findings should encourage rethinking of public health advice about the
cardiovascular benefits of moderate levels of alcohol consumption.
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Chapter 1
Introduction
1.1 Cardiovascular Disease: Public Health Importance
Cardiovascular disease (CVD, comprising coronary heart disease (CHD), stroke and
peripheral vascular disease) is the leading cause of death worldwide.[1] One in 2 men
and 1 in 3 women will experience a coronary heart disease (CHD) event during their
lifetime,[2] with substantial implications for the population burden of disease, health-
care system resources and the economy.[3] Therefore, a reduction in burden of disease
from CHD (through prevention of first and recurrent events) is an important research
and public health goal.
CHD has genetic[4–6] and environmental[7–9] determinants, with twin studies suggesting
that the heritability (the proportion of variance explained by genetic factors) for death
from CHD to be approximately 0.57 in men and 0.38 in women.[6] In high-income
countries, 96% of all clinical CHD events occur after 50 years of age,[2] with the low
event rate in young age arising due to slow progression of subclinical atherosclerosis,
which begins from the second decade of life.[10] The slow progression of atherosclerosis,
an initially asymptomatic disease, generates problems for inferring causal relationships
from observational associations, because it is challenging to disentangle what occurs
first: exposure to a putative risk factor, or subclinical atherosclerosis. However, this
long preclinical phase provides a window of opportunity to prevent the development of
atherosclerosis.
1
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1.2 Public health approaches to combating CHD
The main approaches to CVD prevention involve (i) non-pharmacological interventions
and (ii) pharmacological interventions.
1.2.1 Non-pharmacological approaches to CVD prevention
Population-based preventative approaches for CHD take many forms (Box 1.1), and
typically aim at shifting the population distribution of a causal risk factor. For ex-
ample, a major non-pharmacological intervention, the Comprehensive Cardiovascular
Community Control Programme (CCCP)[11, 12] used a multiple intervention approach
(including health education, screening for risk of cardiovascular disease and a hyperten-
sion programme) with the aim of reducing multiple risk factors. CCCP was based in
multiple countries, however the most widely published study was based in North Fin-
land (North Karelia region).[13] A comprehensive appraisal of the evidence[14] did not
support the hypothesis that this intervention had a major impact on cardiovascular risk
factors compared to those who did not take part in the programme, the main limita-
tion being ascribed to an individualized approach (vs. population-based). In contrast, a
population-wide approach set in Mauritius was efficacious with nation-wide substitution
to soya bean oil (rich in unsaturated fatty acids) from palm oil (rich in saturated fat),
an intervention that reduced total cholesterol.[15]
Box 1.1: Targets for population-based interventions:
 reduce tobacco consumption
 dietary change
– reduce salt
– increase fruit and vegetable consumption
– reduce fat (saturated and trans-fat) intake
 increase physical activity
One area in which progress has been both efficacious and sustainable is the reduction of
tobacco smoking, the second leading cause of global disease burden in humans (after hy-
pertension), accounting for 6.3% of global DALYsa.[16] Since the ground-breaking study
by Doll and Hill in 1954,[17] the first prospective study to confirm the elevated associa-
tion of CVD risk in smokers compared to non-smokers, smoking has become progressively
aDisability-Adjusted Life Year (DALY) - one DALY represents one year lost of healthy life due to
disease.
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less socially acceptable.[18, 19] Population-based interventions through taxation and leg-
islation to ban smoking in public places have been increasingly used to further reduce
smoking prevalence. Recent examples include the smoking ban in Scotland[20] and Eng-
land (Health Act 2006[21]). Implementation of such legislation is supported through
observational evidence that suggests a reduction in hospital admissions for CHD follow-
ing the introduction of smoking bans in UK[22], Italy[23] and USA[24]. More widely,
banning smoking in public places has also led to observed improvements in respiratory
disease.[25] Of note, the benefits of anti-smoking legislation are likely to become more
apparent with longer follow-up.
In addition to the non-pharmacological population health interventions to prevent CVD
(such as reduced consumption of dietary salt, fat and increased physical activity, Box
1.1), a recent emphasis in UK has been placed on policy making to limit the marketing
of unhealthy food to children and improve food labeling.[26] This is in response to a
dramatic increase in the prevalence of obesity in children in high-income countries,[27]
with a consequential increase in the associated sequelae of obesity - i.e. metabolic
diseases and type 2 diabetes.[28, 29] Clearly more action is needed in this arena to
reverse the worrying trend in childhood obesity.[30]
1.2.2 Pharmacological approaches to CVD prevention
In contrast to the above approaches, pharmacological intervention involves prescribing
drugs to individuals at risk of first (primary prevention) or recurrent (secondary preven-
tion) disease. Drugs classes used for prevention of CVD are listed in Box 1.2.
Box 1.2: Major drug classes used for CVD prevention:
 blood pressure lowering
 LDL-C lowering (e.g. HMG-coA reductase inhibitors, statins)
 anti-clotting (anti-platelet drugs such as aspirin)
Treatment trials of blood pressure lowering drugs (such as beta blockers, angiotensin-
converting inhibitors, thiazide diuretics and calcium channel blockers) have shown that,
whatever the class of drug,[31] reducing blood pressure by 5mmHg is associated with a
20-25% reduction in risk of CHD events.[32] Similarly, data from RCTs of lipid-lowering
drugs (predominantly statins) show that a 1 mmol/L reduction in LDL-C results in a
23% reduction in CHD events at 1 year.[33, 34]
One striking feature of the relationship between causal risk factors such as blood pres-
sure or LDL-cholesterol is the nature of the causal effect. Whatever the initial value of
Chapter 1. Introduction 4
the trait, the relative risk reduction for a given reduction in the risk factor is constant
across the distribution, with no threshold (Figure 1.1). This has important relevance
to applying interventions (both non-pharmacological and pharmacological) to the pop-
ulation as a whole. First, interventions to reduce these traits will have an effect on
modifying disease risk of all individuals, irrespective of their absolute levels of their risk
factors. Second, most clinical events occur in individuals with average levels of a risk
factor. This arises from the normal (or log-normal) distribution of causal traits in the
population, and owing to risk factors having a linear (or log-linear) association with
CHD risk: therefore, to have greatest impact at reducing population risk, the majority
of individuals need to reduce their levels of a risk factor, including those with seem-
ingly normal (or low-normal) values of risk factors who might gain little, (the so-called
”prevention paradox”).[35] 	  	  	  	  Permissions	  not	  obtained	  for	  figure	  Please	  refer	  to	  citation	  for	  image	  	  	  	  	  	  	  	  	  	  
Figure 1.1: Relationship between LDL-cholesterol and total cholesterol with
risk of coronary heart disease.
A) Association between LDL-cholesterol reduction from randomized trials of statin ther-
apy and risk of major coronary events.
B) Distribution of total cholesterol in the general population (approximate) showing the
observational association between cholesterol level and risk of CHD events.
Abbreviations: CHD, coronary heart disease; TC, total cholesterol. In both (A) and (B), boxes indicate
weighted point estimate and vertical lines represent the standard errors)
Figure (A) derived from Baigent et al [34]; Figure (B) derived from Jackson et al [36]
For pharmacological prevention to be used at a population level, certain criteria must
be fulfilled. The drug must be:
1. of proven efficacy,
2. safe, so that the risk to benefit ratio is heavily in favour of intervening via phar-
macological treatment as part of a mass strategy
3. cost-effective, to encourage population-wide treatment without penalising health-
care resources
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1.3 Trends in CVD - changing incidence
Worldwide, CVD mortality has changed remarkably over the past few decades. In high
income countries, a fall has been observed (Figure 1.2), whereas in low income countries,
CHD mortality has been increasing. 	  	  	  	  Permissions	  not	  obtained	  for	  figure	  Please	  refer	  to	  citation	  for	  image	  	  	  	  	  	  	  	  	  	  
Figure 1.2: Trend in mortality from coronary heart disease in men aged ≤64
in high-income countries
Reproduced from Bandosz et al [37].
The major risk factors for CVD are similar across the world, and include smoking,
lipid profiles, diabetes, high blood pressure, obesity, diet and physical activity.[38] The
difference in temporal trends between high and low income countries may be explained
by alterations in the major risk factors. In low and middle income countries, tobacco
smoking has increased and diet has become Westernized (i.e. higher in fat and salt).
This is in contrast to high income countries, in which tobacco consumption has fallen.[39]
These alterations drive in part the epidemiological transition (Figure 1.3)[40]: as low
and middle income countries undergo the epidemiological transition, the proportion of
deaths from infectious diseases (arising from over-crowding and lack of basic health-care)
falls and that from degenerative diseases (such as cardiovascular disease) increases.[41]	  	  	  	  Permissions	  not	  obtained	  for	  figure	  Please	  refer	  to	  citation	  for	  image	  	  	  	  	  	  	  	  	  	  
Figure 1.3: The Epidemiological transition.
As life expectancy increases (from improved sanitation, nutritional status, hospital care, etc.), the propor-
tion of deaths arising from infectious disease decreases and is replaced by deaths arising from disease that
takes many years to accumulate (such as atherosclerosis).
Reproduced from Omran[40].
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Despite the substantial improvement in CVD mortality, vascular disease accounts for
30% of deaths in the UKb and despite the use of efficacious treatments, a considerable
residual risk of primary and secondary CVD exists.[42]
1.4 Quest to identify causal risk factors for CVD
If we are to further reduce the risk of CVD, identification of novel causal risk factors may
provide new targets for therapeutic modification. But, how do we know if a biomarker
is causally related to CHD?
Many hundreds of non-genetic risk factors have been identified that associate with risk
of CHD on observational analysis.[43] However, of this plethora, it is not clear how
many represent causal associations. This is important because targeting non-causal risk
factors would not yield reductions in CHD and could entail exposing individuals to drug
treatment that results in adverse drug reactions.
Thus far, LDL-C and BP are two risk factors that are recognized as important be-
cause randomized clinical trials (RCTs) have validated their causal relevance in CHD
pathogenesis.[32, 44–46].
1.5 Study designs available to investigate role of biological
variables
Various study designs exist to investigate whether a relationship exists (and the under-
lying mechanism) between an exposure of interest and the onset of disease (Figure 1.4).
1.5.1 Cell lines and animal models
The aim of in vitro and non-human in vivo models of disease is to provide a quick and
reproducible means to investigate the role of biological markers in disease pathogenesis.
Animal studies provide a means to investigate whether alteration in a risk factor impacts
upon measures of disease. Animal models are particularly effective as they allow the ma-
nipulation of biological systems in a way that is not possible in humans.[47] The mouse
has provided the main animal model for atherosclerosis, due to: detailed knowledge of ge-
netic information; low costs facilitating larger numbers of animals; fast gestation times;
and, a small circulating volume meaning that low amounts of drugs are required.[48]
bData from Office of National Statistics, 2011
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Figure 1.4: Study methods used in Science to investigate biological mechanisms underlying disease processes.
Studies on the left side of the figure are suitable for hypothesis generation, however the pivotal test for casuality arises from randomized clinical trials (RCTs), which if conducted
adequately, obviates both measured and unmeasured confounding. Confounding cannot be excluded from any other study design (unless randomization is built-in, e.g. a lab
experiment with a randomized intervention).
Footnotes Intervene: in those studies marked with a ‘+’, the study involves an intervention (i.e. controlled exposure); Bias/Confounding: these are the two traditional sources
of error in studies, the greater the number ‘+’, the more susceptible the study to these forms of error; Translation: typically only cohorts/randomized trials can directly influence
health policy and/or treatment decisions; Hypothesis/Definitive: it can be argued that RCTs represent the only source of definitive evidence on causality.
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However, for studying atherosclerosis a challenge arises: mice do not spontaneously de-
velop atherosclerosis in their lifetime.[48] Therefore, to mimic the atherosclerosis process
in humans, a genetic knockout mouse that is also fed a high-fat diet for several weeks is
required, which results in atheroma deposition.[49]
Although animal models seem appealing in their availability and relatively quick time to
investigate (as in theory a mouse can ‘model’ in weeks what takes decades in humans),
several reasons potentially limit their translational benefit. First, a systematic review
showed that only 37% of positive findings reported in animal studies were replicated
in human randomized trials, and only 10% actually translated into clinical use (thus
the attrition rate is 90%, an alarming statistic).[50, 51] A “glass-half-full” perspective
would interpret this figure as reassurance that at least some animal models do lead to
translational benefits that are highly relevant to humans. But on the other hand, a 63%
‘false positive’ rate is very high, and means that the majority of findings reported in
animal studies will not yield benefit to man. An additional perspective is to consider the
biomarkers that have been investigated in animal models but that did not show evidence
for a role in disease - these could potentially represent false negatives! Second, system-
atic bias may arise from methodological flaws in animal studies resulting in erroneous
conclusions [51]. Such flaws include:
 absence of an a priori sample size calculation
 selection bias
 lack of randomization to exposure
 lack of blinding to outcome assessment
 outcome reporting bias
 publication bias
Of note, publication bias is of particular concern as it may over-inflate the scientific
focus on a particular biomarker, and has been estimated to account for 13 of the excess
efficacy reported in systematic reviews.[52] This selective reporting and publishing of
positive studies can misdirect academic focus to investigating non-causal associations.
1.5.2 Observational studies in Humans
Even using the ideal ‘animal model’ (i.e. humans) to make observations about human
disease pathogenesis can be prone to error and identified relationships may not be causal
(Box 1.3 and Figure 1.5).
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Box 1.3: Examples of observational evidence that have failed to translate to
true causal associations:
 Hormone replacement therapy (HRT) and CVD: observational evidence
suggested that HRT was cardioprotective[53], however results of a large-scale RCT
(Women’s Health Initiative)[54] showed an increase in CHD risk associated with
HRT use. This discrepancy is likely due to confounding of HRT use by favourable
socioeconomic factors (e.g. diet, exercise) in the observational analysis.
One striking feature is that the confounding was of such magnitude as to bias the
underlying (true) harmful effect of HRT and make it directionally opposite to create
an apparent cardioprotective effect. This serves to illustrate just how misleading
results from observational evidence can be.
 vitamin E and CVD: Large-scale prospective observational evidence supported a
protective role of vitamin E in CHD[55, 56], with dose-response and temporality
criteria fulfilled.a However, RCTs have failed to reproduce this finding[58] and a
meta-analysis of high-dose (≥400 IU/day) vitamin E suggests that contrary to being
beneficial, high-dose vitamin E may increase risk of all-cause moratlity[59]
aA dose-response relationship and temporality (exposure measured prior to outcome) are ar-
guably two Bradford-Hill[57] criteria that are most important in supporting a causal association
between an exposure and outcome when interpreting observational evidence
In simplistic terms, error can be grouped into 4 principle domains:
1 chance: a chance finding is the scenario where a study identified an association
between an exposure and outcome that is not true (a false-positive, or type 1
error). The primary cause of chance findings is small sample sizes, resulting in
a randomly erroneous estimate. Such false positives do not represent the ‘truth’
and are typically not replicated on analysis of larger data-sets (unless there is
publication bias, which can distort the field as a whole[60, 61]).
2 bias: in this scenario, there is deviation from the true association; bias can be
divided into two main forms:
(a) selection bias: this type of bias typically affects case-control studies in which
the controls are not representative of the population from which the cases
arose; on measuring an association between disease status and exposure, se-
lection bias can yield misleading findings. Selection bias can also affect cohort
studies if follow-up is different between exposed and non-exposed groups.
(b) measurement error: error in the measurement of an exposure or outcome
can be either non-differential or differential
i. non-differential: in this example, there is no relationship between the
error in exposure measurement and the outcome (or vice versa). If the
Chapter 1. Introduction 10
(A) exposure outcome
true causal
(B) exposure
confounder
outcome
confounded association
association true causal
(C) exposure outcome
reverse causation
true causal
Figure 1.5: Possible scenarios for an association between an exposure and
outcome
(A) the observed association between an exposure and outcome is causal. If the exposure is mod-
ifiable (e.g. LDL-cholesterol), then an intervention to modify the exposure (e.g. treatment with
HMG-CoA reductase inhibitors, more commonly known as statins) will alter the risk of disease
(e.g. CHD)
(B) the association between the exposure of interest arises due to a relationship with a confound-
ing factor. This creates a confounded association (red line) between the exposure and outcome.
An example of this is an association between yellow teeth and lung cancer, which is confounded
by smoking status. In this example, an intervention to reduce the yellow colouring of teeth is
unlikely to alter risk of lung cancer (whereas reducing smoking would)
(C) the outcome results in altered levels of what is thought to be the ‘exposure’. The “tempo-
rality” criterion of Bradford Hill[57] attempts to minimise this source of confounding, however
in the case of CHD, subclinical disease may alter biomarkers many years prior to the manifesta-
tion of clinical CHD. An example of this is the relationship between C-reactive protein (CRP)
and CHD. An intervention to change CRP is unlikely to alter risk of CHD, as evidence to date
suggests that the association is entirely driven by reverse causality.[62]
error is in the exposure, this usually leads to regression dilution bias in
which the effect estimate is biased towards the null.[63]
ii. differential: this type of bias is systematic and means that the measure-
ment of an exposure is systematically different according to the outcome,
or vice-versa. An example is recall bias, which is particularly common
in case control studies where exposure is determined retrospectively and
knowledge of a persons’s disease status can influence how exposure is
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remembered.c Differential measurement bias can result in either attenu-
ation of the association towards or away from the null, depending on the
scenario.
3 confounding: this is the main limitation of observational studies (Figure 1.5B).
Despite measurement of what may be considered ‘known’ confounders and statis-
tical adjustment in multivariate models, residual confounding can arise from: (i)
measurement error of the confounder; (ii) known but unmeasured confounders,
and/or; (iii) unknown confounders. It is perhaps unknown confounding that is the
most frustrating component - e.g. even in the most richly phenotyped cohorts,
confounders are likely to exist that are not known, and which, despite the best
efforts of the scientific investigators, result in error. Even if all potential con-
founders are measured and adjusted for in a multivariate analysisd, conditioning
on a potential confounder can induce new relationships between exposures and
other confounders by opening ‘back-door’ pathways.[64] Thus, even with careful
selection and measurement of co-variates in analysis, it is impossible to say with
certainty that all confounding has been eliminated, and therefore on observational
(non-genetic) analysis, an association cannot be stated to be causal.
4 reverse causality: in this scenario, disease status (especially subclinical disease)
results in changes in levels of the biomarker of interest (Figure 1.5C). On identify-
ing an association between the biomarker and risk of disease, the biomarker may
erroneously be interpreted as causing disease whereas the reverse is true. This
can affect both case control studies (as cases are collected after disease onset) and
prospective cohorts (where the disease process begins years prior to the clinical
manifestations, as in CHD).
1.6 Randomization of exposure
R.A. Fisher famously stated “randomization relieves the experimenter from the anxiety
of considering and estimating the magnitude of the innumerable causes by which his
data may be disturbed.”[65]
cOne example may be a case-control study of autism, with the investigators interested in vaccination
history. Parents with children with autism are likely to be aware of the media attention on the apparent
(yet false) association of the measles, mumps and rubella (MMR) vaccine with autism. This could subtly
alter how the parents of children with autism recall their child’s vaccine information, potentially creating
an apparent association between vaccination history and risk of autism
dIt is worthy to note that the selection of confounders is a subjective process and what one scientist
may consider a confounder, another may not. This is partly why studies that conduct similar analyses
may adjust for different traits labelled as ‘confounders’
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minimizes confounding
Active
Arm
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Genotype
Group 2
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and/or clin-
ical event
Lifetime follow-
up for ∆ in
biomarker
and/or clin-
ical event
Figure 1.6: Comparison of a Randomized trial to Mendelian randomization.
In both study designs, the random allocation of exposures permits the investigation of associa-
tions between the exposure and outcome that is free from confounding, and from which causal
associations can be inferred. ∆ refers to change
The gold standard of evidence on causal relationships arises when both known and
unknown confounders are equally balanced between exposed and unexposed groups.
This can only occur when the exposure is randomly allocated to individuals and there
are 2 scenarios where this arises (Figure 1.6):
1. RCT: the gold-standard of study design. Participants enrolled into the clinical
trial are randomly allocated a treatment intervention. When a trial is adequately
conductede and suitably powered, it is this randomization that eliminates con-
founding
2. Mendelian randomization: so-called “Nature’s randomized trials”.[67] Alleles
are randomly allocated from parents to offspring. Thus, whether an individual
receives an allele at a locus is independent of confounders in the parents. At the
population level, this means that individuals grouped according to their genotype
status at a particular locus should be similar (with respect to confounders) to
individuals in the alternate genotype group (as depicted in Figure 1.6).
eNot all RCTs are created equal and trial characteristics such as adequacy of allocation concealment
and blinding can greatly influence the robustness of trial findings.[66]
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1.7 Mendelian Randomisation
1.7.1 Gregor Mendel
Mendelian randomization has flourished within the past decade as a tool to differentiate
causal from non-causal relationships between exposures and outcomes. The cornerstone
of this approach was the discovery by the Moravian scientist in 1865, Gregor Mendel
(Figure 1.7), that inheritance of one trait is independent of inheritance of another trait
(so-called ‘Mendel’s second law’). Although Mendel wasn’t aware that the unit of in-
heritance was the “gene”, the law which he established arises from the independent
assortment of alleles, which occurs in the meiotic phase of gametogenesis.[67] The ran-
dom cross-linking between the paternal and maternal chromosomes means that gene
variants are inherited independently of one another, resulting in a genome that is ran-
domly allocated - akin to the random allocation of a drug in a clinical trial (Figure 1.6).f
Figure 1.7: Gregor Mendel, the “founding-father” of modern genetics[68]
1.7.2 History of Mendelian Randomization: first examples
The concept of using genes to investigate deconfounded associations between exposures
and disease risk originally arose from an idea suggested by Katan in 1986.[69] At the
time, the scientific community was uncertain about whether a reduction in cholesterol
would increase the risk of cancer. This was because observational studies had shown
that low serum cholesterol was associated with increased risk of cancer (especially colon
cancer).[70] Despite observational studies measuring cholesterol up to 18 years prior to
the cancer diagnosis,[71] the concern remained that the observational association be-
tween cholesterol and cancer could arise from confounding by another variable or due
to reverse causation (as in Figure 1.5 B and C). Katan suggested using gene polymor-
phisms in APOE to investigate the de-confounded association between cholesterol and
cancer,[69] and in doing so, opened up the Scientific community to the potential use
fIt is important to note that this randomization process applies only to variation in germline DNA
and not somatic mutations or mitochondrial DNA.
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of gene variants as instruments to test casual relationships. Katan’s ideas were further
developed by Davey-Smith and Ebrahim to extend the use of Mendelian randomisation
to environmental exposures.[72, 73] Such was the importance of Katan’s ideas that a
special series of articles in the International Journal of Epidemiology was dedicated to
this.[74–79]
1.7.3 Comparison to Randomized Trial
Although the basic principle is that Mendelian randomization shares many features of
a RCT, distinct differences between the two approaches exist, summarized in Table 1.1.
Drug treatments tend to have a large effect on the pharmacodynamic target (in order to
yield a maximal treatment response), whereas a single SNP tends to have a much weaker
association. This means that the sample size for a Mendelian randomization analysis
may be many-fold greater than for a RCT. Despite this, the cost of a Mendelian random-
ization project is far less than a RCT as a trial involves recruiting patients and heavy
costs for monitoring adverse drug reactions. In contrast, Mendelian randomization stud-
ies can be conducted in general population cohorts who have already been recruited and
followed up for incident events. Furthermore, a trial of a drug means exposing individu-
als to drugs that can have life-threatening adverse drug reactions, whereas measurement
of a SNP involves no intervention.
Given the high-risk profile of drug development, principally due to attrition (Figure 1.8),
the advantageous properties (cost and safety) of Mendelian randomization analyses mean
that their conduct would be well-placed prior to embarking upon clinical trials in the
drug development pipeline. These concepts are further developed during this thesis.
Table 1.1: Comparison of drug in a randomized trial to a single nucleotide polymor-
phism (SNP) in Mendelian randomization
Domain Feature Drug treatment Randomized alloca-
tion of genotype
Design Strength of exposure Typically high Tends to be small
Confounding Absent Absent?
Factorial design possible Yes Potential
Practicality Cost (£) Millions Thousands
Duration Years Months-years
Sample size requirement Usually large Very large
Drug develop-
ment: application
Place in drug development pipeline Late Early
Potential harm of intervention Possibly high None
Risk of negative finding to pharma High Low
Footnote. ? assuming absence of linkage disequilibrium and population stratification, discussed later in this
Chapter
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Figure 1.8: Drug development pipeline.
The drug development process is very high risk. After initially screening thousands of com-
pounds, only a handful is taken forward to investigate in human studies. If these fail, then the
cost can be devastating to both the individual drug companies that have invested millions to bil-
lions of dollars but also to development of new therapies in general. Reproduced from Willmann
et al.[80]
1.7.4 Classification and Application
Mendelian randomization can be broadly categorised into two main types, depending on
the exposure (intermediate phenotype) under investigation:
endogenous trait: these are traits that have originated from within the human body
(e.g. C-reactive protein)
 cis: in this example , the intermediate phenotype is a known cognate protein,
an example of which is secretory phospholipase A2-IIA (as discussed in chap-
ter 3). This is the prototype example of a “simple well-defined phenotype”
referred to by Katan,[74] that is ideal for ‘classical’ Mendelian randomiza-
tion. Because the protein can usually be measured specifically, and a known
gene encodes the protein, in this scenario it is often straight forward to se-
lect a SNP that is specific for the protein exposure of interest (by selecting
a SNP in the gene that specifically encodes the protein) and take it forward
for instrumental variable analysis.
 trans: contrary to the cis-form, in trans MR studies, the intermediate phe-
notype is endogenous and not a protein (such as a circulating lipid fraction,
e.g. HDL-C, or systolic blood pressure). This type of biomarker is more
challenging to investigate using Mendelian randomization as it makes certain
assumptions. For example, use of a single SNP for Mendelian randomization
in this setting relies on the assumption that the SNP does not have effects
on other traits that can result in confounding of the instrumental variable
estimates.[81] An example of using a single SNP to make causal inference
on an endogenous non-protein trait is the investigation of homocysteine and
risk of stroke. Using the MTHFR variant, I investigated the role of homo-
cysteine in stroke and found that in populations with low levels of folic acid,
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the MTHFR variant (which was involved in homocysteine metabolism) had a
large effect on homocysteine levels and was associated with risk of stroke.[81]
exogenous trait: in contrast to endogenous traits, exogenous traits are exposures that
originate outside of the human body. Use of Mendelian randomization analyses
for exogenous traits are subject to the same limitations and assumptions as those
for trans-Mendelian randomization, namely specificity of the SNP for the exoge-
nous trait.[81] An example of using a single SNP to make causal inference on an
environmental exposure (alcohol) is reported in Chapters 6 to 8.
Recent developments have enabled the use of combining several SNPs together into
an allele score.[82] This has advantages for Mendelian randomization when applied to
both endogenous cis/trans and exogenous traits. Use of multiple SNPs will increase
the proportion of variance of the intermediate phenotype, meaning that there will be
greater statistical power. Furthermore, it enables the investigation of non-protein traits
(not encoded for by any single gene), with the bonus that any associations of individual
SNPs in the allele score with traits other than the index phenotype should be non-
systematic and therefore diluted by the combined effects of the multiple SNPs in the
allele score.
Another means to categorise Mendelian randomization is based on the application:
drug target validation - in this scenario (a special type of cis Mendelian Randomi-
sation), Mendelian randomization is used to validate a potential drug target using
a SNP that encodes a drug target receptor. Information from these studies informs
on whether drug targets should be pursued in further studies (ideally randomized
trials). A recent example is use of a SNP in the IL6R gene,[83] which indicates
that targeting the IL-6 receptor may represent a novel means to reduce risk of
CHD. This study also served to validate the role of inflammation (acting via the
IL-6 receptor) in CHD aetiopathogenesis.
validation of risk factors - in this scenario, Mendelian randomization is used to inves-
tigate endogenous or environmental exposures that are amenable to public health
intervention.
1.7.5 Mendelian triangulation
One key component of Mendelian randomization is the instrumental variable analysis,
also known as “Mendelian triangulation,” which refers to the statistical technique in
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which data on the associations between the genetic instrument (SNP) with the interme-
diate phenotype and the outcome are used to generate an un-biased estimate between
the intermediate phenotype and the outcome. The investigator can then compare the
estimate derived from the crude observational analysis to that derived from the instru-
mental variable analysis to investigate whether there is a discrepancy. Absence of a
discrepancy would suggest that the biomarker is causally related to disease. Presence
of a discrepancy could be explained by confounding in the observational analysis. Four
potential scenarios comparing the observational and instrumental variable estimates are
outlined in Table 1.2.
Table 1.2: Comparison of estimates obtained from observational analysis to instrumen-
tal variable analysis
Scenario Observational es-
timate
Instrumental
variable estimate
Potential explanation(s)
1 Associated Null Observational estimate con-
founded or lack of power in IV
estimate
2 Associated Associated Biomarker is likely to be
causal
3 Associated + Associated ++ Causal (IV estimate of greater
magnitude owing to lifetime
exposure to genotype)
4 Null Associated Negative confounding?
Footnotes: IV: instrumental variable, derived for example from a Mendelian randomization analysis.
? this is an unlikely scenario given that if the observational association is null, it is unlikely that the
biomarker would be prioritized for a Mendelian randomization analysis!
1.7.6 Assumptions
There are three basic assumptions in the use of genetic variants as instrumental variables:[84]
1. the SNP (Z in Figure 1.9) must associate with the intermediate phenotype (X in
Figure 1.9)
2. the SNP must not have independent associations with the outcome of interest via
alternative pathways (the dotted red line between Z and Y in Figure 1.9)
3. the SNP must not associate with any confounders (the dotted red line between U
and Z in Figure 1.9)
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ZGene variant X
Intermediate phenotype
U
Confounder(s)
Y Outcome
Figure 1.9: Mendelian randomization concept.
The investigator is primarily interested in the causal relationship between the interme-
diate phenotype (X in figure above) and the outcome (Y). Observational studies that
report this association are limited by potential confounding from known and unknown
confounders (U). Use of an instrument (in this case a gene variant, Z) that associates with
the intermediate phenotype but not with the confounders (owing to Mendel’s second law)
can be used to “triangulate” the true (deconfounded) association between X and Y.
Mendelian randomization makes three assumptions:
(i) The red dotted line between Z and U refers to the assumption that there is no associa-
tion between the gene variant with known and unknown confounders; (ii) The red dotted
line between Z and Y refers to the assumption that there is no association between Z and
Y that is independent of X; (iii) The instrument (Z) must associate with the intermediate
phenotype (X)
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1.7.7 Potential Limitations
Limitations to Mendelian randomization exist, but with large sample sizes and appropri-
ate choice of the genetic instrument, they can be largely overcome. Limitations include:
Small effect size One of the greatest criticisms thrown at Mendelian randomization is
that the genetic instruments typically have a small effect size on the intermediate
phenotype, explaining only a small proportion of variance (R2) in the exposure.
However, this is not universally the case, e.g. the SNP used in Chapter 3 explained
a large proportion of the variance of circulating sPLA2-IIA mass.
It is worthy to note that drugs used in conventional clinical trials tend also to
only explain a small proportion of variance on the pharmacodynamic target. E.g.
the proportion of variance of LDL-C explained by statins is only 8% (data from
Whitehall-II cohort[85]) Yet meaningful conclusions on drug efficacy can come
from trials with a few thousand individuals.
Sample size Due to the small effects of individual SNPs on the intermediate phenotype,
Mendelian randomization studies rely on large sample sizes. Thus, even if the
SNP explains only a small proportion of variance of the intermediate phenotype,
as in the example of C-reactive protein where the proportion of variance is small
(6%),[86] by amassing studies to have suitable power,[62] even a variant with a
relatively weak effect can be used to make meaningful causal inference. Thus
when conducting a Mendelian randomization study, both the impact of the genetic
variant on the intermediate phenotype and the sample size need to be taken into
consideration in order to determine whether there is sufficient power to make
meaningful causal inference.
Confounding There are three ways in which Mendelian randomization studies can be
confounded.[87] These are:
1. Linkage disequilibrium (LD): in this case, the genetic instrument is associated
with another SNP which has a true “causal” association with the outcome
of interest (Figure 1.10A). Thus, the instrumental SNP must be carefully
selected such that LD with other SNPs (typically those in adjacent genes) is
not an issue. This can be investigated using ‘in-house’ data to generate LD
plots, but also various external tools exist including the SNP Annotation and
Proxy Search (Broad Institute)[88] and an online tool provides researchers
with information on long-range LD GLIDERS.[89]g
gOf note, this does not test if the SNP in the gene is responsible for the alteration in the encoded
protein - this comes e.g. from investigating the association of SNPs in the region with for example
mRNA expression of the gene (as I present in Chapter 5 for secretory phospholipase A2).
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2. Population stratification: genotype frequency often differs by population sub-
groups. It is well established that so-called ancestry associates with various
disease frequencies including cardiovascular disease.[90] Thus if individuals
of differing ancestry are used in the same analysis, ancestry may introduce
confounding between the gene and outcome (Figure 1.10B). In a GWAs, con-
founding by population stratification can be assessed by means of a Chi-
squared quantile-quantile(Q-Q) plot, where a striking or early deviation from
the 45 degrees line suggests genomic inflation, as assessed by the lambda
statistic.[91]
In order to minimize potential for population stratification, researchers com-
monly limit genetic analyses to individuals of a single ancestry (e.g. Euro-
pean, African, Asian). However, in this scenario, confounding may still arise
by ‘residual’ population stratification, and it may be necessary to statistically
adjust analyses by principal component traits.h[91, 94]
3. Pleiotropy: in this scenario, a SNP may be non-specific for the trait under
investigation. This can result in an association between the gene and outcome
arising from the association of the SNP with an intermediate phenotype sep-
arate to the one that you are investigating (Figure 1.10C). This can introduce
confounding into the instrumental variable analysis.
An example is APOE genotype, which has effects on multiple traits includ-
ing C-reactive protein, LDL-C and HDL-C. If one were to use APOE to
investigate the effect of CRP on CHD, a positive association between the
genotype and outcome may be incorrectly ascribed to a causal effect of CRP
on CHD. However, this association would arise from the pleiotropic effects
of the APOE gene with the other “true” causal intermediate traits (such as
LDL-C). It ought to be noted that even if pleiotropy is identified, it may
be possible to statistically adjust for traits in order to try and mitigate con-
founding by association of the SNP with another trait.
Some SNPs used for Mendelian randomization may be pleiotropic by the na-
ture of their effect on the phenotype - e.g. SNPs used for trans-MR are often
non-specific for the trait under investigation. For example, if a SNP is in-
volved in metabolism of the exposure of interest, the SNP would associate
with both the biomarker of interest and its metabolites. Thus identification
of pleiotropy in the scenario of a trans-acting SNP may be permissable.
hPrincipal component traits are derived from SNPs in the dataset using EIGENSTRAT[92] and catch
the main axes of genetic variation in the study participants.[93]
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X
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A
Ancestry
Y Outcome
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ZGene variant X
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P
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Y Outcome
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confounded
Figure 1.10: Potential confounding of Mendelian randomization studies.
(A) In this scenario, the original SNP (Z1) chosen as an instrument for the intermediate pheno-
type (X) is in LD with SNP Z2. Z1 is not associated with the outcome via the intermediate phe-
notype. However, an association between Z1 and Z2 through LD induces an association between
Z1 and the outcome. This may then be erroneously interpreted as a causal association between X
and Y.
(B) In this scenario, genotype frequency and disease risk are both associated with ancestry,
which can confound the association between genotype and disease risk.
(C) In this scenario, the gene has associations with several intermediate phenotypes (X and P).
If the sum causal effect is thought to be solely mediated via X, the magnitude of the association
may be confounded.
Canalisation This oft-proclaimed limitation[95] suggests that developmental adapta-
tions can mitigate the disease predisposition arising from deleterious genetic vari-
ants. In practise, few if any biological examples of canalisation in humans have
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been convincingly demonstrated.[96] An alternative take on canalisation is human
intervention to mitigate the effects of genetic variants - e.g. genetic predisposi-
tion to increased LDL-C may make an individual more likely to be prescribed
lipid-lowering drugs (such as statins). This form of canalisation could mitigate the
genetic effect.
These limitations are all, by and large, addressable if Mendelian randomization studies
are adequately powered, and with careful selection of SNPs for use as genetic variants
in instrumental variable analysis.
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1.8 Using genetic information to guide prescription of medicines
(pharmacogenetics)
A separate opportunity to translate genomic information is its potential use to group in-
dividuals into expected therapeutic response to a drug, so-called “personalized medicine”.
As described above, owing to the inherent properties of design, randomized trials are
the optimal method to judge the effect of an intervention on a health outcome. Re-
sults from randomized trials will yield an average treatment effect for all individuals.
However, it is possible that individual characteristics (e.g. presence of comorbidities or
levels of a trait of interest) may modify the individual response to a drug. This individ-
ual response may result in reduced efficacy and/or an increased risk of adverse effects,
which collectively make a substantial contribution to the burden of ill-health.[97] If such
treatment-modifying individual-level characteristics can be identified, this information
can be used to used to target treatments to those predicted to respond more favourably
to treatment: the basis of stratified or ‘personalized’ medicine.
The aims of stratified medicine are to:
1. reduce costs of drug prescribing, by limiting prescribing to selected individuals
that are predicted to benefit from treatment (rather than to all individuals)
2. prevent adverse drug reactions, by preventing exposure of the drug to individuals
with a characteristic that associates with adverse drug reactions
3. maximize therapeutic benefit, by limiting prescribing to individuals with markers
that associate with beneficial outcomes
Stratified medicines can be categorized into two ways[98]: (Figure 1.11):
Absolute In this scenario, the treatment response in terms of relative risk is the same
across subgroups, however the absolute risk difference differs by strata.
For example, primary prevention of CVD using statins is stratified using risk scores
such as Framingham coronary risk score (FRS).[99] Guidance from National In-
stitute for Health and Clinical Excellence (NICE) in England and Wales,[100] the
European Society of Cardiology[101] and the American Heart Association[102] rec-
ommend statins in individuals estimated to have a 10-year risk of CVD in excess
of an agreed threshold value, the precise value of which varies from guideline to
guideline. The relative benefit of statins on risk of CVD is consistent according to
Chapter 1. Introduction 24	  	  	  	  Permissions	  not	  obtained	  for	  figure	  Please	  refer	  to	  citation	  for	  image	  	  	  	  	  	  	  	  	  	  
Figure 1.11: Comparison of differential treatment response based on abso-
lute difference or relative difference In (A) the relative treatment response of the drug
is constant across strata, however the absolute difference differs. In (B), the relative treatment
response differs according to strata.
Reproduced from Hingorani et al.[98]
values of FRS. However, the absolute difference is greater in those with a higher
FRS (as in Figure 1.11(a)). Identification of differences in absolute risk means
that expensive drugs or drugs with high risks of side effects can be targeted to
individuals that will derive most absolute benefit.
Relative This is the more conventional form of interaction, whereby a difference in
the relative treatment effect occurs when stratifying by a subgroup (as in Fig-
ure 1.11(b)).
An example of this would be use of a genetic variable that encodes a drug target
receptor, for example Epidermal growth factor receptor (EGFR) status and treat-
ment response to the EGFR-inhibitor, gefitinib in patients with lung cancer for
which evidence suggests patients experience a more beneficial treatment response
to gefitinib when EGFR is highly expressed.[103, 104]
1.8.1 Traditional analysis of “effect modification”
The traditional analytical method to evaluate effect modification of individual charac-
teristics on drug response (i.e. to identify differences in relative treatment effect) is
sub-group analysis, through interaction testing. However, reliable detection of a dif-
ferential effect among particular subgroups of patients requires larger-sample sizes (i.e.
power is often limited to conduct subgroup analyses within conventional trials). There-
fore it is not entirely surprising that most claims of sub-group effects have not been
replicated.[105]
Use of genomic information for subgroup analyses (Figure 1.12) is discussed in further
detail in Chapter 2, CYP2C19 Genotype, Clopidogrel and Cardiovascular Disease).
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Figure 1.12: Schemata of pharmacogenetics As with any patient characteristic, ge-
nomic information can be used to classify individuals into groups. If this classification can be
shown to modify treatment response (as in this figure, where individuals with genotype status in
Group 2 receive a large risk reduction in response to treatment, whereas Group 1 seem to experi-
ence no benefit), then genomic information could be used to guide prescribing - this is a form of
“personalized” medicine called “pharmacogenetics”.
This type of subgroup analysis is desirable as it forms a means of ‘factorial design’ since
both drug and SNP are randomly allocated. This is in contrast to traditional (phe-
notypic) subgroup analyses, which, can re-introduce confounding yielding misleading
findings.[106, 107]
1.9 Thesis Themes
During the work for this PhD, I will use three different approaches to illustrate the con-
trasting applications of genomics to further the understanding of cardiovascular disease,
with the ultimate aim of making improvements in public health.
Pharmacogenetics: in chapter 2, I will examine the evidence base regarding the clin-
ical use of CYP2C19 genotype to guide antiplatelet treatment.
Mendelian randomization for drug target validation: in chapters 3 to 5, I will
investigate the role of secretory phospholipase A2-IIA (sPLA2-IIA) in CHD. sPLA2-
IIA is a pro-inflammatory enzyme that is thought to play important roles in the
pathogenesis of CVD. I will use Mendelian randomization to provide a decon-
founded association between sPLA2-IIA and CVD risk.
Mendelian randomization for investigation of an environmental exposure: in
chapters 6 to 8, I will use variation in a gene encoding an enzyme involved in the
main metabolic pathway of alcohol, to investigate the evidence-base for a cardio-
protective role of alcohol consumption.
Chapter 2
CYP2C19 Genotype, Clopidogrel
and Cardiovascular Disease
2.1 Introduction
2.1.1 Principles of pharmacogenetics
For more than 50 years,[108] genetic variation has received recognition as a potential
modifier of treatment response (pharmacogenetics). Gene polymorphisms can influence
drug response by encoding enzymes involved in drug handling (absorption, distribution,
metabolism and excretion; a “pharmacokinetic” action) and through encoding proteins
that are drug targets (e.g. cell receptors; a “pharmacodynamic” action) (see Figure 2.1).
With the completion of the human genome project[109] and advances in genomic se-
quencing technologies, facilities that allow rapid and cheap genotyping are increasingly
available. A recent surge in the number of published pharmacogenetic studies has
occurred,[110] which, together with numerous commentary articles, has fuelled expec-
tation that pharmacogenetics will help to deliver a genomic means to personalize drug
prescribing (i.e. personalized or stratified medicine).[111–114]
To investigate why, despite 20 years of active research in this field, the output from the
field of pharmacogenetics seemed to lag that of progress made in gene-disease associ-
ation studies, I previously performed a systematic review and field synopsis,[110] that
identified several features that might account for the slow translation from bench to
bedside. These included:
 an excess of small studies (median sample size 93; Figure 2.2 (A))
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Figure 2.1: Contrast between pharmacodynamic and pharmacokinetic.
The term ‘pharmacodynamic’ refers to the action of the drug on the intended drug tar-
get (in the figure above, a cellular receptor), whereas ‘pharmacokinetic’ refers to the pro-
cess by which enzymes in the body modify the drug (ADME: absorption, distribution,
metabolism, excretion)
 a large proportion of studies (75%) reporting nominally significant (P≤0.05) re-
sults, suggesting possible reporting/publication bias (Figure 2.2 (B))
 a high proportion of reviews/commentaries to original articles (25:1) which may
“stoke the flames” of expectation
 a lack of focus (so-called “mile-wide inch-deep” phenomenon[115]) on gene-drug
combinations with many genes for which only single studies had been performed,
meaning that evidence for replication was missing for many signals, but also ham-
pering efforts to pool data for meta-analyses
Despite these issues, several high-profile pharmacogenetic tests have received attention
for their potential clinical utility. Notable early successes in genes used to predict ad-
verse response to HIV medications[116, 117] have become established in routine clinical
care. Furthermore, a GWAs enabled the discovery of loci associated with statin-related
myopathy[118]. However, these successes are the exception rather than the rule and
have predominantly focused on adverse reactions to drugs: most pharmacogenetic tests
of intended effects have yet to translate into clinical use.[119–121]
One of the most highly anticipated pharmacogenetic tests to predict intended drug effects
was the use of CYP2C19 genotype as a marker of identifying treatment response to the
second most widely-prescribed drug in the world, clopidogrel.[122]
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(A) 	   	   	   	   	   	   	   	   	  (B)	  
Figure 2.2: Characteristics of previous pharmacogenetic studies.
Panel (A) shows the median sample size for studies conducted between 1987-2007 (inclu-
sive), panel (B) shows the P-values reported in full-text of 161 articles. For both, genes
are classified according to whether they are the drug target (pharmacodynamic, shaded
blue), involved in drug metabolism (pharmacokinetic, shaded green) or somatic variants
(shaded purple).
Reproduced from Holmes et al[110]
2.1.2 Clopidogrel and Coronary Heart Disease
Anti-platelet agents such as aspirin and clopidogrel have proven highly effective in the
treatment or prevention of a range of atherothrombotic disorders, including ACS, coro-
nary stent thrombosis and stroke.[123, 124] A recent overview of randomized placebo-
controlled trials including 7,384 cardiovascular events in 79,613 individuals with acute
or chronic coronary heart disease or with multiple CHD risk factors indicated clopido-
grel treatment reduced the odds of cardiovascular events (odds ratio [OR]: 0.88; 95%CI:
0.83, 0.93), but at the expense of a mechanism-based increase in odds of major bleeding
(OR 1.28; 95%CI: 1.13, 1.45).[125] Clopidogrel was approved by the US Food and Drug
Administration (FDA) in 1997 and is currently used by more than 40 million patients
worldwide, being the second most widely prescribed drug after atorvastatin.[122] There-
fore, any change in its prescription guidelines is likely to have important repercussions.
Because cardiovascular disease is common[1, 2] and anti-platelet drugs are the second
most widely prescribed drugs worldwide,[122] they are also an important cause of admis-
sions for gastrointestinal haemorrhage and other bleeding complications.[97] The risk of
gastrointestinal bleeding lies between 1.3-12% within 30 days of commencing dual anti-
platelet therapy.[123, 124] Therefore, to maximize benefit and minimize harm, clinicians
currently target patients at highest risk of thrombotic events and the lowest risk of
bleeding, based on routine clinical assessments. However, there is emerging concern
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that individuals may differ both in their response to the anti-thrombotic effects, and
their susceptibility to the haemorrhagic complications of anti-platelet therapy.[126–132]
It is suggested that the average 12% relative risk reduction in major CV events ascribed
to clopidogrel (as well as the 28% increased risk of major-bleeding) could differ between
subgroups based on presence of CYP2C19 gene variants.[120] Since 2008, several genetic
studies aiming to evaluate this have been conducted, and by 2010, using the available
evidence at the time, the FDA issued a boxed warning[133], used to highlight potentially
fatal, life-threatening or disabling adverse effects and recommended consideration of
CYP2C19 genotype prior to prescribing clopidogrel, warned of reduced effectiveness in
patients who are poor metabolizers, and advised clinicians of the availability of a test to
identify genetic differences in CYP2C19 function.[133] One year after the FDA warning,
a more cautious announcement was made by the American Heart Association/American
College of Cardiologists, arguing insufficient evidence and advising physicians to adhere
to current (non-genetic) guidelines.[134] Amid this uncertainty, FDA-cleared tests for
CYP2C19 genotype[135] were offered direct to consumers with sales escalating.[136]
2.1.3 Clopidogrel metabolism
Clopidogrel is a pro-drug, converted to its active form through metabolism by the hepatic
cytochrome P450 (CYP450) enzyme system including CYP450 2C19 (CYP2C19) (Fig-
ure A.2). Genetic variants in CYP2C19 have been associated in vitro with differences
in CYP2C19 enzyme activity, as indicated by small mechanistic studies with carriers of
some CYP2C19 alleles (e.g. ?2) showing reduced, and carriers of other alleles (e.g. ?17)
having increased activity.[137–139] Individuals have therefore been classified as either
slow or fast metabolizers based on CYP2C19 genotype, which is assumed to modify
the levels of active clopidogrel metabolites, platelet reactivity and thus the mechanism-
based benefits (reduction in CVD events) and harms (increased bleeding) arising from
clopidogrel treatment (see Figure A.1 for further explanation).
2.1.4 GWAs of clopidogrel response
To date, only one GWAs of clopidogrel response has been conducted. In the Amish
PAPI study, Shuldiner et al[140] administered clopidogrel to 429 healthy Amish adults
and measured response to clopidogrel through adenosine diphosphate-stimulated platelet
aggregation. In GWAs analysis, 13 SNPs on chromosome 10q24 (in strong LD with each
other) were identified to associate with platelet aggregation. Of these, rs1277823 showed
strongest association at P=1.5 x 10-13. Of note, this SNP was in LD (at R2=0.87) with
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the SNP that characterizes CYP2C19 *2 (rs4244285).
No GWAs has been conducted to investigate clinical outcomes such as CVD or bleeding
events in relation to clopidogrel treatment.
2.1.5 Technological advances enabling pharmacogenetic analyses
Point of care testing (POCT) is now available and enables a rapid means to determine an
individual’s CYP2C19 genotype.[141] The availability of this and other FDA-approved
‘devices’[135] means that it is now possible to perform the genetic test in the clinic to
rapidly assign an individual to presence/absence of reduced-function CYP2C19 alleles.
However, what is the evidence base for use of CYP2C19 genotype in informing choice
of antiplatelet drug?
2.2 Aims
To ascertain the totality of research evidence, I conducted a systematic review and criti-
cally appraised existing evidence underpinning CYP2C19 loci and clopidogrel response.
2.3 Methods
2.3.1 Search Strategy
I followed guidance from the Human Genome Epidemiology Network (HuGEnet) on gene
disease association studies[142] and the reporting of systematic reviews from PRISMA.[143]
I searched PubMed and EMBASE from inception to 25th October 2011. The search
terms were adapted from a previous HuGENet article[144] and comprised: (i) drug name
(including the generic name, clopidogrel, and trade names e.g. Plavix, clopilet etc.); (ii)
metabolic enzymes (including CYP2C19 ), and; (iii) gene (please see Appendix A for
details of the full search strings) to identify studies describing patients treated with
clopidogrel and reporting treatment response (platelet response or clinical outcomes) in
relation to CYP2C19 genotype (Ensembl Gene ID:ENSG00000165841). Articles with
abstracts containing the keywords clopidogrel and CYP2C19 that reported new data
were eligible for inclusion (i.e. editorials and reviews were omitted). I additionally
interrogated bibliographies of included articles, identified previous meta-analyses and
narrative reviews and searched articles listed in the Pharmacogenomics Knowledge Base
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(http://www.pharmgkb.org, accessed October 25th 2011), Medicines and Healthcare
products Regulatory Agency (MHRA, UK Department of Health) and FDA. Articles
were not restricted to a language.
2.3.1.1 Systematic review of randomized trials of more vs less clopidogrel
In addition to the main search, I also identified randomized trials that compared more
vs. less clopidogrel. This was in order to able to contextualize the effect of CYP2C19
on CVD risk.
I searched PubMed from inception to July 2011 using the search criterion “clopidogrel”
and restricted the search to randomized clinical trials in humans using the PubMed built-
in filter. The retrieved abstracts were filtered for more versus less clopidogrel randomized
trials. I examined the outcomes CVD and major bleeding. Analysis was limited to the
most widely-reported clopidogrel doses (600mg versus 300mg loading dose). I noted the
number of events per treatment arm and synthesized the relative risk. I used fixed-effect
(Mantel-Haenszel) meta analysis to pool summary estimates in Stata v11.2.
2.3.2 Data extraction
I extracted information on 2 separate occasions and checked for consistency of data to
minimize error. Information extracted included: study design; duration of follow-up;
proportion of eligible individuals included in the pharmacogenetic analysis; recruitment
criteria e.g. acute coronary syndrome (ACS), emergency or elective percutaneous inter-
vention or stable CHD; and the proportion of individuals receiving concomitant therapy
with proton pump-inhibitors or aspirin. In the case where it was not clear what outcomes
were reported, I contacted the corresponding authors. Any remaining uncertainties were
resolved by consensus with my supervisors.
To evaluate risk of bias, I recorded how studies ascertained clinical outcomes, whether
studies reported if investigators were blinded to clinical status when ascertaining CYP2C19
genotype, genotype indices (Hardy Weinberg equilibrium and call rate) and the source
of funding.
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2.3.3 Grouping of CYP2C19 for genetic analyses
The main analysis compared individuals with one or more copies of any CYP2C19
genetic variant associated with reduced enzyme function (i.e. ?2, ?3, ?4, ?5, ?6, ?7, ?8)
with individuals categorized as having none of these alleles (?1/?1) or having one or
more ?17 gain-of-function alleles (the reference group). I separately conducted analyses
of the effect of one loss-of-function or two loss-of-function alleles with the same reference
group (to investigate evidence of a genetic dose-response relationship).
2.3.4 Cardiovascular outcomes
The main cardiovascular outcome for the analysis was a composite including any or all
of the following: all-cause mortality, fatal/non-fatal CHD, fatal/non-fatal stroke, stent
thrombosis, target vessel revascularization and hospitalization for ACS. Studies that
exclusively reported stent thrombosis (and no other outcome) were excluded from the
primary analysis, but were included in the analysis for stent thrombosis. Additionally I
conducted separate analyses for the following component end-points: fatal and non-fatal
MI and stroke, stent thrombosis and all-cause mortality. In studies that only reported
hazard ratios, if provided I used the hazard proportion to estimate the number of events
per genotype group, otherwise I substituted the relative risk for the summary hazards
ratio. In one study that did not provide numerical values of effect estimates, I derived
the point estimates and 95%CI from the published forest plots.[145]
2.3.5 Clopidogrel drug metabolite
For analysis of the association of CYP2C19 genotype and clopidogrel metabolites, I
used data from the largest study by Mega et al [146]. For studies of CYP2C19 genotype
and platelet function, I noted the number of individuals and the mean (or median) and
standard deviation (or interquartile range) for the relevant platelet function measure in
different genotype categories.
2.3.6 Analyses
For binary outcomes, I used relative risk (RR) as a measure of effect. I performed meta-
analyses using fixed and random effects modeling and quantified between-study hetero-
geneity using the I2 statistic[147] and Cochrane’s Q statistic. I investigated sources
of heterogeneity using meta-regression and used the method described by Altman and
Bland[148] to test for interaction of summary estimates. I restricted the analysis of
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platelet reactivity to studies with more than 500 participants and calculated standard-
ized mean differences using fixed-effect (inverse variance) models.
I assessed small study bias through: (i) comparison of effect estimates in studies stratified
by number of cardiovascular events (1-99,100-199,≥200); (ii) the Harbord test;[149] (iii)
visual inspection of funnel plots; and (iv) trim and fill analysis.[150] To evaluate the
change in effect estimates with the addition of new evidence, I synthesized cumulative
meta-analysis plots.
I used P<0.05 to suggest evidence against the null hypothesis of no association and all
statistical tests were 2-sided. I used Stata version 11.2 for all statistical analyses.
2.4 Results
2.4.1 Study designs, genotyping and reported outcomes
I identified 32 studies[138, 140, 145, 146, 151–177] including 3,545 CVD events in 42,016
participants (Figure 2.3), with a weighted mean age of 63, of which 29% were female
(Table 2.1).
Only 6 out of 32 studies were nested within a RCT: in five of these, CYP2C19 genotyp-
ing was conducted in participants from both the clopidogrel and comparator arms of a
randomized trial, and of these, for four (referred to as “effect modification” studies) the
comparator was placebo (CURE, ACTIVE-A[164], CHARISMA[151] and CLARITY-
TIMI[145]), and in one (PLATO)[173] the comparator was prasugrel. In the phar-
macogenetic substudy of the TRITON-TIMI trial[146] only the clopidogrel arm was
genotyped.
The remaining 26 studies were either prospective cohorts (24) or case-control (2) studies
limited to individuals receiving clopidogrel (referred to as “treatment-only” studies).[138,
140, 145, 152–163, 165–172, 174–177] The majority of studies (21 of 32) included pa-
tients with ACS at the time of recruitment and 8 included only patients with stable
CHD, mainly recruited at the time of placement of coronary stents (CHD status was
not reported in the remaining 3 studies). Of the 28 star alleles reported to date in
CYP2C19,[178] only 13 (the loss of function *2 to *10 and *12 to 14 inclusive, as well as
the gain-of-function *17) have been evaluated in the pharmacogenetic studies of clopido-
grel. The ?2 allele was typed by 31 of 32 studies (97%); both ?3 and ?17 alleles each by
12 studies (38%), and the remaining ten ? alleles were genotyped in 5 or fewer studies.
Only 6 of the 28 SNPs that uniquely identify the known CYP2C19 ? alleles were listed
in the Human HapMap (builds 21, 22 and 3(2)).[179] Only two studies reported detailed
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Figure 2.3: PRISMA flow diagram for systematic review of CYP2C19 and clopidogrel response.
Chapter 2. CYP2C19 Genotype, Clopidogrel and Cardiovascular Disease 35
linkage disequilibrium between CYP2C19 SNPs[140, 159] and one study imputed an
un-typed SNP.[145]
The genotyping and reporting of the nine other genotyped alleles varied considerable
among studies (Table 2.1). Over half of studies (15 of 25 that reported sources) were
funded directly or via study investigators by the manufacturer of a new, competitor
anti-platelet agent, prasugrel (Table A.1).[180]
Other study characteristics including risk of bias are reported in Table A.1.
2.4.2 Outcomes evaluated
Twenty-six of 32 studies (81%) evaluated a composite outcome, but the individual com-
ponents varied substantially between studies and included both hard clinical end-points
(e.g. ST-segment elevation MI) and softer end-points (such as hospitalization for ACS
or target vessel revascularization). A considerable proportion of disease outcomes were
ascertained but were not reported either individually or as part of the combined end
point (Tables A.2 and A.3).
2.4.3 Effects of CYP2C19 genotype on clopidogrel metabolites and
platelet reactivity
At a dose of 75mg of clopidogrel (the usual maintenance dose) individuals with the
CYP2C19 alleles ?2 , ?3, ?4, ?5, ?6, ?7 or ?8 associated with lower enzyme activity,
had a 0.14 unit reduction in geometric mean active metabolite concentration (AUC0-t;
µ×hour) compared with individuals carrying ?1 or ?17 alleles (Figure 2.4). A similar
reduction in exposure to the active clopidogrel metabolite was observed for the same
genotype comparison at the 600mg clopidogrel dose (0.13 unit reduction in geometric
mean active metabolite concentration; AUC0-t; µ×hour). Of note, at both doses of clopi-
dogrel, the difference in the active clopidogrel metabolite concentration between the two
CYP2C19 genotype categories (?2-?8 vs. ?1 or ?17) was smaller than the difference
between the overall concentration difference between treated and untreated individuals,
regardless of the CYP2C19 genotype (Figure 2.4).
In four studies using the treatment only approach (4,341 individuals; Table A.5)[167, 172,
181, 182] reporting platelet reactivity following 600mg clopidogrel, a genotype dosage-
dependent response was observed with number of ?2 alleles and increased platelet aggre-
gation (i.e. reduced platelet inhibition) when compared to subjects with ?1/?1 genotype
(Figure 2.5).
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Table 2.1: Characteristics of studies included in the systematic review
First Author / Study
Name (Year of
Publication)
Outcome(s)
reported
ACS at
study entry
(%)
Women,
%
Age, Mean,
(SD), y
Participants
(n, % of total
sample size)
Follow-up,
Months
(range)
CYP2C19
? alleles
geno-
typed
Anderson et al [152]/ IHCS
(2009)
CVD-c, MI, death NR 27 63 (NR) 1250 (100) 12 (NR-24) 2
Bouman et al [153]/
MAPCAT (2011)
ST 50.9 21 61.3 (7.7) 112 (1.5) 18 (NR) 2, 17,
(3-8)
Campo et al [154]/ NA (2011) CVD-c, death, ST,
bleeding
61 23 66 (13) 300 (59.2) 12 (NR) 2,17
Collet et al [155]/ AFIJI
(2009)
CVD-c, MI. ST,
death
100 7.7 40.1 (5.1) 259 (68.5) 12 (NR-96) 2 (3-6)
Giusti et al [156]/ RECLOSE
(2009)
CVD-c, ST, death 65.67 25.4 69 (11) 772 (96) 6 (NR) 2
Harmsze et al [159]/ NA
(2010)
ST 24.6 20.5 62.1 (9.4) 596 (NA) NA 2, 3
Harmsze et al [157]/ POPular
(2011)
CVD-c 0 24 63.2 (10.2) 725 (68) 12 (NR) 2, 17
Jeong et al [158]/ACCEL
(2011)
CVD-c 100 30.9 63.0 (12.4) 266 (48) >12 (NR) 2, 3, 17
Komarov et al [160]/NA
(2011)
CVD-c 0 NR 59.4 (NR) 399 (NR) 18 (NR) 2
Malek et al [138]/ NA (2008) MI, ST 100 30 60 (11.4) 105 (100) 12 (NR) 2
Malek et al [161]/ NA (2010) Death 100 33 60(11) 261 (94.6) 48 (NR) 2
Continued on next page
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Table 2.1 – Continued from previous page
First Author / Study
Name (Year of
Publication)
Outcome(s)
reported
ACS at
study entry
(%)
Women,
%
Age, Mean,
(SD), y
Participants
(n, % of total
sample size)
Follow-up,
Months
(range)
CYP2C19
? alleles
geno-
typed
Oh et al [162]/ Sky Registry
(2011)
CVD-c, MI, death,
ST
20.6 34.3 60.8 (9.8) 2146 (64.8) 12 (NR) 2
Ono et al [163]/NA (2011) CVD-c 0 24.3 68.8 (9.8) 202 (100) ≤ 12 (NR) 2, 3
Sawada et al [165]/ NA (2010) CVD-c, MI, death,
ST
9 15 69.6 (9.9) 100 (27.3) 8 (3) 2
Shuldiner et al [140]/ Sinai
Hospital of Baltimore Study
(2009)
CVD-c 0 40.1 64.3 (11.2) 227 (100) 12 (NR) 2
Sibbing et al [168]/
ISAR-REACT, ISAR-REACT
2, ISAR-SMART 2,
ISAR-SWEET (2009)
CVD-c, death, MI,
stroke , ST
34 22 66.5 (10.2) 2485 (46.2) 1 (0.8, 1.2) 2
Sibbing et al [166]/ NA (2010) CVD-c, death, MI,
ST, bleeding
11 22.6 67.4 (10.7) 1524 (94.8) 1 (NR) 17
Sibbing et al [167]/NA (2011) ST NR 22.4 67.5 (10.4) 1566 (95) NA 2
Simon et al [169]/ FAST-MI
(2009)
CVD-c 100 29.4 66.2 (12.2) 2208 (60.2) 12 (NR) 2-5,17
Tello-Montoliu et al [170]/NA
(2011)
CVD-c 100 NR NR 471 (95.5) 6 (NR) 2, 17
Tiroch et al [171]/ NA (2010) CVD-c, death, MI,
ST, stroke
100 25 64.8 (12.7) 928 (100) 12 (NR) 2, 17
Continued on next page
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Table 2.1 – Continued from previous page
First Author / Study
Name (Year of
Publication)
Outcome(s)
reported
ACS at
study entry
(%)
Women,
%
Age, Mean,
(SD), y
Participants
(n, % of total
sample size)
Follow-up,
Months
(range)
CYP2C19
? alleles
geno-
typed
Trenk et al [172]/
EXCELSIOR (2008)
CVD-c 0 21.8 66.4 (9.1) 797 (99.4) 12 (NR) 2
Worrall et al [174]/ NA (2009) CVD-c 100 NR NR 104 (40.2) 12 (NR) 2
Yamomoto et al [175] /NA
(2011)
MI, death, stroke 0 33 68.6 (10.0) 123 (100) 12 (NR) 2,3
Yan et al [176]/ NA (2011) CVD-c 100 17.3 65.2 (10.7) 497 (100) 20 (NR) 2
Yuan et al [177]/ NA (2011) CVD-c NR NR NR 267 (NR) 12 (NR) 2
Mega et al [146]/
TRITON-TIMI 38 (2009)
CVD-c, MI, stroke,
ST, bleeding
100 29.3 60.1 (11.1) 1477 (10.9) NR (6, 15) 2-10 (7,
12-14)
Wallentin et al [173]/ PLATO
(2010)
CVD-c, bleeding,
ST
100 31 62.5 (11.0) 10285 (55.2) NR (NR, 12) 2-8, 17
Bhatt et al [151]/
CHARISMA (2009)
CVD-c, bleeding 0 29.7 64 (9) 4862 (31.2) 28 (NR) 2, 3, 17
Mega et al [145]/
CLARITY-TIMI 28 (2008)
CVD-c 100 19.7 57.5 (10.3) 465 (13.3) 1 (NR) 2
Pare et al [164]/ ACTIVE-A
(2010)
CVD-c, bleeding 0 45.4 71.0 (9.9) 1156 (15.3) 43.2 (NR) 2, 3, 17
Pare et al [164]/ CURE
(2010)
CVD-c, bleeding 100 41 63.8 (11.0) 5059 (40.3) NR (3, 12) 2, 3, 17
Abbreviations: ACS, acute coronary syndrome, comprising ST-segment elevation myocardial infarction, nonST-segment elevation myocardial infarction, and unstable
angina; CVD-c, cardiovascular disease composite; MI, myocardial infarction; NA, not applicable; NR, not reported; PCI, percutaneous coronary intervention; PGx,
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pharmacogenetic; STTH, stent thrombosis.
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Figure 2.4: Relationship between CYP2C19 genotype and active drug metabolite. The
expected mean active clopidogrel metabolite concentration in a Caucasian population for
all individuals treated at 75mg and 600mg, and for individuals with loss-of-function and
normal/increased function CYP2C19 alleles.
The mean active clopidogrel metabolite concentration regardless of genotype AUC0-t = 0.35 µ×hr; dif-
ference in clopidogrel active metabolite concentration between *2-*6 and *1 or *17 AUC0-t = 0.14 µ×hr.
The central tendency and measure of dispersion are obtained from Mega et al [146]: CYP2C19*1 or *17
summary estimates were pooled from ultra and extensive metabolizer groups and *2-*6 from intermedi-
ate and poor metabolizer groups. The height of the plots are proportional to the allele frequency of *2
(the most common loss-of-function * allele; rs4244285 MAF=0.13, Caucasians, dbSNP); i.e. as *1 is more
common (87%) than *2 (13%), the height of the plot for the *1 or *17 group is higher than that for *2,
reflecting the number within the population that will harbor this genotype.
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Figure 2.5: Relationship between CYP2C19 genotype and platelet reactivity.
Meta-analysis of four treatment-only studies[167, 172, 181, 182](Table A.5) including 4,341 individuals
reporting CYP2C19 genotype and platelet reactivity following a 600mg loading dose of clopidogrel.
2.4.4 Association of CYP2C19 genotype and the composite CVD out-
come on treatment-only analysis
A pooled analysis of 22 studies using the treatment-only approach[138, 140, 146, 152,
154–158, 160–163, 165, 168–172, 174, 175, 177](i.e. all study participants were exposed to
clopidogrel with no comparison arm), supplemented by a treatment-only analysis using
data from the clopidogrel-treatment arm of 4 randomized trials[151, 164, 173] with a
total 2,465 clinical events amongst 26,251 individuals, indicated that individuals with
any copy of CYP2C19?2 to ?8 had an increased relative risk (RR) of CVD events (RR
1.18; 95%CI: 1.09, 1.28; I2= 60%; 95%CI: 38%, 75%) using fixed-effects and RR 1.34
(95%CI: 1.15, 1.56) using random-effects models when compared to individuals with ?1
or ?17 alleles (Figure 2.6).
Meta-cumulative analysis, with the genotype group reversed to make the comparison
similar to a more vs. less intensive dose of active clopidogrel metabolite, showed that at
the time of US Food and Drug Administration approval, individuals with ?1 or ?17 had
a RR of CVD events of 0.82 (95%CI: 0.72, 0.93) for fixed-effect and RR 0.72 (95%CI:
0.57, 0.92) for random-effects modeling compared to individuals with ?2 through ?8,
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with some attenuation of the summary estimate with addition of new studies (most
recent estimate: RR 0.86; 95%CI: 0.79, 0.94 for fixed-effect Figure 2.7, and RR 0.76;
95%CI: 0.65, 0.89 for random-effects modeling).
Overall  (I2=60%, 95%CI: 38%, 75%) 
Author, year 
Worrall et al,46 2009 
Bhatt et al,21 2009 
Subtotal  (I2=0%, 95%CI: 0%, 75%) 
Shuldiner et al,37 2009 
Campo et al,23 2011 
Subtotal  (I2=40%, 95%CI: 0%, 80%) 
Yuan et al,49 2011 
Harmsze et al,26 2011 
Sibbing et al,40 2009 
Giusti et al,25 2009 
Malek et al,31 2010 
Pare et al (ACTIVE-A),35 2010 
Simon et al,41 2009 
Mega et al,15 2009 
Komarov et al,29 2011 
Collet et al,24 2009 
Tello-Montoliu et al,42 2011 
200+ CVD events 
100-199 CVD events 
Oh et al,33 2011 
Pare et al (CURE),35 2010 
Tiroch et al,43 2010 
Sawada et al,36 2010 
Trenk et al,44 2008 
Anderson et al,20 2009 
Jeong et al,28 2011 
1-99 CVD events 
Malek et al,30 2008 
Subtotal  (I2=33%, 95%CI: 0%, 65%) 
Wallentin et al,45 2010 
4/24 
54/722 
14/67 
10/81 
11/137 
NR/200 
52/680 
15/247 
10/56 
29/139 
76/635 
46/395 
22/108 
15/73 
NR/NR 
23/1011 
52/650 
60/248 
13/42 
5/245 
48/350 
NR/162 
1/21 
149/1388 
*2-*8 
6/80 
99/1706 
16/160 
11/219 
3/130 
NR/525 
121/1805 
14/525 
20/205 
83/421 
218/1573 
83/1064 
48/291 
11/186 
NR/NR 
10/1135 
178/1880 
184/680 
11/58 
19/552 
89/900 
NR/104 
5/84 
332/3516 
*1 or *17 
1.18 (1.09, 1.28) 
RR (95% CI) 
2.22 (0.68, 7.23) 
1.29 (0.94, 1.77) 
1.26 (1.09, 1.45) 
2.09 (1.08, 4.04) 
2.46 (1.09, 5.57) 
0.97 (0.86, 1.09) 
3.48 (0.99, 12.19) 
1.40 (0.82, 2.30) 
1.14 (0.83, 1.56) 
2.28 (1.12, 4.64) 
1.83 (0.91, 3.68) 
1.06 (0.73, 1.54) 
0.86 (0.68, 1.10) 
1.49 (1.06, 2.10) 
1.23 (0.78, 1.94) 
3.47 (1.68, 7.21) 
1.17 (0.78, 1.75) 
2.58 (1.23, 5.40) 
0.84 (0.63, 1.14) 
0.89 (0.69, 1.15) 
1.63 (0.81, 3.28) 
0.59 (0.22, 1.57) 
1.39 (1.00, 1.93) 
5.14 (1.82, 14.54) 
0.80 (0.10, 6.49) 
1.83 (1.50, 2.23) 
1.14 (0.95, 1.37) 
Lower risk CVD   Higher risk CVD  
1 0.1 0.5 1.5 2 5 10 
Yamomoto et al,47 2011 
Ono et al,34 2011 
5/62 0/36 
2/131 0/71 
NA (-/-) 
NA (-/-) 
      Cases/Total       
A 
Any CYP2C19 *2-*8 
vs. *1 or *17 
Figure 2.6: Effect of CYP2C19 genotype on composite cardiovascular outcome in indi-
viduals treated with clopidogrel, Treatment-only analysis.
Meta-analysis of risk of composite cardiovascular outcome comparing any copy of CYP2C19*2 through *8
to wild-type (*1) or *17 (reference), stratified according to the number of events (1-99, 100-199, ≥ 200)
per study. Plot shows fixed-effects meta analysis model.
2.4.4.1 Assessment for risk of bias
When I stratified studies according to the number of events, a clear trend towards the
null was observed in larger studies (Figure 2.6), providing strong evidence of small study
bias (P=3.2×10-7 on χ2 test for heterogeneity). The Harbord test for small-study bias
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was positive (P=0.001) and the funnel plot was asymmetric (Figure 2.8). When I quan-
tified the potential impact of small study bias using the trim and fill analysis, after
addition of 6 hypothetical missing studies, the summary RR decreased from 1.18 to 1.08
(95%CI: 0.997, 1.178). In the four largest studies reporting ≥200 CVD events (58% of
all reported events) the summary RR was 0.97 (95%CI: 0.86, 1.09).
Trenk et al,44 2008 
Malek et al,30 2008 
Simon et al,41 2009 
Collet et al,24 2009 
Mega et al,15 2009 
Giusti et al,25 2009 
Anderson et al,20 2009 
Sibbing et al,40 2009 
Shuldiner et al,37 2009 
Worrall et al,46 2009 
Bhatt et al,21 2009 
Tiroch et al,43 2010 
Malek et al,31 2010 
Pare et al (ACTIVE-A),35 2010 
Pare et al (CURE),35 2010 
Wallentin et al,45 2010 
Sawada et al,36 2010 
Campo et al,23 2011 
Oh et al,33 2011 
Komarov et al,29 2011 
Yuan et al,49 2011 
Tello-Montoliu et al,42 2011 
Jeong et al,28 2011 
Harmsze et al,26 2011 
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Rx only 
Rx only 
Rx only 
Rx only(*) 
Rx only 
Rx only 
Rx only 
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Rx only 
Rx only 
Rx only 
EM 
EM 
Rx only(*) 
Rx only 
Rx only 
Rx only 
Rx only 
Rx only 
Rx only 
Rx only 
Rx only 
1.69 (0.64, 4.47) 
1.60 (0.66, 3.88) 
1.19 (0.94, 1.51) 
1.05 (0.84, 1.31) 
0.93 (0.77, 1.11) 
0.88 (0.74, 1.05) 
0.84 (0.72, 0.99) 
0.85 (0.74, 0.98) 
0.83 (0.73, 0.95) 
0.83 (0.72, 0.95) 
0.82 (0.72, 0.93) 
0.87 (0.77, 0.97) 
0.86 (0.77, 0.96) 
0.86 (0.78, 0.96) 
0.90 (0.81, 0.99) 
0.89 (0.82, 0.98) 
0.89 (0.82, 0.97) 
0.88 (0.81, 0.96) 
0.87 (0.80, 0.95) 
0.87 (0.80, 0.94) 
0.86 (0.79, 0.94) 
0.86 (0.79, 0.94) 
0.86 (0.79, 0.94) 
0.86 (0.79, 0.94) 
Lower risk CVD   Higher risk CVD  
1 0.1 0.5 1.5 2 5 10 
RR (95% CI) Author (year) 
PGx 
Study Design 
Any CYP2C19 *1  or *17  
vs. *2-*8 
B 
Figure 2.7: Meta-cumulative plot of CYP2C19 wild-type (?1) or ?17 compared to ?2-?8,
to make the relative risk directionally consistent with a more-versus-less clopidogrel trial.
The shaded box shows the level of evidence at the time of FDA boxed warning[133] and
attenuation of the summary estimate with subsequent studies.
EM: effect modification; Rx: treatment; ? although set in an RCT, effect modification analysis
was not permitted. Plot shows fixed-effects meta analysis model.
Subgroup analyses by the main study characteristics did not yield evidence that the
summary estimate differed according to type of CHD at baseline (ACS or stable CHD),
source of funding (Pharma or Academia), whether or not patients received concomitant
proton pump inhibitors (some of which, such as omeprazole, are thought to inhibit the
CYP2C19 enzyme[183]) or whether the study investigators were blinded to the outcome
when ascertaining genotype (Figure A.3).
When each study was omitted, one at a time, in the analysis between any reduced
function CYP2C19 allele and risk of the composite CVD outcome, I did not find evidence
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that any one study overly-influenced the analysis. (Figure A.4)
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Figure 2.8: Funnel plot and trim-and-fill analysis. Trim and fill contour-enhanced fun-
nel plot of the pharmacogenetic studies comparing CYP2C19 ?2 through ?8 versus ?1 or
?17 and risk of CVD events in treatment-only analysis.
Footnote: Circles represent summary estimates from the 24 pharmacogenetic studies contributing towards
the treatment-only analysis in Figure 2.6 with the summary estimate shown by the solid vertical line. Tri-
angles represent 8 hypothetical missing studies generated by the Trim and Fill analysis with the dashed
vertical line illustrating the summary estimate which includes the hypothetical studies.
2.4.5 Association of CYP2C19 genotype and the individual outcomes
on treatment-only analysis
Examining the individual outcomes on treatment-only analysis identified that individu-
als with any copy of CYP2C19?2 to ?8 had a higher risk of fatal/nonfatal MI (RR 1.37;
1.13, 1.65), nonfatal MI (RR 1.48; 95%CI: 1.05, 2.07) and higher risk of stent thrombosis
(RR 1.75; 95%CI 1.50, 2.03). However, for stent thrombosis, as with the composite CVD
outcome, a trend towards the null with larger sample sizes was also observed (Figure 2.9).
In contrast, individuals carrying any copy of CYP2C19?2 to ?8 alleles had a lower risk of
all-cause bleeding when compared to individuals carrying the ?1 or ?17 allele (RR: 0.85;
95%CI 0.76, 0.95; Figure 2.9). Values were similar under a random-effects meta-analysis
model (Table A.6).
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2.4.6 Investigation of a genetic dose-response relationship
Eleven of 32 studies involving 10,291 individuals provided data that allowed me to
obtain the effect of one loss-of-function CYP2C19 allele (>238 CVD events) or two loss-
of-function CYP2C19 alleles (>37 CVD events) compared to the CYP2C19?1 or ?17
reference group. The RR of CVD events among carriers of one loss-of-function allele was
1.77 (95%CI: 1.27, 2.47) for fixed-effect and 2.01 (95%CI: 1.21, 3.34) for random-effects
modeling in studies with <100 cases. In studies with ≥ 100 events, the values for the
same exposure were RR 0.94 (95%CI: 0.80, 1.10) for fixed effect and RR 0.95 (95%CI
0.78, 1.15) for random-effects modeling.
By comparison, the RR of CVD events among carriers of two loss-of-function alleles
was 3.75 (95%CI: 2.40, 5.86) for fixed effect and 3.76 (95%CI 2.34, 6.06) for random-
effects modeling in studies with <100 cases and 1.52 (95%CI: 1.04, 2.21) for fixed effect
and 1.45 (95%CI 0.82, 2.56) for random-effects modeling in studies with ≥ 100 cases
(Figure 2.10).
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All cause mortality 
<100 
MI - fatal/nonfatal 
<100 
100-199 
All studies 
MI - nonfatal 
<100 
100-199 
All studies 
Stent thrombosis 
<100 
100-199 
All studies 
Stroke - fatal/non-fatal 
<100 
Bleeding - all 
<100 
200+ 
All studies 
Bleeding - severe 
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100-199 
200+ 
All studies 
10 
6 
3 
9 
2 
1 
3 
12 
2 
14 
4 
2 
1 
3 
2 
1 
1 
4 
64/3123 
31/1457 
130/1425 
161/2882 
13/1032 
40/395 
53/1427 
135/4415 
137/656 
272/5071 
9/1385 
14/474 
254/722 
268/1196 
45/861 
21/650 
143/1380 
209/2891 
128/6642 
33/2179 
266/3769 
299/5948 
8/1219 
80/1064 
88/2283 
141/9431 
166/1506 
307/10937 
11/3585 
46/1280 
711/1706 
757/2986 
82/2127 
81/1880 
340/3506 
503/7513 
1.28 (0.95, 1.73) 
1.92 (1.15, 3.21) 
1.29 (1.06, 1.58) 
1.37 (1.13, 1.65) 
2.42 (0.95, 6.17) 
1.35 (0.94, 1.93) 
1.48 (1.05, 2.07) 
2.01 (1.60, 2.53) 
1.54 (1.26, 1.88) 
1.75 (1.50, 2.03) 
1.98 (0.77, 5.09) 
0.82 (0.46, 1.48) 
0.84 (0.75, 0.95) 
0.84 (0.75, 0.94) 
1.37 (0.97, 1.96) 
0.75 (0.47, 1.20) 
1.07 (0.89, 1.29) 
1.07 (0.92, 1.25) 
52(2,76) 
25(0,69) 
0(0,89) 
15(0,57) 
0(-,-) 
- 
0(0,89) 
48(0,73) 
0(-,-) 
44(0,70) 
0(0,84) 
0(-,-) 
- 
0(0,89) 
68(-,-) 
- 
- 
60(0,86) 
0.154 
0.253 
0.083 
0.931 
0.128 
     - 
Lower risk 
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Higher risk  
of outcome 
1 0.1 0.5 1.5 2 5 10 
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Outcome, Studies 
*2-*8 *1 or *17 RR (95% CI) 95%CI) 
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P(χ 2) 
  (Cases/Total)    Any CYP2C19 *2-*8 
vs. *1 or *17 
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participants,% 
31 
28 
12 
51 
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33 
Figure 2.9: Association between CYP2C19 genotype (any copy of ?2 through ?8 vs. ?1
or ?17) and risk of individual outcomes in the treatment-only analysis. Each outcome is
stratified by number of events per study.
Footnote: Proportion of total participants calculated by dividing the number of individuals contributing
to each individual outcome by the total number of individuals contributing towards the treatment-only
analysis (n=31,076). Fixed-effects meta-analysis model.
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1-99 CVD events 
Malek et al,10 2008 
Yuan et al,26 2011 
Collet et al,4 2009 
Giusti et al,5 2009 
Komarov et al,9 2011 
Pare et al (ACTIVE-A),31 2010 
Yan et al,25 2011 
Jeong et al,8 2011 
Subtotal  (I2= 8%, 95%CI: 0%, 73%) 
100+ CVD events 
Bhatt et al,29 2009 
Pare et al (CURE),31 2010 
Simon et al,19 2009 
Subtotal  (I2= 51%, 95%CI: 0%, 86%) 
Author, Ref, Year 
0/1 
4/26 
2/9 
2/26 
4/7 
1/9 
NR/39 
NR/34 
8/60 
4/61 
12/58 
copies 
Two 
5/84 
3/130 
11/186 
14/525 
48/291 
83/421 
NR/242 
NR/104 
99/1706 
178/1880 
218/1573 
   (Cases/Total)    
*1 or *17 
6.67 (1.59, 28.04) 
3.76 (0.97, 14.49) 
2.88 (0.69, 12.03) 
3.46 (1.73, 6.92) 
0.56 (0.09, 3.61) 
4.86 (1.62, 14.56) 
11.40 (1.90, 66.70) 
3.75 (2.40, 5.86) 
2.30 (1.17, 4.50) 
0.69 (0.27, 1.80) 
1.49 (0.89, 2.51) 
1.52 (1.04, 2.21) 
NA (-,-) 
RR (95% CI) 
Lower risk CVD   Higher risk CVD  
1 0.1 0.5 1.5 2 5 10 
Two copies of  
loss of function 
CYP2C19 alleles 
vs. none  
B A 
1-99 CVD events 
Malek et al,10 2008 
Yuan et al,26 2011 
Collet et al,4 2009 
Giusti et al,5 2009 
Komarov et al,9 2011 
Jeong  et al,8 2011 
Subtotal  (I2= 45%, 95%CI: 0%, 78%) 
100+ CVD events 
Pare et al (ACTIVE-A),31 2010 
Bhatt et al,29 2009 
Pare et al (CURE),31 2010 
Simon et al,19 2009 
Subtotal  (I2= 31%, 95%CI: 0%, 75%) 
1/20 
7/111 
13/64 
13/221 
18/101 
NR/128 
28/130 
46/662 
48/589 
64/577 
5/84 
3/130 
11/186 
14/525 
48/291 
NR/104 
83/421 
99/1706 
178/1880 
218/1573 
2.73 (0.72, 10.32) 
3.43 (1.62, 7.28) 
2.21 (1.05, 4.62) 
1.08 (0.66, 1.77) 
3.40 (0.94, 12.20) 
1.77 (1.27, 2.47) 
1.09 (0.75, 1.60) 
1.20 (0.85, 1.68) 
0.86 (0.63, 1.17) 
0.80 (0.62, 1.04) 
0.94 (0.80, 1.10) 
0.84 (0.10, 6.80) 
Lower risk CVD   Higher risk CVD  
1 0.1 0.5 1.5 2 5 10 
Author, Ref, Year 
copy 
One 
   (Cases/Total)    
*1 or *17 
RR (95% CI) 
One copy of  
loss of function 
CYP2C19 allele 
vs. none  
Figure 2.10: Meta-analysis of separate effect of one copy or two copies of loss-of-function CYP2C19 alleles (?2 to ?8) compared to normal/increased
function alleles (?1 or ?17) on risk of CVD in treatment-only analysis. Panel A shows effect of one copy loss-of-function allele compared to none; Panel
B illustrates effect of two copies of loss-of-function alleles, compared to none.
Footnote: Fixed-effect meta-analysis model.
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2.4.7 Effect-modification analysis
Genetic studies embedded within randomized trials permitted the evaluation of effect
modification of a genetic variant on treatment response by means of an interaction test.
When I conducted an analysis of effect modification using data from 4 RCTs in which
the comparator was placebo (with more than 1,097 major cardiovascular events in 11,477
subjects), the effect of clopidogrel on major CVD events was not modified by CYP2C19
categories (P for interaction 0.37) (Figure 2.11A). I also found no evidence for a treat-
ment by genotype interaction for major bleeding (P for interaction 0.07; Figure 2.11B).
Values were similar under a random-effects meta-analysis model (Table A.7).
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ACTIVE-A:  Connolly et al,72 2009; Pare et al,35 2010 
original RCT 
genetic substudy 
   *2 or *3 
   *1 or *17 
CURE: Yusuf et al,18 2001; Pare et al,35 2010 
original RCT 
genetic substudy 
   *2 or *3 
   *1 or *17 
CHARISMA: Bhatt et al,19 2006; Bhatt et al,21 2009 
original RCT 
genetic substudy 
   *2 or *3 
   *1 or *17 
CLARITY-TIMI 28: Sabatine et al,71 2005; Mega et al,32 2008 
original RCT 
genetic substudy 
   *2 
   *1 
SUMMARY 
original RCT 
genetic substudy 
   *2 or *3 
   *1 or *17 
Trial name: RCT/PGx 
 Group 
832/3772 
112/560 
29/139 
83/421 
582/6259 
230/2530 
52/650 
178/1880 
534/7802 
153/2428 
54/722 
99/1706 
262/1752 
NR/NR 
NR/NR 
NR/NR 
2210/19585 
>495/>5518 
>135/>1511 
>360/>4007 
    (Cases/Total)     
Clopidogrel 
924/3782 
153/574 
35/139 
118/435 
719/6303 
311/2486 
78/673 
233/1813 
573/7801 
138/2434 
36/708 
102/1726 
377/1739 
NR/NR 
NR/NR 
NR/NR 
2593/19625 
>602/>5494 
>149/>1520 
>453/>3974 
Placebo 
0.89 (0.81, 0.98) 
0.75 (0.61, 0.93) 
0.83 (0.54, 1.28) 
0.73 (0.57, 0.93) 
0.80 (0.72, 0.90) 
0.73 (0.62, 0.85) 
0.69 (0.49, 0.96) 
0.74 (0.61, 0.89) 
0.93 (0.83, 1.05) 
1.11 (0.89, 1.39) 
1.47 (0.98, 2.21) 
0.98 (0.75, 1.28) 
0.69 (0.60, 0.80) 
0.49 (0.28, 0.88) 
0.40 (0.15, 1.10) 
0.55 (0.25, 1.05) 
0.84 (0.79, 0.89) 
0.80 (0.72, 0.89) 
0.87 (0.70, 1.09) 
0.78 (0.69, 0.89) 
Relative 
0.147 
0.612 
0.353 
0.722 
0.169 
0.102 
0.273 
0.611 
0.431 
0.374 
risk (95% CI) 
Lower risk   Higher risk  
1 0.1 0.5 1.5 2 5 10 
Risk of CVD 
251/3772 
32/560 
14/139 
18/421 
231/6259 
102/2530 
21/650 
81/1880 
130/7802 
95/2428 
31/722 
64/1706 
612/17833 
229/5518 
66/1511 
163/4007 
    (Cases/Total)     
Clopidogrel 
162/3782 
23/574 
6/139 
17/435 
169/6303 
75/2486 
15/673 
60/1813 
104/7801 
61/2434 
12/708 
49/1726 
435/17886 
159/5494 
33/1520 
126/3974 
Placebo 
1.55 (1.28, 1.88) 
1.43 (0.85, 2.40) 
2.33 (0.92, 5.90) 
1.09 (0.57, 2.09) 
1.38 (1.13, 1.67) 
1.34 (1.00, 1.79) 
1.45 (0.75, 2.79) 
1.30 (0.94, 1.81) 
1.25 (0.97, 1.61) 
1.56 (1.14, 2.14) 
2.53 (1.31, 4.89) 
1.32 (0.92, 1.91) 
1.41 (1.25, 1.59) 
1.44 (1.18, 1.75) 
1.99 (1.31, 3.02) 
1.28 (1.02, 1.61) 
risk (95% CI) 
Relative 
0.775 
0.869 
0.771 
0.283 
0.090 
0.888 
0.068 
0.189 
Lower risk   Higher risk  
1 0.1 0.5 1.5 2 5 10 
Risk of major bleeding 
CVD Outcome 
Clopidogrel vs. 
placebo 
Major bleeding 
Clopidogrel vs.  
placebo 
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P-value 
(Z test) 
P-value 
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Figure 2.11: Analysis of CYP2C19 genotype on composite cardiovascular end-points in randomized trials where both clopidogrel and placebo arms
were genotyped, “Effect modification” analysis.
Meta-analysis of risk of (A) composite cardiovascular outcome and (B) major bleeding event, comparing clopidogrel to placebo, stratified by: (i) findings from original RCTs;
(ii) genetic substudy, and; CYP2C19* allele status into (iii) any copy of *2 or *3 (iv) *1 or *17. The P value reflects the Z-test for interaction between subgroups, comparing (i)
original RCT and genetic substudy, which assesses the representativeness of the genetic substudy to the original cohort; (ii) *2 or *3 compared to *1 or *17, which tests for effect
modification of the effect of clopidogrel vs. placebo by CYP2C19 genotype. “Summary” represents values pooled by fixed-effects meta-analysis
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2.5 Discussion
A total of 32 studies, including 42,016 individuals and 3,545 cardiovascular events eval-
uated the potential modification of clopidogrel response by CYP2C19 genotype. These
studies encompassed two distinct groups: those in which participants were all treated
with clopidogrel (“treatment only”) and studies set within a randomized trial (“effect
modification” studies).
Evidence derived from “treatment-only” studies indicated that subjects classified as poor
metabolizers (any ?2 to ?8 CYP2C19 allele) when compared to normal/fast metabolizers
(?1 or carriers of the ?17 allele) had, on average, lower levels of the active clopidogrel
metabolites (Figure 2.4), less platelet inhibition (Figure 2.5), lower risk of bleeding
(RR= 0.84; 95%CI: 0.75, 0.94; Figure 2.9), and a higher risk of CVD events (RR= 1.18;
95%CI 1.09, 1.28; Figure 2.6). However, there was evidence of small study and outcome
reporting bias which greatly undermined the validity of the results derived from these
studies. This is supported by the pooled analysis of 4 randomized trials that evaluated
the potential effect modification of CYP2C19 on clopidogrel response and found no
evidence for effect modification on cardiovascular end-points or bleeding (both P-values
for interaction test >0.05; Figure 2.11). Until further evidence is obtained from high-
quality studies (ideally within randomized trials) that overturns existing evidence, the
use of CYP2C19 genotype to guide prescription of clopidogrel should be discouraged.
The studies of CYP2C19 genotype and clopidogrel response are likely to exemplify
several general issues in pharmacogenetic studies serving to highlight important, yet
rectifiable limitations in this field, in particular relating to studies of genetic variants
involved in drug metabolism, such as the CYP-enzymes, which were among the most
common pharmacogenetic studies in my previous field synopsis.[110]
2.5.1 Problems specific to pharmacogenetic studies
In principle, the investigation of drug effect modification by a genetic variant should not
differ from the established approach used for non-genetic variables (such as age, smoking
or gender) and should follow methods established for sub-group analysis in a randomized
trial (the “Preferred-Option” in Figure 2.12).[184] However, due to a combination of
logistic and financial reasons, DNA cannot always be obtained within the setting of
large, multi-center trials. Therefore, research teams aiming to investigate potential
effect modification conferred by genetic variants on drug response typically use a sub-
optimal design (“Default-Option” in Figure 2.12), i.e. observational (prospective cohort
or case-control) studies restricted to subjects receiving the medication of interest - a
treatment-only option. This type of design would be considered invalid for investigating
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the potential for treatment effect modification by a non-genetic variable, but there are
two reasons that support the popularity of this design for pharmacogenetics, a field
where only 5% of studies are set within randomized trials.[110]
The first reason is based on the argument originally described by Motulsky in 1957,[108]
that genetic variation in a drug metabolizing enzyme should have no phenotypic con-
sequence (such as an association with cardiovascular events) in the absence of expo-
sure to a medication (in this case, treatment with clopidogrel). The second reason is
based on Mendel′s second law - the random allocation of genetic variants from par-
ent to offspring, which should mean that groups categorized by genotype for a drug
metabolizing enzyme should not differ systematically except in their response to drug
treatment (Figure A.1).[67] These two implicit assumptions make the “treatment-only”
design an appealing one. I now critically discuss the validity and implications of these
assumptions for the design and interpretation of pharmacogenetic studies that used the
treatment-only design.
2.5.2 Assumptions of the “treatment-only” study design in PGx
Studies using the treatment-only design make the assumption that the signal derived
from the comparison of 2 genotype groups (e.g. in the case of CYP2C19, any ?2 to
?8 vs. ?1 or ?17) indirectly evaluates the effect-modification of CYP2C19 loci on the
clopidogrel-cardiovascular events association. However, this approach in statistical terms
evaluates the CYP2C19 variant as a predictor of a clinical event (like a genetic associa-
tion study) with the feature that all subjects are homogenously exposed to clopidogrel.
Several years of genetic research using the hypothesis-free statistical approach of GWAs
have indicated that the Motulsky assumption[108] may not always be valid or applicable
to all genetic variants within the CYP enzymes. The hepatic CYP450 enzymes form a
family of mixed function oxidases that serve multiple functions including, but extending
beyond, the metabolism of drugs and xenobiotics.[185] Several CYP enzymes contribute
to endogenous steroid hormone and lipid biosynthesis and genetic loci encompassing
drug metabolizing CYP genes have recently been identified by genome wide association
studies as harboring variants conferring susceptibility to CHD (CYP17A1 ),[186] elevated
blood pressure (CYP1A1,[187] CYP1A2 [187] and CYP17A1 [187, 188]), affecting smok-
ing behavior (CYP2A6, CYP2B6 )[189] and altering vitamin D level (CYP2R1 )[190]
(Table A.4), all of which may be risk factors for chronic diseases. A candidate gene analy-
sis has also identified associations of CYP2C19 genotype with inflammation markers[191]
which have been linked to increased cardiovascular risk, but to date there have been no
large-scale genetic studies implicating CYP2C19 as a gene with independent associa-
tions with cardiovascular events. Thus, associations of genetic variants that encode CYP
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Difference in 
drug levels (+) 
Gene  
(CYP2C19) 
Clinical event 
(Increase CV risk) 
Gene 
(PON1) 
Clinical event 
(Increase CV risk) 
Scenario-1: gene effect on outcome only observed when exposed to drug Scenario-2: gene effect on outcome also observed without the drug 
Difference in 
drug levels (+) 
Intervention 
(Clopidogrel 75 mg)   
Genotype-1 
(CYP2C19 *2-carriers) 
Low levels Clopidogrel 
Genotype-2 
(CYP2C19  *1/*17) 
High levels Clopidogrel 
CV events  
rate higher 
CV events  
rate lower 
Random allocation of 
alleles 
Treatment-only analysis 
(More vs. less RCT) 
Default -Option 
Intervention 
(Clopidogrel 75 mg)   
Genotype-1 
(CYP2C19  
*2-carriers) 
Low levels 
Clopidogrel 
Genotype-2 
(CYP2C19   
*1/*17 allele) 
High levels  
Clopidogrel 
CV events  
rate higher 
CV events  
rate lower 
Random allocation of 
alleles 
PGX study within an RCT 
Comparator  
(Placebo)   
Genotype-1 
(CYP2C19  
*2-carriers) 
Additional  
non-drug effect (?) 
Genotype-2 
(CYP2C19   
*1/*17 allele) 
Additional  
non-drug effect  (?) 
CV events  
rate higher  (?) 
CV events  
rate lower (?) 
Random allocation of 
alleles 
Preferred-Option 
Is there RCT data with genetic material available ? 
Yes No 
Additional  
non-drug-effect (+) 
Analytical method:  sub-group analysis of the effect of the 
intervention on clinical pre-specified outcomes according to 
genetic categories.   
Assumptions: no confounding across genetic categories. 
plausible assumption due to Mendel’s second law. 
Limitation: Larger sample-sizes than those needed to detect 
the main drug-effect are needed. Limited DNA within trials. 
Analytical method:  genetic association study limited to drug-users. 
Ideally using only the outcomes for which the intervention is proven 
effective.  
Assumptions: No presence of an “additional to the drug” effect. No 
confounding across genetic categories. plausible assumption due to 
Mendel’s second law. 
Limitation: Larger sample-sizes needed to detect (often) smaller 
effects  than those observed in placebo-active drug trials 
Potential scenarios and options for analysis when conducting PGX studies in drug metabolizing enzymes. 
Figure 2.12: Potential scenarios and options for analysis when conducting pharmacogenetic studies in drug metabolizing enzymes.
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enzyme with disease risk among individuals exposed to a drug may not necessarily be
due to differential drug metabolism.
2.5.3 Scenarios of “treatment-only” studies in pharmacogenetics
To exemplify the assumptions of the treatment-only analysis in more detail, consider
three different scenarios (Figure 2.13):
1. in the first, the gene (e.g. CYP2C19 ) alters drug pharmacokinetics which leads
to different categories of active drug exposure, but has no effect on disease risk in
the absence of drug treatment,
2. in the second example, the gene (e.g. PON1, which was recently reported to influ-
ence CVD risk in clopidogrel treated patients)[153] affects drug pharmacokinetics
but has a potential additional effect on disease risk independent of drug use because
the encoded protein may alter HDL-C function;[192] and
3. in the third, the gene (e.g. APOE )[193] does not alter drug metabolism or action
but is associated with the disease outcome of interest.
In all three scenarios, the genetic variant will be associated with the outcome in a
treatment-only design study, but only in the first case would this be the exclusive result
of modification of a treatment effect.
In the first scenario, a treatment-only analysis may be a useful alternative if access to
genetic information in a randomized trial proves difficult. However, the expected effect
of the genotype on treatment outcome should be proportional to the effect of the genetic
variant on the effective dose of the medication.
In the second and third examples, the assumption of no association of the genetic vari-
ant with a clinical event in non-drug exposed subjects is violated and therefore the
treatment-only analysis in this setting is not a true pharmacogenetic analysis, but rather
a gene-disease association study in a drug exposed group. Therefore, in the latter two
situations, if the investigator is still interested in the potential for these genes to alter
drug response, the effect-modification approach is the optimal study design. In the case
where randomized trial data are not initially available, an alternative strategy could be
to use independent sources of evidence to confirm the lack of association between the
genetic locus of interest and the disease outcome before proceeding to an observational
study in which all individuals are exposed to the medication of interest. Any subsequent
association observed in the treatment-only study should ideally then be verified using
prospectively collected data from a randomized trial.
C
h
a
p
ter
2
.
C
Y
P
2
C
1
9
G
en
o
type,
C
lo
p
id
ogrel
a
n
d
C
a
rd
io
va
scu
la
r
D
isea
se
54
CYP2C19 gene Treatment-only analysis  
 
using end-points of proven 
efficacy for  the medication  
 
 
Result: increase in risk ( G+ vs. G-)  
 
Interpretation: the high-risk observed is due (& 
proportional)  to differences in drug-levels accounted by 
the gene-variant. The magnitude of the effect is almost 
always lower than that observed by placebo-active drug 
trials.  
 
APOE gene 
Scenario-1: Genes  in metabolizing enzymes without additional non-drug effect 
Scenario-3: Genes  associated with clinical events 
G -  
G +  
Levels of active drug  
Treatment-only analysis  
 
using end-points of proven 
efficacy for  the medication  
 
 
Result: increase in risk ( G+ vs. G-)  
 
Interpretation: the observed higher risk is due (& proportional)  
to differences in the trait (LDL-cholesterol) but not to difference 
in drug-levels. 
G -  
G +  
Levels of active drug  
Difference in levels (positive) 
Difference in levels (absent) 
PON1 gene 
Treatment-only analysis  
 
using end-points of proven 
efficacy for  the medication  
 
 
Result: increase in risk ( G+ vs. G-)  
 
Interpretation: the high-risk observed could be 
accounted by difference in drug-levels plus the non-drug 
effect. The magnitude of the effect could be larger than 
that observed by placebo-active drug trials.  
Scenario-3: Genes  in metabolizing enzymes with additional non-drug effect 
G -  
G +  
Additional non-drug effect 
(e.g. Difference in CV trait) 
G -  
G +  
Levels of active drug  
Difference in levels (present) 
Potential scenarios and its interpretation when conducting pharmacogenetic studies in “treatment-only” individuals  
Figure 2.13: Potential scenarios and implications for interpretation when conducting pharmacogenetic studies using the “treatment-only” design.
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2.5.4 Implausible effect sizes
A less familiar limitation of the treatment-only design relates to the often implausibly
large effects reported by this type of study, in particular when the genetic-variant af-
fects the metabolism of a medication (which makes a treatment-only study similar to a
randomized trial of more-versus-less intense dose of medication). As with randomized
trials of more-versus-less intensive drug therapy, the expected effect in pharmacogenetic
studies evaluating genetic variation on metabolizing enzymes will depend on the differ-
ence in concentration of the active medication in the different genotype categories for a
given administered dose, and on the position on the dose-response curve (Figure A.5).
Mechanistic studies show that the difference in the active form of clopidogrel conferred
by the CYP2C19 genotype, at both 75mg and 600mg was small-to-moderate, with a
large overlap of the distributions of AUC of the active metabolite (Figure 2.4). The
influence of CYP2C19 loci on the active form of clopidogrel can yield differing effects
on clinical outcomes depending on the location of the administered dose on the dose-
response curve (Figure A.5, scenario 1), with a larger effect if the dose under evaluation
(e.g. 75 mg of clopidogrel) is located on the linear part of the curve and substantially
smaller if it is on the plateau part of the curve (Figure A.5, scenario 2).
Although it is difficult to know with certainty on which part of the dose-response func-
tion clopidogrel is located, and indeed the gradient of the linear component of the dose-
response curve, it is perhaps safe to assume, based on the modest effect of the CYP2C19
genotype on enzyme activity, that the relative difference in risk of CVD events between
genotype categories in a treatment-only design study should be smaller than the overall
relative difference in CVD risk in placebo-controlled trials of 75mg clopidogrel, which is
12% (95%CI: 7%, 17%).[125]
If it is assumed that the association of the concentration of the active metabolite of
clopidogrel with CVD events follows a log-linear relationship, the expected effect for
fast metabolizers when compared with poor metabolizers (analogous to a RCT com-
parison of more versus less clopidogrel) will produce a relative risk of 0.95 (obtained
by raising the overall estimate of clopidogrel vs. placebo (OR 0.88) to the power of
the fractional difference in CYP2C19 (0.14/0.35) i.e. 0.88(0.14/0.35)=0.95 (Figure A.5,
scenario 1), or even lower if the dose (75mg/day) lies on the dose-response plateau (Fig-
ure A.5, scenario 2). This expected effect estimate is closer to null than the summary
effect estimate from treatment-only studies reported at the time of the FDA approval
(RR 0.82; 95%CI 0.72, 0.93; Figure 2.7), and even the most up-to-date summary effect
estimate (RR: 0.87, 95%CI 0.80, 0.95). In summary, the reported effect of CYP2C19
genotype on CVD risk among clopidogrel treated patients is implausibly large.
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Two further pieces of evidence support the conclusion that the effect estimate for
treatment-only studies should be smaller than that observed in placebo trials of clopido-
grel. Firstly, genetic studies have demonstrated that variants at the CYP2C19 locus only
explain 12% of the variance in clopidogrel response.[140] Secondly, my meta-analysis of
randomized trials investigating the effect of more versus less intensive clopidogrel ther-
apy, with a much greater difference in active form of clopidogrel than those differences
conferred by CYP2C19 loci, [194–200] has shown, at most, a small reduction in the risk
of major CVD events (RR of 0.90; 95%CI 0.80, 1.00; Figure 2.14). However this value
is likely to be an overestimate, since I identified evidence of small-study bias (P-value
Harbord test= 0.045).
The most likely explanation for the discrepancy between earlier estimates from pharma-
cogenetic studies using the treatment-only design and that expected based on the effect
of the CYP2C19 genotype on the level of the active clopidogrel metabolite is small-study
bias; by the time of FDA approval of the boxed warning, only one study had more than
200 CVD events (Figure 2.7). The estimate of treatment-only studies after considering
the potential impact of small-study bias provided a closer estimate (RR of 0.92 using
trim and fill) to the one predicted (RR of 0.95). However, this should be considered an
estimate, since methods for small-study bias correction can only approximate the true
unbiased effect, and therefore the most credible conclusion is of no effect modification of
the CYP2C19 on clopidogrel response (as observed on restriction to large treatment-only
studies ≥200 CVD events and on subgroup analysis of effect modification studies).
2.5.5 Separating mechanism-based intended effects from adverse ef-
fects
Irrespective of the precise magnitude of effect modification, where the major harms of
a drug are mechanism based (as is the case for clopidogrel), any attempt to individu-
alize dose according to genotype to reduce the risk of poor treatment response (i.e. an
increased CVD risk) is likely to be offset by an opposing effect on the rate of harm (i.e.
bleeding) (Figure A.1). The net benefit of genotyping to adjust dose may therefore not
be as great as initially anticipated. In the case where genetic variants under investi-
gation lie in drug metabolizing enzymes, the interaction will likely be quantitative (i.e.
differences in degree) rather than qualitative (differences in kind),[184] thus even if a
real difference between subgroups is detected, cost-effectiveness analyses would be the
decisive test of clinical utility.
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Small study bias P=0.045 (Harbord) 
Overall  (I-squared = 50.3%, p = 0.060) 
Study 
Mehta (1079/25086) 
Patti (21/255) 
Fernandez (22/400) 
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Yong (33/256) 
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600/75 vs 300/75 
600/75 vs 300/75 
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Dose Clopidogrel  
(mg/day) 
600/150 vs 300/75 
600/0 vs 300/0 
600/75 vs 300/75 
600/75 vs 300/75 
0.90 (0.80, 1.00) 
0.94 (0.84, 1.06) 
0.32 (0.12, 0.85) 
0.83 (0.37, 1.88) 
RR (95% CI) 
0.44 (0.19, 1.02) 
1.00 (0.53, 1.89) 
0.51 (0.10, 2.63) 
0.39 (0.17, 0.90) 
higher clopidogrel 
 better   
lower clopidogrel 
 better  
1 0.5 0.8 2 3 
Overall  (I-squared = 0.0%, p = 0.673) 
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1.23 (1.05, 1.45) 
1.23 (1.05, 1.45) 
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2.00 (0.61, 6.54) 
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outcomes 
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A B 
Figure 2.14: Meta-analysis of randomized trials of more-vs-less clopidogrel.
Trials compared 600mg vs 300mg loading dose of clopidogrel.
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2.5.6 Limitations of the star allele nomenclature
Of the catalogued variant alleles in CYP2C19,[201] one or more of nine reduced activity
alleles (?2, ?3, ?4, ?5, ?6, ?7, ?8, ?9, ?10), and one increased activity allele (?17) was
genotyped in the 32 studies of clopidogrel response (Table 2.1). However, the amount
of evidence available for each allele differed substantially (Table 2.1). Most studies
grouped all patients with presumed low enzyme activity alleles (?2 to ?8) into a single
category, which assumes the degree of functional impairment is similar, or into predicted
metabolizer phenotypes (e.g. poor, intermediate, extensive). If a ? allele was not typed
at all, the participant was presumed to lack the variant allele in that position. Thus
many patients in the ?1 category (used to denote an individual lacking all alternative
alleles) may have been misclassified. Collectively, these limitations could lead to gene
misclassification (a form of measurement error in the exposure), which may result in
bias.[202] These limitations could easily be rectified through use of the NCBI Reference
Sequences system(RefSeq)[203] to catalogue genetic variants, which is used in all other
contexts.
2.5.7 Problems recognized in other fields
Some of the problems unveiled in this appraisal, for example those relating to study de-
sign, are specific to pharmacogenetic studies. Other problems, for example small study-
bias, are well recognized in other areas of epidemiological research,[204, 205] which are
particularly concerning because pharmacogenetics is perceived as a field where advances
in genomic medicine could have their earliest translational applications.
2.5.8 Placing these findings into context
The findings I report in this chapter are in stark contrast to three previous reviews,[206–
208], but concordant with one appraisal that was published in most recent proximity
to this work.[209] Although one of the original systematic reviews of CYP2C19 and
clopidogrel did find evidence of small study bias,[206] this was not examined in detail,
or given due prominence in the article.
Perhaps the most important prior meta-analysis is that of individual participant data,[207]
however, the authors limited the analysis to individuals predominantly receiving percu-
taneous intervention therapy for ACS.
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It is interesting to note that the association of CYP2C19 loci with clopidogrel response
identified from GWAs did not replicate in this analysis for CVD events. Rs1277823 (in
LD with the SNP that characterizes CYP2C19 *2, rs4244285 at R2=0.87) was identified
as a GWAs locus for clopidogrel response.[140] I replicated this association in meta-
analysis of four studies that investigated the association of CYP2C19 with platelet
function (Figure 2.5). However, despite this replication of platelet function, no associa-
tion between CYP2C19 LoF was identified on treatment-only (limited to large studies),
or effect modification analysis where the outcome was CVD events. This discrepancy
could be explained by platelet function (detected using currently-available assays) not
impacting upon cardiovascular events, a hypothesis supported by three recent random-
ized trails. The GRAVITAS[210], TRIGGER-PCI[211] and ARCTIC[212] randomized
trials all failed to identify evidence that acting upon platelet function tests (e.g. through
randomized allocation to higher dosing or alternative antiplatelet therapy) altered risk of
CVD, casting into doubt whether platelet function is causally linked to CHD risk. Taken
together, this suggests that although CYP2C19 LoF alleles may associate with platelet
reactivity following clopidogrel loci, this does not translate into a clinically-meaningful
difference in risk of CHD.
Given the high-profile nature of this pharmacogenetic variant, when this analysis was
published,[213] it drew high attention from the media, including reports on the television
news-channel CNN[214] and popular cardiovascular newsletters including theheart.org[215]
and a blog on Nature website.[216]
This analysis and interpretation have been criticized by several papers,[217–221] and
high-profile cardiologists claimed the article was ‘remarkably misleading’[222] and ‘set
the field potentially back a bit’[216].
Critics made the following claims:[223, 224]
 that the omission of studies that only reported stent thrombosis from the composite
outcome meant we omitted relevant data
 that we included outcomes for which clopidogrel has no evidence of being efficacious
(e.g. stroke)
 that the apparent presence of small study bias was due to presence of larger studies
being set in patients with stable CHD (for which no evidence exists for clopidogrel),
rather than true publication bias
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In response[225], the summary estimate was not altered by including the three studies
that only reported stent thrombosis (yielding a summary effect estimate of RR 1.21, 95%
CI: 1.12, 1.30 for CVD events), and the evidence for small study bias persisted (P<0.01
for Harbord test of small-study effects). Second, we argued that the outcomes included
in the analysis were appropriate since clopidogrel has been shown to be beneficial to
patients with a mixture of stable and unstable CHD,[125] and furthermore, evidence
from the ACTIVE-A trial[226] validates the use of clopidogrel to prevent CVD events
in patients with atrial fibrillation.
Finally, I responded to the criticism that the small study bias was an artefact gener-
ated by larger studies being set in patients without ACS by stratifying the analysis
of CYP2C19 on the CVD event composite by the proportion of individuals with PCI
and/or stent insertion at baseline (Figure 2.15), and also by CHD status at baseline
(Figure A.3). Neither of these analyses showed evidence of heterogeneity between the
strata in each of the subgroups, making this an unlikely explanation.
mellitus are associated with lower inhibition of platelet reactivity with clopidogrel.
J Am Coll Cardiol. 2008;52(13):1052-1059.
5. Nissen SE. Pharmacogenomics and clopidogrel: irrational exuberance? JAMA.
2011;306(24):2727-2728.
In Reply: We considered all included trials to be within
the remit of our systematic review, including those
involving patients receiving clopidogrel for indications
other than PCI.1-3 However, based on the letters from Dr
Shuldiner and Dr Mega and their colleagues, we excluded
these studies, which yielded a summary relative risk (RR)
of 1.22 (95% CI, 1.11-1.33) for the association of
CYP2C19 genotype with cardiovascular disease (CVD)
events. The addition of the 3 studies alluded to by Mega
et al, excluded by us because they focused solely on stent
thrombosis, yielded a summary RR of 1.21 (95% CI,
1.12-1.30) for CVD events. These modest effect estimates
also remain affected by small-study bias.
Absence of heterogeneity in the RRwhen stratified by PCI
or stent insertions (FIGURE) argues against inclusion of stud-
ies with low rates of PCI weakening the overall associa-
tion, as the writers suggest. This is supported by analysis of
the CURE trial results when restricted to individuals re-
ceiving PCI and stent insertion, which showed no evi-
dence for a genotype by treatment interaction on risk of CVD
events.4
Several pieces of evidence challenge the emphasis placed
on stent thrombosis as an outcome by Mega et al. These
i clude (1) the smalle association of CYP2C19 with stent
thrombosis in larger studies (Figure 4 in article); (2) an
attenuation in effect with accumulating data from a RR of
3.35 (95% CI, 2.12-5.27) when the FDA issued the boxed
warning to the present RR of 1.75 (95% CI,1.50-2.03)
(Figure 4 in article); and (3) the absence of a genotype by
treatment interaction on stent thrombosis in trial data
from PLATO.5
Mega et al challenge our conclusions, but thesewere based
on the totality of evidence and we caution against focusing
on a selected subgroup of outcomes, particularly when there
is evidence of selective outcome reporting (eTable 2B) and
small-study bias. Furthermore, the 4 trials that evaluated
the genotype by treatment interaction on CVD events re-
ported a null effect (Figure 5 in article).
Shuldiner et al question the grouping of heterozygous and
homozygous individuals; however, this is consistent with
several previous meta-analyses. Furthermore, only 11 of 32
studies provided data for individuals with 2 loss-of-
function alleles. Among these studies (eFigure 3), effectswere
again larger in the smaller studies.
We agreewith Shuldiner et al that our findings differ from
prior meta-analyses (except Bauer et al6), but ours in-
cludedmore studies and compared findings from treatment-
only and effect-modification analyses. Overreliance on sur-
rogate outcomes (such as pharmacokinetic data) can be
misleading,making analysis of clinical events important.Mul-
tiple genetic and nongenetic influences on clopidogrel re-
sponse xist, as Dr Siasos and colleagu s indicate, al-
though these should be distributed evenly amongCYP2C19
genotype groups.
A systematic review has the remit of investigating sources
of bias that may undermine the overall validity. In the case
ofCYP2C19 g notype, clopidogrel and CVD events (includ-
ing stent thrombosis), small-study and outcome reporting
bias together with assumptions in study design cast seri-
ous doubt on the clinical utility of CYP2C19 genotype test-
ing to guide antiplatelet prescribing.
Michael V. Holmes, MBBS, MSc
Aroon D. Hingorani, FRCP, PhD
Juan P. Casas, MD, PhD
Author Affiliations:Department of Epidemiology and Public Health, University Col-
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Figure.Meta-analysis of Studies Evaluating the Effect of CYP2C19 *2 to *8 vs *1 or *17 on Cardiovascular Disease (CVD) Events
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101.00.1
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Stratification
No. of Cases/Total No.
∗2 to ∗8 ∗1 or ∗17
No. of
Studies
I2
(95% CI), %
Relative Risk
(95% CI)
P for
Meta-regression
PCI at recruitment, %
≤99 373/3376 832/85468 61 (17-82)1.15 (1.03-1.29)
100 269/3378 503/656016 59 (28-77)1.31 (1.14-1.50)
74/758 226/2171Not reported 2 46 (NA) a0.95 (0.74-1.21)
.47
Stent insertion at recruitment, %
≤71 262/2465 536/60847 58 (0-83)1.22 (1.07-1.40)
91-100 273/3295 556/700812 58 (20-77)1.27 (1.11-1.45)
181/1752 469/4185Not reported 7 63 (12-85)0.99 (0.84-1.17)
.24
Data are stratified by the proportion of participants receiving percutaneous coronary intervention (PCI) or stent insertion (fixed effects modeling). The meta-regression
was adjusted for study design and sample size. Error bars indicate 95% confidence intervals.
aUnable to estimate the 95% confidence interval because only 2 studies contributed to the overall estimate.
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Figure 2.15: Meta-analysis of Studies Evaluating the Effect of CYP2C19 ?2 to ?8 vs ?1
or ?17 on Cardiovascular Disease (CVD) Ev nts.
Data were stratified by the proportion of participants receiving percutaneous coronary interven-
tion (PCI) or stent insertion (fixed effects modeling). The meta-regression was adjusted for study
design and sample size. Error bars indicate 95% confidence intervals.
aUnable to estimate the 95% confidence interval because only 2 studies contributed to the overall
estimate.
2.6 Conclusions
In conclusion, I identified several features that cast into doubt the association between
CYP2C19 genotype and clopidogrel response. Based on these findings, there is no
evidence to support the use of CYP2C19 genotyping in clinical practice to adjust clopi-
dogrel dose or to inform the choice of anti-platelet agent. These problems are unlikely
to be exclusive to this particular example of pharmacogenetic research, and as a general
rule, pharmacogenetic studies should fully exploit randomized trials to harness robust
information on gene-drug interactions. To aid this, pharmaceutical companies ought to
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make drug pharmacokinetics and dose-response data available to help researchers pri-
oritise meaningful drug-gene combinations. As funding to support this type of research
increases (both UK Medical Research Council and US National Institutes for Health
have prioritized this area), so capacity should be built to aid the robust design, conduct,
analysis and reporting of pharmacogenetic studies.
Chapter 3
Secretary Phospholipase A2 and
Cardiovascular Disease:
Background
3.1 Introduction
3.1.1 Atherosclerosis as the substrate of Coronary Heart Disease
Atherosclerosis is an asymmetrical focal thickening of the inner-most layer of the arte-
rial wall (the tunica intima). The disease process is progressive and when the thickening
becomes sufficient that blood flow is occluded through the coronary artery (usually
precipitated by plaque rupture and subsequent coronary thrombus formation), the my-
ocardium becomes deprived of oxygen, resulting in myocardial infarction.[227]
The atherosclerotic plaque itself is composed of a necrotic core, consisting of lipids,
cellular debris and foam cells (macrophages that have engulfed lipid particles). The
necrotic core is surrounded by smooth muscle cells and collagen that creates a cap.
Inflammatory cells (consisting of T cells, macrophages and mast cells) infiltrate the
area, especially in the region where the atheromatous plaque expands, the so-called
‘shoulder’ (Figure 3.1).
3.1.1.1 Lipid theory of atherosclerosis
Elevated levels of circulating LDL-C results in activation of arterial endothelial cells and
LDL-C infiltration and retention in the tunica intima. The modification of LDL-C in
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Figure 3.1: Anatomy of an atherosclerotic plaque.
The grey shaded area represents the necrotic core (containing lipids and cellular debris), surrounded by a
fibrous cap of smooth muscle cells and collagen. Infiltrating the lesion are inflammatory cells, particularly
abundant at the shoulder region. Derived from Hansson and Libby.[228]
the tunica intima encourages endothelial cells to express receptors that further encour-
ages migration and influx of inflammatory cells. This results in migration of circulating
monocytes into the tunica intima where they become macrophages and phagocytose the
modified LDL-C through the macrophage scavenger receptor resulting in the foam cell,
a hallmark feature of the atherosclerotic plaque.[228, 229]
3.1.1.2 Inflammation theory of atherosclerosis
Inflammation has been proposed to play a central role in all stages of the atherosclerotic
process.[230, 231] For example, the precursor of the atheromatous plaque is the fatty
streak, which is an asymptomatic lesion that can be found in children as young as 3 years
of age.[232] Fatty streaks consist predominantly of the inflammatory cells macrophages
and T-cells.
Furthermore, inflammatory cells, including macrophage-derived foam cells and T-cells,
make a substantial component of cells in the advanced atherosclerotic lesion, (Fig-
ure 3.2).
Various sources of evidence provide further support that inflammation is an important
determinant of heart disease:
 Chronic systemic inflammation as a stimulus for atherosclerosis: autoimmune dis-
eases such as rheumatoid arthritis, in which there is a chronic inflammatory state,
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Figure 3.2: Schemata to show the central role of inflammation in the initiation and pro-
gression of an atherosclerotic plaque.
Abbreviations for inflammatory cytokines: M-CSF: macrophage colony-stimulating factor; MCP-
1:monocyte chemotactic protein 1; MMP: metalloproteinase; PAI-1, plasminogen activator inhibitor 1;
PDGF, platelet-derived growth factor; TF tissue factor; UPA urokinase plasminogen activator. Derived
from Badimon et al.[233]
are associated with higher risk of coronary heart disease due to accelerated coro-
nary atherosclerosis.[234, 235]
 Acute systematic inflammation as a trigger for acute vascular events: Emerging
evidence supports the hypothesis that an acute inflammatory insult arising from
e.g. periodontitis[236] or influenza[237], may increase the risk of coronary heart
disease.[238] Furthermore, there is weak evidence from randomized trials that in-
fluenza vaccination may protect against cardiovascular disease.[239]
3.1.2 Inflammation and Coronary Heart Disease
This model suggests that inflammatory cytokines play a key role in the initiation and
progression of atherosclerosis (Figure 3.2).[229] Thus, an appealing means to halt the
disease process of atherosclerosis may be to inhibit inflammatory pathways.[231] Much
research activity has therefore focussed[240] on delineating the role of candidate inflam-
matory biomarkers in CHD (see Box 3.1 on page 65 for two contrasting examples of
inflammation biomarkers and their potential role in CHD).
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Box 3.1: Candidate inflammation biomarkers
C-reactive protein Despite compelling observational evidence on the
association between C-reactive protein (CRP) and cardiovascular events,[241]
a RCT of a therapy that specifically modulates CRP has not been conducted
(due to lack of a specific orally-available drug). Mendelian randomization
studies have repeatedly shown that the association between CRP and
cardiovascular events, rather than being causal, is likely to arise from
reverse causality or confounding.[62] This serves as an important example
to the issues of causality discussed in Chapter 1 (association does not
equate causation) and to make causal inference, study designs in which
randomization is employed to remove confounding is a necessary requirement
to be certain of a causal relationship (as no other study design can mitigate
this source of error).
Interleukin-6 Interleukin 6 (IL-6) represents another candidate biomarker.
IL-6 is secreted by T cells and macrophages[242] and observational investi-
gations provide strong evidence of a monotonic dose-response relationship
between circulating IL-6 levels and risk of CHD.[243] No clinical trial has
been conducted with a drug that modulates IL-6 levels (or inhibits its recep-
tor) to investigate the role of IL-6 in CVD. A recent large-scale Mendelian
randomization study showed that individuals that harbour a genetic variant
that alters the ability of IL-6 to bind to its target receptor, the IL-6 receptor
(encoded for by the IL6R gene), have an altered risk of CVD.[83] Although
this does not directly implicate IL-6 per se in CVD, by extension a causal
role of IL-6 can be extrapolated (assuming specificity of both IL-6 to the
IL-6 receptor and vice-versa).
3.1.3 The interface between lipids and inflammation
Inflammation is the process by which tissues become swollen and irritated in response
to endogenous (e.g. autoimmune disease) or exogenous (e.g. trauma, foreign body,
infection) stimuli. Inflammation is characterised by five cardinal signs (rubor - redness,
calor - heat, tumor - swelling, dolor - pain, and functio laesa - loss of function). Whether
an inflammatory process persists or not is thought to be determined by the interplay of
several cytokines,[244] and the transition from acute to chronic inflammation is regulated
by several factors. Two of these regulatory mediators are thought to be prostaglandins
and leukotrienes.[245] This is of importance as the inflammation in cardiovascular disease
is typified by a chronic disease process (Figure 3.2).[231]
Prostaglandins and leukotrienes have been described as lipid mediators, with potent
pro-inflammatory functions.[246, 247]. They have wide-reaching effects on other cells,
which ultimately leads to the propagation of the inflammatory cascade.[245]
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Prostaglandins and leukotrienes are metabolites derived from arachidonic acida (through
the actions of cyclo-oxygenase and 5-lipoxygenase enzymes, respectively). The rate-
limiting step for the liberation of arachidonic acid from the bilipid layer is phospholipase
enzymes[248] (Figure 3.3). 	  	  	  	  Permissions	  not	  obtained	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Figure 3.3: Synthesis of inflammatory cytokines from arachidonic acid.
Footnotes: COX: cyclo-oxygenase; 15-HPETE: 15-hydroperoxyeicosatetraenoic acid; 5-HPETE; 5-
hydroperoxyeicosatetraenoic acid; LP: lipoxins; LT: leukotrienes; PG; prostaglandins
Derived from Ogawa et al.[249])
3.1.4 Phospholipase enzymes
Phospholipase enzymes are a family of enzymes that share the common function of
hydrolyzing phospholipids into fatty acids and other lipophilic substrates.[248] There
are four main classes of phospholipase enzymes (A, B, C and D), labelled according to
their catalytic function (Figure 3.4). 	  	  	  	  Permissions	  not	  obtained	  for	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Figure 3.4: Catalytic activity of phospholipase enzymes on phospholipids.
Phospholipase A1 and A2 cleave the sn-1 and sn-2 bonds, respectively; B can cleave either one of the sn-
1 or sn-2 bonds; C cleaves the phosphoryl ester at C3 of glycerol; D cleaves phosphodiester bond of the
glycerolipid phosphatidylcholine. R1 and R2 represent carbon chains of fatty acids.
aarachidonic acid is derived from the cell membrane phospholipids through the action of phospholipase
A2 enzymes
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 Phospholipase A: (A1 and A2) - cleaves the sn bond; A1 and A2 subtypes cleave
the sn-1 or sn-2 bond, respectively. Cleavage of the sn-2 bond by PL-A2 releases
arachidonic acid
 Phospholipase B: (also known as lysophospholipase) cleaves the acyl chains from
both sn-1 and sn-2 positions of a phospholipid
 Phospholipase C: cleaves the phospholipid phosphatidylinositol bisphosphate (PIP2)
into diacyl glycerol (DAG) and inositol triphosphate (IP3). IP3 release results in
increased intracellular calcium[250], which together with DAG activates protein
kinase C, altering cellular activity.
 Phospholipase D: yields phosphatidic acid and free choline from the hydrolysis
of the phosphodiester bond of the glycerolipid phosphatidylcholine. Phosphaditic
acid is a bioactive lipid and can be converted into diacylgycerol and lysophospha-
tidic acid. These metabolites are considered important for movement of vesicles,
endocytosis and receptor signalling in humans.[251, 252]
3.1.5 Phospholipase A2 enzymes
Phospholipases A2 (PLA2) are a diverse family of enzymes present in most types of
cells.[248] The PLA2 enzymes are involved in a wide range of cellular processes including
lipid metabolism, host defence, cell membrane homeostasis and signal transduction.[253,
254] The PLA2s share a common catalytic function: the hydrolysis of the bond between
the sn-2 fatty acyl bond of phospholipids present in lipoproteins and cell membranes, re-
leasing arachidonic acid and lysophospholipids (Figure 3.4). As discussed above, arachi-
donic acid is subsequently metabolised by cyclooxygenase and lipoxygenase to yield the
eicosanoids prostaglandins, leukotrienes and thromboxane A2 (Figure 3.3), important
mediators of inflammation.
Phospholipases A2 can be further classified as secretory, cytosolic and lipoprotein-
associated:
secretory phospholipases A2 (sPLA2) are extracellular, acute phase reactants that
are suggested to be pro-atherogenic.[255–257] Eleven sPLA2 isoforms have been
identified in mammals (IB, IIA, IIC, IID, IIE, IIF, III, V, X and XIIA and
XIIB).[258] sPLA2 is thought to modify LDL-C particles in the circulation and ar-
terial wall, producing pro-inflammatory lysophospholipids and non-esterified free
fatty acids. This effect potentially increases aggregation of LDL-C onto ves-
sel wall proteoglycans, promoting foam cell formation and the development of
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atherosclerosis. sPLA2-IIA is thought to be the most highly expressed of the
sPLA2 enzymes[259] and its mass can be quantified specifically in plasma by
ELISA.[260] In contrast, no specific assay exists to quantify the mass of other
sPLA2 isoforms. However, an assay exists for ‘sPLA2 enzyme activity’
b, which
has been reported[259] to represent a composite of sPLA2-IIA, V and X isoforms
(see Figure 3.5 for more information).
cytosolic phospholipase A2 (cPLA2) is intracellular and expressed in macrophages,
platelets, neutrophils, and fibroblasts. cPLA2 has a molecular mass of 85 kD,[261]
has selective activity for the hydrolysis of arachidonyl phospholipids in the sn-2
position, releasing arachidonic acid. cPLA2 is primarily thought to be involved in
cell signalling[262]
lipoprotein-associated phospholipase A2 (Lp-PLA2) is synthesized in macrophages
and activated platelets. Lp-PLA2 circulates bound to LDL-C and is expressed
in atherosclerotic plaques.[263, 264] Observational analyses reveal strong associa-
tions between circulating Lp-PLA2 and CHD, ischaemic stroke, vascular and non-
vascular death.[265] Lp-PLA2 therefore represents a potential therapeutic target
for CVD prevention, and darapladib [266], an Lp-PLA2 inhibitor is currently in
phase III clinical trials (SOLID-TIMI 52[267]: 13,000 patients with ACS with a
primary end-point of CV death, nonfatal MI or nonfatal stroke; STABILITY[268]:
16,000 patients with stable CHD followed-up for a primary outcome of major ad-
verse cardiovascular event). Of note, a previous Mendelian randomization study
using a SNP in the PLA2G7 gene identified no association between Lp-PLA2 and
CHD[269], and the results of these two clinical trials are eagerly awaited.[270]
3.1.6 Secretory phospholipase A2-IIA
The sPLA2-IIA isoform is ubiquitous in the human body, including neutrophils and
macrophages (where sPLA2 are stored in secretory granules), in tissues including spleen,
bone marrow, body fluids and in tears.[274] sPLA2-IIA is a disulfide-rich, stable enzyme
with a molecular weight of approximately 16kDa.[254]. The positively charged regions
of sPLA2-IIA are thought to enable interaction with glycosaminoglycans on cell mem-
branes.
bThe sPLA2 enzyme activity assay is based on the decay of a substrate (1,2-dithio analog of dihep-
tanoyl phosphatidylcholine). When the hydrolysis of the substrate at the sn-2 position occurs, free thiols
are produced, which is detected using Ellman’s reagent(5,5-Dithiobis(2-nitrobenzoic acid)).
Derived from sPLA2 assay kit, Cayman chemical
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Figure 3.5: Comparison of two measures to quantify circulating sPLA2. sPLA2 en-
zyme activity (measured by selective fluorometric assay[271, 272]) comprises measures
of sPLA2-IIA, sPLA2-V and sPLA2-X, whereas sPLA2-IIA mass can be specifically quan-
tified using an enzyme-linked immunosorbent assay [273].
sPLA2-IIA is an acute phase reactant.[275, 276] In healthy individuals, serum concentra-
tions of sPLA2-IIA are low, and can increase several-fold in response to an inflammatory
stimulus, such as myocardial infarction (Figure 3.6).
3.1.7 Divergent roles of sPLA2-IIA
The roles of sPLA2 have been investigated in a wide range of diseases, including cardiovascular,[278]
neurodegenerative[279], infectious[280] (including septic shock[281]) respiratory,[282] neoplastic[283,
284], inflammatory and autoimmune diseases (such as pancreatitis, rheumatoid arthri-
tis and inflammatory bowel disease).[285–288] For these diseases, with the exception of
infection and neoplasia, higher levels of sPLA2-IIA tend to show association with an
increase in disease severity.
In contrast, sPLA2-IIA has been characterised as showing bactericidal effects, with
higher levels being protective against infection.[289–292] This potentially brings into
question the suitability of inhibiting sPLA2-IIA as a therapeutic goal for cardiovascular
disease prevention.[293]
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Figure 3.6: Change in sPLA2-IIA mass during acute coronary syndrome. The increase
in sPLA2-IIA mass is more pronounced in acute myocardial infarction (AMI) than in
unstable angina. Point estimates represent the median and whiskers denote the inter-
quartile range (IQR). Figure created from data reported in Nijmeijer et al [277]
The role of sPLA2 in tumorigenesis is less clearly defined. sPLA2 levels are elevated in
neoplastic tissue (including gastrointestinal, colorectal, prostate and lung tumours)[294–
298]. However, small-scale evidence from human cancer tissue does not show evidence
that PLA2G2A (the gene encoding sPLA2-IIA) is altered in tumour cells.[283]
The disparate evidence on the potentially protective role of sPLA2 in infection and
harmful effect of sPLA2 in CVD is worthy of further discussion. Although the focus
on my investigation for this thesis is the role of sPLA2 in cardiovascular disease (thus
the remainder of this, and the following two chapters that report findings from my
investigative work will be focussed on sPLA2 and cardiovascular traits and events), it is
important to mention that if a causal association were to be identified between sPLA2
and CVD, meaning that inhibition could be of vascular benefit, any protective effect
would need to be considered in light of the potential for harm, if individuals treated
with an sPLA2 inhibitor would be at increased risk of infection.[299] The balancing
of benefits vs. harms is not unique to this candidate drug for cardiovascular disease
prevention, but also exists for some of the most widely drugs available, including aspirin
(in which bleeding is a considerable cause of morbidity and mortality)[300] and the lipid-
lowering HMG-coA reductase inhibitors (more commonly known as statins, which are
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associated with myalgia and an increased risk of type 2 diabetes).[301]
3.1.8 Biological plausibility of sPLA2-IIA in atherosclerosis
In addition to the liberation of arachidonic acid from cell membrane phospholipids
(yielding pro-inflammatory metabolites that propagate atherosclerosis, as outlined in
Figure 3.2)[302], there are several specific mechanisms by which sPLA2 isoenzymes are
considered to be pro-atherogenic (Figure 3.7). These include:
 activation of endothelial cells, which may contribute to ‘endothelial dysfunction’[303],
increases adhesion molecules such as ICAM (intercellular adhesion molecule 1) and
VCAM (vascular cell adhesion molecule),[304] increasing leukocyte migration from
the blood lumen into the tunica intima[305], a characteristic of atherosclerotic
plaques, as shown in Figure 3.2
 oxidation of LDL-C, which is both directly chemotactic to monocytes and stimu-
lates the release of monocyte chemoattractant protein-1 (MCP-1) from endothelial
cells (attracting monocytes into the arterial lesion where they differentiate into
macrophages)[306]. Oxidized LDL-C also binds to non-proteoglycan components
of the matrix in the atherosclerotic lesion[307]
 modifying circulating LDL to increase the negative charge of LDL particles, making
them more pro-atherogenic
 hydrolysis of LDL phospholipid, yielding small, dense LDL-C, a lipid fraction
considered to be highly atherogenic[308]
 activating a site on LDL (resulting in a conformational change in apoB100) that
makes it more likely to bind to glycosaminoglycans in the proteoglycan matrix
located in the tunica intima[309]
3.1.9 Experimental association of sPLA2 with CHD in animal studies
Animal experiments have been used to investigate the relationship between sPLA2-IIA
with lipid markers and development of atherosclerosis. Transgenic mice that express
human sPLA2-IIA to levels similar to those observed in the acute phase response in
humans have lower levels of HDL-C (due to increased catabolism of HDL sub-particles)
and increased levels of triglycerides.[310] Thus an increase in sPLA2-IIA associates with
a reduction in HDL-C and an increase in triglycerides, a lipid profile consistent with
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Figure 3.7: Model of propagation of atherosclerosis by sPLA2.
sPLA2 is present circulating in the blood and in tissues. In the tunica intima, sPLA2 is thought to
modify LDL-C, which attracts monocytes that migrate into the tunica intima where they become
macrophages, and phagocytose the modified LDL-C, yielding foam cells. sPLA2-mediated oxidation of
LDL-C is thought to make the LDL-C particles stick to proteoglycans in the atheromatous lesion. Lp-
PLA2: lipoprotein-associated phospholipase A2; Lyso-PC: lysophosphatidylcholine; Ox-LDL: oxidized
LDL
Reproduced from Mallet et al [259]
higher sPLA2 being detrimental to CVD risk.
Furthermore, when low density lipoprotein receptor deficient (LDLR -/-) mice were trans-
planted with bone marrow from sPLA2-IIA transgenic mice, they showed increased
markers of oxidative stress in vivo, increased macrophage and foam cell formation in
atherosclerotic lesions, and increased atherosclerotic lesion size at the aortic root com-
pared to control mice.[311]
These findings from animal models of atherosclerosis support the hypothesis of sPLA2-
IIA being detrimental to health and contributing towards cardiovascular disease.
3.1.10 Observational association of sPLA2 with CVD in humans
Autopsy studies have shown expression of sPLA2 on immunostaining of human atheroscle-
rotic plaques[293, 312, 313], which was particularly highly expressed in foam cells[293],
in areas of calcification and in the necrotic core of the plaque. In contrast, cells that did
not originate from the diseased carotid intima did not express sPLA2.[312] Furthermore,
post-mortem examinations of patients that died following AMI have identified evidence
of localisation of sPLA2 in the infarcted myocardium on immunohistochemistry.[277]
However, the presence of sPLA2 in atherosclerotic tissue does not prove cause and effect
and sPLA2 may be elevated in response to disease (reverse causality), or the associ-
ation may arise due to an association with another trait that is causally-related (i.e.
confounding, as discussed in Chapter 1).[293]
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Perhaps two of the most important Bradford-Hill criteria[57] that lend weight to a
potential causal association between sPLA2-IIA and CHD are (i) temporality and (ii)
dose-response relationships. Evidence in favour of a temporal relationship between the
levels of circulating sPLA2 and risk of CHD has emerged from several prospective cohorts
in which sPLA2 was measured prior to incident[314, 315] and recurrent[260, 316–319]
CHD events. Furthermore, a dose-response relationship has also been identified between
levels of sPLA2 and risk of CHD.[260, 314, 320]
However, as was the case for C-reactive protein (see Box 3.1 on page 65), which associates
with incident CHD events decades prior to the initial event,[321] the long subclinical
phase of atherosclerosis (which lasts several decades) means that measurement even years
prior to the clinical event does not rule out reverse causality. And of course the absence of
randomization in both animal models and traditional observational epidemiology makes
confounding an equally plausible, alternative explanation.[322]
3.1.11 GWAs studies of CHD
At the time of starting this work, no GWAs had identified a SNP in the PLA2G2A
locus as associated with CHD. However, this did not deter my enthusiasm to pursue
a Mendelian randomization investigation of sPLA2-IIA. For example, this could be ex-
plained by lack of comprehensive coverage of the PLA2G2A locus on GWAs chips (a
familiar scenario for the APOE locus). Furthermore, lack of association could reflect a
type II error arising from inadequate power. Indeed, loci in HMGCR have not appeared
as GWAs SNPs for CHD, even though RCTs of statins (which inhibit HMG-coA reduc-
tase, encoded for by HMGCR) have provided conclusive evidence of an association with
CHD.
3.1.12 Drug development: sPLA2 as a drug target
On the background of the evidence from animal studies and observational studies in
humans, the hypothesis was naturally generated that targeting sPLA2 may represent a
novel means to prevent development of atherosclerosis, and thus reduce risk of CHD.[323]
sPLA2 inhibitors have been designed on the basis of the catalytic dyad
c, which differen-
tiates them from cytoplasmic PLA2 and LpPLA2.
cThe sPLA2 enzymes contain a catalytic dyad at the active site, which consists of aspartic acid and
histidine. In contrast, cytoplasmic and lipoprotein-associated PLA2 have a catalytic triad (consisting of
aspartic acid, histidine and serine).[324] This subtle difference allows the selective inhibition of sPLA2
enzymes.
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The first drug that showed selective inhibition of sPLA2 was reported in 1995.[325]
Through use of crystal structures of sPLA2, a panel of drugs was developed with com-
pounds structurally similar to indomethacin (an indoled non-steroidal anti-inflammatory).
Out of 12 compounds developed, LYS3311727 had the lowest Xi50 (the mole fraction
for 50% inhibition of sPLA2 using a chromogenic assay) while retaining specificity for
sPLA2.[325]
Further chemical modification of LY311727 to improve binding to sPLA2-IIA yielded
varespladib (A-001).[326, 327] Methylation of varespladib into the pro-drug varespladib
methyl (A-002), provided an orally-active drug that is metabolised by esterases into the
active compound, varespladib.
3.1.13 Varespladib
Varespladib (Figure 3.8) was originally designed to be a specific inhibitor of the sPLA2-
IIA isoform.[325] However, as was the case for other PLA2 inhibitors (such as inhibitors
of cytosolic PLA2),[328] as new PLA2 isoforms have been identified, drugs that were
originally considered to be specific to a particular isoform of PLA2 have shown inhibitory
activity for the new isoforms (i.e. exerting non-specific effects).[328]
In the case of varespladib, although it was initially thought to be selective for the IIA
isoform of sPLA2, subsequent investigations revealed varespladib also inhibited the -V
and -X isoforms[329, 330].
The potency of a compound in inhibiting the activity of a substrate can be quantified as
the concentration of drug required to inhibit activity by 50% (denoted as the IC50).[331]
Thus to contrast the effects of varespladib on the IIA, III and X isoforms of sPLA2, one
method is to compare the IC50 estimates for varespladib on these traits. Importantly for
varespladib, the IC50 estimates for the sPLA2 isoenzymes were obtained from different
animal models and using different drug compounds of varespladib, which may muddy
the interpretation. Specifically, the mouse model that estimated IC50 values for -IIA
was a transgenic mouse expressing human sPLA2 and the drug compound used was
varespladib (A-001)[329] whereas for IC50 values of -V and -X isoforms, a transgenic
mouse with human recombinant V and X was studied using the drug compound vares-
pladib methyl (A-002)[330]). Thus the IC50 estimates may not be directly comparable
with one another. The IC50 values from these sources yielded values that were lower for
IIA (indicating higher drug efficacy) than for V and X (9, 77 and 15 nM , respectively,
Figure 3.10).[329, 330]
dIndoles are aromatic heterocyclic organic compounds that contain indole rings, consisting of a ben-
zene ring and nitrogen-containing pyrrole ring
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Figure 3.8: Structure of the first-in-class orally-available sPLA2 inhibitor for CVD pre-
vention, varespladib methyl
3.1.14 Animal studies of varespladib efficacy
Several animal studies have been conducted to investigate the effects of varespladib
on animal models of atherosclerosis.[330, 332] APOE -/- mice fed with 16 weeks of
a Western diet to induced atherosclerosis, and treated with A-002 had reduced total
cholesterol, and considerable reductions in plaque content after 1 month of treatment
compared to APOE -/- mice fed the same diet but treated with the drug vehicle (lacking
varespladib).[330]
Guinea pigs fed a high-fat diet and treated with varespladib had reduced atherosclerotic
lesions compared to those treated with placebo.[332]
Thus animal models provide an encouraging indication that varespladib may reduce
atherosclerosis. However, the majority of animal models (approximately 90%) that
suggest positive findings for predicting the efficacy of treatments fail to translate to
treatments that are efficacious at improving outcomes when investigated in man.[51]
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3.1.15 Safety of varespladib in humans: data from phase II randomized
trials
Four phase II randomized trials of varespladib in patients with heart disease have been
conducted.[333–336] Being phase II trials they were not designed or powered to in-
vestigate hard (clinical) outcomes, but they did investigate surrogate markers (such
as changes in blood lipids and sPLA2 traits), the findings of which are reported in
Chapter 5. Of note, side effects occurred at higher rates in varespladib-treated individ-
uals than those receiving placebo. Side effects included headache, [334], nausea,[334]
diarrhoea,[334, 335] syncope,[335] arthralgia,[335], and, elevated liver enzymes (alanine
transaminase).[333, 334] However, these adverse events were typically mild and no dose-
response relationship was identified.[334]
3.1.16 Treatment trials of varespladib for CV efficacy: phase III RCTs
The first phase III randomized trial of sPLA2 inhibition for the prevention of CV events
commenced in 2010,[337] which coincided with the start of my investigative work re-
ported in this thesis. The trial, The Vascular Inflammation Suppression to Treat Acute
Coronary Syndrome for 16 Weeks (VISTA-16, NCT01130246), was a placebo-controlled
clinical trial that recruited patients with ACS and randomized them to receive either
500mg/day varespladib methyl, or placebo for 16 weeks on the background of standard
therapy (including atorvastatin). The primary outcome was a composite end-point con-
sisting of cardiovascular death, non-fatal MI, non-fatal stroke or documented unstable
angina with objective evidence of ischaemia requiring hospitalisation.[337]. In addition
to clinical events, secondary outcomes were investigated, including changes in levels of
sPLA2, LDL-C, CRP and IL-6.
The objective was to recruit 6500 individuals in order to accrue 385 outcomes based
on a presumed varespladib treatment efficacy of a 25% risk reduction in the event rate.
This would achieve 80% power at a 5% type 1 false positive rate.
This trial would therefore provide the first deconfounded evidence for the causal role
of sPLA2-IIA in CVD, and more importantly, inform on whether modifying sPLA2-IIA
could serve as a new means to address the considerable residual risk of CVD which exists
despite current pharmacotherapy.[338]
Chapter 3. Secretary Phospholipase A2 and Cardiovascular Disease 77
3.1.17 Genetic variants encoding sPLA2-IIA
sPLA2-IIA mass is encoded for by the PLA2G2A gene located on chromosome 1, which
contains 6 exons, 4 of which are coding (Figure 3.9). A study that used tagging SNPs in
PLA2G2A gene identified six SNPs that accounted for the majority of variation within
the PLA2G2A locus.[339] Two SNPs, rs11573156 and rs3767221, were identified to have
strong associations with sPLA2-IIA mass.[339]
sis-prone knockout mice, either low density receptor Ldlr2/2 or
Apolipoprotein E (Apoe) 2/2, atherosclerosis is enhanced
[9,10,11,12].
The observational studies in prospective cohorts and in the
setting of acute coronary syndrome patients support these findings,
with both higher sPLA2-IIA levels, and notably higher sPLA2
activity, showing significant association with risk of CAD [9–11].
SPLA2-IIA is the most abundantly expressed of the sPLA2
proteins [12], and is mainly expressed in the liver, where it is
secreted into the circulation, and in the arterial wall where further
modification of sd-LDL takes place.
We previously identified six tagging SNPs (tSNPs), capturing
92% of the variation of PLA2G2A (Chr1, NC_000001.10) [13].
These were genotyped in a cohort of patients with type 2 diabetes
and their association with sPLA2-IIA levels and lipid traits was
examined. Two tSNPs showed strong association with sPLA2-IIA
levels. Compared to individuals homozygous for the common C
allele for rs11573156 C.G (NC_000001.10:g20306146G.C) in
the 59UTR of PLA2G2A (Figure 1), the rare G homozygotes had
2.2 ng/ml higher sPLA2-IIA levels (p = 1.9610214). For the
second variant, rs3767221 T.G
(NC_000001.10:g20301781A.C) in the 39UTR (Figure 1), the
opposite effect was seen with the rare G homozygotes having
significantly lowe (1.8 ng/ml) sPLA2-IIA lev ls (p = 2.5610210)
compared to the wild-type T carriers [13]. The ultimate aim of our
study was to identify a robust functional genetic variant which
could be used to determine if the relationship between high
sPLA2-IIA levels and coronary heart disease risk was causal or not,
a process termed Mendelian Randomization.
Results
llele-specific Expression of PLA2G2A in Human iver
To examine the potential allele-specific expression of PLA2G2A,
we analysed PLA2G2A expression data from the ASAP study.
Measurements of PLA2G2A mRNA expression were investigated
in the following tissues; liver, mammary arteries, dilated and non-
dilated ascending aorta and heart. PLA2G2A mRNA was shown to
be most significantly expressed in the aortic adventitia, liver and
heart (Figure 2). The most significant allele-specific differential
expression of PLA2G2A mRNA was found to be in the liver. The
SNP rs11573156 as not measured directly on the Illumina
Human 610W-Quad Beadarray, so the rs10732279 SNP (Figure 1)
was used as a proxy (r2 = 0.91 in Caucasian Europeans, HapMap).
This proxy SNP showed the greatest overall differential expression
of PLA2G2A and explained 29.3% of the variance in PLA2G2A
mRNA in the liver, suggesting that this SNP may have a functional
effect. The genotype effect of rs10732279 on PLA2G2A liver
mRNA is presented in Figure 3a; compared to the common A
homozygotes, carriers of the rare G allele had roughly 25% higher
expression of PLA2G2A (p = 1.67610217).
Rs3767221 was not covered on the array nor was there a strong
proxy for this SNP. However, using the 1000 genomes database
we were able to impute rs3767221 and these results predicted an
association of rs3767221 with PLA2G2A, albeit with less accuracy
than for rs11573156. The mach1 r2 value was shown to be 0.41.
When the differential values of PLA2G2A for this imputed SNP
were analysed they showed a significant association of
p = 3.661024 (this was weaker than that seen for rs10732279,
the proxy for rs11573156) with carriers of the common allele (T)
showing higher expression compared to samples homozygous for
the rare allele (G) (Figure 3b).
Rs3767221 T.G is Associated with Altered PLA2G2A
Promoter Activity
Results from the luciferase assays for rs3767221 T.G are
shown in Figure 4. A significant difference was seen, with the G
allele showing ,55% lower luciferase activity compared to the T
allele (T=62.1 (95% CI 59.1 to 65.1) G= 27.8 (95% CI 25.0 to
30.6), p = 1.22610235). An EMSA (Figure 5) confirmed differen-
tial binding of nuclear protein between the T and G alleles,
illustrated by the additional band seen with the biotin-labelled
rs3767221 G, compared to rs3767221 T. This additional band
seen with the G variant was competed out by the un-biotinylated
G probe, but not the non-specific Sp1 probe, suggesting specific
binding of a transcription factor in the presence of the G allele but
not the T allele. The difference in transcription factor binding
associated with this 39UTR SNP could influence the rate of
transcription and/or mRNA stability, thus affecting PLA2G2A
expression and levels of sPLA2-IIA.
To investigate this further, rs3767221 G samples were
competed with an unlabelled SREBP 1 consensus sequence. For
rs3767221 G, a distinct reduction in the intensity of the band was
seen, suggesting that SREBP 1 may be involved in the differential
bindi g to the alleles of rs3767221 (Figure 5).
Rs11573156 C.G is Associated with Alternative Splicing
of PLA2G2A
The luciferase assays for rs11573156 C and G alleles showed
very low transcription, being in the order of 1.2 to 1.6 relative
Figure 1. A map of the PLA2G2A gene (6 exon transcript). This map identifies rs11573156, rs10732279 and rs3767221 in the 59UTR, intronic and
39UTR, respectively. Translated exons are distinguished by hatching. Untranslated exons are unfilled. The gene is normally reverse transcribed.
doi:10.1371/journal.pone.0041139.g001
Functional Analysis of Two PLA2G2A Variants
PLoS ONE | www.plosone.org 2 July 2012 | Volume 7 | Issue 7 | e41139
Figure .9: Map of th PLA2G2A gene
The rs11573156 SNP is thought to be involved in exon skipping of exon 2, and by doing
so, influences levels of sPLA2-IIA mass Derived from Exeter et al.[340]
A recent study that characterized these two SNPs identified both to be functional.[340].
Through detailed investigation, the authors suggested that rs11573156 influenced circu-
lating levels of sPLA2-IIA mass through exon skipping (in which exon 2 was differentially
expressed according to presence of the minor allele of rs11573156). In contrast, rs3767221
T>G was thought to operate through differential transcription factor binding.
3.1.18 Use of a PLA2G2A genetic variant for Mendelian randomiza-
tion
In Chapter 1, I introduced the concept of Mendelian randomization. Specifically, Fig-
ure 1.6 compares the properties of genetic information to that of a randomized clinical
trial.
Thus, it is possible to use genetic variation in PLA2G2A to conduct experiments in
which confounding is minimized to interrogate the causal relationship between sPLA2-
IIA mass and CHD.
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3.2 Aims
I aimed to undertake a ‘natural’ Mendelian randomization trial with genetic data, to
complement the VISTA-16 trial, and in doing so, to investigate whether sPLA2-IIA is
a valid therapeutic target for CHD prevention. Both sources of evidence (RCT design
of VISTA-16 and Mendelian randomization from this thesis) would be free from con-
founding. Just as in the VISTA-16 trial in which individuals were randomly allocated to
receive a drug that reduces sPLA2,[337] I used a ‘naturally randomly-allocated’ genetic
variant that also associated with lower levels of sPLA2. The only subtle difference was
that the gene variant was specific for the IIA isoform of sPLA2 (the isoenzyme that
varespladib was developed with the intention of specifically inhibiting)[323], whereas
varespladib has inhibitory activity against the IIA, V and X isoforms. Figure 3.10 con-
trasts the Mendelian randomization analysis using a genetic variant in PLA2G2A with
that of the phase III RCT of varespladib.
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Footnote: Varespladib has greatest effect on sPLA2-IIA but additional effects on sPLA2-V and X, whereas PLA2G2A rs11573156 is specific for sPLA2-IIA. 
 
Figure 3.10: Comparison of (A) a randomized trial of varespladib (as in the VISTA-16 trial[337]), with (B) random allocation of PLA2G2A
rs11573156
Varespladib has greatest inhibitory effect on sPLA2-IIA but additional effects on sPLA2-V and X, whereas PLA2G2A rs11573156 is specific for the sPLA2-IIA isoform
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The project included the following components:
1. Investigating the observational association between sPLA2-IIA mass, sPLA2 en-
zyme activity and cardiovascular risk factors and events in studies set in both the
general population and in patients with ACS, reported in Chapter 4
2. Selection of a SNP in PLA2G2A as a genetic instrument for Mendelian random-
ization analysis, reported (together with the remaining items listed below), in
Chapter 5
3. Evaluation of the association between the PLA2G2A SNP and
(a) circulating sPLA2-IIA mass and sPLA2 enzyme activity (including an analysis
on the association of SNPs in PLA2G2A with messenger RNA expression of
PLA2G2A, PLA2G5 and PLA2G10 )
(b) cardiovascular biomarkers
(c) cardiovascular events overall and separated by subtype
4. An overview of published randomized clinical trials of varespladib
5. An instrumental variable analysis using the PLA2G2A variant to obtain a de-
confounded estimate between sPLA2-IIA and CHD through ‘Mendelian triangula-
tion’
Chapter 4
sPLA2 and Cardiovascular Traits
and Events: Observational
Analysis
In this chapter, I will outline the methods and report the findings for the observational
association between sPLA2 and cardiovascular biomarkers and events.
4.1 Methods
4.1.1 General overview of studies contributing towards the observa-
tional associations between sPLA2 and CHD events
A collaboration of 36 studies was established including 109,179 individuals of European
descent (listed in Table B.1). The analyses reported in this chapter were limited to
those studies with measures of sPLA2. Approval from relevant ethical committees was
obtained for collaborating studies. All analyses, unless otherwise stated, were performed
using Stata 12.1 (StataCorp, Texas USA).
4.1.2 Measurement of sPLA2-IIA mass and sPLA2 enzyme activity
sPLA2-IIA mass and sPLA2 enzyme activity were measured in seven and six of the
collaborating studies, respectively (Table B.5). I grouped studies according to the pop-
ulation sampled, and the timing of blood sample. Studies were placed into one of two
categories: (i) studies set in individuals that were predominantly free from established
81
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CHD (EPIC-Norfolk[341], a nested case-cohort study in the general population and
UDACS[342], a cross-sectional study of men with type 2 diabetes), and; (ii) studies set
in ACS with samples taken within 48 hours of ACS event (FAST-MI[343], GRACE-
France[344], GRACE-Scotland[345] and the MIRACL trial[346]). Owing to the time of
blood sampling being greater than one month after the acute coronary event, samples for
one study (KAROLA[347]) were not included in the analysis. This was because sPLA2
is an acute phase reactant,[256][276] therefore the association with recurrent events may
differ according to the timing of blood sampling.
Details of the assay methods used in each study (including quality control estimates -
e.g. information on duplicates) are provided in Table 4.1.
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Table 4.1: Characteristics of assays in studies conducted to measure sPLA2 IIA mass and sPLA2 enzyme activity
sPLA2 trait Parameter EPIC-Norfolk FAST-MI GRACE-
France &
Scotland
MIRACL UDACS
sPLA2-IIA mass
Assay ELISA[273]
(Cayman
Chemical
Company,
Ann Arbor,
Michigan)
Time-resolved
fluoroim-
munoassay
(an
ELISA-like
assay)[348]
ELISA[273]
(Cayman
Chemical
Company,
Ann Arbor,
Michigan)
ELISA[273]
(Cayman
Chemical
Company,
Ann Arbor,
Michigan)
ELISA[273]
(Cayman
Chemical
Company,
Ann Arbor,
Michigan)
Duplicates Intra-assay
variation
between
duplicates
was 9.2%
Intra and
interassay
coefficient of
variation was
<15%
Intra and
interassay
coefficient of
variation was
<10%
Intra-assay
variation
between
duplicates
was 9.2%
Intra- and
inter- assay
coefficients of
variation were
6.0 and
10.3%,
respectively
Lower
detection
limit
0.4 ng/ml 0.5 ng/ml 0.02 ng/ml 0.4 ng/ml 0.02 ng/ml
Laboratory CLB/Sanquin
Research lab,
Amsterdam
Valbonne,
France
Paris Cardio-
vascular
Research
Center
Paris Cardio-
vascular
Research
Center
Dr Camejos
lab,
Gothenburg
University,
Sweden
Continued on next page
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Table 4.1 – Continued from previous page
sPLA2 trait Parameter EPIC-Norfolk FAST-MI GRACE-
France &
Scotland
MIRACL UDACS
sPLA2 enzyme
activity
Assay Selective
fluorometric
assay[271,
272]
Selective
fluorometric
assay[271,
272]
Selective
fluorometric
assay[271,
272]
Selective
fluorometric
assay[271,
272]
Not measured
Duplicates Intra- and
inter-assay
coefficient of
variation was
<10%
Intra- and
inter-assay
coefficient of
variation was
<10%
Intra and
inter-assay
coefficient of
variation was
<10%
Intra and
inter-assay
coefficient of
variation was
<10%
N/A
Lower
detection
limit
0.10
nmol/min per
ml
0.10
nmol/min per
ml
0.10
nmol/min/ml
0.10
nmol/min/ml
N/A
Laboratory Paris Cardio-
vascular
Research
Center
Paris Cardio-
vascular
Research
Center
Paris Cardio-
vascular
Research
Center
Paris Cardio-
vascular
Research
Center
N/A
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4.1.3 Distribution of sPLA2-IIA mass and sPLA2 enzyme activity
I plotted histograms of sPLA2-IIA mass and sPLA2 enzyme activity in the study for
which I had access to individual participant data (EPIC-Norfolk). Owing to a skewed
distribution, I log(e) transformed sPLA2-IIA mass and sPLA2 enzyme activity, which
normalized both distributions (Figure 4.1). Thus log(e) transformed sPLA2 was used
for all analyses (unless otherwise stated).
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Figure 4.1: Distribution of sPLA2-IIA mass and sPLA2 enzyme activity in EPIC-
Norfolk
Prior to log(e) transformation (left panes), both sPLA2 traits have a right-skewed distribution.
Following log(e) transformation, both sPLA2 traits have a normal (Gaussian) distribution.
4.1.4 Correlation between sPLA2-IIA mass and sPLA2 enzyme activ-
ity
I investigated the correlation between log sPLA2-IIA mass and log sPLA2 enzyme ac-
tivity in each study that measured both traits using Pearsons correlation coefficient. I
plotted the pair-wise values in each study, and super-imposed the regression line of best
fit.
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4.1.5 Association of sPLA2-IIA mass and sPLA2 enzyme activity with
cardiovascular traits and potential confounders
I evaluated the cross-sectional association between log sPLA2-IIA mass and log sPLA2
enzyme activity with established and emerging cardiovascular risk factors in the EPIC-
Norfolk study. This was conducted for the following traits: age, body mass index (BMI),
C-reactive protein (CRP), systolic blood pressure (SBP), diastolic blood pressure (DBP),
high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol (LDL-
C), triglycerides (TG), apolipoprotein A1, apolipoprotein B, gender, type 2 diabetes
(T2D) and smoking status. First, I created tertiles of sPLA2-IIA mass and sPLA2
enzyme activity, and tabulated the mean and standard deviation (SD) for continuous
traits and proportion of cases for binary traits for each tertile. Secondly, I performed
univariate linear and logistic regression analyses for continuous and binary traits, respec-
tively, using natural logarithm (log[e]) transformed sPLA2 IIA mass and sPLA2 enzyme
activity as the explanatory (independent) variables.
4.1.6 Association of sPLA2-IIA mass and sPLA2 enzyme activity with
cardiovascular events
To investigate the association between circulating sPLA2-IIA mass and sPLA2 enzyme
activity with incident vascular events in general populations, I used the EPIC-Norfolk
study and to investigate the association with recurrent events in patients with ACS, I
used four ACS cohorts (FAST-MI, GRACE France, GRACE Scotland and MIRACL).
The outcomes for the analysis varied according to availability and study design. In
the EPIC-Norfolk nested case-control study, cases were selected for fatal/nonfatal MI
and therefore this was the outcome used for the analysis. In contrast, for the ACS
studies (GRACE-France, GRACE-Scotland, FAST-MI and MIRACL), the outcome was
a composite of all-cause mortality or MI. For further details, please see outcomes defined
in Table B.6 and descriptive text on page 215 in Appendix B.
4.1.7 Shape of the association between sPLA2-IIA mass and sPLA2
enzyme activity with cardiovascular traits and clinical events
To evaluate the shape of the association between sPLA2-IIA mass, sPLA2 enzyme activ-
ity and cardiovascular events, I used minimally-adjusted logistic regression models with
log sPLA2-IIA mass and log sPLA2 enzyme activity as independent continuous variables
(assuming a linear effect). I then added a quadratic term (fitting both [sPLA2 × sPLA2]
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and sPLA2 into the model) and repeated the regression analysis. I tested the null hy-
pothesis, that the linear model explained the data better, by using the likelihood ratio
test. This was conducted in all studies individually.
4.1.8 Multivariate analysis to investigate the association of sPLA2
traits and CHD
In order to investigate whether the association between sPLA2 and fatal/nonfatal MI
was influenced by confounding, I conducted a step-wise multivariate analysis. In the
general population cohort (EPIC-Norfolk), I first created a minimally adjusted model
between log sPLA2-IIA mass or log sPLA2 enzyme activity with MI, adjusted only for
age and gender. I then added BMI, blood pressure and T2D to the model (but did not
include lipids at this stage as they may mediate a potential association between sPLA2
and CVD[256]). In the next model, I also adjusted for LDL-C, HDL-C and TG. Finally,
in order to investigate the independent effect of sPLA2-IIA mass and sPLA2 enzyme
activity with MI, I adjusted for the corresponding (non-index) trait.
For the ACS cohorts, a similar strategy was employed, however the fully-adjusted model
consisted of age, gender, BMI and blood pressure.
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4.2 Results
4.2.1 Correlation between sPLA2 mass and sPLA2 enzyme activity
Log sPLA2-IIA mass and log sPLA2 enzyme activity showed strong pair-wise correlation
in all four studies (all P values for correlation <0.0001). The Pearsons correlation
coefficients between sPLA2-IIA mass and sPLA2 enzyme activity in the ACS studies were
0.50, 0.51 and 0.58 whereas for the general population study, it was 0.18 (Figure 4.2).
4.2.2 Observational Analysis of sPLA2-IIA mass, sPLA2 enzyme ac-
tivity and cardiovascular risk factors
sPLA2-IIA mass and sPLA2 enzyme activity showed associations with several emerging
and established cardiovascular risk factors including age, SBP, LDL-C, BMI, CRP and
sex (Tables 4.2 and 4.3).
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Figure 4.2: Correlation between sPLA2-IIA mass and sPLA2 enzyme activity in studies with both measures
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Table 4.2: Association between tertiles of sPLA2-IIA mass and established and emerging cardiovascular risk factors in 3371 individuals in the EPIC-
Norfolk nested case control study
Tertile (min-max, ng/ml) of sPLA2-IIA mass
1 (0.4-6.8) 2 (6.8-11.3) 3 (11.3-114.5)
Continuous traits N Mean SD N Mean SD N Mean SD P value∗∗
Age (yrs) 1125 63.51 8.24 1124 64.93 7.59 1122 66.07 7.17 1.10x10-17
BMI (kg/m2) 1125 26.2 3.28 1120 26.69 3.66 1122 27.03 3.99 5.46x10-9
CRP* (mg/dl) 1100 0.22 1.05 1108 0.53 1.15 1104 1.01 1.21 1.67x10-74
Systolic BP
(mmHg)
1122 139.54 17.85 1122 140.63 17.64 1120 141.83 19.21 4.36x10-3
Diastolic BP
(mmHg)
1122 84.13 11.08 1122 84.49 11.2 1120 84.51 11.99 0.69
HDL-C (mmol/l) 1073 1.31 0.38 1051 1.35 0.4 1059 1.36 0.4 0.03
LDL-C (mmol/l) 1073 4.05 0.98 1052 4.17 1.03 1059 4.2 1.05 0.01
Triglyceride*
(mmol/l)
1114 0.57 0.5 1106 0.56 0.51 1105 0.55 0.51 0.06
Apolipoprotein A1
(mg/dl)
977 156.23 28.26 972 160.14 28.58 972 163.27 31.02 9.03x10-6
Apolipoprotein B
(mg/dl)
1029 129.79 32.28 1024 133.38 31.28 1038 134.31 33.42 0.07
Binary traits N Propor-
tion
SD N Propor-
tion
SD N Propor-
tion
SD P value∗ ∗ ∗
Female sex (%) 1125 21.33 40.98 1124 35.68 47.93 1122 53.21 49.92 8.94x10-59
T2D (%) 1124 3.2 17.62 1123 3.03 17.14 1120 4.11 19.85 0.06
Ever smoker (%) 1116 62.01 48.56 1106 62.3 48.49 1113 62.8 48.35 0.78
∗ log transformed (as skewed distribution) thus units do not apply; ∗∗ derived from univariate linear regression using log sPLA2-IIA mass as the independent variable;
∗ ∗ ∗ derived from univariate logistic regression using log sPLA2-IIA mass as the independent variable.
C
h
a
p
ter
4
.
sP
L
A
2
a
n
d
C
a
rd
io
va
scu
la
r
T
ra
its
a
n
d
E
ven
ts:
O
bserva
tio
n
a
l
A
n
a
lysis
91
Table 4.3: Association between tertiles of sPLA2 enzyme activity and traditional cardiovascular risk factors in 3371 individuals in EPIC-Norfolk
Tertile (ηmol/min/ml) of sPLA2 enzyme activity
1 (1.7-4.0) 2 (4.0-4.9) 3 (4.9-23.1)
Continuous traits N Mean SD N Mean SD N Mean SD P value∗∗
Age (yrs) 1107 64.19 7.84 1107 64.54 7.89 1107 65.8 7.48 7.17x10-7
BMI (kg/m2) 1107 26.02 3.44 1106 26.61 3.75 1104 27.32 3.71 1.00x10-15
CRP* (mg/dl) 1086 0.41 1.2 1087 0.53 1.16 1090 0.83 1.14 1.87x10-16
Systolic BP
(mmHg)
1103 138.62 18.33 1105 139.76 18.13 1106 143.71 18.01 7.46x10-10
Diastolic BP
(mmHg)
1103 83.22 11.34 1105 83.88 11.02 1106 86.03 11.69 2.57x10-7
HDL-C (mmol/l) 1088 1.38 0.4 1070 1.35 0.4 980 1.28 0.38 2.99x10-8
LDL-C (mmol/l) 1088 3.93 0.94 1070 4.14 0.99 981 4.37 1.1 4.26x10-21
Triglyceride*
(mmol/l)
1091 0.29 0.39 1093 0.52 0.44 1092 0.87 0.5 5.40x10-168
Apolipoprotein A1
(mg/dl)
976 159.74 28.98 956 160.62 29.45 955 159.18 29.93 0.94
Apolipoprotein B
(mg/dl)
1038 120.49 26.91 1024 130.77 29.12 993 146.7 35.2 5.61x10-72
Binary traits N Propor-
tion
SD N Propor-
tion
SD N Propor-
tion
SD P value∗ ∗ ∗
Female sex (%) 1107 33.06 47.07 1107 35.95 48.01 1107 41.73 49.33 1.27x10-5
T2D (%) 1107 2.62 15.98 1105 4.43 20.6 1106 3.35 17.99 0.1
Ever smoker (%) 1095 60 49.01 1098 59.56 49.1 1092 67.58 46.83 2.42x10-4
∗ log transformed (as skewed distribution) thus units do not apply; ∗∗ derived from univariate linear regression using log sPLA2 enzyme activity as the independent
variable; ∗ ∗ ∗ derived from univariate logistic regression using log sPLA2 enzyme activity as the independent variable.
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4.2.3 Shape of the association between sPLA2-IIA mass, sPLA2 en-
zyme activity and cardiovascular events
The relationship between sPLA2-IIA mass, sPLA2 enzyme activity and risk of MI demon-
strated a log-linear association (likelihood ratio test for quadratic vs. linear P>0.05 for
sPLA2-IIA mass and sPLA2 enzyme activity in all studies; Table 4.4). This indicated a
constant proportional decrease in the relative odds per 1 log unit lower sPLA2-IIA mass
or sPLA2 enzyme activity.
Table 4.4: Assessment of departure from linearity in the relationship between sPLA2-IIA
mass, sPLA2 enzyme activity and cardiovascular events, adjusted for age and gender.
Study/
Setting
Outcome
One log unit reduction in
sPLA2-IIA mass and events
One log unit reduction in sPLA2
enzyme activity and events
Total,
(n)
Linear OR
(95%CI)
LRT
P-value
Total,
(n)
Linear OR
(95%CI)
LRT
P-value
General population
EPIC-
Norfolk
Fatal/
nonfatal
MI
3371 0.67 (0.59,
0.75)
0.747 3321 0.30 (0.22,
0.41)
0.91
Acute coronary syndrome
GRACE-
Scotland
Death/MI 158 0.77 (0.49,
1.19)
0.737 164 0.46 (0.14,
1.48)
0.1
GRACE-
France
Death/MI 277 0.95 (0.64,
1.42)
0.195 278 0.40 (0.16,
1.00)
0.165
FAST-MI Death/MI 855 1.14
(0.87,1.49)
0.642 1011 0.68 (0.40,
1.14)
0.165
Footnotes: LRT: Likelihood ratio test (test for departure from linearity)
4.2.4 Observational Analysis of sPLA2-IIA mass, sPLA2 enzyme ac-
tivity and cardiovascular events
Lower levels of sPLA2-IIA mass and lower levels of sPLA2 enzyme activity each were
associated with a reduced risk of cardiovascular events in the general population with
an OR for fatal/nonfatal MI of 0.67 (95%CI: 0.59, 0.75) and 0.30 (95%CI: 0.22, 0.41)
per one log unit lower sPLA2-IIA mass and sPLA2 enzyme activity, respectively, after
adjustment for age and gender (Figure 4.3 and Table 4.4).
Adjustment for cardiovascular risk factors diminished the association between sPLA2-
IIA mass and sPLA2 enzyme activity with incident MI in the general population, though
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the association persisted following multivariate adjustment (Figure 4.3). Interestingly,
both associations (sPLA2-IIA mass and sPLA2 enzyme activity with MI) remained after
adjustment for one another.
For ACS cohorts, sPLA2-IIA mass did not show association with all-cause mortality/MI
on adjustment for age and gender (OR per one log unit reduction in sPLA2-IIA mass:
0.93; 95%CI: 0.84, 1.04).
In contrast, sPLA2 enzyme activity was associated with recurrent events, however the
association was weak with an OR of 0.82 (95%CI: 0.69, 0.98) on adjustment for age and
gender and OR 0.77 (95%CI 0.64, 0.93) following additional adjustment for BMI and
BP (Figure 4.3).
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Figure 4.3: Association of a 1 log unit lower sPLA2-IIA mass (orange) or sPLA2 enzyme activity (blue) with fatal/nonfatal MI in general population
studies (EPIC-Norfolk) and all-cause mortality/MI in ACS studies (FAST-MI, GRACE Scotland, GRACE France and MIRACL).
Footnotes: In Model 1, only age and gender were introduced as covariates. I then additionally adjusted for covariates (blood pressure, BMI, T2D) that could confound the asso-
ciation between sPLA2 and CHD (Model 2). Because lipids may mediate the association between sPLA2-IIA and CHD, I did not include lipids in model 2, but included them in
model 3 (only available in the general population cohort). Finally, to investigate whether there was an independent association between sPLA2-IIA mass, sPLA2 enzyme activity
and CHD, I additionally included sPLA2 enzyme activity where sPLA2-IIA mass was the explanatory variable (and vice-versa; Model 4).
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4.3 Discussion
In chapter 3, I introduced the basis of the inflammation hypothesis for cardiovascular
disease. I then described the phospholipase A2 enzymes, which represent an important
component of the inflammatory pathway, liberating arachidonic acid from phospholipid
constituents of bilipid membranes.[324] Specifically, secretory phospholipase A2-IIA, a
ubiquitous iso-enzyme, represents a potential new therapeutic target[323] for treating
the inflammatory component of cardiovascular disease by hypothetically being involved
in the initiation and progression of the atherosclerotic plaque (Figure 3.7).[259]
4.3.1 Correlation between sPLA2 traits
Analysing data from one large general population cohort and four ACS cohorts, I exam-
ined the relationship between sPLA2-IIA mass and sPLA2 enzyme activity and found
that the two traits were strongly associated with one another (P<0.0001 for all associ-
ations, Figure 4.2), but that the correlation was low in the general population cohort
(Pearson’s r=0.18)and moderate (Pearson’s r'0.5) in studies set in ACS.
It is interesting that the correlation between the two sPLA2 traits differed according to
clinical setting. Given the assays for both sPLA2-IIA mass and sPLA2 enzyme activity
were conducted using similar techniques, and with similar markers of test validity (Ta-
ble 4.1), this discrepancy is unlikely to arise from differences in experimental technique.
One potential explanation is that since sPLA2-IIA is an acute phase reactant,[349] it
may account for the majority of sPLA2 enzyme activity during the acute phase of a coro-
nary syndrome. This would therefore increase the apparent correlation between the two
sPLA2 measures during ACS (as an acute coronary event involves an increased inflam-
matory milieu)[350] compared to a general population cohort, in which most individuals
would be expected to have only a low level of systemic inflammation.[351]
4.3.2 Association between sPLA2 traits and cardiovascular traits
I identified associations between both sPLA2-IIA mass and sPLA2 enzyme activity with
established and emerging cardiovascular risk factors, including both non-modifiable risk
factors such as age and gender but also established modifiable risk factors for CHD in-
cluding BMI, SBP and LDL-C (Tables 4.2 and 4.3). This association is important to
note for several reasons. First, it introduces the possibility that the association between
Chapter 4. sPLA2 and Cardiovascular Traits and Events: Observational Analysis 96
sPLA2 with cardiovascular events could be affected by confounding. As discussed in
Chapter 1 (Figure 1.5), one of the requisites for a confounder is that an association
should exist between the exposure of interest and the potential confounder.
Alternatively, the association between sPLA2 IIA-mass or sPLA2 enzyme activity and
risk factors could indicate that they lie on the same causal pathway between sPLA2
and vascular events. For example, data from animal models[352] and randomized tri-
als have suggested that blood lipids could be on the causal pathway between sPLA2
and CHD.[333–335] Indeed, an association between both sPLA2 traits was detected
with HDL-C and LDL-C on cross-sectional analysis in the general population cohort
(Tables 4.2 and 4.3). This is important because adjustment for blood lipids in the as-
sociation between sPLA2 and CHD might result in a diminution of effect, but rather
than reflecting confounding, this attenuation in the effect estimate could arise from ad-
justment for a mediator.[353] For this reason, I added blood lipids into the multivariate
model (when I tested the association between sPLA2 and CHD) separately to other risk
factors (such as age, gender, smoking, which in contrast, are unlikely to be on the causal
pathway). This allowed a more thorough investigation into the nature of the association
between sPLA2 traits and MVE.
4.3.3 Association between sPLA2-IIA mass and vascular events
sPLA2-IIA mass showed association with fatal/nonfatal myocardial infarction in one
large general population nested case control study (EPIC-Norfolk), and this association
remained robust even after adjusting for the potential confounding effect of other covari-
ates (such as age, gender and cardiovascular traits including blood pressure; Figure 4.3).
This ‘independent association’ (between sPLA2-IIA mass and CHD) is of importance as
it supports the possibility that sPLA2-IIA mass may be a causal risk factor for incident
CHD.
The association between sPLA2-IIA mass with all-cause mortality/MI in the four ACS
cohorts was less clear. No association was identified using the minimally-adjusted model,
and this null association persisted when potential confounders were introduced into the
model. This is surprising as it is in contrast to published reports of the association of
sPLA2 with recurrent events in ACS cohorts.[260, 316, 318, 319, 337, 354] However, it
is worthy to note that the dataset used for the analyses in patients with ACS that I
report in this chapter is the largest dataset established to date to investigate the nature
of the association between sPLA2-IIA and recurrent CHD events. Despite this, with
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confidence intervals that span odds ratios from 0.81 to 1.03, I cannot rule out a false
negative due to a limited number of events. On the other hand, the lack of association
may reflect the pace at which the evidence has emerged. To expand, initial studies
often overestimate the effect of a biomarker on a health outcome, and as more evidence
accrues the effect may diminish and in some cases, such as this, the effect estimate may
disappear altogether; this is known as the winners curse phenomenon.[61, 355]
The discrepancy in the association between sPLA2-IIA mass with CHD events in the
general population and ACS cohorts is worthy of discussion. First, there were three-fold
more events for the general population cohort compared to the ACS studies, which means
the analysis in the ACS cohorts may have been insufficiently powered to detect a true
association (creating a false negative or type II error). Alternatively, this discrepancy
could reflect the underlying biology: i.e. that sPLA2 may be more important for incident
CHD than for recurrent events. A similar suggestion has been made for C-reactive
protein (except the opposite way round- i.e. that C-reactive protein is important for
recurrent events rather than incident disease)[356], however whether specific risk factors
could be important only for incident and not recurrent CHD remains under question.[357]
4.3.4 Association between sPLA2 enzyme activity and vascular events
The association between sPLA2 enzyme activity and fatal/nonfatal MI in general popu-
lation cohorts was very strong on minimal adjustment (OR per log unit reduction 0.30;
95%CI, 0.22 to 0.41) however this diminished to OR 0.50 in the fully adjusted model,
which suggested that the adjusted co-variates may be confounders. However, even in
the fully-adjusted model, strong evidence of association persisted.
Again, and as for sPLA2-IIA mass, the association between sPLA2 enzyme activity and
cardiovascular events in cohorts of patients with ACS was less clear (Figure 4.3). Both
minimally adjusted and fully-adjusted models showed only weak associations with re-
current CHD events. And as for sPLA2-IIA in ACS, this may reflect reduced power to
detect an association.
Nonetheless, these findings of (albeit a weak) association between sPLA2 enzyme activity
and recurrent CHD do provide some reassurance that sPLA2 may be an important
enzyme for CHD, although the question of which of the three sPLA2 isoforms (IIA, V
or X) is contributing towards this association is another question that requires further
investigation.
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4.3.5 Independent association between sPLA2-IIA mass, sPLA2 en-
zyme activity and vascular events
Interestingly, there was little alteration in the effect estimate for the association between
sPLA2-IIA and CHD when sPLA2 enzyme activity was introduced into the model for the
analysis based in the general population. This may indicate that not all the sPLA2-IIA
mass variance was detected by sPLA2 enzyme activity.
The same was true when sPLA2-IIA mass was introduced into the model in which
sPLA2 enzyme activity was the independent variable (again in the general population
setting). This is to be expected since sPLA2 enzyme activity is considered to represent
a composite of -IIA, V and X. Adjusting for sPLA2-IIA should therefore not completely
attenuate the association as V and X (separate isoforms that are considered to have their
own, independent role in atherogenesis[358]) are not measured in the specific sPLA2-IIA
assay.
4.4 Conclusions
The findings from this chapter yield important insights into the nature of the association
between the sPLA2 traits, cardiovascular traits and events. In summary:
 sPLA2-IIA mass and sPLA2 enzyme activity are strongly associated with each
other, but the correlation is higher in studies in which the sample is obtained
within 48 hours of an ACS event than in the healthy population
 both sPLA2 measures (IIA-mass and enzyme activity) showed very strong associa-
tion with several established cardiovascular risk factors, opening up the possibility
of confounding and/or a potential mediation effect in the association of sPLA2
with CHD
 sPLA2-IIA mass shows strong association with incident CHD, which remains ro-
bust to incorporation of potential confounders
 in contrast, sPLA2-IIA mass did not show association with recurrent CHD events
in patients with ACS, both in minimally-adjusted or fully-adjusted analysis
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 sPLA2 enzyme activity also showed robust association with incident CHD events,
and again the effect persisted with incorporation of potential confounders. How-
ever, the point estimate of the effect estimate did diminish on adjustment, sug-
gesting that the covariates may either partially confound the association, or may
lie on a causal pathway between sPLA2 enzyme activity and CHD
 sPLA2 enzyme activity showed weak evidence of association with recurrent CHD
events in patients with ACS both on minimally and fully adjusted analyses
 in the general population study, there was evidence that both sPLA2 measures
had association with CHD that was independent of the other
In the next chapter, I will use a genetic variant for instrumental variable analysis[359] to
test whether the observational association of sPLA2 measures with CHD events arises
due to a causal relationship, or whether the estimates I report here for incident CHD
events have arisen due to residual confounding (from unmeasured or imprecisely mea-
sured confounders) and/or reverse causality.
Chapter 5
Randomized Evidence on sPLA2
and Cardiovascular Disease based
on Genetic Studies and Trials
In Chapter 4, I investigated the observational association between sPLA2-IIA mass,
sPLA2 enzyme activity and cardiovascular traits and disease events and identified an
association between sPLA2-IIA mass with incident CHD events, which remained robust
to statistical adjustment for potential confounders. This provided evidence of an in-
dependent association between sPLA2-IIA mass and CHD that may be suggestive of
a causal relationship. However, as outlined in Chapter 1, observational associations in
which potential confounding has been minimized through statistical adjustment may
still not reflect the ‘true’ underlying causal relationship due to residual confounding.
Such observational associations do, however, generate hypotheses that require formal
testing for causality, through use of a randomized design.
In this Chapter, I will describe the Methods and Results for the genetic analysis, in-
cluding a “Mendelian triangulation” (instrumental variable) analysis. I also report the
conduct and results of a systematic review and meta-analysis of randomized trials of the
sPLA2-lowering drug, varespladib methyl.
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5.1 Methods
5.1.1 General overview of studies participating in the sPLA2 collabo-
ration
An international collaboration was established of 36 studies including 109,179 individu-
als of European descent (listed in Table B.1). Of the 36 studies, 19 were set in general
populations (consisting of 14 cohorts, three nested case-control studies and two case-
control studies) and ten studies were of patients with ACS (comprising nine cohorts and
one nested case-control study).
In addition, I included four case control studies of coronary artery disease, one cohort of
patients with established arterial vascular disease or risk factors for CVD (SMART[360]),
and one nested case-control study of coronary artery restenosis in patients with ACS
undergoing percutaneous coronary intervention (GENDER[361]). These additional six
studies were analysed and reported separately.
Finally, tissue samples from one cohort of patients undergoing aortic valve surgery
(ASAP[362]) were used to investigate the association of SNPs in the PLA2G2A re-
gion with mRNA expression in several tissues (including the aortic adventitia, heart and
liver), which was replicated in an external data source comprising 206 transplant donor
liver samples.[362]
Approval from relevant ethical committees was obtained for collaborating studies. I used
Stata 12.1 (StataCorp, College Station, Texas, USA) to conduct analyses.
5.1.2 Genetic analysis
Access was available to individual participant data in all contributing studies. All studies
contributed towards the genetic analysis apart from the MIRACL trial[363], a trial of
3086 participants with Acute Coronary Syndrome that were randomized to atorvastatin
or placebo, which was excluded because of lack of availability of genetic data.
A pre-specified Stata script was developed to standardize the genetic analysis in the col-
laborating studies. I arranged the genotype coding to be directionally concordant with
the effects of pharmacological treatment by varespladib - i.e. both the SNP and the drug
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lowered sPLA2-IIA mass and sPLA2 enzyme activity. Traits that were not normally dis-
tributed (sPLA2-IIA mass, sPLA2 enzyme activity (see Figure 4.1 for histograms pre
and post transformation), C-IMT, CRP, triglyceride and IL6 concentrations) were loge
transformed, and differences between genotype groups were reported as a percentage
difference.[364] I obtained the percentage difference estimate by exponentiating the as-
sociation between PLA2G2A with the log transformed trait to obtain the relative dif-
ference. I then converted the relative difference to a percentage by subtracting one from
the relative difference and multiplying the fraction by 100.
To avoid the potential for established CVD to alter the magnitude of the genotype-trait
association, the analysis of associations between genotype and continuous traits was
restricted to controls in retrospective case-control studies. I included all individuals from
cohort studies and nested case-control studies as measurement of variables at recruitment
was made prior to occurrence of the clinical event.
5.1.3 Selection of the genetic instrument and evaluation of its speci-
ficity and effect size
5.1.3.1 SNP selection
Six tagging single nucleotide polymorphisms (SNPs) that captured >90% of the genetic
variation in PLA2G2A (located on chromosome 1) in Europeans[339] were evaluated in
three studies (EPIC-Norfolk, GRACE-France and UDACS). The per-allele association
of each SNP with sPLA2-IIA mass and sPLA2 enzyme activity was investigated.
Rs11573156 showed strongest association with sPLA2-IIA mass and sPLA2 enzyme ac-
tivity and was prioritized for analysis in the remaining studies (Figure 5.1). The geno-
type frequency was consistent across the studies (Figure B.2), and no study deviated
from Hardy Weinberg Equilibrium (Table B.4).
5.1.3.2 Specificity of genetic instrument for PLA2G2A expression
The Advanced Study of Aortic Pathology (ASAP)[362] was used to investigate the speci-
ficity of the SNP for sPLA2-IIA. In ASAP, patients undergoing aortic valve surgery at the
Karolinska University Hospital, Stockholm Sweden were recruited.[362] Tissue biopsies
were taken from liver, heart, mammary arteries and dilated and non-dilated ascending
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Figure 5.1: P-values for the associations between the 5 tagging SNPs in PLA2G2A and
sPLA2-IIA mass and sPLA2 enzyme activity.
The analysis was conducted in EPIC-Norfolk, GRACE-France and UDACS and the estimates
were pooled across studies. The individual estimates per study are reported in Tables B.2
and B.3
aorta during surgery. A total of 700 tissue samples from 272 different patients were in-
vestigated. The medial and adventitial layers of the vascular specimen were separated.
All tissue samples were incubated with RNAlater (Ambion, Austin, Texas, USA) and
homogenised for mRNA extraction.[362]
Affymetrix GeneChip Human Exon 1.0 ST expression arrays were used to quantify
mRNA expression, and participants were also genotyped using Illumina Human 610W-
Quad Beadarray (including 101 SNPs in the region 200kb up and downstream from the
PLA2G2A locus).
Raw data were pre-processed using the RMA algorithm[365] and the core group of
metaprobesets, resulting in normalized and log(2) transformed expression data. Gene
expression and eQTL effects were evaluated as follows: genotypes were re-coded as 0, 1
and 2 and included as predictors in a linear additive model with gene expression as the
response variable. The association analyses of PLA2G2A SNPs with mRNA expression
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was conducted using R 2.13.0 and Bioconductor.[366] Alignments and plots of exon-level
microarray data were performed using the GeneRegionScan package.[367]. For replica-
tion of the SNP showing strongest association with PLA2G2A mRNA expression, an
external data source comprising 206 transplant donor liver samples[368] was used.
These mRNA analyses were conducted by Dr. Lasse Folkerson in collaboration with me.
5.1.3.3 Strength of genetic instrument (rs11573156C>G) on sPLA2
I estimated the association between PLA2G2A rs11573156 and sPLA2 measures, as well
as the proportion of variance (R2) of these measures explained by the PLA2G2A variant.
For each study with traits and genotype available (Table B.5), per C-allele associations
of the PLA2G2A rs11573156 variant with log sPLA2-IIA mass and log sPLA2 enzyme
activity were estimated.
5.1.3.4 Association between genetic instrument and putative and estab-
lished cardiovascular risk factors
Twenty studies of individuals in which blood sampling occurred prior to the cardiovas-
cular event were used to test the association of the PLA2G2A rs11573156 variant (per
C-allele) with cardiovascular risk factors within each study, using linear regression for
continuous traits and logistic regression for binary traits. I pooled results using fixed
and random effect meta-analysis.
5.1.4 Cardiovascular outcomes
For the general population studies, the composite MVE outcome was separated into
prevalent and incident events, whereas for studies of ACS patients, all events after
recruitment were included and labelled as recurrent. Prevalent MVE was a composite of
nonfatal MI and nonfatal stroke, and incident MVE was a composite of fatal/nonfatal
MI and fatal/nonfatal stroke. For ACS cohorts the recurrent MVE were a composite
of nonfatal MI, nonfatal stroke and all-cause mortality. Individual components of the
MVE outcome were also available for general population studies and ACS cohorts and
were reported separately. See Appendix B.1.1 on page 215 for outcomes definitions per
study and Table B.6 for study contribution to the composite outcomes.
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5.1.5 Association between genetic instrument and major vascular events
I conducted two genetic approaches to evaluate the role of sPLA2 on MVE. First, I
performed a genetic association analysis of the PLA2G2A rs11573156 variant with MVE,
and second, an instrumental variable analysis that quantified a causal effect of a one log
unit lower sPLA2-IIA mass and sPLA2 enzyme activity on MVE, under the assumptions
of instrumental variable analysis, i.e. of a log-linear association between the biomarker
and the outcome.[84]
A total of 26 studies contributed to these two approaches, comprising 17 in general
populations and ninea studies in patients with ACS.
5.1.5.1 Genetic association analysis
For the genetic association analysis, I quantified the within-study odds ratio (OR) per
C allele of PLA2G2A rs11573156 with MVE using logistic regression and I pooled the
results using fixed and random-effects meta-analysis. I quantified between-study het-
erogeneity using I2.[147] Meta-analyses were stratified by clinical setting into general
population studies or studies of patients with ACS.
5.1.5.2 Instrumental variable analysis
I used the ratio instrumental variable estimator to estimate the unconfounded effect of
log sPLA2-IIA mass and log sPLA2 enzyme activity on cardiovascular outcomes. For
this, I first conducted a fixed-effects meta-analysis of the PLA2G2A rs11573156 SNP
(per C-allele) on log sPLA2-IIA mass and log sPLA2 enzyme activity across studies with
these phenotypes available separately for general population and ACS studies. Assum-
ing a single (fixed) effect of the PLA2G2A SNP on log sPLA2-IIA mass and log sPLA2
enzyme activity separately for general population and ACS studies, I applied the pooled
estimate to studies that did not have information on sPLA2.
Using study-specific associations between the PLA2G2A SNP and each outcome, I cal-
culated the instrumental variable estimate for log sPLA2-IIA mass and log sPLA2 en-
zyme activity by dividing the rs11573156-outcome association by the pooled estimate
of the association of rs11573156 and log sPLA2-IIA mass and sPLA2 enzyme activ-
ity. This analysis took into account the uncertainty in both the rs11573156-sPLA2 and
aThe MIRACL trial did not have genetic data available, and thus could not contribute towards the
genetic analyses
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rs11573156-outcome associations by using the delta methodb to estimate the standard
errors of ratio instrumental variable estimates.[369] I pooled the study specific instru-
mental variable estimates using fixed effects meta-analysis.
This instrumental variable technique enabled me to include studies that did not have
measures of sPLA2-IIA mass or sPLA2 enzyme activity. This should increase the preci-
sion of pooled IV estimates. However, this may occur at a loss to the internal consistency
of the instrumental variable estimate for studies without measures of sPLA2.[370–372]
Finally, I compared the summary instrumental variable estimates to the expected esti-
mates based on the observational association between sPLA2-IIA mass, sPLA2 enzyme
activity and cardiovascular events (reported in Chapter 4).
5.1.6 Systematic review of randomized trials of varespladib
In order to be able to quantify the effect of varespladib methylc on sPLA2-IIA mass and
sPLA2 enzyme activity and circulating biomarkers, I conducted a meta-analysis of phase
II randomized trials. I followed Preferred Reporting Items for Systematic reviews and
Meta-Analyses (PRISMA) guidelines[143] on conducting a systematic review. PubMed
was used to search MEDLINE on January 28th 2013. The following search term was used,
incorporating both the generic and proprietary drug names and consisting of U.S. Na-
tional Library of Medicine (NLM) Medical Subject Headings (MeSH)[373] and free text
terms (‘‘varespladib’’[Substance Name] OR ‘‘varespladib methyl’’[Substance
Name] OR varespladib OR A002 OR LY333013). This search was supplemented by
hand-searching references of recent commentary articles on sPLA2 and varespladib.[256,
293, 323, 337, 374, 374, 375]
The abstracts of all retrieved articles were scrutinized and were preliminarily included
if they were randomized trials in which individuals were allocated to varespladib or
placebo. The full text of articles satisfying the initial screening were then examined.
Trials were included if they reported sPLA2-IIA mass and/or enzyme activity, cardio-
vascular biomarkers or outcomes.
Articles that were finally included were then examined, and the following values were
recorded:
bThe delta method, also known as the method of propagation of errors, is a way of estimating the
variance of a transformation of one or more variables through using a calculus method termed “Taylor
series expansion”
cVarespladib methyl is the first-in-class sPLA2 inhibitor designed for the prevention of cardiovascular
disease
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 phase of trial (e.g. phase I, II, III or IV)
 number of individuals randomized
 duration of trial
 dose of varespladib and frequency of dosing
 primary and secondary outcome(s)
 baseline health status (e.g. presence of CVD) of recruited participants
 levels of sPLA2-IIA mass or sPLA2 enzyme activity and cardiovascular biomarkers
in the active and control arms at baseline and at follow-up
To facilitate pooling of biomarker data across trials, the most frequently used time point
for sampling was identified. In trials that did not measure biomarkers at this preferred
time, values reported at a time in closest proximity to the preferred time were used.
I quantified the effect of varespladib on sPLA2-IIA mass or sPLA2 enzyme activity and
cardiovascular biomarkers by estimating the difference in each biomarker from baseline to
follow-up in the placebo arm and subtracting this estimate from the corresponding value
for the active arm. By doing so, I obtained estimates of the effect of the intervention
(that were free from confounding).
I estimated the dose-response relationship between varespladib and circulating sPLA2-
IIA mass by conducting a meta-regression analysis using the “metareg”[376] command
in Stata.
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5.2 Results
5.2.1 Selection and validation of the genetic instrument for sPLA2-IIA
Of the six identified tagging SNPs in the PLA2G2A gene, rs11573156 C>G showed the
strongest association with sPLA2-IIA mass (P=5.49x10
-180) and sPLA2 enzyme activity
(P=3.29x10-5) and was prioritized for analysis in the remaining studies (Figure 5.1).
From the tissues available in ASAP study, PLA2G2A was mainly expressed in the liver,
aortic adventitia and heart. PLA2G2A mRNA levels were considerably higher than
those of PLA2G5 and PLA2G10 (Figure B.1).
To evaluate the specificity of the genetic instrument (rs11573156), the association of
SNPs in PLA2G2A with mRNA expression of the different sPLA2 isoforms was analysed,
each encoded by separate genes (PLA2G2A for sPLA2-IIA, PLA2G5 for sPLA2-V and
PLA2G10 for sPLA2-X).
The SNP showing strongest association with PLA2G2A mRNA expression in liver was
rs10732279 (P=8.71x10-19; Figure 5.2 and Figure B.1), in strong LD with rs11573156
(R2=0.91 in Europeans, HapMap release 21) and explained 31% of the variation in
PLA2G2A mRNA expression. These findings were replicated in an external data source
comprising 206 transplant donor liver samples (P=4.76 x 10-8).[368] In contrast, rs10732279
did not show association with either PLA2G5 or PLA2G10 mRNA expression (P=0.04
and P=0.88, respectively) confirming the specificity of the genetic instrument for the
sPLA2-IIA sub-type (Figure 5.2).
5.2.2 Association of rs11573156 with sPLA2-IIA mass and sPLA2 en-
zyme activity
In 3 studies of 1400 individuals with ACS and 2 general population studies of 3533
individuals, an allele dose-dependent association was observed between rs11573156 and
sPLA2- IIA mass and enzyme activity (Figure 5.4). For each additional C allele of
rs11573156, sPLA2-IIA mass was reduced by 38% (95%CI: 36%, 40%; P=1.2x10
-216) in
studies of general populations and 44% (95%CI: 37%, 50%; P=1.64x10-21) in studies of
ACS patients. The pooled proportion of variance (R2) of sPLA2-IIA mass explained
by rs11573156 was 21% (95%CI: 18%, 23%) in general population and 6% (95%CI: 3%,
9%) in ACS studies, indicating that this variant was a strong genetic instrument for
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(A)                                (B)                                 (C)  
Figure 5.2: Manhattan plots of the association of SNPs in PLA2G2A region and expression of: (A) PLA2G2A mRNA; (B) PLA2G5 mRNA, and;
(C) PLA2G10 mRNA, in mammary artery (red dots), liver (blue dots), tunica medica (green dots), tunica adventitia (cyan dots) and heart (brown
dots).
Data obtained from the ASAP study[362].
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sPLA2-IIA mass.
The effect of the rs11573156 variant on sPLA2 enzyme activity was considerably smaller
than that for sPLA2-IIA mass at 3% (95%CI: 1%, 5%; P=1.8x10
-4) in studies of general
populations and 23% (95%CI: 19%, 27%; P=4.0x10-22) for studies of ACS patients
(Figure 5.4).
5.2.3 Systematic review and meta-analysis of the effects of varespladib
on circulating sPLA2-IIA, sPLA2 enzyme activity and cardiovas-
cular traits from clinical trials
Four randomized trials were identified (Figure 5.3) [333–336] of 1300 participants with
a mean age of 61 yrs. Three trials recruited patients with stable CHD and one recruited
patients at the time of ACS (Table 5.1). The primary outcomes were changes in sPLA2-
IIA level, LDL-C or cardiac enzymes and follow-up ranged between one and six months.	  
Figure 5.3: PRISMA flow diagram illustrating the search strategy used to identify ran-
domized trials of sPLA2 lowering therapies.
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Figure 5.4: Meta-analysis pooled estimates of the association between PLA2G2A rs11573156 with (A) sPLA2-IIA mass and (B) sPLA2 enzyme ac-
tivity, separated by study setting into general populations (EPIC-Norfolk, UDACS; blue) and acute coronary syndrome (GRACE-Scotland, GRACE-
France, FAST-MI; red). Numbers in brackets represent the number of studies, participants, and between-study heterogeneity (measured by I2).
NA=not applicable; I2 values cannot be computed in the presence of <3 studies in Stata
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A meta-regression of dose-finding trials indicated a dose-dependent reduction in sPLA2-
IIA mass with increasing daily doses of varespladib in the range 100-1000mg/day (P for
meta-regression=0.06, Figure 5.5).
I also identified associations between varespladib treatment (500mg/day) and apolipopro-
tein B (-0.78 SD; 95%CI:-1.05, -0.52) and LDL-C particle size (0.23 nm; 95%CI: 0.19,
0.26; Table 5.4). The effect of varespladib on sPLA2 enzyme activity was not reported in
any clinical trial, as levels in the treatment arm were beneath the lower limit of detection
of the assay.[333–335]
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Figure 5.5: Dose-response relationship between varespladib and sPLA2-IIA mass reported in randomized trials.
Footnotes: Grey circles and vertical whiskers represent mean (±95%CI) study-level difference in sPLA2-IIA mass from baseline to 8 weeks comparing varespladib to placebo. Red
line represents meta-regression slope (±95%CI, green lines) of dose of varespladib and difference in sPLA2-IIA mass.
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Table 5.1: Characteristics of the randomized trials of varespladib identified in the systematic review.
Trial name RCT
phase
Years
con-
ducted
Clinical
setting
Primary end-point Age,
mean
(SD)
Sex, %
female
Number
ran-
domised
Varespladib dose,
mg (dosing
frequency/day)
Trial
duration,
months
FRANCIS-
ACS
[333]
IIB 2008-
2010
ACS Change in LDL-C
from baseline to 8
weeks
59.05
(10.5)
25.3 625 500 (once) 6
PLASMA
[334]
II 2007 Stable CHD Change in sPLA2 con-
centration or enzyme
activity from baseline
to 8 weeks
62 (11) 24 393 50/100/250/500
(twice)
2
PLASMA-2
[335]
II 2007 Stable CHD Change in sPLA2 con-
centration from base-
line to 8 weeks
64 (12) 11 138 250/500 (once) 2
SPIDER-
PCI
[336]
II 2007-
2009
Stable CHD
patients
undergoing
elective PCI
Elevation of cardiac
enzymes (CK-MB,
Troponin I) up to 24h
PCI
63.4
(9.9)
12.5 144 500 (twice) 1
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5.2.4 Contextualising the genetic effects on sPLA2-IIA with the sPLA2
inhibitor varespladib
The most common dose of varespladib (500mg/day) reduced sPLA2-IIA by 78% (95%CI:
62%, 94%) (Figure 5.5). This estimate (78%) was about twice that observed for posses-
sion of one common (C) allele of rs11573156 compared to none (38% to 44% depending
on the population studied), and roughly equivalent to possession of two common (C)
alleles of rs11573156 compared to none (what can be considered an “extreme” genotype
comparison).
5.2.5 Association between rs11573156 with cardiovascular risk factors
and carotid atherosclerosis
In contrast to the observed association between circulating sPLA2-IIA mass and sPLA2
enzyme activity (Tables 4.2 and 4.3), I did not find associations between the C-allele of
rs11573156 and cardiovascular risk factors such as blood pressure, LDL-C, glucose and
BMI (Tables 5.2, 5.3, and 5.4) or surrogate markers for CHD such as C-IMT. However,
I observed associations of a small magnitude between rs11573156 and IL-6 (2.54% per
C-allele; 95%CI: 0.68 to 4.44), fibrinogen (0.005% per C-allele; 95%CI: 0.001 to 0.009)
and triglycerides (0.78% per C-allele; 95%CI: 0.04 to 1.5) (Table 5.4).
5.2.6 Association between rs11573156 and cardiovascular outcomes in
general population studies
In 13 population studies (8021 incident MVE in 56,359 individuals), the summary per
C allele OR for the association of rs11573156 with incident MVE (comprising fatal and
nonfatal MI or stroke) was 1.02 (95%CI: 0.98, 1.06). The summary OR for the individual
outcomes were: incident nonfatal MI 1.04 (95%CI: 0.98, 1.10); incident nonfatal stroke
1.00 (95%CI: 0.93, 1.07), and; incident fatal MI/stroke 1.01 (95%CI: 0.93, 1.10). For
details see Figure 5.6 and 5.7.
In 12 studies (7513 prevalent MVE in 55,523 individuals), the summary per C allele OR
for the association of rs11573156 with prevalent MVE (MI or stroke) was 0.99 (95%CI:
0.95, 1.03). For the individual outcomes, the summary OR for prevalent MI was 0.98
(95%CI: 0.93, 1.03) and for prevalent stroke 1.03 (95%CI: 0.93, 1.15) (Figure 5.6 and 5.8).
Findings from random-effects meta-analysis were similar and are presented in Table B.7.
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General Population: Incident events
Major vascular events
Þ Nonfatal MI
Þ Nonfatal Stroke
Þ Fatal MI/Stroke
General Population: Prevalent events
Major vascular events
Þ MI
Þ Stroke
Acute Coronary Syndrome: Recurrent events
Major vascular events
Þ Nonfatal MI
Þ Nonfatal Stroke
Þ Fatal MI/Stroke 
Outcome
Setting,
13 (8021/56359)
13 (4208/51016)
11 (2304/46790)
12 (1509/48118)
12 (7513/55523)
12 (6411/54884)
8 (1102/37280)
9 (2520/15768)
8 (1158/14152)
6 (223/12283)
9 (1139/15724)
(events/participants)
Studies
1.02 (0.98, 1.06)
1.04 (0.98, 1.10)
1.00 (0.93, 1.07)
1.01 (0.93, 1.10)
0.99 (0.95, 1.03)
0.98 (0.93, 1.03)
1.03 (0.93, 1.15)
0.96 (0.90, 1.03)
0.99 (0.89, 1.09)
0.85 (0.69, 1.06)
0.96 (0.87, 1.06)
allele) (95% CI)
Odds ratio (per
26(0,51)
22(0,59)
19(0,59)
41(0,70)
38(0,63)
52(7,75)
0(0,67)
0(0,45)
28(0,67)
0(0,74)
0(0,64)
(95%CI)
I2,%
Lower  Higher 
1.5 2
Odds ratio
Association between PLA2G2A rs11573156
and CVD outcomes (per C allele)
Figure 5.6: Meta-analysis pooled estimates of the association between PLA2G2A rs11573156 and major vascular events (including individual compo-
nents) stratified by clinical setting into general population and ACS patients.
Footnotes: Each plot represents the PLA2G2A rs11573156 per C allele OR, with genotype grouping arranged to mimic the effects of pharmacological lowering of sPLA2-IIA.
I.e. if lowering of sPLA2-IIA mass were to reduce risk of cardiovascular events, the OR in the plot should be less than one. Major vascular events comprise fatal/nonfatal MI or
stroke. Fatal MI/stroke included all-cause mortality for some ACS studies (see Table B.6 for further details).
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5.2.7 Association between rs11573156 and recurrent cardiovascular
events in patients with acute coronary syndrome
Nine studies (2520 recurrent MVE in 15,768 participants with ACS) contributed to-
wards the analysis, yielding a summary per C allele OR for rs11573156 with recurrent
MVE (fatal/nonfatal MI or stroke) of 0.96 (95%CI: 0.90, 1.03). The summary OR for
individual components were: nonfatal MI 0.99 (95%CI: 0.89, 1.09); nonfatal stroke 0.85
(95%CI: 0.69, 1.06), and; fatal MI/stroke 0.96 (95%CI: 0.87, 1.06) (Figure 5.6 and 5.9)
Findings were consistent in a random-effects meta-analysis (Table B.7).
5.2.8 Extreme genotype comparison
Individuals homozygous for the rs11573156 C allele had a 57%-62% lower sPLA2-IIA
mass compared to those homozygous for the G allele (Figure 5.4), which was similar
in magnitude to the 78% reduction seen with 500mg/day varespladib dose used in the
phase-III VISTA-16 trial. Using this genotype comparison, a null effect was again ob-
served for MVE in all clinical settings: incident (5,175 cases, OR 0.99; 95%CI: 0.89,
1.10); prevalent (3,545 cases, OR: 1.00; 95%CI: 0.88, 1.13), and; recurrent (1,626 cases,
OR 0.89; 95%CI: 0.74, 1.06).
5.2.9 Association between rs11573156 and other cardiovascular events
In a meta-analysis including 4 studies (4224 cases in 6619 participants), no association
between the C allele of rs11573156 was identified for angiographically-determined coro-
nary artery disease (OR 0.99; 95%CI: 0.91, 1.08; Figure 5.8). In a study set in patients
with established vascular disease or high cardiovascular risk (SMART), the association
between the C allele of rs11573156 with recurrent MVE (fatal/non-fatal MI or stroke)
was OR 0.92 (95%CI: 0.80, 1.07). For the study set in patients with ACS undergo-
ing PCI (GENDER), the association between the C allele of rs11573156 with coronary
artery restenosis was OR 1.04 (95%CI: 0.82, 1.31).
C
h
a
p
ter
5
.
sP
L
A
2
a
n
d
C
V
D
:
G
en
etic
a
n
d
In
stru
m
en
ta
l
V
a
ria
ble
A
n
a
lysis
118
Overall  (I-squared = 22.5%, p = 0.216)
EPIC-NethL
BWHHS
UCP
CCHS
NPHS-II
BRHS
Rotterdam
EAS
TPT
PREVEND
Study
PROSPER
IMPROVE
EPIC-Norfolk
(326,2144)
(46,3271)
(632,1632)
(607,10072)
(158,2693)
(83,3275)
(351,5953)
(63,822)
(Cases/
(166,3857)
(177,7707)
Total)
(318,3991)
(24,3045)
(1257,2554)
1.04 (0.98, 1.10)
0.87 (0.72, 1.05)
1.76 (0.98, 3.16)
0.93 (0.79, 1.09)
1.09 (0.95, 1.24)
1.05 (0.80, 1.38)
1.11 (0.76, 1.62)
1.16 (0.97, 1.40)
1.13 (0.72, 1.77)
1.03 (0.79, 1.34)
1.22 (0.94, 1.57)
OR (95% CI)
1.22 (0.99, 1.51)
0.99 (0.51, 1.94)
0.96 (0.84, 1.10)
lower  higher 
1.5 2
Odds ratio
per C allele of rs11573156
Incident Nonfatal MI in General population
Overall  (I-squared = 19.4%, p = 0.259)
NPHS-II
PROSPER
CCHS
TPT
Study
EPIC-NethL
PREVEND
BWHHS
EAS
Rotterdam
IMPROVE
BRHS
(58,2693)
(170,3991)
(636,10230)
(57,3748)
Total)
(415,2285)
(160,7707)
(61,3273)
(48,822)
(Cases/
(551,5745)
(27,3021)
(121,3275)
1.00 (0.93, 1.07)
1.32 (0.82, 2.13)
1.00 (0.76, 1.31)
1.03 (0.90, 1.16)
1.53 (0.93, 2.50)
OR (95% CI)
1.09 (0.91, 1.30)
1.09 (0.84, 1.41)
0.70 (0.47, 1.03)
0.81 (0.51, 1.28)
0.89 (0.78, 1.03)
0.93 (0.50, 1.73)
1.08 (0.79, 1.49)
lower  higher 
1.5 2
Odds ratio
per C allele of rs11573156
Incident Nonfatal Stroke in General population
Overall  (I-squared = 41.2%, p = 0.067)
BRHS
NPHS-II
EPIC-Norfolk
PROSPER
EAS
CCHS
Study
EPIC-NethL
PREVEND
BWHHS
IMPROVE
Rotterdam
TPT
(231,3275)
(93,2693)
(226,1523)
(171,3991)
(74,717)
(204,10375)
Total)
(Cases/
(78,1896)
(29,7707)
(68,3170)
(6,3027)
(229,5953)
(100,3791)
1.01 (0.93, 1.10)
1.02 (0.81, 1.28)
0.72 (0.52, 1.00)
0.87 (0.69, 1.10)
1.28 (0.96, 1.71)
1.19 (0.78, 1.81)
1.30 (1.03, 1.65)
OR (95% CI)
1.38 (0.92, 2.06)
0.79 (0.45, 1.38)
1.07 (0.71, 1.62)
0.89 (0.24, 3.23)
0.87 (0.70, 1.07)
0.94 (0.68, 1.30)
lower  higher 
1.5 2
Odds ratio
per C allele of rs11573156
Fatal MI/Stroke in General population
Figure 5.7: Meta-analysis of the effect of PLA2G2A rs11573156 in general population studies and risk of: (A) incident nonfatal myocardial infarction
(B) incident nonfatal stroke, and; (C) fatal myocardial infarction or stroke.
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Overall  (I-squared = 52.1%, p = 0.018)
EAS
CYPRUS
BRHS
Study
IMPROVE
CCHS
PREVEND
PROSPER
BHF-FHS
Whitehall II
Rotterdam
BWHHS
PROCARDIS
(43,879)
(Cases/
(40,734)
(374,3835)
Total)
(185,3234)
(303,10375)
(289,8087)
(541,3990)
(1538,3960)
(173,5018)
(701,5904)
(88,3405)
(2136,5463)
0.98 (0.93, 1.03)
0.53 (0.34, 0.83)
0.73 (0.45, 1.20)
1.04 (0.86, 1.24)
OR (95% CI)
0.91 (0.71, 1.15)
1.07 (0.89, 1.28)
1.13 (0.93, 1.38)
1.04 (0.89, 1.22)
1.04 (0.94, 1.16)
1.12 (0.86, 1.46)
0.99 (0.87, 1.13)
1.09 (0.76, 1.56)
0.85 (0.77, 0.94)
lower  higher 
1.5 2
Odds ratio
per C allele of rs11573156
Prevalent MI in General population
Overall  (I-squared = 0.0%, p = 0.451)
BWHHS
EAS
Study
BRHS
Rotterdam
CCHS
PREVEND
CYPRUS
PROSPER
(48,3405)
(20,881)
Total)
(186,3835)
(170,5974)
(145,10375)
(79,8085)
(4,734)
(450,3991)
(Cases/
1.03 (0.93, 1.15)
1.34 (0.80, 2.25)
0.64 (0.34, 1.23)
OR (95% CI)
1.10 (0.85, 1.42)
0.98 (0.76, 1.26)
1.24 (0.94, 1.62)
0.84 (0.59, 1.19)
1.90 (0.24, 14.91)
1.01 (0.85, 1.20)
lower  higher 
1.5 2
Odds ratio
per C allele of rs11573156
Prevalent Stroke in General population
Overall  (I-squared = 0.0%, p = 0.890)
Study
AMC-PAS
LIFE Heart
PennCath
MedStar
Total)
(Cases/
(549,740)
(1773,3041)
(1027,1516)
(875,1322)
0.99 (0.91, 1.08)
OR (95% CI)
0.99 (0.75, 1.30)
0.98 (0.87, 1.10)
1.06 (0.88, 1.28)
0.96 (0.80, 1.16)
lower  higher 
1.5 2
Odds ratio
per C allele of rs11573156
Prevalent CAD
Figure 5.8: Meta-analysis of the effect of PLA2G2A rs11573156 in general population studies and risk of: (A) prevalent myocardial infarction; (B)
prevalent stroke, and; (C) coronary artery disease
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Overall  (I-squared = 28.4%, p = 0.201)
FAST-MI
IHCS
CURE
KAROLA
MERLIN-TIMI 36
GRACE Scotland
PROVE-IT TIMI 22
GRACE France
Study
(Cases/
(33,973)
(372,2382)
(262,4334)
(49,1008)
(138,1606)
(149,1354)
(149,2232)
(6,263)
Total)
0.99 (0.89, 1.09)
0.64 (0.38, 1.09)
1.04 (0.86, 1.26)
1.12 (0.91, 1.38)
0.64 (0.41, 1.01)
0.84 (0.64, 1.11)
0.97 (0.73, 1.28)
1.11 (0.83, 1.48)
1.20 (0.25, 5.61)
OR (95% CI)
lower  higher 
1.5 2
Odds ratio
per C allele of rs11573156
Recurrent Nonfatal MI in ACS patients
Overall  (I-squared = 0.0%, p = 0.726)
FAST-MI
GRACE Scotland
Study
KAROLA
PROVE-IT TIMI 22
CURE
IHCS
(14,973)
(31,1354)
Total)
(41,1008)
(Cases/
(22,2232)
(52,4334)
(63,2382)
0.85 (0.69, 1.06)
0.66 (0.29, 1.46)
0.76 (0.43, 1.33)
OR (95% CI)
0.88 (0.52, 1.48)
0.74 (0.38, 1.44)
0.77 (0.51, 1.18)
1.16 (0.74, 1.82)
lower  higher 
1.5 2
Odds ratio
per C allele of rs11573156
Recurrent Nonfatal Stroke in ACS patients
Overall  (I-squared = 0.0%, p = 0.549)
KAROLA
GRACE Scotland
MERLIN-TIMI 36
IHCS
CURE
GENDEMIP
GRACE France
FAST-MI
Study
PROVE-IT TIMI 22
(59,1008)
(134,1488)
(86,1606)
(410,2382)
(233,4334)
(Cases/
(72,1432)
(12,269)
(107,973)
Total)
(26,2232)
0.96 (0.87, 1.06)
1.12 (0.71, 1.76)
0.90 (0.67, 1.20)
0.88 (0.62, 1.24)
1.08 (0.90, 1.30)
0.97 (0.78, 1.19)
1.05 (0.73, 1.53)
0.90 (0.33, 2.51)
0.69 (0.50, 0.95)
OR (95% CI)
0.92 (0.49, 1.76)
lower  higher 
1.5 2
Odds ratio
per C allele of rs11573156
Fatal MI/Stroke or All-cause Mortality in ACS patients
Figure 5.9: Meta-analysis of the effect of PLA2G2A rs11573156 in studies of acute coronary syndrome and risk of: (A) incident nonfatal myocardial
infarction; (B) incident nonfatal stroke, and; (C) fatal myocardial infarction or stroke.
C
h
a
p
ter
5
.
sP
L
A
2
a
n
d
C
V
D
:
G
en
etic
a
n
d
In
stru
m
en
ta
l
V
a
ria
ble
A
n
a
lysis
121
Table 5.2: Summary associations of PLA2G2A rs11573156 per C allele with cardiovascular risk factors and markers of atherosclerosis
Studies in general populations Studies in Acute Coronary Syndrome populations
Biomarker (units) No. of studies
(individuals)
Summary effect (95%
CI)
P value No. of studies
(individuals)
Summary effect
(95% CI)
P value
(I2, %) (I2, %)
Systolic BP (mmHg) 18 (63,325) -0.11 (-0.36, 0.14) 0.46 (26) 6 (5530) -0.66 (-1.63, 0.31) 0.18 (0)
Diastolic BP (mmHg) 18 (63,326) -0.10 (-0.24, 0.04) 0.17 (30) 6 (5528) 0.05 (-0.51, 0.61) 0.86 (17)
Glucose (mmol/l) 12 (43,186) 0.01 (-0.01, 0.03) 0.32 (12) 5 (4907) 0.09 (-0.04, 0.21) 0.17 (0)
BMI (kg/m2) 20 (67,764) 0.02 (-0.03, 0.07) 0.39 (18) 5 (5310) -0.21 (-0.44, 0.02) 0.07 (0)
C-IMT (mm)* 6 (12,237) -0.34 (-0.91, 0.24) 0.25 (0) - - -
Footnotes Abbreviations: BMI: body mass index; C-IMT: carotid intima medial thickness; DBP: diastolic blood pressure; SBP: systolic blood pressure. * relative units
presented as variable log transformed (units do not apply).
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Table 5.3: Summary effects of PLA2G2A rs11573156 per C allele with potential confounders stratified by study setting
Studies in general populations Studies in Acute Coronary Syndrome populations
Trait No. of studies Odds Ratio (95% CI) P value
(I2, %)
No. of studies
(cases/non-cases)
Odds Ratio (95%
CI)
P value
(cases/non-
cases)
(I2, %)
Age (yrs) 20 (NA/68,387) -0.04 (-0.12, 0.05)† 0.36 (15) 6 (6230) -0.05 (-0.44, 0.35) 0.82 (0)
Gender (female/all) 14
(28,578/57,861)
1.00 (0.98, 1.03) 0.75 (0) 5 (1788/5946) 1.01 (0.92, 1.11) 0.83 (0)
Smoking status (ever
smoker/never
smoker)
19
(39,790/69,614)
1.00 (0.98, 1.03) 0.78 (6) 4 (2,332/5,113) 0.95 (0.86, 1.06) 0.36 (0)
T2D (prevalent) 18
(5,773/63,097)
1.05 (1.00, 1.10) 0.06 (16) 3 (773/4,045) 0.97 (0.85, 1.11) 0.65 (0)
Statin treatment 13
(8,284/45,509)
1.00 (0.95, 1.05) 0.93 (28) 5 (3,944/5,988) 0.93 (0.84, 1.03) 0.17 (0)
BP-lowering
treatment
13
(10,810/48,738)
1.02 (0.98, 1.06) 0.31 (9) 4 (4,269/5,302) 0.92 (0.82, 1.04) 0.18 (0)
Footnotes Abbreviations: T2D: type 2 diabetes; † effect estimate represents beta coefficient for age, with denominator reflecting total number of participants.
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Table 5.4: Summary effects of varespladib (500mg/day) and PLA2G2A rs11573156 on biomarkers reported in randomized trials
Randomized trials of varespladib (500mg/day) Genetic studies of rs11573156 (per C allele)
Biomarker (units) No. of trials
(individuals)
Summary effect (95%
CI) *
P value,
(I2, %),
Setting No. of studies
(individuals)
Summary effect
(95% CI)
P value,
(I2, %)
sPLA2 measures
sPLA2-IIA mass
(pmol/L)
3 (624) -13.13 (-21.99, -4.27) 4 x 10-3 (0) General
population
1 (3035) -38.62 (-40.49,
-36.68)
2.61x10-204 (-)
ACS 3 (1243) -43.73 (-50.04,
-36.68)
1.64x10-21 (0)
sPLA2 enzyme
activity
(nmol/min/L)†
- - - General
population
1 (2990) -2.96 (-4.47, -1.42) 1.8x10-4 (-)
ACS 3 (1400) -22.59 (-26.51,
-18.45)
3.98x10-22 (82)
BIOMARKERS REPORTED IN RCTs WITH ≥500 INDIVIDUALS
HDL-C (mmol/l) 3 (637) 0.01 (-0.06, 0.07) 0.84 (0) General
population
18 (59,086) 0.000 (-0.005, 0.005) 0.96 (0)
ACS 4 (3274) 0.01 (-0.01, 0.03) 0.44 (13)
LDL-C (mmol/l) 3 (610) -0.20 (-0.42, 0.01) 0.063 (0) General
population
17 (53,465) 0.01 (-0.01, 0.02) 0.40 (42)
ACS 5 (3357) 0.02 (-0.04, 0.07) 0.54 (0)
Triglyceride
(mmol/l)†
3 (637) -0.12 (-0.35, 0.11) 0.32 (0) General
population
15 (53,079) 0.78 (0.04, 1.50) 0.04 (12)
ACS 4 (3285) -0.21 (-2.94, 2.58) 0.88 (0)
Interleukin-6
(pmol/L)†
1 (513) 0.00 (-6.34, 6.34) 1 (0) General
population
6 (14,980) 2.54 (0.68, 4.44) 0.01 (0)
ACS 2 (1895) -1.82 (-8.08, 4.84) 0.58 (0)
Continued on next page
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Table 5.4 – Continued from previous page
Randomized trials of varespladib (500mg/day) Genetic studies of rs11573156 (per C allele)
Biomarker (units) No. of trials
(individuals)
Summary effect (95%
CI) *
P value,
(I2, %),
Setting No. of studies
(individuals)
Summary effect
(95% CI)
P value,
(I2, %)
BIOMARKERS REPORTED IN RCTs WITH <500 INDIVIDUALS
C-reactive Protein
(mg/l)
2 (467) -0.32 (-3.50, 2.86) 0.84 (0) General
population
15 (52,348) 0.71 (-0.68, 2.12) 0.32 (0)
ACS 6 (3318) -0.86 (-6.73, 5.39) 0.78 (0)
Fibrinogen (g/l)† - - - General
population
11 (35,430) 0.005 (0.001, 0.009) 0.02 (0)
ACS - - -
Apolipoprotein A
(g/l)
- - - General
population
7 (27,012) 0.001 (-0.005, 0.007) 0.66 (0)
ACS 1 (931) -0.22 (-0.98, 0.54) 0.57 (-)
Apolipoprotein B
†Ψ
2 (249) -0.78 (-1.05, -0.52) 8.0x10-9 (94) General
population
7 (27,168) 0.43 (-0.11, 0.98) 0.12 (26)
ACS - - -
LDL size (nm) 2 (247) 0.23 (0.19, 0.26) 1.4x10-41 (19) General
population
1 (2774) 0.01 (-0.03, 0.05) 0.57 (-)
ACS - - -
HDL size (µm) - - - General
population
1 (2774) 0.01 (-0.02, 0.04) 0.60 (-)
ACS - - -
LDL particles
(nmol/l)
2 (247) -19.01 (-516.86,
478.84)
0.94 (0) General
population
1 (2774) 3.70 (-23.19, 30.60) 0.79 (-)
ACS - - -
HDL particles
(umol/l)
1 (157) 0.70 (-8.08, 9.48) 0.88 (-) General
population
1 (2774) -0.16 (-0.51, 0.19) 0.38 (-)
Continued on next page
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Table 5.4 – Continued from previous page
Randomized trials of varespladib (500mg/day) Genetic studies of rs11573156 (per C allele)
Biomarker (units) No. of trials
(individuals)
Summary effect (95%
CI) *
P value,
(I2, %),
Setting No. of studies
(individuals)
Summary effect
(95% CI)
P value,
(I2, %)
ACS - - -
Footnotes Abbreviations: see Glossary. † relative units presented for the genetic analysis as variable log transformed (units do not apply) * represents mean difference
in biomarker from baseline to 8 weeks (most parsimonious time-point) comparing varespladib 500mg/day to placebo Ψ RCT summary effect for Apolipoprotein B is the
standardized mean difference as different units reported in RCTs.
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5.2.10 Instrumental variable analysis of sPLA2-IIA mass, sPLA2 en-
zyme activity and CVD
5.2.10.1 General population studies
With information on the association of the C-allele of rs11573156 with sPLA2-IIA mass
and sPLA2 enzyme activity, and information on the association of the rs11573156 C-
allele with MVE, I was able to triangulate the ‘causal’ effect for a one log unit lower
sPLA2-IIA and sPLA2 enzyme activity (Figure 5.10).
sPLA2
PLA2G2A rs11573156
MVE
“true association”
estimate 1 estimate 2
Figure 5.10: Triangulation of the causal association between sPLA2 traits and major
vascular events (MVE)
The “true association” is obtained by dividing estimate 2 by estimate 1. The variance of this
instrumental variable estimate was obtained using the delta method (as previously described).
For the general population studies, instrumental variable analysis showed a null effect
between sPLA2-IIA mass and incident MVE (OR per one log unit lower sPLA2-IIA
mass: 1.04; 95%CI: 0.96, 1.13). This was in clear contrast to the expected association
based on observational analysis (OR 0.69, 95%CI: 0.61, 0.79) (Figure 5.11).
Similarly, whereas observational studies showed an OR of 0.50 (95%CI: 0.35, 0.71) for
incident MVE per one log unit reduction in sPLA2 enzyme activity (Figure 4.3), I ob-
tained only null associations for the instrumental variable estimates for sPLA2 enzyme
activity and incident MVE (OR 1.87, 95%CI: 0.47, 7.49). However, in this case the con-
fidence intervals were wide due to the weak effect of the rs11573156 variant on sPLA2
enzyme activity in the general population (as shown in Figure 5.4).
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5.2.10.2 Acute Coronary Syndrome studies
For the ACS studies, the instrumental variable estimate for sPLA2-IIA mass and recur-
rent MVE was null (OR per one log unit lower sPLA2-IIA mass: 0.93; 95%CI: 0.83,
1.05). This was consistent with the null findings from observational studies (OR 0.92;
95%CI: 0.81, 1.03). For sPLA2 enzyme activity, no association was identified for the
instrumental variable estimate with MVE (OR 0.86, 95%CI: 0.66, 1.12), but the results
were similar to those obtained from observational studies (OR 0.77, 95%CI: 0.64, 0.93)
(Figure 5.11).
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0.69(0.61,0.79)
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Þ Nonfatal MI
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Major Vascular Events
Fatal/nonfatal MI
Observational analysis
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13(4208/51016)
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sPLA2 ENZYME ACTIVITY
0.95(0.64,1.42)
0.54(0.23,1.26)
0.86(0.58,1.28)
0.86(0.66,1.12)
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Odds Ratio (95%CI)
Þ Nonfatal MI
Þ Nonfatal Stroke
Þ Fatal MI/Stroke
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Studies(Cases/Total)
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Figure 5.11: Observational and instrumental variable estimates per 1 log unit lower sPLA2-IIA mass and sPLA2 enzyme activity with cardiovascular
events
The observational analyses were adjusted for age, gender, BMI, blood pressure, T2D, LDL-C, HDL-C, TG in general population cohorts (corresponding to Model 3 in Figure 4.3)
and for age, gender, BMI and BP in ACS cohorts (corresponding to Model 2 in Figure 4.3).
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5.3 Discussion
In this chapter, I described the methods and presented results from use of a genetic
approach to make causal inference on the role of sPLA2-IIA in CVD. This method of
investigation provides an un-biased approach to evaluate the causal role of sPLA2-IIA
and in doing so, evaluates whether inhibition of sPLA2-IIA might represent a valid ther-
apeutic target for cardiovascular prevention.
5.3.1 SNP selection
For the SNP selection process, out of six SNPs that had been previously identified to
detect the majority (≥90%) of variation within the PLA2GA gene in individuals of
European descent,[339] I selected the SNP that had the largest effect on circulating
sPLA2-IIA mass and took it forward to conduct the Mendelian randomization analysis.
5.3.1.1 Specificity of genetic instrument for sPLA2-IIA mass
Using data on the expression of mRNA, I demonstrated the specificity of this rs11573156
SNP (using a proxy SNP with which rs11573156 was in high LD on the Illumina chip,
rs10732279) for the sPLA2-IIA isoform, by showing no evidence of association between
the proxy SNP with mRNA expression of sPLA2-V or sPLA2-X (Figure 5.2). This was
important because if the SNP had shown association with other sPLA2 isoforms, the
interpretation of the genetic and instrumental variable analyses might be problematic
due to issues of non-specificity that would arise. This could mean that an apparent as-
sociation may not be due to sPLA2-IIA and/or a negative result could arise by negative
confounding from association of the SNP with another trait. Fortunately, the specificity
of the SNP for the intermediate phenotype illustrated in the mRNA Manhatten plot
meant this was not a likely scenario.
5.3.1.2 Strength of genetic instrument on sPLA2-IIA mass
The effect of the PLA2G2A rs11573156 variant on sPLA2-IIA mass and sPLA2 enzyme
activity is worthy of comment. The rs11573156 SNP explained between 6% to 21% of
the variance of sPLA2-IIA, a value that is several times higher than that observed for
all the GWAs hits combined on blood pressure (R2=1% for 29 SNPs)[377] and similar
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to that for 49 SNPs for LDL-C together (R2=12%).[378] Thus a single SNP explained
a huge proportion of variance of the intermediate trait in this case, reducing the risk of
weak instrument biasd.[379]
5.3.2 Comparison of findings from genetic association analysis with
findings from observational analysis for continuous traits
In contrast to the observational findings presented in Chapter 4, which revealed strong
associations between the two sPLA2 traits (sPLA2-IIA mass and sPLA2 enzyme activ-
ity) and several established cardiovascular risk factors in the general population studies,
I did not identify corresponding associations between the PLA2G2A rs11573156 C-allele
variant with these risk factors (Table 5.4). This is important for two reasons. First,
it shows the relative specificity of the SNP for sPLA2 phenotypes. Second, it makes it
unlikely that these cardiovascular traits could lie on a potential causal pathway between
sPLA2 and CVD (this possibility was discussed in the Discussion section of Chapter 4).
I did identify a weak association between the SNP and fibrinogen and interleukin 6
(Table 5.4), however curiously, the direction of effect was opposite to that expected. I.e.
the SNP that lowered sPLA2-IIA may be expected to lower inflammatory markers (by
having less arachidonic acid yielded stimulating less IL-6[380]), however the opposite was
observed and the SNP associated with increases in both IL-6 and fibrinogen. However,
these findings require replication.
5.3.3 Comparison of findings from genetic association analysis with
findings from observational analysis for major vascular events
Despite the strength of association of the genetic variant on sPLA2-IIA and accruing a
collaboration of 32 studies with >8,000 incident, >7,500 prevalent and >2,500 recurrent
MVE, I found no association between rs11573156 and prevalent, incident, or recurrent
major vascular events on a genetic association (or instrumental variable) analysis. These
dThe whole purpose of conducting Mendelian randomization analyses is to minimize the bias caused
by confounding between the exposure of interest and outcome. However, instrumental variable analyses
do suffer from finite sample bias termed weak instrument bias. The bias arising from a weak instrument
is in the direction of the observed confounded association. The strength of the genetic instrument can be
quantified by the F-statistic (or R2) obtained from conducting a regression of the intermediate phenotype
on the genetic variant. The bias of the instrumental variable estimator is quantified as the relative bias
compared to the observational estimate: as approximately 1/F. Thus when the F-statistic is 10, the IV
estimate has 10% of the bias of the observational estimate.[379]
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findings provide strong evidence that the observational association between sPLA2-IIA
mass and cardiovascular events is due to residual confounding or reverse causality.
5.3.4 Placing these findings into context of the VISTA-16 phase III
clinical trial
One of the main reasons of conducting a Mendelian randomization experiment is to
serve as a proxy for a randomized trial. Fortuitously, at the same time as the Mendelian
randomization experiment reported in this Chapter was conducted, a phase III trial was
also carried out, which can be considered as a “positive control” (although the drug
was not specific for the sPLA2-IIA isoform, whereas the SNP was; Figure 3.10). The
VISTA-16[337] trial of varespladib was stopped due to lack of efficacy following a rec-
ommendation by the Independent Data Safety Monitoring Board.[381, 382]
The VISTA-16 trial (NCT01130246) had enrolled 5189 individuals out of a planned 8500
(i.e. just over 60% of the intended sample size), and randomized individuals recruited
within 96hrs of hospitalization for ACS to 500mg/day varespladib or placebo for 16
weeks duration of therapy. Follow-up was for 6 months with the primary outcome
being a composite outcome of cardiovascular death, non-fatal MI, non-fatal stroke or
documented unstable angina (i.e. an outcome very similar to the outcome used for
MVE in the Mendelian randomization analysis that I present in this Chapter).
The Data Safety Monitoring Board (DSMB) conducted an interim analysis of VISTA-16
when 383 events (of which 212 were adjudicated to be primary composite events) were
accrued, relating to approximately 50% of the primary outcome events that were desired
according to the power calculation (full details provided on page 234 of Appendix C).
Analysis was by intention to treat and found that allocation to varespladib resulted in
a hazards ratio of 1.24 (P=0.16) compared to placebo for the primary outcome (fatal
CVD, nonfatal MI/stroke, unstable angina). The interim analysis also identified an in-
creased occurrence of nonfatal MI (HR 1.67; P=0.01) in patients randomized to receive
varespladib. Given these interim findings, the DSMB recommended the study’s prema-
ture termination.[381, 382]
It is reasonable to speculate that the null findings from this Mendelian randomization
analysis provides an explanation for the lack of efficacy of varespladib in the VISTA-16
trial. I.e. that sPLA2-IIA is not causally involved in CHD aetiopathogenesis.
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5.3.5 Lack of association of sPLA2 with MVE on observational analysis
in ACS cohorts and implications for drugs targeting sPLA2 for
CVD prevention
The lack of observational association between sPLA2 traits with recurrent MVE in the
ACS setting may seem to challenge the pursuit of a drug that inhibits sPLA2-IIA mass
for the prevention of recurrent events (such as in the VISTA-16 trial). However, two
things are worthy of comment. First, when the VISTA-16 trial was initially planned,
there was small-scale evidence that sPLA2-IIA mass associated with recurrent CHD
events in patients with ACS.[337] Furthermore, the association of sPLA2-IIA mass with
recurrent events in patients with stable CHD is widely reported.[318, 320, 383] Second,
evidence on the observational association between a biomarker and disease is typically
initially measured in general population studiese, while trials of preventative therapies
are usually first undertaken in the secondary prevention setting (as these “high-risk”
individuals have more clinical events, which increases statistical power and allows for a
smaller clinical trial to be conducted).[384]
5.3.6 Limitations
This work has several limitations that are worthy of mention. First, I did not have
data from a common set of participants with all three key variables: sPLA2 measures,
genetic information and cardiovascular events. However, this is a common scenario
with large-scale meta-analyses of Mendelian randomization studies that include novel
biomarkers,[371, 385] and the instrumental variable approach I used helps to overcome
this problem. Specifically, by assuming a common fixed effect of the SNP on the in-
termediate phenotypes (sPLA2-IIA mass and sPLA2 enzyme activity), I was able to
apply this estimate to studies that did not have sPLA2-IIA mass and sPLA2 enzyme
activity measured. This enabled the synthesis of instrumental variable estimates for all
contributing studies.
Second, due to the specificity of rs11573156, the genetic analyses do not provide in-
formation on the role of sPLA2-V or -X in CVD and cannot exclude a possible causal
role for these subtypes. Varespladib was originally designed to inhibit the sPLA2-IIA
form.[329], but studies have shown that varespladib has additional effects on subtypes
-V and -X,[386] however with 5-10 fold lower inhibitory efficacy.[387] The genetic data
do however provide strong evidence against a causal role of the sPLA2-IIA isoform in
ein this case, there is strong evidence of an association between both sPLA2 traits with incident
MVE, as shown in Figure 4.3
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incident and recurrent MVE. This is further reinforced by the negative findings from
the VISTA-16 trial.[381]
Third, given the smaller number of subjects in studies set in ACS, I had reduced power to
exclude a small association with recurrent MI or stroke if they were real, as evidenced by
the partial overlap of the expected and observed effect estimates for sPLA2-IIA mass and
sPLA2 enzyme activity with CVD in this setting. However, the genetic analysis includes
2520 recurrent MVE in patients with ACS, which is more than 6-fold greater than the
385 primary events that VISTA-16 intended to recruit.[337] Furthermore, comparing
individuals homozygous for the rs11573156 C allele to those homozygous for the G allele
(an “extreme” genotype comparison, excluding individuals heterozygous for rs11573156)
resulted in a 62% reduction in sPLA2-IIA mass, similar to the effect of 500mg/day
varespladib (78% reduction). Even this extreme genotype comparison failed to show
association with incident or recurrent MVE (OR 0.99; 95%CI: 0.89, 1.10 and OR 0.89;
95%CI: 0.74, 1.06, respectively).
5.3.7 Comparison to other Mendelian randomization studies of sPLA2
The findings I report here are in contrast to a previous small Mendelian randomization
study, based in the KAROLA study.[383] The KAROLA study contributed towards the
genetic analysis of ACS studies presented in this Chapter. Examination of the forrest
plot (Figure 5.9) shows KAROLA to have an association consistent with a beneficial
effect of sPLA2-IIA reduction in preventing recurrent nonfatal CHD events (OR 0.64,
95%CI, 0.64 to 1.01) however the upper limit of the 95% CI included the null value
of 1.0. However, it can be seen from Figure 5.9 that the larger ACS collections (with
several-fold more events) had null associations of the rs11573156 SNP with recurrent
CHD events, making it likely that the association identified in KAROLA represented a
chance finding. Furthermore, the composite of fatal MI/stroke or all-cause mortality in
KAROLA yielded an OR of 1.12, which was directionally opposite to that for nonfatal
MI, meaning that the estimates were not internally consistent for components of the
MVE outcomes in KAROLA (Figure 5.9).
5.3.8 Implications for future Mendelian randomization work in sPLA2
traits
The work I present here has important implications for ongoing development of drugs for
other (non-IIA) sPLA2 inhibitors.[388] A Mendelian randomization study using genetic
instruments for other sPLA2 isoforms would be an important complement to the current
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study and will help to inform the drug-development process of these new compounds,
before proceeding into phase III trials. However, identification of a specific instrument
for other non-IIA sPLA2 isoforms will require development of assays that quantify their
mass to be able to test the strength and specificity of the genetic instrument, an essential
step that I conducted in this work. These novel biomarkers would then also need to be
validated in large-scale epidemiological studies.
However, conducting a Mendelian randomization analysis for sPLA2-V and sPLA2-X
based on sPLA2 enzyme activity (as an intermediate trait) alone would represent an
imprecise approach and may lead to the selection of inappropriate genetic instruments
that may yield invalid conclusions about the validity of sPLA2-V or sPLA2-X as drug-
targets for cardiovascular events.
5.4 Conclusion
In conclusion, this large-scale Mendelian randomization study does not support the
hypothesis that sPLA2-IIA mass is causally linked to cardiovascular events and thus
sPLA2-IIA does not represent an appropriate drug-target for cardiovascular disease pre-
vention. The concordance of the genetic findings with the lack of efficacy of the vares-
pladib phase III randomized trial[381] supports the use of this genetic approach earlier
in drug development to prioritise which drug targets to follow in human randomized
trials and reduce the risk of expensive late-stage drug failure.
Chapter 6
Alcohol and cardiovascular
disease
6.1 Introduction
6.1.1 Alcohol consumption and the global burden of disease
Alcohol consumption is considered to be a contributory cause to more than 200 ICD-
10 conditions (Box 6.1) and is most strongly associated with liver cirrhosis and oro-
pharangeal cancers.[389, 390]
Box 6.1. Examples of diseases to which alcohol
contributes:
 Injuries (accidental and intentional)
 Liver cirrhosis
 Cancer
 Neuropsychiatric disorders
 Low birth-weight
From Rehm et al [389]
In the 2010 global burden of disease survey, alcohol consumption was the third leading
risk factor for death and disability (after high blood pressure and smoking), accounting
for 5.5% of global disability-adjusted life years.[391] Given the considerable worldwide
consumption of alcohol (Figure 6.1), even a small increase in disease risk attributable
to alcohol could have potentially huge impacts on population health.
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Figure 6.1: Worldwide distribution of alcohol consumption
From Rehm et al [389]
6.1.2 Alcohol and coronary heart disease
Despite the un-disputed effects of alcohol on cancer, injuries and mental health, the
role of alcohol in cardiovascular health remains the source of ongoing debate.[392–394]
Observational studies consistently report that, compared to individuals that abstain,
moderate alcohol intake (even up to as much as 90 grams per day) is associated with a
reduction in risk of CVD (Figure 6.2).[395, 396]
This potential cardioprotective effect of alcohol is thought to operate through several
pathways (Box 6.2) including alterations in circulating blood lipid levels, most no-
tably raised HDL-C (which has been proposed to mediate approximately half of the
cardioprotective association of alcohol[397, 398]) and reduced platelet aggregation pre-
venting thrombus formation,[398–401] a key step in the manifestation of a myocardial
infarction.[402] Observational evidence also suggests that alcohol may reduce the risk
of diabetes, through increased insulin sensitivity, mediated through adiponectin.[403]
Some studies have suggested that red wine may be particularly cardioprotective due to
flavonoid and resveratrol content[404]; however this is controversial, as recent reports
suggest that this evidence may have been in part fabricated.[405]
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Box 6.2: Associations of alcohol with traits thought to be involved in cardiovascular
disorders
 Lipids
– HDL-C: observational studies show that HDL-C is strongly inversely related to
cardiovascular disease,[406] and that alcohol increases HDL-C in a dose-dependent
fashion.[407] Therefore, by increasing HDL-C, it is suggested that alcohol may
reduce CHD risk. However, the cardioprotective role of HDL-C has been brought
into question through a recent Mendelian randomisation study using multiple
SNPs, which failed to identify a causal relationship between HDL-C and CHD[408],
and a phase III clinical trial of a drug that increased HDL-C (dalcetrapib), which
was terminated due to futility.[409]
– Triglycerides: observational studies indicate that alcohol intake reduces
triglycerides, a circulating lipid component that strongly associates with increased
cardiovascular risk on observational anlaysis[406]
 Inflammation: alcohol shows a U-shaped association with fibrinogen.[410] This is of
potential relevance as atherosclerosis is considered to have an inflammatory
component[230] and although fibrinogen is not itself thought to be causally related to
CVD[411], it may reflect underlying inflammation. If alcohol acts as a ‘general’
anti-inflammatory agent, then this could mediate a reduced risk of CVD
 Haemostasis (blood coagulation): alcohol is associated with an improved coagulation
diathesis - i.e. observational studies suggest that alcohol makes blood less likely to
coagulate as evidenced by increased levels of plasminogen (a circulating blood enzyme
that degrades plasma proteins involved in fibrin clots).[401] As described in Chapter 3, a
fibrin clot (or thrombus) complicating a ruptured atherosclerotic plaque is often the
initiator of an acute myocardial infarction.
 Insulin sensitivity: alcohol shows an inverse dose-response relationship with type 2
diabetes (T2D) risk[412]. It is possible that the mechanism could be mediated via
adiponectin.[413–415] Alcohol increases adiponectin, which is inversely associated with
risk of T2D.[416] T2D is itself associated with a 3-4 fold increase in CVD risk,[417] thus
the prevention of T2D may be another mechanism by which alcohol reduces CVD risk.
 Oestrogens: alcohol intake is associated with higher oestrogen levels.[418] Women are
recognized as having a substantially lower risk of CHD than men,[419] and this was
thought to be, at least, partially mediated through circulating oestrogen levels. However,
the oestrogen-cardioprotection hypothesis was cast into doubt by evidence from RCTs of
hormone replacement therapy (drug combinations that include oestrogen) that, contrary
to the observational associations,[53] detected that oestrogen-containing hormone
replacement therapy increased CVD risk.[54]
Despite the reported beneficial effects of alcohol on cardiovascular health, there is a pos-
itive dose-response association between alcohol consumption and blood pressure across
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Figure 6.2: Association of alcohol with CHD from 51 observational studies.
The nadir is at 25g/day and the point where the relative risk is greater than that of ab-
stainers is 90g/day. The blue dashed horizontal line represent the null effect (relative
risk=1.0) where alcohol has no effect on risk of CHD, compared to non-drinkers.
Adapted from Corrao et al [395]
the whole distribution range of alcohol consumption.[420–422] Therefore if the cardio-
protection of alcohol were ‘real’ (i.e. not due to confounding or bias), alcohol would
need to have an effect on other traits that more than offset the blood-pressure raising
effect.
6.1.3 Influence of purported effects of alcohol on CHD on UK govern-
mental guidance
This observational association between alcohol and CVD has influenced guidance from
the UK government on safe drinking practices.[423] Original guidelines (circa 1987)
were based on a Royal College of Physicians report ‘The medical consequences of alco-
hol abuse; a great and growing evil’, which stated that there was no safe level of alcohol
consumption, and, considering the association of alcohol with various diseases, ‘sensible
limits’ of 21 and 14 British unitsa in men and women per week were advised (including
2 or 3 days without any alcohol).[423]
However, in 1995, a government inter-departmental working group considered the evidence-
base that alcohol might be protective to CHD, and revised guidance to suggest that daily
or near-daily drinking was permissible, with recommended limits of up to 4 units of alco-
hol per day.[424] This was highly controversial,[425] with the main criticisms levied that
the working group did not contain scientists and that it sanctioned two key behaviours
a1 British unit=10 ml or 7.9g ethanol = 0.57 US units
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that were recognized as strongly associated with alcohol-related harm and dependency -
namely (i) daily drinking, and (ii) an increase in the recommended safe limit of alcohol
volume per week.
More recently, a Science and Technology Committee (appointed by the House of Com-
mons) in 2012 called for an update on the 1995 guidelines. The committee recommended
that more emphasis should be placed on the evidence of harm from alcohol, and called
for a more measured interpretation of the potential beneficial effects of alcohol on CVD
risk.[426] This re-review is currently underway with updated guidance expected in late
2013.[427]
It is interesting that government advice on alcohol consumption should be altered to
increase the safe consumption amounts on the basis that it may afford cardiovascular
protection. Given the vast data accrued that demonstrates the harm from alcohol,[428]
it is important to weigh the possible beneficial effects on CVD together with the es-
tablished harm.[429] For example, it is estimated that alcohol is responsible for 863,300
hospital admissions and 30,000 to 40,000 deaths per annum in the UK with the eco-
nomic impact of alcohol costing GBP20-55 billion per annum.[430] A recent study that
modelled data for benefits (cardiovascular) and harms (cirrhosis and cancer) arising
from alcohol using estimates derived solely from observational data showed that, taking
the magnitude and directionality of the different associations into account, the optimal
population consumption of alcohol should be 5g per day (approximately half a British
unit).[431] This is well below the present guidance.
6.1.4 Limitations of observational evidence
To date, most large-scale epidemiological investigations of alcohol intake and its associ-
ation with human health have been conducted using observational (non-interventional)
research, which are limited in the inferences that can be made (see Chapter 1, Introduc-
tion).
Some additional limitations are specific for alcohol, and are worthy of mention. These
include:
measurement error: most studies rely on self-reported alcohol consumption, which is
a subjective trait, thus, accurate measurement may be hindered by recall biases.
For example, survey estimates of alcohol consumption substantially underestimate
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consumption in relation to data from sales [432] and may be influenced by specific
aspects of the question and the reference period.
selection bias: heavy drinking individuals may be under-represented in traditional co-
hort studies.[433]
reverse causality: one of the potential explanations for the J-shape association be-
tween alcohol and CHD (Figure 6.2) is that the relative protection from indi-
viduals that consume low amounts of alcohol could arise from individuals clas-
sified as abstainers who have in fact stopped drinking due to disease (so-called
“sick-quitters”[434, 435]) or they may be ill for other reasons. Contamination of
non-drinkers by sick-quitters and use of this group as the reference can spuriously
create an apparent protective effect for individuals that drink moderately (a form
of reverse causality).
confounding: alcohol is highly correlated with several confounders such as age[436],
gender[437], marital status[438], smoking[439], socioeconomic status,[440–442] men-
tal health[443], physical activity[444] and educational attainment[445–447]. If con-
founding traits are more strongly associated with alcohol at differing levels of alco-
hol exposure (i.e. non-linear confounding[443, 448]), this could create an apparent
J-shape curve.
These features severely limit inference on the causal relevance of alcohol for CVD based
on observational evidence alone.
6.1.4.1 The J-shaped curve
The reported J-shape in the association between alcohol and CVD is not unique to
this scenario. For example, other J-shaped relationships between exposures and disease
outcomes have been reported for:
1. obesity and all cause mortality[449]
2. exercise and CVD[450]
3. sleep and CVD[451, 452]
There has been debate about whether J-shapes can ever reflect true causal associations,
or whether they fundamentally represent an artifact, and the potential implications that
this uncertainty has for approaches to translating such observational data to improve-
ments in population health.[453–457] For example, in all the above cases, a J-shape can
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be introduced by reverse causation influencing the baseline group (i.e. analogous to the
“sick-quitters” phenomenon) or confounding by social factors in those exposed to low
levels of the exposure of interest. For instance, a J-shape was thought to exist between
BP and CVD[458, 459], however this was over-turned by subsequent larger studies, that
have shown a dose-response relationship and the absence of a plateau (i.e. no “safe” level
beneath which a further reduction in BP does not afford further CVD protection).[460]
6.1.5 Experimental and interventional studies
Several interventional studies of alcohol exposure have been conducted to investigate the
association of alcohol with cardiometabolic traits. A recent systematic review and meta-
analysis summarized data from interventional studies,[461] and identified that alcohol
showed strong positive associations with HDL-C, adiponectin and apolipoprotein-A1
and negative associations with LDL-C and fibrinogen. These data provide support for
the hypotheses that alcohol increases HDL-C and reduces inflammatory markers, and
by doing so, adds credibility that alcohol may be cardioprotective.
However, a few limitations of the data reported in the recent meta-analysis[461] are
worthy of comment. Of the 63 interventional studies identified by the systematic re-
view, only 32 (representing 1112 of 1762 participants, 63%) of them were randomized
in design. Thus the majority of studies were subject to the usual limitations of non-
randomized evidence (i.e. in this case, participant and investigator bias may have played
an important source of error). Second, the sample size of the interventional studies was
very small, with the median sample size being only 19 (min=5, max=100), as shown
by the frequency histogram in Figure 6.3. Finally, all studies were of short duration
(range 1 to 8 weeks), making it questionable whether the findings can be extrapolated
into long-term differences in exposure to alcohol.
Although the authors reported no evidence of small study bias, in the absence of any
large studies (i.e. no single study had a sample size greater than 100 individuals), the
test of small study bias would only compare the effects between the existing small stud-
ies and would not be able to detect presence of bias.[462]
With the preponderance of small studies, potential for bias (both at the study and
publishing level) and confounding, and the lack of interventional studies designed to in-
vestigate clinical outcomes (such as CHD or stroke), the available experimental evidence
of alcohol from interventional studies is inadequate to draw conclusions on the effect of
alcohol on risk of cardiovascular disease.[392]
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Figure 6.3: Frequency histogram of the sample size of studies included in the
meta-analysis of interventional studies of alcohol reported by Brien et al[461]
6.1.6 Ideal study design
The ideal scenario, which would yield the most reliable evidence on the causal relevance
of alcohol in CVD, would entail randomizing a large group of individuals to receive
differing amounts of alcohol, with participants followed up over several years for incident
vascular events. There is sufficient clinical equipoise (i.e. lack of decisive evidence) as
to whether alcohol is beneficial at low doses to cardiovascular health to support such a
trial. However, the other (non-CVD) harms from alcohol,[389, 390] together with the
high-cost of such a trial are likely to make it impractical. Furthermore, maintenance of
blinding and challenges in identifying the optimal means to the intervention (e.g. dietary
advice vs. a concealed liquid to drink daily) may add further complexities to this trial
design.[463]
Fortunately, there is an alternative yet complimentary investigative avenue that provides
an opportune means of yielding deconfounded evidence - Mendelian randomisation.
6.1.7 Genetic contribution to alcohol consumption
In order to be able to use a gene as an instrumental variable for alcohol consumption,
a proportion of variance of alcohol consumption must be related to the genetic variant.
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Figure 6.4: Alcohol metabolism. The rectangles represent enzymes involved in
metabolism. Acetaldehyde is the first active breakdown product generated during alco-
hol metabolism. Additional pathways exist through the hepatic enzymes.
A meta-analysis of 72 studies that estimated the heritability of alcohol misuse yielded
a weighted mean heritability estimate of 0.12 (95%CI: 0.11, 0.12).[464] This indicates
that a reasonable proportion of variability in alcohol consumption arises from genetic
predisposition, suggesting that it may be possible to use Mendelian randomization to
investigate causal relationships between alcohol and vascular disease.
6.1.8 Use of Mendelian randomization to investigate alcohol consump-
tion
Unlike ‘traditional’ Mendelian randomization that uses a gene variant that has speci-
ficity for an endogenous biomarker such as sPLA2-IIA, as I described in Chapter 5
(Randomized Evidence on sPLA2 and Cardiovascular Disease based on Genetic Stud-
ies and Trials), alcohol is an exogenous exposure and its consumption is a behavioural
characteristic that is determined by many social and cultural factors including age, ed-
ucation, smoking status, diet, religion and gender.[465, 466] Thus alcohol consumption
per se is not directly encoded by any single gene. However, the metabolism of alcohol
provides an opportunity to use a SNP involved in the metabolic pathway as a proxy for
alcohol consumption.
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6.1.9 Metabolism of alcohol
The metabolism of alcohol occurs principally in the liver.[467] Alcohol is metabolised
by several enzymes (Figure 6.4),[468] the first of which is alcohol dehydrogenase, which
oxidizes alcohol and yields acetaldehyde. Acetaldehyde is a metabolite that yields par-
ticularly unpleasant symptoms of flushing, tachycardia and nausea, and a correlation
has been reported between the level of circulating acetaldehyde and the symptomatic
flushing response to alcohol consumption.[469]
Acetaldehyde is then oxidized to acetate, a step that is catalysed by aldehyde dehy-
drogenase. Acetate is finally metabolized in tissues into carbon dioxide (expired in the
breath) and water.
In addition to this primary metabolic pathway, other enzymes such as the hepatic cy-
tochrome P450 CYP2E1 enzyme can play a role in alcohol metabolism.[470]
Variants in genes encoding the enzymes involved in alcohol metabolism may alter the
catalytic properties of the encoded enzyme, which can impact upon alcohol metabolism,
and in particular influence levels of acetaldehyde.[471] Individuals that possess genetic
polymorphisms that associate with higher acetaldehyde exposure in response to alco-
hol consumption are therefore less inclined to consume alcoholic beverages - a form of
negative feedback.[471, 472]
6.1.10 Alcohol dehydrogenase (ADH1B)
Alcohol dehydrogenase catalyses the oxidation of alcohol to acetate and forms the ini-
tial step in the metabolic pathway of alcohol (Figure 6.4). The ADH1B enzyme was
first characterised in 1977, when it was termed II-ADH.[473] The gene that encodes
the ADH1B enzyme (alcohol dehydrogenase 1B (class I), beta polypeptide, ADH1B), is
located on chromosome 4 and contains 9 exons (Figure 6.5).
The ADH1B rs1229984 SNP is bi-allelic with the two variants being G and A. The A al-
lele has an allele frequency of approximately 2-5% in Europeans.[474, 475] Possession of
the A-allele results in a change in amino acid from Arginine to Histidine. This amino acid
alteration results in increased ADH1B enzyme activity - activity is increased by 40 to
100 times (as measured by Vmax and Km, respectively for ethanol oxidation).[476, 477]
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Figure 6.5: ADH1B gene with exons illustrated as boxes.
The location of rs1229984 SNP is also shown. Obtained from dbSNP.
6.1.10.1 Association of ADH1B rs1229984 with alcohol indices
Several studies have examined the effect of the ADH1B rs1229984 allele on measures of
alcohol consumption.
For example, compared to individuals homozygous for the G-allele, individuals carrying
the rare (A-allele) variant at the rs1229984 locus:
 have a higher maximum rate of alcohol metabolism (Vmax)[478]. This fits with the
hypothesis that A-allele carriers, who have higher ADH1B enzyme activity, have
an increased conversion of alcohol to acetaldehyde. This increased acetaldehyde
concentration for a given exposure to alcohol would be expected to reduce exposure
to alcohol consumption on average when compared to individuals who do not carry
the A-allele
 report subjective feelings of flushing in response to alcohol[471, 479]
 are less likely to report alcohol dependence.[480–484]
 consume fewer units of alcohol per week[485]
 are more likely to report abstention from alcohol[485]
Collectively, the evidence supports the hypothesis that individuals that carry the A-allele
at the rs1229984 locus are exposed to less alcohol consumption.
6.1.10.2 Association of ADH1B rs1229984 with recognized associations of
alcohol
One way to test that the genetic variant is serving as a proxy for alcohol consumption
is to examine the association of the variant with a ‘known’ outcome for alcohol - for
example oesophageal cancer.
Chapter 6. Alcohol and cardiovascular disease 146
Previous investigations of ADH1B rs1229984 have shown association of the A-allele with
a reduced risk of alcohol-related diseases including upper aerodigestive cancer [486] and
esophageal cancer[487] (and this is in the expected direction as rs1229984 A-allele car-
riers consume less alcohol).
Prior to 2013, the association of ADH1B with cardiovascular outcomes and biomarkers
was limited to single studies[488, 489] and/or meta-analyses[490] of small numbers of
studies lacking adequate statistical power to detect meaningful effects.
Thus a natural extension to previous work is to build up a large-scale collaboration to
use the rs1229984 variant to investigate the role of alcohol in CHD.
6.1.11 Use of ADH1B rs1229984 to investigate CHD
When using a genetic variant to investigate the association of alcohol with CHD, it is
worthy to consider the underlying observational association and the implications this
has for the interpretation of an estimate obtained from a genetic analysis. Recall that
in Figure 6.2 the observational association between alcohol and CHD was curvilinear,
with a nadir at 25g/day.
In Figure 6.6, two potential scenarios are contrasted. First, on the left we have indi-
viduals that consume low amounts of alcohol. We can see that if an individual is an
A-allele carrier, because they are expected to drink a lower amount of alcohol than an
individual that is homozygous for the G-allele (owing to the underlying genetic variant,
the implications this has on alcohol metabolism and the feedback this has on alcohol-
related behaviours), the A-allele carrier would be expected to have a higher relative risk
of CHD (compared to the GG carrier). This is because the left hand side of the figure
is to the left of the nadir (the point at which the RR of CHD is lowest compared to
non-drinkers), and therefore any reduction in alcohol (e.g. resulting from carriage of the
A-allele of rs1229984) is associated with an increased risk of CHD.
In contrast, when we examine the right of Figure 6.6, we are now on the right side of
the minimum. Individuals that possess the A-allele (that drink less alcohol than GG
carriers) would be expected to have a lower risk of CHD compared to individuals that
are homozygous for the GG variant. This is because at this part of the curve, a reduction
in alcohol is associated with a reduction in CHD risk.
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The implication is that, if the curvilinear association is ‘true’, the association of the
ADH1B rs1229984 on CHD risk will vary according to the amount of alcohol consumed,
and where this lies on the curve.
In contrast, if the ‘true’ association is linear then the effect of the SNP will be consistent
at all levels of alcohol intake.
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Figure 6.6: Implications of the observational association between alcohol and CHD on
the interpretation of genetic associations of ADH1B with CHD
6.1.12 Consideration of worldwide ADH1B genotype frequency
The ADH1B genotype frequency is strongly associated with geographical location (Fig-
ure 6.7), which probably represents the pattern of population migration from Africa to
Europe and North America (Figure 6.8). However, alternative explanations include the
geographical variation in consumption of fermented rice.[491]
This worldwide difference in ADH1B genotype frequency introduces the potential for
confounding by population stratification, especially as geographical region is associated
with both alcohol intake (Figure 6.1)[492] and cardiovascular events.[493]
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Figure 6.7: Contour plot of the allele frequency of ADH1B worldwide. The darker the
shading, the higher the proportion of individuals that carry the ADH1B rs1229984 A-
allele variant. Reproduced from Li et al.[494]	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Figure 6.8: Routes of migration of ADH1B genotype. The letters (H1-H7) refer to hap-
lotypes. Reproduced from Li et al.[495]
Fortunately, practical solutions to this problem exist (as outlined in Chapter 1), includ-
ing limiting analysis to European individuals, interrogating the genotype frequency of
included studies (to identify evidence of non-European admixture), and adjusting for
population stratification where possible using principal components analysis.[94]
6.1.13 Mendelian randomization investigations of alcohol and human
health using ALDH2 genotype
Aldehyde dehydrogenase is an enzyme that is responsible for catalysing the oxidation
of acetaldehyde into acetate, the second step in the metabolic pathway of alcohol (Fig-
ure 6.4). The ALDH2 rs671 variant, a non-synonymous SNP, is located on chromosome
12. The A variant (Glu504Lys in exon 12, also termed ∗2) results in a change from a
glutamate at amino acid 487 to lysine, which results in decreased enzymatic activity of
ALDH2. Individuals homozygous for the A allele have almost no enzyme function and
individuals with one copy of the A-allele have 60% lower enzyme activity than those
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homozygous for the G allele.[496]
ALDH2 rs671 genotype associates with several alcohol-related phenotypes including the
flush response to alcohol intake (a consequence of acetaldehyde),[497] volume of alcohol
intake[498], including binge drinking[499] and alcoholic liver disease.[498]
To date, Mendelian randomization studies have predominantly used a SNP in the alde-
hyde dehydrogenase 2 family gene (ALDH2 rs671, also known as ?2) as an instrument for
alcohol consumption.[487, 489, 500–524] Robust associations have been reported between
ALDH2 rs6712 and several alcohol-related disorders including hypertension, esophageal
cancer and head and neck cancer.[511, 525, 526] These serve as positive controls since
the causal role of alcohol in these diseases is not disputed. However, the genetic variant
is monomorphic in individuals of European descent, and therefore cannot be used in
these populations for instrumental variable analysis.
6.2 ADH1B-CVD project
6.2.1 Rationale
The rationale for this project was to interrogate the causal relationship between alco-
hol consumption and cardiovascular risk factors and disease outcomes using a SNP in
ADH1B as a proxy for alcohol intake using the principles of Mendelian randomization.
6.2.2 Aims
The project had several objectives:
1. to assemble an international collaboration to yield data with sufficient numbers of
individuals in order to be able to make meaningful inferences about the relationship
between alcohol consumption and cardiovascular traits and outcomes
2. to investigate the observational association between alcohol consumption and car-
diovascular biomarkers and risk factors as well as potential confounders
3. to validate the use of ADH1B rs1229984 as an instrument for alcohol exposure in
populations of European descent
4. to investigate the association of ADH1B rs1229984 with CVD biomarkers, risk
factors, potential confounders and CVD events
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5. to use instrumental variables analysis to estimate the un-biased (causal) associa-
tions between alcohol consumption and cardiovascular traits
Chapter 7
ADH1B-Cardiovascular Disease
Collaboration: Overview and
Observational Associations
between Alcohol and
Cardiovascular Traits
7.1 Introduction
In this chapter, I will introduce the observational component of the ADH1B -CVD col-
laboration. The rationale for the observational analyses was to validate the dataset as
showing associations consistent with the published literature, but also to add to the
scientific literature on the relationship between alcohol consumption and emerging car-
diovascular risk factors, such as IL-6 and C-IMT.
7.2 Methods
7.2.1 International collaboration
An international collaboration was established by inviting cohorts and large case-control
studies with information on alcohol consumption, ADH1B rs1229984 genotype and car-
diovascular traits to participate (details of invitation letter provided in Appendix C, on
page 305). The collaboration commenced in 2009, and over the period from 2009 to
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2013 expanded to include 56 studies with over 260,000 participants.
Studies contributing towards the observational analyses are denoted in Table C.1.
7.2.2 Measures of alcohol consumption
Several measures of alcohol consumption were evaluated:
Units per week the principle alcohol trait of interest was weekly volume of alcohol
in British units (1 British unit = 7.9 grams pure ethanol or half a pint of beer, a
small glass of wine or a single measure of spirits). For studies in which this variable
was not already present, I either calculated weekly volume of alcohol by summing
the individual components of beverage-specific drink questions, or by converting
alcohol recorded in grams/week into British units.
Binge drinking binge drinking was defined as consumption of five or more drinks in a
single occasion in the past month, or the closest possible definition to this. Please
refer to Table C.2 for specific information on this measure in participating studies.
Self-reported abstainer definitions of self-reported abstaining varied between studies
from lifelong abstention to individuals who had been abstaining for the past six
months (see Table C.2 for details of study-specific definitions).
Top-tertile per study Individuals were grouped into tertiles in each study, separately
for men and women, based on their alcohol consumption in units/week. Individuals
grouped in the top-tertile of alcohol consumption were compared to the lower two
tertiles.
GGT plasma level of gamma-glutamyltransferase (GGT), a liver enzyme that is in-
creased in a dose-dependent fashion in relation to alcohol consumption,[527, 528]
was used as a marker of heavy alcohol consumption.
7.2.3 Data handling
Non-normally distributed continuous variables, including weekly units of alcohol, were
logarithmic transformed on the natural scale. In order to include individuals who de-
clared drinking zero weekly units alcohol, a value of one was added prior to transfor-
mation (otherwise this transformation would have rendered them as missinga). Non-
high density lipoprotein cholesterol (non-HDL-C) cholesterol was derived by subtracting
HDL-C from total cholesterol. Hypertension was defined as a systolic BP of ≥140mmHg
and/or a diastolic BP of ≥90mmHg.[529]
aas log(0)=undefined
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7.2.4 Statistical analysis
In order to be able to compare the effect of alcohol on different traits, all continuous
traits were standardized prior to the observational analysis. To assess the shape of the
association between log weekly alcohol consumption units and each trait, in a total of
28 studies (131,490 individuals), statistical models were constructed using individual
participant data (IPD). In each study, each cardiovascular trait was treated as the
dependent variable and linear and quadratic terms were fitted for alcohol consumption,
adjusted for age and gender. The study-specific beta coefficients and 95%CI for the
linear and quadratic terms for alcohol consumption across the studies were pooled using
fixed-effects (inverse variance) meta-analysis. If the 95%CI of the pooled quadratic term
did not include the null value (of 0), I used this as evidence to suggest a non-linear
relationship was the appropriate model to reflect the association between alcohol and
the trait. Plots were generated of the pooled estimates using the summary regression
coefficients as a function to illustrate the shape of the observational association between
alcohol and each trait across studies.
7.2.5 Proportion of variance explained by alcohol
For each of the continuous traits, I estimated the proportion of variance (R2) explained
by alcohol consumption. The purpose was to try and gauge whether negative results
from the genetic analysis could be ascribed to lack of power. In the pooled IPD dataset,
I estimated the R2 and 95%CI using bootstrapping (with n=1000 repetitions) adjusted
for age, gender and study. I then repeated the model without the log weekly units/week
alcohol variable and subtracted the R2 estimate from the second model from the first,
in order to obtain the R2 from alcohol alone. The lower boundary of the lower 95%CI
estimate of the derived R2 was limited to zero.
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7.3 Results
Twenty-eight studies with 131,490 individuals provided individual participant data that
contributed towards the observational analysis (Table C.1). Of the 26 traits, summary
estimates for the studies contributing towards the observational analysis for 24 of 26
traits were similar to the studies that did not contribute (Figures C.2 to C.18).
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7.3.1 Availability of traits and proportion of variance of traits ex-
plained by alcohol on observational analysis
Figure 7.1 shows the availability of different variables across the studies contributing
towards the collaboration, ordered by the proportion of all individuals (n=261,991) with
data available. The trait with the greatest number of individuals was body mass index,
with 232,570 individuals and the trait with the least was cotinine (with 9378 individuals).
Alcohol explained the greatest proportion of variance of HDL-C R2=3.75% (95%CI, 2.94,
4.57).
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Figure 7.1: Total number of individuals for each trait and the proportion of variance
(R2) of each trait explained by alcohol in the collaborating studies. R2 values are ex-
pressed as a percentage.
7.3.2 Observational analysis between alcohol consumption and cardio-
vascular biomarkers
Observational analysis revealed that with exception of lipoprotein(a) and BNP, all other
cardiovascular biomarkers, life-style and social variables were associated with alcohol
consumption (Figures 7.2, 7.3, 7.4 and 7.5), with most relationships being curvilinear in
nature (Table C.9).
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All coagulation and inflammation biomarkers showed a curvilinear association with al-
cohol consumption. In general, light-to-moderate drinkers had the lowest values and
heavy drinkers had the highest values compared to non-drinkers. Similar curvilinear
associations were observed for systolic blood pressure (BP), glucose, and carotid intima
medial thickness (C-IMT).
Light-to-moderate drinkers showed the lowest levels of measures of smoking habit, body
mass index (BMI) and waist circumference and the highest levels of education and phys-
ical activity.
Associations of alcohol consumption with lipids and apolipoproteins varied in shape and
strength. Apolipoprotein A1 and HDL-C showed the strongest positive dose-response
with alcohol consumption, with no evidence of a plateau, and with heavy drinkers (>50
units/wk) having the highest mean values by 0.8 SD compared to non-drinkers (Fig-
ure 7.2). In contrast, the nature of the association between alcohol with non-HDL-C
was more shallow.
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Figure 7.2: Observational association between alcohol consumption and other variables (1)
Footnotes: The dose response relationship is derived from the best fit model obtained from each comparison. The values plotted represent the predicted estimates
derived from the regression model that includes a linear and quadratic term for alcohol consumption (log units/week). The vertical dotted lines represent the cut-
points for the main alcohol categories used in the analysis: 7 and 21 units/week.
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Figure 7.3: Observational association between alcohol consumption and other variables (2)
See footnote to Figure 7.2 for further details.
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Figure 7.4: Observational association between alcohol consumption and other variables (3)
See footnote to Figure 7.2 for further details.
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Figure 7.5: Observational association between alcohol consumption and other variables (4)
See footnote to Figure 7.2 for further details.
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7.4 Discussion
The data I present in this Chapter serve to illustrate the observational association of
alcohol consumption with multiple cardiovascular risk factors, biomarkers and potential
confounders. Of the 28 traits I investigated, alcohol showed strong association with all
but two of them and the vast majority (24 of 26) of associations were curvilinear in
nature.
This is important for several reasons. First, the curvilinear association of alcohol with
established and emerging risk factors (e.g. SBP[31], non-HDL-C[530], smoking-related
traits, IL-6[83]) introduces the possibility that one or more could act as potential non-
linear confounders of the association of alcohol consumption with risk of CVD. Alterna-
tively it is possible that some of these traits might mediate a causal association between
alcohol consumption and CHD risk. For example, if we look at the plots for SBP, non-
HDL-C and IL-6, they all have evidence of non-linear positive associations with alcohol
consumption, similar to the relationship of alcohol with CHD shown in Figure 6.2 in
Chapter 6. Thus, if we assume all three traits (SBP, non-HDL-C and/or IL-6) were
to mediate the alcohol association and that the J-shape was a true reflection of the
relationship between alcohol and these traits (i.e. not influenced by error from bias or
confounding) then it is conceivable to think that the true association between alcohol
and risk of CVD may also be J-shaped.
These findings also validate the dataset for the Mendelian randomization analysis I
present in the next Chapter. For example, the association with SBP is similar to that
previously reported.[421] Second, the association with HDL-C appears to be almost
linear, and this positive dose-response relationship is in agreement with the estimates
reported from prior meta-analyses of interventional studies.[401, 461] Interestingly, I
identified strong evidence of association between alcohol and other biomarkers (e.g.
TG, CRP, IL-6 and fibrinogen) that did not show association with alcohol in the inter-
ventional meta-analyses.[401, 461] However, the sample size reported in this Chapter is
many-fold greater (see Figure 6.3) than in those prior studies, meaning the results from
interventional studies could well represent Type II (false negative) errors.
These data also increase understanding to the relationships of alcohol with cardiovas-
cular biomarkers. For example, the association of alcohol with C-IMT provides novel
insights into the underlying relationship, and importantly, mimics the same association
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that has been reported with CHD (Figure 6.2). As C-IMT is recognized as an impor-
tant surrogate marker for CHD[531, 532], it is perhaps expected that it should share
the same observational association with alcohol as CHD (i.e. J-shaped in nature). Of
course, this does not help delineate the underlying causal association as the same con-
founding factors could influence the relationship between alcohol and C-IMT as for CHD.
Another characteristic of the observational plots presented in this Chapter is the concor-
dance of directionality between biologically related, but independently-measured traits.
For example, there was concordance in the nature of the association for the following
pairs of traits: SBP and DBP; HDL-C and Apolipoprotein-A1; LDL-C and Apolipoprotein-
B; CRP and IL-6. This consistency helps to affirm the nature of the association of alcohol
with blood pressure, lipid and lipoproteins, and inflammatory markers.
7.5 Conclusion
In this Chapter, I reported the observational associations between alcohol and cardiovas-
cular biomarkers and lifestyle variables. These analyses illustrate the wide-reaching as-
sociations of alcohol with numerous measures that could represent potential confounders
and/or mediators in the pathway between alcohol and CHD. This has implications on
the credibility of using observational evidence on the association of alcohol with CHD
to make health-related policy judgements. Fundamentally, it shows the necessity to use
evidence from an unbiased source to make causal inference.
This is the basis for the next Chapter, which will investigate the genetic association
between a SNP that encodes an enzyme central to alcohol metabolism (ADH1B), used
as a proxy for alcohol intake, and CHD events.
Chapter 8
ADH1B-Cardiovascular Disease
Collaboration: Genetic and
Instrumental Variable
Associations
In Chapter 6, I described the outline of the ADH1B -CVD project and in Chapter 7
presented the observational associations between alcohol consumption, cardiovascular
biomarkers, and other covariates that could either confound or mediate the association
of alcohol with CVD events.
In this chapter, I will present an investigation of the causal role of alcohol in cardio-
vascular disease using ADH1B rs1229984 as an instrument for alcohol intake. This
analysis had two components: first I conducted a genetic association analysis (using the
ADH1B rs1229984 SNP) with alcohol consumption, lifestyle factors and cardiovascular
biomarkers and disease events and; second, I conducted a formal instrumental variable
analyses to “triangulate” the true (causal) effect of alcohol consumption on cardiovas-
cular biomarkers.
8.1 Methods
8.1.1 Genetic analysis
A standardized script was written and deployed in all participating studies. This homog-
enized the analysis procedure, preventing subtle differences between analyses affecting
163
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the overall meta-analysis estimates.
For the genetic analysis, I used a dominant model for the analysis: i.e. one and two
copy carriers of the A allele were grouped and compared to individuals homozygous for
the G-allele (reference group).
The association between ADH1B rs1229984 A-allele and each continuous trait was esti-
mated by obtaining the means and standard deviations separately for rs1229984 A-allele
carriers and non-carriers. For binary variables, the univariate log odds ratios and stan-
dard errors comparing the A-allele carriers to non-carriers were obtained. All effect
estimates were pooled using fixed-effects and random-effects modelling. I quantified
heterogeneity using the I2 statistic.[533]
In a subset of studies, information was available on lipid lowering and blood pressure
lowering treatment. For these studies, individuals who were documented as receiving
anti-hypertensive medications had 15mmHg added to their values of systolic blood pres-
sure (SBP) and 10mmHg to diastolic blood pressure (DBP).[534] For individuals on
lipid-lowering drugs, 2.096 mmol/l was added to total cholesterol and 0.461 mmol/l
to triglycerides (constants derived from Whitehall II study[535] following methods de-
scribed by Tobin).[534, 536]. The association of the SNP with medication adjusted traits
was used as a sensitivity analysis. As no difference was identified between medication-
adjusted and unadjusted values, the analyses presented thereafter were based on unad-
justed values.
All participants with non-missing data contributed towards analysis of continuous traits
as the majority of study participants were free from coronary heart disease (CHD) at
recruitment. The only exception was the SMART study[537] (a cohort of patients with
established cardiovascular disease or with multiple risk factors), which only provided
data for carotid intima medial thickness (C-IMT) and N-terminal fragment B-type na-
triuretic peptide (BNP).
8.1.2 Meta-analysis of rs1229984 A-allele and cardiometabolic events
I used counts of cases and non-cases per genotype group to generate the corresponding
log odds ratio and standard error. A continuity correction was not used, therefore if
a study contained a “0” count for any binary trait, the study was excluded from the
meta-analysis. I conducted meta-analyses using inverse variance weighting for the fixed
effects models, and DerSimonian and Laird for random effects models.
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8.1.3 Subgroup analyses
I investigated differences in the overall association between the gene variant and each
variable by conducting subgroup analyses based on individual-level and study-level char-
acteristics.
The principal subgroup analysis of interest was alcohol consumption (an individual-level
characteristic), with study participants grouped according to their weekly volume of
alcohol consumption into none, >0 to <21 and ≥21 units/week. The rationale for this
sub-group analysis was two-fold. First, it allowed evaluation of the effect of the gene
variant in individuals not consuming alcohol. Because the rs1229984 SNP is expected
to have an effect only when an individual is exposed to alcohol, in individuals con-
suming no alcohol, I anticipated there should be no association between the SNP and
cardiovascular biomarkers and disease outcomes. Second, in individuals that consumed
alcohol, stratifying by volume of alcohol permitted the investigation of a dose-response
relationship between alcohol and cardiovascular biomarkers and outcomes. The limita-
tion of this approach is that stratifying on an intermediate trait may introduce “collider
bias”[538] by introducing confounding via a back-door pathway (described in Figure C.19
on page 304).[64]
To investigate whether collider bias was likely to influence the association between
ADH1B rs1229984 on analyses stratified by alcohol, I also stratified the association
of ADH1B rs1229984 with potential measured confounders (with the caveat that this
analysis would be limited only to measured confounders). Thus, by stratifying the
confounders by alcohol, if an association were to be identified (between alcohol and a
confounder that was not present on the unstratified analysis), this would suggest that
such stratified analyses should not be conducted.[539]
In addition to alcohol volume, the following characteristics at the individual/study level
were chosen a priori for secondary subgroup analyses:
 gender (women, men)
 geographical region (North Europe, West Europe/Australia, Central/South Eu-
rope, East Europe, USA)
 age (mean age of study participants, dichotomized into <60 years, ≥60 years)
 Hardy Weinberg Equilibrium (dichotomized into studies not showing evidence of
Hardy Weinberg Disequilibrium (P>0.001), and those showing evidence of Hardy
Weinberg Disequilibrium (P≤0.001))
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 genotyping platform (dichotomized into those that genotyped ADH1B rs1229984
on a single SNP platform, or as part of a chip or array)
 year of blood sampling for DNA extraction (split into 1980 to <1990, ≥ 1990 to
<2000, and ≥2000 to present)
 whether the study contributed towards the observational analysis presented in
Chapter 7.
8.1.3.1 Investigation of subgroup analyses using metaregression
For the subgroup analysis based on alcohol consumption, I organised alcohol categories
into a logical order (0, >0 to<21, ≥21 units/week). This categorical variable was entered
into a metaregression analysis. Each group was assigned the corresponding median
alcohol intake in units/week obtained from a pooled individual participant dataset using
the following values: group >0 to <21: 6.24 units/wk; ≥21: 32.88 units/wk. The P
value for heterogeneity that I report for alcohol subgroups was derived from this meta-
regression analysis. For all other (non-alcohol) subgroup analyses, I tested for presence
of heterogeneity between strata using unordered categorical metaregression, with the
‘i.’ prefix for the variable name in the metaregression model. All meta-regressions were
conducted using the metareg command in Stata.
8.1.4 Sensitivity analysis
For volume of alcohol in units/week (the main alcohol phenotype), I performed a mea-
surement error sensitivity analysis according to the level of information obtained from
the self-reported alcohol questions in the original study questionnaires. If the origi-
nal alcohol intake questions recorded information on beverage-specific consumption (i.e.
consumption questions were asked separately for beer, wine and spirits rather than all
beverages combined), the study was labelled “specific” in relation to the subgroup anal-
ysis by alcohol questionnaire, otherwise the study was labelled “non specific”. I used
this information to perform a sensitivity analysis according to the type of questionnaire
used in each study.
8.1.5 Investigating potential for confounding by population stratifica-
tion
In 11 studies of over 40,000 individuals, principal component analysis was possible based
on the IBC CardioChip data.[540] In these studies, to investigate the possibility of
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residual confounding by population stratification, I conducted two analyses. First, I
conducted univariate linear or logistic regression analyses with each cardiovascular trait
and disease outcome as the dependent variable, and rs1229984 A-allele carrier status as
the independent variable. In the second analysis, I incorporated the first three principal
components traits into each of the models.
I tested for evidence of an association between available PC traits with log weekly units
of alcohol in the largest dataset that I had access to individual participant data and
included only PC traits that showed association. Since each of the three PC traits
demonstrated association with log weekly units of alcohol (at P<0.05), I incorporated
all three PC traits in analyses to adjust for potential residual population stratification.
I compared the beta-coefficient or log odds estimates derived from the univariate and
principal component adjusted models for evidence that adjustment for principal compo-
nents attenuated any of the estimates. A difference between the two models (unadjusted
and adjusted) would suggest that the unadjusted association was influenced by residual
population stratification.
8.1.6 Instrumental variable analysis
In order to estimate the de-confounded effects of alcohol on cardiovascular traits, I
used two stage least squares instrumental variable (IV) analysis. However, this made
the strong assumption of a linear association between alcohol and cardiovascular traits.
The instrumental variable analysis was conducted for all traits that had a nominally
significant (P<0.05) association with ADH1B rs1229984 on genetic association analysis.
8.1.6.1 Linear instrumental variable meta-analysis
I used the ratio instrumental variable (IV) estimator to estimate the unconfounded ef-
fect of log weekly units of alcohol on biomarkers. For this, I conducted a fixed-effects
meta-analysis of ADH1B rs1229984 on log weekly units of alcohol across studies that
had information on alcohol in units/week. I used this pooled estimate for the IV anal-
ysis, thus assuming a fixed effect of ADH1B rs1229984 on log units/wk alcohol intake
across studies. This also enabled the incorporation of studies that did not have alcohol
measured to contribute towards the IV analysis.
Using study-specific associations between ADH1B rs1229984 and each continuous trait
and outcome, I calculated the instrumental variable effect estimate for alcohol by divid-
ing the ADH1B -trait association by the pooled estimate of the association of ADH1B
and log units/wk of alcohol consumption.[84, 370] This analysis took into account the
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uncertainty in both the ADH1B -trait and ADH1B -alcohol association by using the delta
method to estimate the standard errors of ratio instrumental variable estimates.[541] I
incorporated studies that did not have information on alcohol into the instrumental vari-
able analysis by applying the pooled effect estimate of the ADH1B -log units/wk associa-
tion to them.[370, 372, 541] I pooled study-specific instrumental variable estimates using
fixed- (inverse variance) and random-effects (DerSimonian and Laird) meta-analysis.
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8.2 Results
8.2.0.2 Studies included in the collaboration
Of the 56 studies included in the collaboration, there were 38 cohorts, 6 nested case-
control studies, 3 case-cohort, 4 randomized trials, 4 case-control and 1 cross-sectional
study. The studies originated from Europe (n=44), North America (n=11) and Aus-
tralasia (n=1) (Appendix C).
There were a total 261,991 participants in the analysis, of which 48% were female, and
the mean age was 58 years (range 26, 75) (Table C.1). Characteristics of the alcohol
questionnaires in each study are summarized in Table C.2. The median number of
alcohol units consumed in each study is shown in Table C.4. There were 20,259 CHD
events, 10,164 combined subtypes of stroke cases, 4339 ischemic stroke cases and 14,549
type 2 diabetes cases (Table C.5, defined in Table C.3). Means and distributions for
continuous traits in all studies are presented in Tables C.6, C.7 and C.8.
8.2.1 Allele frequency of ADH1B rs1229984 SNP
The ADH1B rs1229984 SNP was directly genotyped in all collaborating studies (Ta-
ble C.1). When I grouped studies by geographical location, the allele frequency was
consistent in all geographical regions (Figure C.1). The call rate (the proportion of indi-
viduals assigned a genotype out of all individuals who were genotyped) was >90% in all
contributing studies (Table C.1). For 9 studies, the Hardy Weinberg Equilibrium P-value
was ≤ 0.001 (Table C.1). Stratifying the effect estimates in the relationship between
ADH1B rs1229984 with each of the traits by studies that were and were not in Hardy
Weinberg Equilibrium did not show evidence of heterogeneity (Figures C.2 to C.18).
8.2.2 Association of ADH1B with alcohol phenotypes
To validate the use of rs1229984 as an instrument for alcohol, I investigated the asso-
ciation between the rs1229984 SNP and the following alcohol consumption measures:
self-reported volume, abstention, top third of drinking per study, binge drinking and
measures of the liver enzyme GGT.
When I compared carriers of the rs1229984 A-allele to non-carriers, carriers consumed
fewer units of alcohol per week (-17.5% units/wk; 95%CI, -19.1 to -15.8) and had lower
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odds of being in the top third of drinking volume (OR 0.70; 95%CI, 0.67 to 0.73). Fur-
thermore, carriers of the rs1229984 A-allele had lower odds of binge drinking (OR 0.78;
95%CI, 0.73 to 0.84), increased odds of being self-reported abstainers (OR 1.27; 95%CI,
1.21 to 1.34) and lower levels of GGT (-1.8%; 95%CI, -3.4 to -0.3) (Table 8.1). The
association with alcohol volume remained unaltered when stratified by laboratory pro-
cedures or study characteristics (Figure C.2).
Table 8.1: Meta-analysis pooled estimates of the association between ADH1B rs1229984
(A-allele carriers vs. GG-subjects) and indices of alcohol consumption.
Trait (units) Studies,
Cases/Individuals
Effect estimate (95%
confidence interval)
P value I2, %
(95%CI)
% difference
Volume (ln units/wk) 46, NA/219752 -17.47 (-19.10, -15.80) 1.4 x 10-78 66 (54, 75)
Ln GGT (U/L) 15, NA/97755 -1.84 (-3.40, -0.26) 0.02 36 (0, 65)
Odds Ratio
Top tertile of alcohol
intake
45, 69229/222332 0.70 (0.67, 0.73) 5.9 x 10-69 60 (45,71)
Binge drinker 21, 22198/131290 0.78 (0.73, 0.84) 1.4 x 10-12 47 (13, 68)
Alcohol abstainer 32, 24482/189854 1.27 (1.21, 1.34) 2.6 x 10-19 73 (62, 81)
Footnote: For definitions of binge drinker and alcohol abstainer, please refer to Table C.2. GGT:
Gamma-glutamyl transferase; NA: not applicable
8.2.3 Association of ADH1B rs1229984 with cardiovascular biomark-
ers
Carriers of the rs1229984 A-allele had lower systolic BP (-0.88 mmHg; 95%CI, -1.19 to
-0.56) compared to non-carriers (Table 8.2).
Concordant with this, rs1229984 A-allele carriers had lower odds of hypertension (104,570
cases; OR 0.94; 95%CI, 0.91 to 0.98) compared to non-carriers. Rs1229984 A-allele car-
riers had lower levels of interleukin-6 (IL-6) (-5.2%; 95%CI, -7.8 to -2.4), C-reactive
protein (CRP) (3.4%; 95%CI, -5.7 to -1.1), BMI (-0.17kg/m2; 95%CI, -0.24 to -0.10)
and waist circumference (-0.34cm; 95%CI, -0.58 to -0.10). Rs1229984 A-allele carriers
also had lower non-HDL-C (-0.03 mg/dl; 95%CI, -0.05 to -0.01) (Table 8.2).
When the analysis was stratified by alcohol consumption, a more pronounced effect of
rs1229984 on these cardiovascular traits was observed in individuals with higher alco-
hol consumption (P<0.05 for most comparisons) (Figure 8.1). In contrast, the effect of
rs1229984 on these traits did not differ systematically according to exploratory subgroup
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Table 8.2: Meta-analysis pooled estimates of the association between ADH1B rs1229984
(A-allele carriers vs. GG-subjects) with cardiovascular biomarkers irrespective of alcohol
intake.
Trait (units) Studies,
Individuals
Mean difference (95%CI) P-value I 2, %
(95%CI)
Blood pressure
SBP (mmHg) 48, 227559 -0.88 (-1.19, -0.56) 4.1 x 10-8 26(0,48)
Anthropometric
BMI (kg/m2) 51, 232570 -0.17 (-0.24, -0.10) 3.4 x 10-6 52(33,65)
Waist circumference
(cm)
42, 140923 -0.34 (-0.58, -0.10) 6.2 x 10-3 41(14,59)
Inflammation
ln IL-6 (pg/ml) 17, 30950 -5.15 (-7.82,-2.40) 2.90 x 10-4 33(0,62)
ln CRP (mg/l) 42, 124498 -3.40 (-5.68,-1.05) 4.60 x 10-3 1(0,36)
Lipids
Non-HDL-C
(mmol/l)
46, 202794 -0.03 (-0.05, -0.01) 5.1 x 10-3 25(0,48)
ln TG (mmol/l) 46, 205824 1.61 (0.66,2.57) 8.90 x 10-4 36(8,55)
HDL-C (mmol/l) 46, 203440 -0.004 (-0.012, 0.003) 0.259 54(37,67)
Footnote: For log(e) transformed traits, the percentage difference in the geometric
mean is reported rather than the mean difference
analyses by laboratory procedures or major study characteristics (P>0.05 for 51 of 57
comparisons; Figure C.5, C.6, C.7, C.8 and C.11). Although I observed that rs1229984
A-allele carriers had higher triglyceride levels (1.6%; 95%CI, 0.7 to 2.6), this effect was
not modified by alcohol categories (P value for heterogeneity=0.69, Figure 8.1).
There were no overall differences in HDL-C (-0.004 mmol/l; 95%CI, -0.012 to 0.003)
between rs1229984 A-allele carriers and non-carriers. However, an association between
rs1229984 A-allele carriage with HDL-C was observed in the highest category of alcohol
consumption (0.03 mmol/l; 95%CI, 0.01 to 0.05), but in the opposite direction to that
expected from observational findings. In subgroup analysis by laboratory procedures
and major study characteristics, rs1229984 A-allele carriers from Northern Europe had
lower levels of HDL-C (-0.04 mmol/l; 95%CI, -0.05 to -0.02). Since this geographical
specificity could reflect residual population stratification in samples outside Northern
Europe, we adjusted for principal components in a subset of individuals not from North
Europe. The unadjusted model for the association between rs1229984 A-allele and HDL-
C (0.02 difference in SD; 95%CI, -0.02 to 0.06) did not differ from the model adjusted
for population structure (0.01 difference in SD; 95%CI, -0.03, 0.05) (Figure 8.3). Similar
null results were observed for Apo-A1 (Table 8.3).
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Figure 8.1: Meta-analysis pooled estimates of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and cardiovascular dis-
ease biomarkers showing association on crude analysis, stratified by alcohol intake.
Footnote: for log transformed traits, the percentage difference in the geometric mean is reported rather than the mean difference. To convert from British to US units, divide by
1.75 (i.e. 1 British unit=10 ml or 7.9g ethanol = 0.57 US units). The test for trend was conducted by meta-regression. ∗ For hypertension the plotted values represent the odds
ratio (95%CI)
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Figure 8.2: Meta-analysis pooled estimates of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and cardiovascular dis-
ease biomarkers not showing association on crude analysis, stratified by alcohol intake.
Footnote: for log transformed traits, the percentage difference in the geometric mean is reported rather than the mean difference. To convert from British to US units, divide by
1.75 (i.e. 1 British unit=10 ml or 7.9g ethanol = 0.57 US units). The test for trend was conducted by meta-regression.
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Rs1229984 A-allele carriage was not associated with carotid intima medial thickness,
electrocardiographic measures of left ventricular hypertrophy, fibrinogen, von Willebrand
factor, factor VII, fasting glucose, BNP or lipoprotein(a) overall (Table 8.3). For these
traits, similar null results were observed when stratified for alcohol consumption or
by other exploratory sub-groups (P>0.05 for 47 of 48 comparisons, Figures C.10, C.12,
and C.13), with the exception of fasting glucose and lipoprotein(a), where the strength of
association was more pronounced in heavy drinkers compared to other alcohol categories
(P values for heterogeneity 0.07 and 0.01, respectively, Figures 8.2).
8.2.4 Association of ADH1B rs1229984 and lifestyle factors
Carriage of the rs1229984 A-allele was not associated with physical activity. Rs1229984
A-allele carriers did have higher odds of ever smoking (OR 1.06; 95%CI, 1.02 to 1.09).
However, the association with ever smoking was in the opposite direction to that seen in
observational analysis and no association was observed for other quantitative measures
of tobacco exposure such as cigarettes per day, pack years or cotinine levels (Figure 8.4).
Rs1229984 A-allele carriers showed higher total years in education (0.04 SD; 95%CI,
0.01 to 0.08). No differential effect of ADH1B rs1229984 on any of the life-style factors
was identified on stratifying by alcohol intake (making it unlikely that stratifying by
alcohol introduced bias) or by other exploratory sub-groups (P>0.05 for all comparisons;
Figures 8.4, C.14, C.15 and C.16).
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Figure 8.3: Subgroup and sensitivity analysis of the meta-analysis pooled estimate of
the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) with HDL-
C.
Footnote: The mean difference values for the principal components analysis subgroup represent the beta
coefficient for one SD difference in HDL by rs1229984 with and without adjustment for PCA. P value for
heterogeneity for alcohol represents a test for trend, whereas for other subgroups, it represents a test for
heterogeneity (see Methods).
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Table 8.3: Meta-analysis pooled estimates of the association between ADH1B rs1229984
(A-allele carriers vs. GG-subjects) and cardiovascular biomarkers, irrespective of alcohol
intake, limited to traits not showing association at a nominal P value equal to 0.05.
Trait (units) Studies,
Individuals
Mean difference
(95%CI)
P-value I 2, %
(95%CI)
DBP (mmHg) 48/227550 -0.08 (-0.25, 0.10) 0.401 23(0,47)
ln Fibrinogen (g/l) 27/136647 -0.07 (-0.60,0.47) 0.808 41(7,63)
Glucose (fasting,
mmol/L)
35/88388 -0.03 (-0.06, 0.00) 0.064 36(4,58)
ln Lipoprotein(a) (mg/dl) 14, 46287 0.75 (-3.11,4.76) 0.709 38(0,67)
Apolipoprotein B (g/) 13, 41865 -0.00 (-0.01, 0.01) 0.357 51(8,74)
Apolipoprotein A-1 (g/l) 12, 39544 0.00 (-0.01, 0.02) 0.57 48(0,73)
ln C-IMT (mm) 18, 30897 -0.09 (-0.95,0.77) 0.839 10(0,47)
Von willebrand
factor(IU/dl)
11, 25450 0.07 (-2.43, 2.58) 0.956 41(0,71)
Sokolow-Lyon (mm)∗ 4, 21460 22.03 (-19.86, 63.93) 0.303 0(0,84)
QRS Voltage Sum (mm)∗ 4, 21445 90.62 (-106.19,
287.42)
0.367 47(0,82)
QRS Voltage Product
(mm)∗
4, 21440 8.13 (-17.07, 33.32) 0.527 61(0,87)
Cornell Product (V.S)∗ 4, 21408 -2.08 (-5.73, 1.57) 0.264 51(0,84)
ln BNP (ng/l) 8, 20794 -3.02 (-9.79,4.28) 0.407 54(0,79)
Factor VII (U/ml) 10, 20509 0.30 (-1.34, 1.93) 0.721 0(0,62)
Footnote: for log transformed traits, the percentage difference in the geometric mean is reported rather
than the mean difference. ∗ denotes indices of left ventricular hypertrophy measured via electrocardio-
gram. DBP: diastolic blood pressure; BNP: brain-derived natriuretic peptide
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Figure 8.4: Meta-analysis pooled estimates of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and lifestyle traits and
liver enzyme overall and stratified by alcohol intake
Footnote: Alcohol units are British; to convert from British to US units, divide by 1.75 (i.e. 1 British unit=10 ml or 7.9g ethanol = 0.57 US units). P value for
heterogeneity represents a test for trend (see Methods). The “All individuals” estimates (colored red) also include studies without measures of alcohol.
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8.2.5 Association of ADH1B rs1229984 and coronary heart disease
Rs1229984 A-allele carriage, associated with a 17.5% reduction in volume of alcohol
consumption, showed reduced odds of CHD (20,259 events; OR 0.90; 95%CI, 0.84 to
0.96). When the analysis was restricted to non-drinkers the association was null (OR
0.99; 95%CI, 0.88 to 1.10) whilst among drinkers (>0 units/week alcohol), carriers of the
rs1229984 A-allele had reduced odds of CHD (OR 0.85; 95%CI, 0.78 to 0.93). Further
subdivision of the drinkers category into >0 to <7, ≥ 7 to <21 and ≥ 21 units/week
showed the same protective effect of the variant across all alcohol categories (P value for
heterogeneity=0.71; Figure 8.5).
	  
Figure 8.5: Meta-analysis pooled estimate of the association between ADH1B rs1229984
(A-allele carriers vs. GG-subjects) and CHD stratified by categories of alcohol intake.
Footnote: Alcohol units are British; to convert from British to US units, divide by 1.75 (i.e. 1 British
unit=10 ml or 7.9g ethanol = 0.57 US units).
8.2.6 Association between ADH1B rs1229984 with stroke (combined
subtypes and ischaemic-only) and diabetes
Analysis of the rs1229984 A-allele did not show association with a combined stroke out-
come (including ischaemic and hemorrhagic sub-type) (10,164 cases; OR 0.98; 95%CI,
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0.90 to 1.07). When I limited the analysis to studies that reported only ischemic stroke,
rs1229984 A-allele carriers had a lower odds of ischaemic stroke (7 studies, 4339 events,
OR 0.83; 95%CI, 0.72 to 0.95) than non-carriers (Figure 8.7).
There was no association between the rs1229984 A-allele with type 2 diabetes (14,549
cases; OR 1.02; 95%CI, 0.95 to 1.09; Figure 8.6).
	  
Figure 8.6: Meta-analysis pooled estimates of the association between ADH1B
rs1229984 (A-allele carriers vs. GG-subjects) and stroke and type 2 diabetes overall, and
stratified by alcohol intake.
Footnote: to convert from British to US units, divide by 1.75 (i.e. 1 British unit=10 ml or 7.9g ethanol =
0.57 US units). The “All individuals” estimate includes studies without measures of alcohol. The test for
trend was conducted using meta-regression. Box shading is proportional to the number of cases in each
stratum.
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8.2.7 Stability of summary estimates to choice of meta-analysis model
Despite the high I2 values for some traits,a random effect estimates for associations
of ADH1B rs1229984 with all outcomes were similar to those from fixed effect models
(Figures C.2 to C.18), meaning that presence of important statistical heterogeneity was
unlikely.[66]
Overall  (I-squared = 46.7%, p = 0.081)
WHI
EPIC Norfolk
Portugese
HIMS
ISGS-SWISS
EPIC Netherlands
HAPIEE Czech
Study
(1590,7346)
(415,20819)
(569,1002)
(514,4191)
(794,1124)
(315,4948)
(142,6520)
(Cases,Individuals)
0.83 (0.72, 0.95)
0.83 (0.67, 1.01)
1.01 (0.67, 1.52)
0.61 (0.43, 0.87)
0.82 (0.56, 1.20)
0.52 (0.31, 0.89)
1.13 (0.67, 1.90)
1.29 (0.79, 2.10)
OR (95% CI)
  1.5 1.2
Odds ratio
Figure 8.7: Meta-analysis of the association between ADH1B rs1229984 (A-allele carri-
ers vs. GG-subjects) and ischemic stroke
8.2.8 Stability of summary estimates to adjustment for population
structure
I repeated the analyses for continuous and binary traits with adjustment for princi-
pal component traits (Tables 8.1, 8.2 and 8.3), to investigate for evidence of residual
population stratification. I did not identify evidence of attenuation of the effect esti-
mates between rs1229984 A-allele and each of the traits after adjusting for principal
components traits (Figures 8.9 and 8.8).
aA high I2, indicative of presence of between-study heterogeneity, can mean that summary effect
estimates from random and fixed effects models may differ, as the random effects model will assign
relatively more weight to small studies compared to the fixed effects model
Chapter 8. ADH1B-CVD Collaboration: Genetic and Instrumental Variable
Associations 181
Top tertile alcohol
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Unadjusted
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Ever smoker
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CHD
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Adjusted
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7 (9367,29284)
7 (9223,28713)
6 (2460,21882)
6 (2380,21297)
7 (4516,32979)
7 (4514,32968)
11 (21519,41584)
11 (20900,40123)
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ADH1B association with binary traits
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Figure 8.8: Meta-analysis pooled estimates of the association between ADH1B
rs1229984 (A-allele carriers vs. GG-subjects) and binary traits adjusted for principal com-
ponents analysis
8.2.9 In silico analysis of potential for confounding between ADH1B
rs1229984 with other SNPs identified from prior GWAs
The ADH1B rs1229984 gene variant was not in linkage disequilibrium with previously-
reported GWAs loci for any cardiovascular trait (Table C.10).
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Figure 8.9: Meta-analysis pooled estimates of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and continuous traits
adjusted for principal components analysis.
Footnote: Beta coefficient (SD) represents the beta coefficient per standard deviation of each trait
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8.2.10 Causal analysis of alcohol on cardiovascular traits and events
The F-statistic for the first-stage gene-alcohol association in the pooled individual par-
ticipant dataset was 244, indicating that ADH1B rs1229984 was an adequate instrument
for instrumental variable analysis.[84]
With data on the ADH1B -alcohol association and ADH1B -traits, the next step was
to “triangulate” the true (causal) association between alcohol with those traits (Fig-
ure 8.10).
alcohol
rs1229984 A-allele
CV traits
“true association”
estimate 1 estimate 2
Figure 8.10: Triangulation of the causal association between alcohol and cardiovascular
traits.
The true estimate is obtained by dividing estimate 2 by estimate 1, whilst incorporating the un-
certainty in both estimates.
The standard instrumental variable approach assumes a linear (or log-linear) relation-
ship between the intermediate phenotype and outcome of interest.[84] This may be prob-
lematic when investigating alcohol, as much of the observational associations between
alcohol with cardiovascular risk factors and outcomes are J-shaped.[542]
The instrumental variable estimates for alcohol consumption (log units/wk) derived from
a linear instrumental variable analysis using 51 studies that included 232,570 participants
are reported in Table 8.4. For each log unit increase in alcohol volume (units/week),
SBP increased by 4.37 mmHg (95%CI: 2.75, 6.00), non-HDL-C increased by 0.15 mmol/L
(95%CI: 0.04, 0.25). A one log unit increase in weekly unit of alcohol increased BMI
by 0.81 kg/m2 (95%CI: 0.44, 1.17) and waist circumference by 1.59 cm (95%CI: 0.34,
2.84). IL-6 increased by 0.27% (95%CI, 0.12, 0.42) and TG reduced by -0.08% (95%CI,
-0.13, -0.04). Estimates were comparable using a random effects model, except for
triglycerides, where the estimates derived from random effects model yielded a weaker
association (Table 8.4).
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Table 8.4: Meta-analysis pooled instrumental variable estimates of the effect of a one log unit increase in alcohol volume consumption (units/wk) on
selected cardiovascular traits
Trait (units) or Outcome Studies Individuals/
Cases
Meta-
analysis
model
IV mean
difference
Lower
95%CI
Upper
95%CI
P-value
SBP (mmHg) 48 227559 Fixed 4.37 2.75 6.00 1.3E-07
48 227559 Random 4.55 2.46 6.65 2.04E-05
Non-HDL-C (mmol/l) 46 202794 Fixed 0.15 0.04 0.25 5.4E-03
46 202794 Random 0.17 0.04 0.30 0.01
BMI (mg/kg2) 51 232570 Fixed 0.81 0.44 1.17 1.69E-05
51 232570 Random 0.95 0.36 1.53 1.6E-03
Waist circumference (cm) 42 140923 Fixed 1.59 0.34 2.84 0.01
42 140923 Random 1.74 -0.07 3.56 0.06
Ln CRP (% difference) 42 124498 Fixed 0.18 0.06 0.31 0.00364
42 124498 Random 0.19 0.06 0.31 4.5E-03
HDL-C (mmol/l) 46 203440 Fixed 0.02 -0.01 0.06 0.23
46 203440 Random 0.02 -0.04 0.08 0.55
Ln IL-6 (% difference) 17 30950 Fixed 0.27 0.12 0.42 3.6E-4
17 30950 Random 0.27 0.06 0.48 0.01
Ln-TG (% difference) 46 205824 Fixed -0.08 -0.13 -0.04 7.1E-04
46 205824 Random -0.05 -0.12 0.01 0.12
Footnotes: The IV estimate was obtained using two regressions: (i) a pooled ADH1B-mean difference in log units/wk of alcohol (where 1 log unit = 2.7 units/wk,
2 log units = 7.4 units/wk; 3 log units = 20.1 units/wk, 4 log units = 54.6 units/wk), obtained from a meta-analysis of ADH1B rs1229984 (A-allele carriers vs. GG
homozygotes) on log weekly alcohol units using all studies; (ii) individual study-level ADH1B-trait estimates of individual studies. The IV analysis divides the individual
study-level ADH1B-trait association by the pooled ADH1B-log units/wk alcohol, incorporating errors in both estimates.
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8.3 Discussion
The purpose of this Mendelian randomization analysis was to use a gene variant (ADH1B
rs1229984) to investigate the relationship between alcohol and cardiovascular disease. I
helped to assemble a large international collaboration of over 250,000 participants. This
was in order to yield a sample size so that a Mendelian randomization analysis would
be sufficiently powered to have meaningful conclusions.
In Chapter 7, I identified that the datasets amassed were valid and consistent with
published observational associations between alcohol and multiple cardiovascular traits.
8.3.1 Validation of ADH1B rs1229984 as a proxy for alcohol intake
In this Chapter, I first showed that ADH1B rs1229984 A-allele carriage was suitable for
use as a genetic instrument for alcohol intake. I showed that rs1229984 A-allele carriers
had reduced exposure to all alcohol-related phenotypes, including those that were self-
reported (e.g. volume, abstention and binge drinking) and objective (using the liver
enzyme GGT as a marker of heavy alcohol consumption). Compared to non-carriers,
carriers of the rs1229984 A-allele consumed lower volumes of alcohol, were less likely to
be in the top third of drinkers, less likely to report drinking patterns consistent with
binge drinking and more likely to be abstainers. A-allele carriers also had lower levels
of circulating GGT. This confirmed the validity of this genetic variant as a proxy for
various measures of alcohol consumption.
8.3.2 Genetic association between rs1229984 and cardiovascular traits
I then investigated the association of the gene variant with cardiovascular traits and
events. Rs1229984 A-allele carriers had a reduced odds of hypertension and lower levels
of systolic blood pressure, CRP, IL-6, BMI, waist circumference, and non-HDL-C than
non-carriers. Thus, individuals that consumed less alcohol by virtue of their ADH1B
genotype had lower levels of traits that are established or emerging risk factors for
cardiovascular disease (obesity[543], blood pressure[544] and inflammation[83]).
I investigated these genetic associations within subgroups of alcohol consumption (0, ≥0
to <21 and ≥21 units/week) to investigate whether the effect of the gene variant on these
traits differed according to alcohol consumption, indicating a dose-response relationship.
This also allowed investigation of whether the genetic associations were consistent for
those consuming low amounts of alcohol (the part of the dose-response curve associating
with a protective cardiovascular profile on observational association). A close inspection
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of the genetic associations according to alcohol categories revealed differential effects
with null or substantially reduced associations in non-drinkers, as expected under the
assumption that the effect of this allele is only explained by exposure to alcohol, and
a more pronounced association in heavy drinkers when compared to light-to-moderate
drinkers.
8.3.3 Expected effect of alcohol on risk of CHD
From the reported J-shape in observational studies, I would expect that for drinkers
below the nadir (12-25 units/wk), a 17.5% reduction in alcohol consumption, corre-
sponding to carriage of the rs1229984 A-allele, would lead to a small increase in the risk
of CHD, while for those with alcohol consumption above the nadir, a similar reduction
in alcohol consumption would lead to a decrease in CHD risk (Figure 6.6). In contrast,
the findings presented in this Chapter reveal that individuals with a genetic predispo-
sition to consume less alcohol had lower, not higher, odds of developing CHD, and this
association was constant across all alcohol categories including those located below the
minimum risk point estimated from the observational association (>0 to 21 units/wk,
Figure 8.5). This argues against presence of a J-shape relationship and suggests that
there is no safe amount or cardioprotective threshold for alcohol consumption. As with
cardiovascular traits, the association of the rs1229984 A-allele with CHD was null for
non-drinkers.
8.3.4 Potential explanations for the absence of association of ADH1B
rs1229984 with HDL-C and other traits
The lack of association of the ADH1B rs1229984 A-allele with HDL-C, coagulation
markers, diabetes and combined subtypes of stroke was unexpected. Failure to detect an
association with HDL-C could have arisen due to lack of power; however rs1229984 was
associated with traits (e.g. CRP, IL-6) for which alcohol volume, on observational analy-
sis, had a less powerful effect and where sample size for genetic analysis was several times
smaller than for HDL-C (Figure 7.1). Sub-group analyses also suggest it was unlikely
that laboratory technique or type of alcohol questionnaire could be explanations. The
association of HDL-C with rs1229984 A-allele carriers restricted to Northern European
studies, concordant with observational studies, suggested that population stratification
may be an explanation for the lack of association in non-Northern European studies.
However, adjustment for population structure using principal components analysis in
these studies also identified no association between rs1229984 A-allele and HDL-C. It is
possible that confounding by linkage disequilibrium with an HDL-C raising allele could
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obscure an association with rs1229984, but the in-silico analysis found no support for
this hypothesis (Table C.10). It is also possible that other substrates metabolized by
the ADH1B enzyme may dilute the HDL-C association,[545] but it is unlikely that they
would account for the differential effect of the rs1229984 variant by alcohol categories ob-
served with several traits. More broadly, the cardioprotective effect ascribed to HDL-C
in light-to-moderate drinkers has recently been brought into question by the halting of a
randomized trial of a drug designed to increased HDL-C,[409] while another Mendelian
randomization study found no association of an HDL-C gene score with cardiovascular
events.[408]
The genetic analysis did not show rs1229984 A-allele carriers to have lower levels of
coagulation markers. These results appeared more robust for fibrinogen, but for factor
VII and von Willebrand factor the reduced sample size limited my ability to refute a
small effect. Although I observed an overall null association of the rs1229984 A-allele
with type 2 diabetes and glucose, a stratified analysis by alcohol consumption showed
that among heavy drinkers, carriers of the rs1229984 A-allele had lower levels of glucose.
The lower number of stroke events is an important limitation, as well as the fact that the
combined stroke outcome could have obscured some differential associations of alcohol
by pathological subtype of stroke (ischemic and hemorrhagic) and aetiological subtype
of ischemic stroke (large artery, small artery, cardio-embolic, other) as suggested by
recent overviews from observational studies.[546] In this regard, a subset of studies that
reported ischemic stroke did show an association between the rs1229984 A-allele with a
reduced risk of ischaemic stroke, however this requires further replication.
8.3.5 Association of ADH1B with lifestyle factors
One of the advantages of a Mendelian randomization study is to reduce the bias in
observational studies. In contrast to the observational analyses that showed associations
of alcohol with physical activity and different measures of exposure to smoking (as I
reported in Chapter 7), ADH1B rs1229984 was not associated with physical activity,
or any of the more precise measures of exposure to smoking (i.e. cigarettes/day, pack
years or cotinine). However, an association was observed with the binary ever/never
smoking trait but this was in the opposite direction to the association with CHD and
therefore unlikely to explain it. There was also some evidence for a difference in years
of education, however given the diversity of measures used across studies and the small
magnitude of effect, this association requires further investigation and replication.
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8.3.6 Instrumental variable analysis
The instrumental variable estimates reported in Table 8.4 allowed the quantification of
the causal effects for each log unit increase in alcohol, however this technique is limited as
it assumes a linear relationship between alcohol and each of the traits. Given that many
of the observational associations show a curvilinear relationship (as shown in Chapter 7),
these instrumental variable estimates must be interpreted with caution.
The limitation of this linear instrumental variable approach highlights the need to de-
velop novel techniques to enable the investigation of non-linear instrumental variable
analysis.
8.3.7 Contrast with other Mendelian randomization studies
The use of ADH1B genotypes to investigate the effect of alcohol on CHD represents a
natural extension of previous Mendelian randomization studies that used genetic varia-
tion in alcohol metabolizing enzymes to investigate the association between alcohol and
various traits. For example, studies have shown associations between ALDH2 rs671 with
blood pressure, BMI, non-HDL-C, HDL-C, coronary artery disease,[507, 515, 525, 547]
liver disease and various cancers.[511] However, in Europeans the ALDH2 rs671 SNP is
monomorphic[548] and cannot be used for Mendelian randomization.
8.3.8 Contrast with existing data and implications for interpretation
The data I present in this chapter run contrary to a large body of observational ev-
idence that suggests low dose alcohol is cardioprotective.[395] However, these are the
first reported data between alcohol and CVD to be free from confounding. The lack of
consistency with observational data is not entirely surprising or novel to this scenario.
Just as with vitamin C, vitamin A and hormone replacement therapies (and indeed
sPLA2-IIA as reported in Chapters 3 to 5), observational associations are prone to error
from confounding and bias, and to reveal the “true” association, a randomized design is
needed.
One question is how these findings will be interpreted by the Scientific and lay commu-
nity. When communicating such findings, it is important to emphasize that the purpose
of this experiment was not to identify a genetic test that could predict individuals that
consume more (or less) alcohol or that might be at increased risk of CHD on exposure
to alcohol, but rather the motivation was as a substitute for a randomized trial. Critics
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may argue that it is not reasonable to inform public health policy on data from a single
SNP. However, interpreted in the light of the context (i.e. an estimate of the association
between alcohol with CHD that is free from confounding), policy-makers and the gen-
eral public should be encouraged to read these findings as providing evidence against
the cardioprotective hypothesis of low-dose alcohol.
8.4 Conclusions
In this Chapter, I presented findings from use of a genetic variant to make unbiased
estimates of the nature of the association between alcohol and CVD traits and events.
These data are the first of their kind to be synthesized to generate large-scale, reliable
evidence. The data do not support a protective effect of alcohol at any dose of alcohol
consumption. Therefore, there is no evidence to support drinking alcohol to reduce
cardiovascular risk. In light of these findings and the recognized harm that alcohol
causes, governmental policy should be revised to advise individuals to minimize alcohol
consumption.
Chapter 9
Discussion and Conclusions
9.1 Introduction
The purpose of this thesis was to use practical examples to illustrate how human genetic
variation can be used for translation into improvements in human health. This encom-
passed a number of complementary applications, including: (i) use of genetic variants
to stratify drug prescribing in an attempt to target treatments to individuals that are
predicted to respond more favourably to drug treatment (“stratified medicine”); (ii) use
of a genetic variant as a proxy for a drug target to predict the results of a phase III
clinical trial, and; (iii) use of a genetic variant to answer a question on causal relevance
of an environmental exposure that would be challenging to obtain from a conventional
randomized clinical trial.
9.2 Reaping the rewards of genomic research
Although initial genetic studies have focussed on genomic discovery yielding many thou-
sands of GWAs articles that have identified genetic loci using an agnostic (hypothesis-
free) approach, the challenge now lies in how to translate these discoveries into improve-
ments in clinical health.
9.2.1 Pharmacogenetics
Pharmacogenetics is one such translational approach that promises to revolutionize the
way treatments are prescribed to patients, by harnessing genetic variants to create sub-
groups of the population. This research methodology is thought to be one of the most
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‘proximal to use’, as a detailed understanding of how the genetic variant influences
treatment response is not a pre-requisite for clinical use. I.e. once a gene that associates
with drug response is identified, assuming the required metrics are satisfied (magnitude
of effect, cost, clinical utility), it can be rapidly adopted in the clinical setting. One such
example are HLA SNPs associated with adverse drug reactions to carbamazepine,[549]
recommended to guide treatment prescribing by the UK MHRA.[550]
This is in contrast to loci discovered that associate with biomarkers or disease traits for
which the function is not known. In these examples, further studies are often required
to elucidate the mechanism by which the genetic variant influences disease risk prior to
being able to advance along the translational pipeline from discovery to clinical use.
My chapter on pharmacogenetics investigated the potential use of a genetic variant
(CYP2C19 ) to identify individuals who are likely to respond to a widely-prescribed
drug, clopidogrel, for the prevention of CVD. Despite what was hoped to be the most
promising cardiovascular pharmacogenetic biomarker available[169], the evidence base
for the use of CYP2C19 was heavily undermined by small-study bias and lack of evi-
dence of a gene-by-drug treatment interaction. This undermines the validity of the use
of this genetic variant for identifying those who are likely to benefit from clopidogrel. As
such, my conclusion is that the available evidence does not support the use of CYP2C19
in clopidogrel prescribing.
These findings add further doubt to a field of research that is hampered by small study
bias, lack of focus on particular gene-drug pairs; and, publication bias.[110] In general,
genomic information is more likely to be informative when the association between a
gene variant with an outcome has an effect estimate of large magnitude. This arises
from well-established doctrines of screening - i.e. to have a sufficient detection rate to
be clinically useful, the odds ratios need to be high - typically values in excess of 10.[551]
Values beneath this mean that the overlap in treatment response between the genetic
groups may render the genetic variant to be of insufficient discrimination to be clinically
useful.
Estimates of large magnitude in pharmacogenetics studies have tended to arise from
studies that have investigated adverse drug reactions.[118] Therefore, to increase the
possibility of yielding pharmacogenetic variants that can be quickly translated into clin-
ical use, investigators ought to focus on adverse drug reactions for which genetic variants
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may have qualitative interactions (differences in kind) with treatment response, in con-
trast to intended drug reactions (which are more likely to yield quantitative, differences
in magnitude, drug interactions). Furthermore, use of a hypothesis-free approach (such
as a GWAs) using datasets enriched for adverse drug reactions (e.g. case control collec-
tions) will not constrain the Scientist to pursuing a limited number of SNPs in candidate
genes thought to play a biological role in drug metabolism, but will instead open the
possibility for new discoveries that can have immediate translational benefit.
For intended drug effects, more focus should be placed on the underlying epidemiological
approach, and in particular harnessing the power of randomized trials, where a pharma-
cogenetic study is akin to a factorial design trial (as both drug and gene are randomly
allocated, the former by man, the latter by Nature).
9.2.2 Mendelian randomization
A second example of post-GWAs translation that is gaining increasing acknowledgement
as a “natural randomized trial” is the use of genetic variants to make causal inference
on disease. These Mendelian randomization experiments exploit the random allocation
of genetic variants for instrumental variable analysis. The two contrasting examples I
present in this thesis (sPLA2 and alcohol) illustrate the flexibility of Mendelian random-
ization applications: one for an endogenous trait (sPLA2) encoded by a specific gene,
and the other an exogenous trait (alcohol) that is influenced by multiple behavioural
and social factors.
9.2.3 Mendelian randomization for drug target validation
In Chapters 4 and 5, I investigated the role of sPLA2-IIA as a therapeutic target for
CHD. The translational implications of the work I report go hand-in-hand with the re-
sults of a phase III clinical trial. Both the Mendelian randomization study and the phase
III clinical trial provide bias-free evidence that sPLA2-IIA is very unlikely to represent
a valid drug target for CHD prevention.
Although sPLA2-IIA may be considered a “niche” enzyme, the findings of my work
have wider implications for the drug development pipe-line, which in its present form
costs billions of dollars, has a high attrition rate and is said to be unsustainable (Fig-
ure 9.1).[552, 553] Relatively inexpensive Mendelian randomization projects could be
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conducted as part of the drug discovery pipeline, which could revolutionize the process
by which drug targets are prioritized for clinical trials.	  	  	  	  Permissions	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Figure 9.1: Probability of success to market at different stages of drug development
pipeline
Reproduced from Arrowsmith[552]
The Mendelian randomization investigation into sPLA2-IIA shows the critical impor-
tance of which drug targets to prioritize for phase III clinical trials. This is highlighted by
the example of the drug company, Anthera, which conducted the phase III clinical trial
VISTA-16. At the time that VISTA-16 was terminated due to lack of efficacy,[381, 382]
the stock price of the shares fell by over 50% (Figure 9.2). This led to the company
having to lay off half of its staff,[554] illustrating the devastating effect of having a phase
III clinical trial fail. And, notably, it could have been averted had a Mendelian random-
ization study such as the one reported in this thesis been conducted prior to embarking
upon the phase III trial. The findings that I present in this thesis would provide strong
evidence against pursuing a phase III randomized trial for a drug that targeted sPLA2-
IIA, and would suggest that drug development focus on alternative biomarkers to target.
Finally, this study design complements previous work that validated the IL-6 receptor
as a therapeutic target in CVD[83] (providing strong evidence for the re-purposing of
an existing drug in clinical use for rheumatoid arthritis). These two examples (sPLA2
and IL6R) provide contrasting examples of the use of Mendelian randomization study
design to prioritize therapeutic targets.
9.3 Mendelian randomization for casual analysis of envi-
ronmental exposures
In Chapters 7 and 8, I described the use of a genetic variant to investigate the role of
alcohol in cardiovascular disease. This is an epidemiological question that has important
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VISTA-16 terminated
Figure 9.2: Stock price of Anthera Pharmaceuticals prior to and after announcement of
VISTA-16 termination
The vertical arrow shows the time the VISTA-16 was terminated.[381] Stock prices derived from
http://www.nasdaq.com
public health questions (as alcohol consumption is so widely prevalent within the pop-
ulation and worldwide) but also a question that would be otherwise difficult to answer
through use of traditional means (such as a more conventional clinical trial). The next
best option is to conduct a Mendelian randomization analysis using a gene variant that
associates with alcohol intake, and this is the first-in-kind scaled analysis to address this
important topic.
Using this approach, I found that a gene variant that acts as a proxy for several alcohol
phenotypes yielded evidence to indicate that alcohol consumption showed increased risk
of CHD at all levels of intake, making it unlikely that alcohol has cardioprotective prop-
erties. These findings are of critical importance given that the UK government has used
observational data (suggesting a protective effect of alcohol on CVD at low volumes) to
inform, and what’s more relax, public guidance on safe drinking levels.
The Mendelian randomization project of alcohol is, to my knowledge, the largest Mendelian
randomization project conducted to date and the one that has the greatest potential for
public health translation. For this reason, the data I present in Chapters 7 and 8 can
be considered not only the first deconfounded findings of their kind, but also the best
evidence that is available. Importantly, they suggest that the hitherto reported cardio-
protective effects of alcohol are most likely the result of bias/confounding. This would
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place alcohol in the same domain as vitamin A, C and hormone replacement therapy:
i.e. that observational evidence suggesting a beneficial effect was all overturned by
randomized evidence which were contrary to the observations.
In the absence of clinical trials powered for cardiovascular events, the findings I present
suggest that alcohol intake should be minimized for all individuals.
9.4 Future aims for Mendelian randomization
The next frontiers of Mendelian randomization are two-fold. First, using multiple SNPs
in combination, and second, investigation of non-linear effects.
9.4.1 Multiple SNPs
In both the PLA2G2A-sPLA2 and ADH1B -alcohol example, I used a single SNP for
Mendelian randomization analysis. However, it is possible to combine multiple SNPs
together to improve specificity for the index trait, particularly important when the trait
is not a protein, such as a circulating lipid. Furthermore, as a genetic instrument con-
sisting of multiple SNPs would be expected to explain a greater proportion of variance
of the index trait (compared to a genetic instrument consisting of a single SNP), us-
ing multiple SNPs in combination also increases statistical power, meaning that smaller
sample sizes may be required to show similar results.[82]
Working with colleagues at University of Warwick and LSHTM, I have developed a
series of Stata scripts that conduct Mendelian randomization experiments combining
multiple SNPs together. I am using these scripts to investigate the role of blood lipids
and glycaemic traits in CVD, and these will form my next major research outputs.
9.4.1.1 Pushing the frontier: multiple SNPs to investigate putative epi-
demiological interactions
A natural extension of using allele scores may be to conduct factorial design studies
with allele scores for two traits that are thought to interact with one another. An
example of this could be to investigate the hypothesis of the ‘metabolically healthy
but obese’ individual. The theory is that although obesity associates with an adverse
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metabolic profile (such as increased fasting glucose, insulin and risk of type 2 diabetes),
there may be a subgroup of individuals with obesity that do not suffer the typical
metabolic sequelae, termed “metabolically-healthy obesity”.[555] A recent hypothesis is
that inflammation may mediate the risk between obesity and metabolic consequences,
thus there may be an interaction between obesity and inflammation.[556]
One way to formally investigate whether this could be possible would be to conduct a
factorial design analysis using allele scores for obesity and inflammation and investigate
glycaemic traits and risk of type 2 diabetes as outcomes. If there is a true interaction,
we should expect a differential risk of type 2 diabetes in individuals with alleles that
predispose to obesity that harbor fewer genetic variants associated with inflammation
to those that harbor more variants associated with inflammation. This type of ‘blue-
sky thinking’ represents a genetic take on a traditional factorial design conducted in a
randomized trial - but as with the conventional factorial trial, the randomized properties
of the allele scores should benefit from the same alleviation from confounding.
9.4.2 Non-linear Mendelian randomization
Conventional instrumental variable analyses rely upon the assumption that the associa-
tion between the biomarker of interest and trait/outcome is linear.[84] Sometimes, as in
the example of sPLA2 where I investigated the nature of the association between sPLA2
and CVD, this assumption is valid. However, as evidenced in the example of alcohol, the
best fit model may suggest that the underlying relationship is non-linear. In the latter
circumstance, it may be desirable, rather than imposing a linear model for instrumental
variable analysis, to conduct non-linear Mendelian randomization.
In the example of alcohol, we are interested in whether a causal association between
alcohol and CVD could have a J-shaped relationship. Novel methodologies are under
development using local average treatment effects (LATEs) that allow for the investiga-
tion of non-linear effects. This represents on-going work at the LSHTM/UCL Genetic
Epidemiology Group.[557]
9.5 Conclusions
In this thesis, I have used genomic information to investigate the role of genes as phar-
macogenetic markers, and I exploited the unique properties of genotype (according to
Mendel’s second law) to make causal inference on a potential drug target (sPLA2-IIA
mass) and a ubiquitous exposure of critical importance to public health policy (alcohol)
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on risk of cardiovascular disease.
These serve as contrasting examples to highlight the potential for translational genomic
research to make advances in public health. As Mendelian randomization techniques
develop, they will undoubtedly become a routine part of the drug discovery pipeline.
Furthermore, there will be other opportunities to investigate environmental exposures
that, like alcohol, are challenging to answer via conventional means. Taken together, ge-
netic epidemiology will undoubtedly play an important role in future Scientific research,
as we strive to answer important questions on human disease aetiopathogenesis, with
the ultimate goal of improving public health.
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CYP2C19 and clopidogrel
response
A.1 Supplementary Methods
A.2 Search strategy for identifying studies in the system-
atic review
A.2.1 PubMed Search String
A.2.1.1 MeSH Search
(1) clopidogrel [Substance Name]; (2) 2-oxo-clopidogrel [Substance Name]; (3) clopido-
grel carboxylic acid [Substance Name]; (4) clopidogrel resinate [Substance Name]; (5)
platelet aggregation inhibitors [MeSH]; (6) 1 OR 2 OR 3 OR 4 OR 5; (7) ”Cytochrome P-
450 Enzyme System”[Mesh]; (8) ”Cytochromes”[Mesh]; (9) ”CYP2C9 protein, human”
[Substance Name]; (10) (”P-Glycoprotein”[Mesh] OR ”ABCB1 protein, human ”[Sub-
stance Name] OR ”ABCB1 protein, mouse ”[Substance Name] OR ”multidrug resistance
protein 3 ”[Substance Name]); (11) (”Cytochrome P-450 CYP1A2”[Mesh] OR ”CYP1A2
protein, human ”[Substance Name]); (12) ”S-mephenytoin N-demethylase ”[Substance
Name]; (13) ”CYP3A4 protein, human ”[Substance Name]; (14) ”CYP3A5 protein, hu-
man ”[Substance Name]; (15) (”Cytochrome P-450 CYP3A”[Mesh] OR ”CYP3A pro-
tein, human ”[Substance Name]); (16) CYP2C19 protein, human [Substance Name]; (17)
198
Appendix A. Supplemental Information for CYP2C19 and clopidogrel response 199
”Esterases”[Mesh] ; (18) purinoceptor P2Y12 [Substance Name]; (19) ITGB3 protein,
human [Substance Name]; (20)7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13 OR 14 OR
15 OR 16 OR 17 OR 18 OR 19; (21) Genotype[MeSH]; (22) ”Genetic Association Stud-
ies”[Mesh]; (23) Genes[MeSH]; (24) Alleles[MeSH]; (25) Polymorphism, Genetic[MeSH];
(26) 21 OR 22 OR 23 OR 24 OR 25; (27) 6 AND 20 (28) 6 AND 26; (29) 27 OR 28
A.2.1.2 Text Word search
(1) clopidogrel; (2) 2-oxo-clopidogrel; (3) Plavix; (4) Clopilet; (5) Ceruvin; (6) Clavix; (7)
Clopigrel; (8) Clasprin; (9) 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8; (10) cytochrome*;
(11) cytochrome-P450; (12) cytochrome P-450; (13) ABCB1*; (14) CYP1A2*; (15)
CYP2B6*; (16) CYP3A4*; (17) CYP3A5*; (18) CYP2C19*; (19) CYP2C9*; (20) es-
terase*; (21) P2RY12*; (22) ITGB3*; (23) 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR
16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22; (24) genotype*; (25) gene; (26) allele*;
(27) polymorphism*; (28) 23 OR 24 OR 25 OR 26; (29) 9 AND 23; (30) 9 AND 28; (31)
29 OR 30
A.2.2 EMBASE Search String
A.2.2.1 Expanded (exp) headings search
(1) clopidogrel/exp; (2) ’antiplatelet drug’/exp; (3) plavix/exp; (4) 1 OR 2 OR 3; (5)
’cytochrome’/exp; (6) ’p450’/exp; (7) ’cytochrome p450 2c9’/exp; (8) ’cytochrome p450
2c19’/exp; (9) ’multidrug resistance protein 3’/exp; (10) cytochrome p450 1a2’/exp ;
(11) ’cytochrome p450 2b6’/exp; (12) ’cytochrome p450 3a4’/exp; (13) ’cytochrome
p450 3a5’/exp; (14) 5 OR 6 OR 7 OR 8 OR 9 OR 10 OR 11 OR 12 OR 13; (15)
’genotype phenotype correlation’/exp; (16) genotype’/exp; (17) ’association’/exp; (18)
’genes’/exp; (19) ’alleles’/exp; (20) ’polymorphism genetic’/exp; (21) 15 OR 16 OR 17
OR 18 OR 19 OR 20; (22) 4 AND 14 AND 21
A.2.2.2 Text word search
(1) clopidogrel$; (2) 2 oxo clopidogrel; (3) clopidogrel carboxylic acid; (4) clopidogrel
resinate; (5) ’antiplatelet drug’; (6) plavix; (7) clopilet; (8) ceruvin; (9) clavix; (10)
clavix; (11) clopigrel; (12) clasprin; (13) 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 OR
9 OR 10 OR 11 OR 12; (14) Cytochrome$ ; (15) Cytochrome P450; (16) ’cytochrome
p450 2c9’ OR CYP2C9; (17) ’multidrug resistance protein 3’ OR MDR1 OR ABCB1
OR P-glycoprotein OR P glycoprotein; (18) ’cytochrome p450 1a2’ OR CYP1A2; (19)
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’cytochrome p450 2b6’ OR CYP2B6; (20) ’cytochrome p450 3a4’ OR CYP3A4; (21)
cytochrome p450 3a5 OR CYP3A5; (22) cytochrome p450 2c19 OR CYP2C19; (23)
esterase; (24) ’p2y12’ OR p2ry12; (25) itgb3 gene’ OR itgb3; (26) 14 OR 15 OR 16
OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23 OR 24 OR 25; (27) genotype’; (28)
’association’; (29) ’genes’; (30) ’alleles’; (31) ’polymorphism genetic’; (32) 27 OR 28 OR
29 OR 30 OR 31; (33) 13 AND 26 AND 32
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Table A.1: Characteristics of the studies included in the systematic review: risk of bias
First Author, Ref/
Study Name (Year)
Compar-
ator
drug
PPI at
baseline,
%
Aspirin at
baseline,
%
Outcome
ascertain-
ment
blinded to
genotype
Genotype
ascertained
with blinding
to outcome
Study
authors
received fees
from phar-
maceutical
industry
Genotype
call rate
provided,
(%)
Hardy-
Weinberg
Equilib-
rium, P
value
Reporting
of
outcome
ascertain-
ment
Anderson et al [152]/
IHCS (2009)
NA NR NR NR NR NR No 0.0008 NA
Bouman et al [153]/
MAPCAT (2010)
NA 50.2 91.3 Yes Yes No Yes (>95) 0.5336 clear
Campo et al [154]/ NA
(2011)
NA 53 99 NR NR Yes No 0.8134 clear
Collet et al [155]/ AFIJI
(2009)
NA 32 97.3 Yes NR Yes No 0.2432 clear
Giusti et al [156]/ RE-
CLOSE (2009)
NA 94.8 100 Yes NR No No 0.6218 clear
Harmsze et al [159]/ NA
(2010)
NA 22.7 100 NR NR Yes No 0.1571 clear
Harmsze et al [157]/
POPular (2011)
NA 19.9 100 NR NR Yes NR 0.0637 clear
Jeong et al [158]/ACCEL
(2011)
NA 1.5 100 NR NR Yes NR 0.7544 NA
Komarov et al [160]/NA
(2011)
NA 18 NR NR NR NR NR 0.8384 NA
Malek et al [138]/ NA
(2008)
NA NR 100 NR NR No No 1 unclear
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Table A.1 – Continued from previous page
First Author, Ref/
Study Name (Year)
Comparator
drug
PPI at
baseline,
%
Aspirin at
baseline,
%
Outcome
ascertain-
ment
blinded to
genotype
Genotype
ascertained
with blinding
to outcome
Study
authors
received fees
from phar-
maceutical
industry
Genotype
call rate
provided,
(%)
Hardy-
Weinberg
Equilib-
rium, P
value
Reporting
of
outcome
ascertain-
ment
Malek et al [161]/ NA
(2010)
NA NR 96.9 NR NR No No 0.2273 clear
Oh et al [162]/ Sky Reg-
istry (2011)
NA 4.4 100 Yes NR No No NA clear
Ono et al [163]/NA (2011) NA 28.4 100 NR NR No NR 0.6006 unclear
Sawada et al [165]/ NA
(2010)
NA 50 100 NR NR NR No NA clear
Shuldiner et al [140]/
Sinai Hospital of Balti-
more Study (2009)
NA NR 100 Yes NR Yes Yes (98.7) >0.05 *** clear
Sibbing et al [168]/
ISAR-REACT, ISAR-
REACT 2, ISAR-SMART
2, ISAR-SWEET (2009)
NA NR 96.8 Yes NR Yes No 0.3765 clear
Sibbing et al [166]/ NA
(2010)
NA 18.1 75.8 Yes Yes Yes No NA clear
Sibbing et al [167]/NA
(2011)
NA 18.1 100 NR Yes Yes 100 0.3205 clear
Simon et al [169]/ FAST-
MI (2009)
NA 72.7 98 Yes NR Yes No 0.8049 unclear
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Table A.1 – Continued from previous page
First Author, Ref/
Study Name (Year)
Comparator
drug
PPI at
baseline,
%
Aspirin at
baseline,
%
Outcome
ascertain-
ment
blinded to
genotype
Genotype
ascertained
with blinding
to outcome
Study
authors
received fees
from phar-
maceutical
industry
Genotype
call rate
provided,
(%)
Hardy-
Weinberg
Equilib-
rium, P
value
Reporting
of
outcome
ascertain-
ment
Tello-Montoliu et al
[170]/NA (2011)
NA NR NR NR NR NR NA NA NA
Tiroch et al [171]/ NA
(2010)
NA NR 97.7 Yes Yes No No 0.1868 clear
Trenk et al [172]/ EX-
CELSIOR (2008)
NA NR 100 NR NR No No 0.3015 clear
Worrall et al [174]/ NA
(2009)
NA NR NR NR NR NR NA NA NA
Yamomoto et al [175]/NA
(2011)
NA 25.8 100 NR NR No NR 0.3755 unclear
Yan et al [176]/ NA
(2011)
NA 22.3 98 Yes NR No NR 0.389 unclear
Yuan et al [177]/ NA
(2011)
NA NR NR NR NR NR NR 0.773 NA
Mega et al [146]/
TRITON-TIMI 38 (2009)
Prasugrel NR 99 Yes NR Yes No NA clear
Wallentin et al [173] /
PLATO (2010)
Ticagrelor 41 96.5 Yes NR Yes Yes (>98.8) 0.2356 clear
Bhatt et al [151]/
CHARISMA (2009)
Placebo NR 99.7 Yes NR Yes NA 0.5319 clear
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Table A.1 – Continued from previous page
First Author, Ref/
Study Name (Year)
Comparator
drug
PPI at
baseline,
%
Aspirin at
baseline,
%
Outcome
ascertain-
ment
blinded to
genotype
Genotype
ascertained
with blinding
to outcome
Study
authors
received fees
from phar-
maceutical
industry
Genotype
call rate
provided,
(%)
Hardy-
Weinberg
Equilib-
rium, P
value
Reporting
of
outcome
ascertain-
ment
Mega et al [145]/
CLARITY-TIMI 28
(2008)
Placebo NR 98.6 Yes NR NR NA NA clear
Pare et al [164]/
ACTIVE-A (2010)
Placebo NR 82.7$ Yes NR Yes Yes (>98) >0.05 clear$
Pare et al [164]/ CURE
(2010)
Placebo NR 66.1 Yes NR Yes Yes (>98) >0.05 clear
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Table A.2: Components of the composite primary cardiovascular outcomes reported by studies contributing to the meta-analysis.
Outcome Subtype Proportion (%) of all participants contributing to treatment-only analysis (n=31,076)
Not measured Measured but not
reported in composite
CVD outcome
Measured and reported
in composite CVD
outcome
Mortality All-cause 19.18 49.95 30.88
Cardiovascular 42.55 0 57.45
Myocardial infarction Not specified 33.64 17.81 48.55
Nonfatal 51.69 17.42 30.89
ST-elevation 89.52 2.48 8
Non-ST-elevation 92 0 8
ACS Hospitalisation for ACS 74.09 23.59 2.32
Unstable angina 99.35 0 0.65
Stroke Not specified 50.96 13.66 35.38
Nonfatal 69.09 14.06 16.85
Ischaemic 56.74 38.3 4.97
Stent thrombosis Not specified 61.25 28.65 10.1
Definite 58.99 31.79 9.22
Probable 75.87 20.68 3.45
Sub-acute 99.66 0 0.34
Other Urgent revascularization 59.68 20 20.32
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Table A.3: Outcomes reported individually by studies contributing to the meta-analysis.
Outcome Subtype Proportion (%) of all treatment-only participants (n=31,076)
Not measured Measured but
not reported
individually
Measured but
reported only as
part of composite
Measured and
reported
individually
Mortality All-cause 17.68 47.42 12.86 22.04
Cardiovascular 40.22 7.81 36.26 15.71
Myocardial infarction Not specified 54.34 9.67 22.92 13.07
Nonfatal 48.7 11.84 27.07 12.39
ST-elevation 89.52 2.48 0 8
Non-ST-elevation 92 0 0 8
ACS Hospitalisation for ACS 79.4 10.15 10.46 0
Unstable angina 99.35 0 0.65 0
Stroke Not specified 63.52 13.66 19.83 2.99
Nonfatal 70.59 7.81 16.85 4.75
Ischaemic 56.74 30.3 3.92 9.04
Stent thrombosis Not specified 54.73 16.51 5.76 23
Definite 54.23 0 11.35 34.41
Probable 71.11 15.78 10.62 2.48
Sub-acute 99.66 0 0 0.34
Bleeding All 66.94 14.63 0 18.44
Minor 51.28 30.28 5.72 12.72
Major 41.61 14.23 5.72 38.44
Other Urgent revascularization 54.85 27.81 9.27 8.06
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Table A.4: Genome-wide associations of polymorhpisms in CYP450 enzymes with traits
Gene(s) Disease/Trait OR or Beta coefficient
[95%CI or SE]
P value(s) Refer-
ence
(PMID)
CYP1A1 Caffeine
consumption
0.12 [0.08-0.16] mg/day;
0.31 [0.17-0.44] cups per
day
5 x 10-14
21490707,
21357676
CYP1A1 Diastolic blood
pressure
0.43 [0.35-0.51] mm Hg 1 x 10-23
19430483
CYP1A2 Caffeine
consumption
0.08 [0.06-0.10] mg/day;
0.31 [0.17-0.44] cups per
day
3 x 10-7; 5 x
10-14 21490707,
21357676
CYP1A2 Diastolic blood
pressure
0.43 [0.35-0.51] mm Hg 1 x 10-23
19430483
CYP2A6 Smoking
behaviour
0.33 [0.22-0.44]; 0.39
[0.27-0.51] cigs/day
1 x 10-8; 2 x
10-12 20418890,
20418888
CYP2B6 Smoking
behaviour
0.2 [0.12-0.28] cigs/day 6 x 10-6
204818888
CYP2C8,
CYP2C9,
CYP2C19
Clopidogrel
response
NR 2 x 10-13
19706858
CYP2C18 Acenocoumarol
maintenance
dose
NR 8 x 10-12
19578179
CYP2R1 Vitamin D level-
s/insufficiency
0.25 [0.15-0.35] unit 3 x 10-17
20541252,
20418485
CYP3A43 Serum dehy-
droepiandros-
terone sulphate
levels
0.11 [0.07-0.15] umol/ 2 x 10-11
21533175
CYP4F2 Alpha-tocopherol
(vitamin E)
0.03 (0.01) mg/L 1.4 x 10-8
21729881
CYP17A1 Coronary heart
disease
1.12 [1.08-1.16] 1 x 10-9
21378990
CYP17A1 Parkinson’s
disease
1.25 7 x 10-8
19915575
CYP17A1 Systolic blood
pressure
1.05 [0.74-1.36] mm Hg ;
1.16 [0.92-1.40] mm Hg
1 x 10-10; 7 x
10-24 19430479,
19430483
CYP19A1 Alzheimer’s
disease CSF
protein
NR 2 x 10-9
20932310
CYP19A1 Height 0.06 [0.04-0.07] cm 7 x 10-7
20189936
CYP20A1 Height 1.05 [0.62-1.48] cm 2 x 10-6
20966902
CYP27B1 Multiple sclerosis 1.23 5 x 10-11
19525955
CYP27C1 Self-related
health
0.03 2 x 10-6
20707712
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Table A.5: Details of the studies included in the analysis of CYP2C19 genotype and platelet response
First
Author
(ref)
Study
participants at
baseline
No. Sex (%
female)
Age
(mean,
SD)
Clopido-
grel dose
(mg/-
day)
Platelet Aggregometer Units of
platelet
assay
ADP
dose
(µmol/L)
Time from
clopidogrel
to platelet
measure
Giusti
[182]
ACS admitted
to CCU
1419 27 69 (11) 600 4-channel (APACT 4,
Labor Biochemical Tech)
MPA (2), 10 24hr after
loading
Trenk
[172]
Non-ACS CAD
or risk factors
for CAD
797 22 66 (10) 600 4-channel FACSCalibur
(Becton Dickinson)
RPA 5 After
loading
Frere
[181]
non-STEMI
ACS
601 24 64 (12) 600 PAP4 Aggregomenter
(Biodata Corp)
ADP-Ag 10 12hr after
loading
Sibbing
[167]
CAD and
planned PCI
1524 22.8 67.2
(10.7)
600 Multiplate analyzer
(Dynabyte)
AUxmin 6.4 ≥2hr after
loading
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Table A.6: Association of CYP2C19 ?2-?8 vs. ?1 or ?17 on risk of clinical events in
treatment-only analysis using random-effects meta-analysis.
Outcome RR (95%CI)
All-cause mortality 1.56 (0.92, 2.64)
Myocardial infarction fatal/nonfatal 1.39 (1.10, 1.74)
Myocardial infarction nonfatal 1.45 (1.03, 2.03)
Stent thrombosis 1.88 (1.46, 2.41)
Stroke fatal/nonfatal 2.69 (0.55, 13.29)
Bleeding all 0.84 (0.75, 0.94)
Bleeding - severe 1.13 (0.82, 1.55)
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Table A.7: Analysis of CYP2C19 genotype on composite cardiovascular end-points and
major bleeding in randomized trials using random-effects meta-analysis.
Outcome Stratum RR (95% CI) of clopidogrel vs. placebo P value (Z test)
CVD composite
Original RCT 0.83 (0.74, 0.93)
0.73Genetic substudy 0.79 (0.62, 1.01)
CYP2C19 ?2 or ?3 0.84 (0.54, 1.31)
0.77CYP2C19 ?1 or ?17 0.78 (0.66, 0.92)
Major bleeding
Original RCT 1.41 (1.25, 1.59)
0.89Genetic substudy 1.44 (1.18, 1.75)
CYP2C19 ?2 or ?3 1.99 (1.31, 3.02)
0.07CYP2C19 ?1 or ?17 1.28 (1.02, 1.61)
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A.4 Supplementary Figures
Intervention 
(Clopidogrel 75 mg)   
Genotype-1 
(CYP2C19 *2-carriers) 
Low levels 
 Clopidogrel 
Genotype-2 
(CYP2C19  *1/*17) 
High levels 
 Clopidogrel 
CV events  
rate higher 
CV events  
rate lower 
Random allocation of 
alleles 
Bleeding events 
rate lower 
Bleeding events 
rate higher 
Low platelet 
inhibition 
High platelet 
 inhibition 
Figure A.1: Schemata for random allocation of CYP2C19 alleles akin to the random
allocation of an intervention in a RCT 	  	  	  	  Permissions	  not	  obtained	  for	  figure	  Please	  refer	  to	  citation	  for	  image	  	  	  	  	  	  	  	  	  	  
Figure A.2: Schemata for metabolism and activation of clopidogrel by CYP2C19. Re-
produced from ten Berg and Deneer.[219]
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CHD at baseline 
ACS 
Stable CHD 
Mixed 
Not stated 
Source of funding 
Pharma non-RCT 
Pharma RCT 
Non-pharma 
Not stated 
Concomitant proton pump inhibitors 
<22.3% 
25.8-45% 
50+% 
Not reported 
Concomitant aspirin 
<97.3% 
97.5-99.8% 
99.9%+ 
Not reported 
Blinding to outcome when ascertaining genotype 
Blinded 
Not stated 
10 
9 
5 
2 
7 
5 
7 
7 
4 
4 
4 
14 
6 
4 
11 
5 
1 
25 
353/3242 
191/1722 
113/2061 
59/487 
167/1536 
330/3294 
119/1890 
100/792 
45/1119 
171/1654 
114/1005 
386/3734 
307/2986 
192/1359 
132/2548 
85/619 
60/248 
656/7264 
853/8588 
449/3917 
167/3742 
92/1030 
377/3943 
775/8587 
252/3217 
157/1530 
58/1426 
343/3809 
254/2375 
906/9667 
745/8013 
496/3536 
174/4327 
146/1401 
184/680 
1377/16597 
1.13 (1.01, 1.26) 
1.11 (0.95, 1.29) 
1.49 (1.18, 1.90) 
1.47 (1.07, 2.02) 
1.21 (1.03, 1.42) 
1.13 (1.00, 1.28) 
1.10 (0.89, 1.36) 
1.37 (1.11, 1.68) 
1.63 (1.21, 2.19) 
1.21 (1.02, 1.45) 
1.07 (0.87, 1.32) 
1.15 (1.03, 1.28) 
1.12 (0.99, 1.27) 
1.01 (0.87, 1.18) 
1.57 (1.28, 1.92) 
1.34 (1.08, 1.67) 
0.89 (0.69, 1.15) 
1.22 (1.12, 1.33) 
71(45,84) 
39(0,74) 
48(0,81) 
48(-,-) 
79(57,89) 
43(0,79) 
67(22,86) 
0(0,74) 
62(0,87) 
88(-,-) 
76(34,91) 
43(0,69) 
66(18,85) 
75(31,91) 
44(0,74) 
0(0,79) 
- 
58(33,73) 
0.364 
0.263 
0.094 
0.802 
0.566 
1 0.1 0.5 1.5 2 5 10 
Stratification Studies *2 to *8 *1 or *17 95%CI) 
P (meta- 
Regression)§ RR (95% CI) 
I2 (%, 
Any CYP2C19  
*2-*8 vs. 
 *1 or *17 
       Cases/Total        
Lower risk   Higher risk  
Relative risk of CVD events 
Figure A.3: Subgroup analysis of association between CYP2C19 and CVD in
”treatment-only” analysis.
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Figure A.4: Influence of removing one study at a time on the meta-analysis summary
estimate. Meta-analysis of the risk of CVD events in individuals with any loss-of-function
CYP2C19 alleles (*2 to *8) compared to normal/increased (*1 or *17) alleles.
Analysis only permits inclusion of studies that reported counts (of cases/total) per genotype,
therefore the summary estimate of 1.16 differs slightly from the summary of 1.18 reported in
Figure 2.6, which also includes studies that only report summary estimates.
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1
 
1
2
 
C
V
D
 R
R
R
 (
%
) 
75 
Clopidogrel dose (mg/day) 
0 300 600 
1
 
1
2
 
C
V
D
 R
R
R
 (
%
) 
75 
Clopidogrel dose (mg/day) 
0 300 600 
Scenario-2: usual dose on ‘plateau’ 
part of dose-response curve 
Scenario-1: usual dose on ‘linear’ 
part of dose-response curve 
5% 
CVD 
RRR § 
0.5% 
CVD 
RRR 
All participants  
Fast metabolisers (*1 or *17) 
Poor metabolisers (any *2 to *8) 
Figure A.5: Potential scenarios for more versus less clopidogrel.
In Scenario 1, 75mg/day clopidogrel lies on the linear part of the dose-response curve, therefore for a given change in drug exposure (e.g. as instrumented by CYP2C19), the rel-
ative risk reduction (RRR) for CVD will be considerable (5%). Scenario 2 illustrates the situation in which 75mg/day clopidogrel lies on the plateau: here the same proportional
change in clopidogrel exposure conferred by CYP2C19 will yield a smaller change in CVD RRR.
Appendix B
Supplemental Information for
sPLA2 and CVD
B.1 Definition of myocardial infarction and stroke in the
collaborating studies
B.1.1 General Population Studies
BHF-FHS MI: Direct assessment of hospital records or confirmation by a general
practitioner (GP) of a documented MI
BRHS MI: Events were identified from GP records and confirmed with the GP using
WHO criteria. Stroke: Events were identified from GP records and confirmed with
GP (acute disturbance of cerebral function of presumed vascular origin lasting 24
hours).
BWHHS MI/stroke: Events were obtained from self-report, GP records and con-
firmed with the GP using WHO criteria. Fatal events were defined using the
following ICD-10 codes: ICD10: I20-I25 and I60-I65.
CCHS MI: ICD8: 410; ICD10: I21-I22; Stroke: ICD8: 432-434, ICD10: I63
CYPRUS MI: based on clinical history and electrocardiogram (ECG) findings (which
were centrally reported by a cardiologist and vascular internist); Stroke: Hospital
records and self-report
215
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EAS MI: AHA criteria or death certification recording ICD-10 codes: I20-I25. Stroke:
Symptom onset ≤48 hours previously and lasting ≥24 hours, CT evidence of cere-
bral infarction or haemorrhage, or hospital discharge diagnosis or death certifica-
tion recording ICD10: I60-I65.
EPIC-Netherlands MI: ICD-9:410; ICD-10: I21, I22; Stroke: ICD-9:430-434, 436;
ICD-10: I60-I66
EPIC-Norfolk MI: ICD9 codes 410-414
IMPROVE MI/stroke: Medical records and death certificates
NPHSII MI: ICD-9: 410; Stroke: ICD-9: 430-436
PREVEND MI: Cardiac events were reviewed by a clinical event committee and
divided into ST-segment elevation myocardial infarctions (STEMI) or non-ST-
elevation acute coronary syndromes (ACS). ST-segment elevation MI was defined
as chest pain and ST elevation >1 mm in at least two contiguous leads. Non-ST-
elevation acute coronary syndrome was defined as chest pain with positive car-
diac markers (troponin or creatinine kinase) and/or dynamic ST-segment changes
(ICD-9 410, 411); Fatal MI/stroke: based on ICD-10 codes: I01-99
PROCARDIS MI: documentation of two or more of (a) typical ischaemic chest pain,
pulmonary oedema, syncope or shock; (b) development of pathological Q-waves
and/or appearance or disappearance of localized ST elevation followed by T-wave
inversion in two or more standard electrocardiograph leads; (c) increase in con-
centration of serum enzymes consistent with MI (e.g. creatine kinase more than
twice the upper limit of normal). Symptomatic ACS: documentation of hospi-
talization for one of the following indications: (a) unstable angina diagnosed by
typical ischemic chest pain at rest associated with reversible ST-depression in two
or more standard electrocardiograph leads; (b) thrombolysis for suspected MI (as
indicated by localized ST-elevation in two or more standard electrocardiograph
leads) even without later development of T-wave inversion, Q-waves, or a signifi-
cant enzyme rise; or (c) emergency revascularization (i.e. during same admission)
following presentation with typical ischemic chest pain at rest.
PROSPER MI/stroke: participants were monitored every 3 months for clinical events
Rotterdam Information was obtained from general practitioners and discharge report-
s/letters from medical specialists. Two research physicians independently coded
all reported MI and stroke events according to ICD-10 and a medical expert re-
viewed all events. Fatal events were defined as deaths related until 28 days after
MI or stroke using ICD-10 codes: I20-I25, I46, R96 and I50.
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TPT For both MI and Stroke, diagnosis was by WHO criteria, and verified by an
independent reviewer
Whitehall II MI/stroke events were obtained from ICD-9 codes 390.0458.9 and ICD-
10 codes I00I99.
B.1.2 Acute Coronary Syndrome studies
CURE MI: recurrent MI was defined by the presence of at least two of the following:
ischemic chest pain; elevation of serum levels of cardiac markers or enzymes (tro-
ponin, creatine kinase, creatine kinase MB isoenzyme, or other cardiac enzymes)
to at least twice the upper limit of normal reference range or three times the upper
limit of normal within 48 hours after percutaneous coronary intervention (or to
a level 20% higher than the previous value if the level had already been elevated
because of an early myocardial infarction); and electrocardiographic changes com-
patible with infarction. Stroke was defined as a new focal neurologic deficit of
vascular origin lasting more than 24 hours. Death from cardiovascular causes was
defined as any death for which there was no clearly documented nonvascular cause.
FAST-MI MI: Recurrent MI was defined as recurrent symptoms with a new rise in car-
diac markers. Follow-up data were collected through contacts with the attending
physicians, patients, or family. Vital status of missing participants was assessed
from the registries of the patients birthplaces.
GENDEMIP Fatal MI/stroke: mortality data were obtained from death certificates
(ICD-10 codes I00-I99) by the Institute of Health Information and Statistics of
the Czech Republic, which includes from the date of admission (2006-2009) to
November 2011.
GRACE Scotland/France MI: STEMI diagnosis was based on new ST-segment
elevation >1 mm in any location, or if a new left-bundle-branch block was iden-
tified on ECG, with at least one positive cardiac biochemical marker of necrosis
raised above the diagnostic threshold for infarction. Non-STEMI was diagnosed
if the marker of necrosis was raised without ST-segment elevation on index or a
subsequent ECG. Deaths were recorded during the index period (06 days) and
subsequently (>6 days).
IHCS MI/stroke: information was obtained from physician report and hospital read-
mission for MI or stroke using ICD-9 codes.
KAROLA MI/stroke: Information was obtained from the primary care physician
using a standardized questionnaire. For fatal events, information was obtained
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from the death certificate, and the main cause of death was coded according to the
ICD-9. Secondary cardiovascular events were defined either as CVD as the main
cause of death (as stated in the death certificate), nonfatal myocardial infarction
(MI), or ischemic stroke.
MERLIN-TIMI36 MI: criteria adapted from American College of Cardiology (in-
cluding symptoms suggestive of ischemia/infarction associated with ECG, cardiac
biomarker or pathological evidence of infarction. Outcomes were adjudicated by
a clinical events committee.
MIRACL MI: cardiac enzyme and ECG data using NOVOCODE classification.[558]
PROVE-IT TIMI 22 MI: Myocardial infarction was defined by the presence of symp-
toms suggestive of ischemia or infarction, with either electrocardiographic evidence
(new Q waves in two or more leads) or cardiac-marker evidence of infarction, ac-
cording to the standard TIMI and American College of Cardiology definition.
B.1.3 Other studies
AMC-PAS MI/CAD: MI, surgical or percutaneous revascularisation, coronary an-
giograph with ≥70% stenosis in a major epicardial artery
GENDER Restenosis: defined as clinical restenosis (comprising death, MI and target
vessel revascularisation) within 9 months. All outcomes were evaluated by an
independent committee.
LIFE Heart MI/CAD: AMI or 50% stenosis on coronary angiography
MedStar MI/CAD: 50% stenosis on coronary angiography
PennCath MI/CAD: AMI or 50% stenosis on coronary angiography
SMART MI/Stroke information from hospitalizations and outpatient clinic visits was
obtained from participants by 6-monthly questionnaire. If a possible event was
reported by participants, all available relevant data were collected. Death was
reported by relatives, the GP or the specialist who treated the participant. All
events were classified independently by committee, comprising physicians from
different departments.
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B.2 Supplementary Tables
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Table B.1: Characteristics of the studies included in the sPLA2 collaboration
Study Study
design
Geographical
location
Sampling frame Participants
included
Baseline
year(s)
Proportion
Female, %
Age, mean
(SD)
Studies in General Population
BHF-FHS [559] C-C UK Direct media
campaign
4521 1998-2003 36.67 50.53(13.90)
BRHS [560] Cohort UK General practice 3835 1998-2000 0 68.74(5.49)
BWHHS [561] Cohort UK General practice 3405 1999-2001 100 68.91(5.49)
CCHS [562] Cohort Denmark General population 10375 1991-1994 55.68 56.57(16.26)
CYPRUS [563] Cohort Cyprus Mayors list 734 2003-2008 52.97 61.27(10.26)
EAS [564] Cohort UK General practices 857 1987 50.64 64.38(5.82)
EPIC-Netherlands [565] Nested C-
C
Netherlands Existing cohorts 5194 1993-1997 78.11 54.03(10.22)
EPIC-Norfolk [341] Nested C-
C
UK General practices 3039 1993-1997 34.65 64.68(7.88)
GRAPHIC [566] Cohort UK Nuclear families 2024 2003-2005 49.56 39.19(14.48)
IMPROVE [567] Cohort Europe Clinic 3236 2004-2005 52.83 64.35(5.17)
NPHS-II [568] Cohort UK General practices 2693 1989-1994 0 56.11(3.33)
PREVEND [569] Cohort Netherlands Community 8114 1997 50.86 49.05(12.76)
PROCARDIS [570] C-C Sweden, UK,
Germany, Italy
Hospital 5463 1998-2002 41.06 60.72(9.04)
PROSPER [571] RCT UK, Ireland,
Netherlands
General practices 3991 1997-1999 51.79 75.28 (3.35)
Rotterdam [572] Cohort Netherlands District participants 5974 1989-1993 59.37 69.38(8.91)
TPT [573] RCT UK General practice 4014 1984-1989 0 56.06(6.74)
UCP [574] Nested C-
C
Netherlands National drug
registry
1632 1985-2005 25.49 62.76 (9.64)
Continued on next page
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Table B.1 – Continued from previous page
Study Study
design
Geographical
location
Sampling frame Participants
included
Baseline
year(s)
Proportion
Female, %
Age, mean
(SD)
UDACS [342] Cohort UK Clinic 564 2001-2002 41.13 66.73(11.09)
Whitehall II [85] Cohort UK Workplace 5018 1985-1988 26.44 43.90(5.93)
Studies in Acute Coronary Syndrome Patients
CURE [575] RCT 28 countries Hospitals 4334 1998-2000 40.90 64.20(11.00)
FAST-MI [343] Cohort France Nationwide ACS
registry
973 2005-ongoing 29.19 66.09(13.65)
GENDEMIP [576] Cohort Czech Republic 5 Coronary Units 1432 2006-2009 25.98 57.08(8.62)
GRACE-France [344] Cohort France Hospitals 274 2000-2002 20.44 60.13(12.67)
GRACE-Scotland [345] Cohort Scotland Hospitals 1488 1999-2009 30.04 64.84
(12.04)
IHCS [577] Nested C-
C
USA Single hospital 2382 1994-ongoing 29.14 62.99
(12.29)
KAROLA [347] Cohort Germany Rehabilitation
clinics
1019 1999-2000 15 58.93 (7.96)
MERLIN-TIMI 36 [578] RCT 17 countries Hospitals 1606 2004-2007 34.1 63.43
(10.81)
MIRACL [363] RCT 19 countries Hospital 2587 1997-1999 34.80 65.7 (11.8)
PROVE-IT TIMI 22 [579] RCT 8 countries Hospitals 2260 2000-2003 22.51 57.48
(11.06)
Other Studies
AMC-PAS [580] C-C Netherlands Hospital clinic 740 1990-2000 19 44.05(3.91)
ASAP[362] Cohort Sweden Hospital clinic 272 2006-present 32.83 62.86
(11.52)
GENDER [361] C-C Netherlands Hospital clinic 866 1999-2001 26 62.01
(11.09)
Continued on next page
A
p
p
en
d
ix
B
.
S
u
p
p
lem
en
ta
l
In
fo
rm
a
tio
n
fo
r
C
h
a
p
ter
3
.
sP
L
A
2
a
n
d
C
V
D
222
Table B.1 – Continued from previous page
Study Study
design
Geographical
location
Sampling frame Participants
included
Baseline
year(s)
Proportion
Female, %
Age, mean
(SD)
LIFE Heart [581] C-C Germany Hospital clinic 3128 2006-present 32.83 62.86
(11.52)
MedStar [582] Cohort USA Single-centre
hospital
1322 2004-2007 54.59 59.76(8.86)
PennCath [582] C-C USA Single-centre
hospital
1516 1998-2003 51.92 59.29(9.69)
SMART [360] Cohort Netherlands Hospital clinic 8297 1996-1998 32.24 56.51(12.42)
Footnotes Abbreviations: C-C: case control; ICU: intensive care unit; RCT: randomized clinical trial; X-S: cross sectional. All cohorts were prospective in design. AMC-
PAS: Premature Atherosclerosis Patients and Sanquin Blood Bank Controls; ASAP: Advanced Study of Aortic Pathology; BHF-FHS: British Heart Foundation Family
Heart Study; BRHS: British Regional Heart Study; BWHHS: British Womens Health and Heat Study; CCHS: Copenhagen City heart Study; CURE: The Clopidogrel in
Unstable angina to prevent Recurrent Events; Cyprus: Cyprus Study; EAS: Edinburgh Artery Study; EPIC: European Prospective Investigation into Cancer and Nutrition;
GENDEMIP: GENetic DEterminant of Myocardial Infarction in Prague; GRACE: Global Registry of Acute Coronary Events; GRAPHIC: Genetic Regulation of Arterial
Pressure of Humans in the Community; IHCS: Intermountain Heart Collaborative Study; IMPROVE: IMPROVE Study; KAROLA: Langzeiterfolge der KARdiOLogischen
Anschlussheilbehandlung; LIFE Heart: Leipzig Heart Study; Med-Star: Med-Star Study; MERLIN-TIMI 36: Metabolic Efficiency With Ranolazine for Less Ischemia in
NonST-Elevation Acute Coronary Syndromes ; MIRACL: Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering; NPHS-II: Northwick park Heart Study;
PennCATH: University of Pennsylvania Catheterization study program; PREVEND: Prevention of Renal and Vascular End-stage Disease; PROCARDIS: PRecOcious
Coronary ARtery DISease; PROSPER: PROspective Study of Pravastatin in the Elderly at Risk; PROVE-IT TIMI 22: Pravastatin Or atorVastatin Evaluation and
Infection Trial; Rotterdam: Rotterdam Study; SMART: Second Manifestations of ARTerial disease; TPT: Thrombosis Prevention Trial; UDACS: University College
London Diabetes And Cardiovascular Disease Study; UCP: Utrecht Cardiovascular Pharmacogenetics; Whitehall II: Whitehall II Study; FAST-MI: French Registry of
Acute ST-Elevation or NonST-elevation Myocardial Infarction; GRACE: Global Registry of Acute Coronary Events.
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Table B.2: Associations of PLA2G2A gene variants with sPLA2-IIA mass in EPIC-
Norfolk and GRACE-France.
SNP Genotype
group
EPIC-Norfolk GRACE-France
N sPLA2-IIa mass
(ng/ml), median
(IQR)
N sPLA2-IIa mass
(ng/ml), median
(IQR)
rs3767221 11 1210 10.10 (6.80, 16.10) 101 3.62 (2.15, 8.67)
(5128T>G) 12 1444 8.60 (5.90, 12.90) 127 3.42 (1.66, 5.71)
22 490 6.90 (5.00, 9.20) 48 1.84 (1.13, 3.18)
P value1 1.31x10-39 0.0003
P value2 1.32x10-30 0.0017
rs876018 11 2295 8.86 (6.10, 13.72) 199 2.90 (1.62, 6.78)
(4982T>A) 12 820 8.15 (5.80, 12.60) 68 3.12 (1.61, 8.27)
22 86 7.67 (5.7, 11.8) 10 3.14 (1.94, 5.55)
P value1 0.002 0.96
P value2 0.002 0.8
rs955587 11 2557 8.97 (6.23, 13.95) 202 3.47 (1.73, 8.02)
(3758G>A) 12 589 7.70 (5.41, 10.9) 66 2.35 (1.53, 4.30)
22 41 5.7 (4.71, 8.15) 5 1.32 (7.90, 1.77)
P value1 1.07x10-14 0.002
P value2 4.64x10-10 0.003
rs3753827 11 935 10.42 (7.20, 15.80) 85 3.68 (1.84, 7.33)
(1022G>T) 12 1606 8.61 (5.90, 13.00) 136 2.79 (1.62, 6.52)
22 701 7.10 (5.27, 9.76) 55 2.58 (1.36, 5.76)
P value1 2.55x10-43 0.09
P value2 6.43x10-40 0.15
rs11573156 11 1834 6.80 (5.08, 9.0) 178 2.26 (1.37, 4.24)
(763C>G) 12 1046 12.00 (8.74, 16.47) 88 4.35 (2.61, 1.25)
22 159 16.10 (10.94, 23.73) 9 7.30 (4.66, 18.84)
P value1 1.08x10-170 2.27x10-8
P value2 7.82x10-193 2.48x10-6
rs1774131 11 1433 7.22 (5.30, 10.40) 141 2.35 (1.53, 5.55)
(655T>C) 12 1312 9.6 (6.70, 14.71) 116 3.47 (1.80, 7.08)
22 341 11.9 (8.40, 18.00) 20 9.88 (3.54, 19.19)
P value1 1.05x10-63 0.0007
P value2 1.01x10-54 0.002
Footnotes: Genotype groups 11: homozygotes for the common allele (CC); 12: heterozygotes (CG);
22: homozygotes for the rare allele (GG). P values represent test for trend: 1 univariate; 2 adjusted for
age, gender and CHD
Appendix B. Supplemental Information for Chapter 3. sPLA2 and CVD 224
Table B.3: Associations of PLA2G2A gene variants with sPLA2 enzyme activity in
EPIC-Norfolk and GRACE-France.
SNP Genotype
group
EPIC-Norfolk GRACE-France
N sPLA2 activity
(nmol/min/mL),
median (IQR)
N sPLA2 activity
(nmol/min/mL),
median (IQR)
rs3767221 11 1192 4.45 (3.85, 5.22) 101 2.00 (1.50, 2.70)
(5128T>G) 12 1418 4.40 (3.85, 5.15) 127 2.00 (1.40, 2.90)
22 486 4.33 (3.81, 4.97) 48 1.80 (1.20, 3.30)
P value1 0.08 0.5
P value2 0.17 0.36
rs876018 11 2261 4.42 (3.85, 5.16) 199 2.00 (1.30, 3.00)
(4982T>A) 12 807 4.37 (3.83, 5.09) 68 2.00 (1.50, 2.90)
22 86 4.37 (3.84, 5.15) 10 1.65 (1.20, 1.90)
P value1 0.64 0.57
P value2 0.84 0.5
rs955587 11 2519 4.41 (3.84, 5.15) 202 2.00 (1.40, 2.90)
(3758G>A) 12 579 4.42 (3.85, 5.18) 66 1.60 (1.20, 2.80)
22 41 4.58 (3.87, 4.92) 5 1.80 (1.50, 1.80)
P value1 0.7 0.04
P value2 0.9 0.12
rs3753827 11 935 4.48 (3.90, 5.21) 85 1.80 (1.50, 2.90)
(1022G>T) 12 1606 4.36 (3.81, 5.13) 136 2.00 (1.50, 2.95)
22 701 4.40 (3.83, 5.12) 55 1.70 (1.00, 2.50)
P value1 0.13 0.09
P value2 0.14 0.03
rs11573156 11 1834 4.33 (3.78, 5.04) 178 1.85 (1.20, 2.80)
(763C>G) 12 1046 4.47 (3.90, 5.23) 88 2.00 (1.50, 3.20)
22 159 4.56 (3.91, 5.39) 9 2.80 (1.50, 2.80)
P value1 0.00004 0.03
P value2 0.0002 0.07
rs1774131 11 1415 4.35 (3.78, 5.10) 141 1.80 (1.20, 2.90)
(655T>C) 12 1287 4.45 (3.87, 5.16) 116 2.00 (1.50, 2.95)
22 336 4.37 (3.89, 5.14) 20 2.15 (1.60, 2.80)
P value1 0.05 0.13
P value2 0.08 0.17
Footnotes: Genotype groups 11: homozygotes for the common allele (CC); 12: heterozygotes (CG);
22: homozygotes for the rare allele (GG). P values represent test for trend: 1 univariate; 2 adjusted for
age, gender and CHD
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Table B.4: Genotyping characteristics in the collaborating studies
PLA2G2A rs11573156 Hardy-Weinberg statistics
Study Genotyping platform Call rate
(%)
Proxy SNP used
(LD r2)
CC CG GG Estimated
disequilibrium
coefficient
Exact
significant
probability
Studies in General Population
BHF-FHS IBC CardioChip 100 N/A 2720 1552 249 0.004 0.16
BRHS KASPar 97.2 N/A 2379 1267 186 0.003 0.31
BWHHS IBC CardioChip 99.8 N/A 2066 1150 189 0.005 0.08
CCHS ABI TaqMan 99.8 N/A 5482 4089 804 0.002 0.28
CYPRUS ABI TaqMan 94.3 N/A 456 236 42 0.01 0.13
EAS ABI TaqMan 96.4 N/A 547 257 53 0.017 0.004
EPIC-Netherlands IBC CardioChip 100 N/A 2961 1927 306 -0.001 0.76
EPIC-Norfolk ABI TaqMan 91.5 N/A 1834 1046 159 0.002 0.53
GRAPHIC IBC CardioChip 100 N/A 1201 728 95 -0.004 0.28
IMPROVE ABI TaqMan 91.6 N/A 1941 1109 186 0.005 0.1
LIFE Heart Homogeneous
fluorescence-based
melting curve†
95.5 N/A 1738 1196 194 -0.007 0.2
MedStar Affymetrix 6.0 98.3 Multiple SNPs
(0.77)
726 511 85 -0.006 0.62
NPHS-II ABI TaqMan 97 N/A 1617 936 140 0.001 0.78
PennCath IBC CardioChip 98.6 N/A 916 540 60 -0.017 0.03
PREVEND KASPar 98 N/A 4635 2974 505 0.002 0.34
PROSPER Illumina 660K chip 97.5 N/A 2571 1246 174 0.004 0.15
Rotterdam Illumina Infinium II
HumanHap550 (v3)
100 Multiple SNPs
(0.79)
3290 2322 362 -0.004 0.08
Continued on next page
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Table B.4 – Continued from previous page
PLA2G2A rs11573156 Hardy-Weinberg statistics
Study Genotyping platform Call rate
(%)
Proxy SNP used
(LD r2)
CC CG GG Estimated
disequilibrium
coefficient
Exact
significant
probability
TPT ABI TaqMan 97.5 N/A 2367 1423 224 0.001 0.6
UCP IBC CardioChip 100 N/A 939 595 98 0.001 0.79
UDACS ABI TaqMan 94.2 N/A 337 195 32 0.004 0.63
Whitehall II IBC CardioChip 91.7 N/A 2992 1774 252 -0.001 0.63
Studies in Acute Coronary Syndrome Patients
CURE ABI TaqMan 98.9 N/A 2475 1578 281 0.0039 0.18
FAST-MI SNPlex 98.3 N/A 623 301 49 0.008 0.12
GENDEMIP PCR-RFLP 96.7 N/A 750 559 123 0.007 0.19
GRACE France ABI TaqMan 97.8 N/A 178 87 9 -0.004 0.85
GRACE Scotland ABI TaqMan 97.8 N/A 901 506 81 0.004 0.37
IHCS ABI TaqMan 92.4 N/A 1475 792 115 0.002 0.5
KAROLA ABI TaqMan 98.9 N/A 560 399 49 -0.012 0.04
MERLIN-TIMI 36 IBC CardioChip 99.9 N/A 935 578 93 0.001 0.78
PROVE-IT TIMI 22 IBC CardioChip 99.7 N/A 1392 756 112 0.003 0.5
Other Studies
AMC-PAS IBC CardioChip 99.6 N/A 117 64 10 0.004 0.83
GENDER Illumina Human
610-Quad
100 rs10732279 (0.91) 503 313 50 0.001 0.93
SMART KASPar 98.2 N/A 4649 2882 465 0.001 0.52
Footnote: Abbreviations: LD: linkage disequilibrium; N/A (not applicable) in column titled “Proxy SNP used” indicates rs11573156 directly genotyped; † methodology
described in Holdt et al [583]
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Table B.5: Data availability for sPLA2 assays, cardiovascular biomarkers and measures of atherosclerosis in the collaborating studies
Study sPLA2 assays Circulating biomarkers/anthropometric traits
IIA
mass
Activity SBP LDL-C HDL-C TG IL6 CRP Glucose BMI C-IMT
STUDIES IN GENERAL POPULATION
AMC-PAS • • • • • • •
BFH-FHS
BRHS • • • • • • • •
BWHHS • • • • • • • •
CCHS • • • • • • •
CYPRUS • • • • • • •
EAS • • • • • • • • •
EPIC-Netherlands • • • • • • •
EPIC-Norfolk • • • • • • • •
GRAPHIC • • • • • • •
IMPROVE • • • • • • • •
LIFE Heart • • • • • • •
MedStar • • • •
NPHS-II • • • • • •
PennCath • • • •
PREVEND • • • • • • • •
PROSPER • • • • • •
Rotterdam • • • • • •
TPT • •
UCP •
UDACS • • • • • • • • •
Whitehall II • • • • • • • •
Continued on next page
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Table B.5 – Continued from previous page
Study sPLA2 assays Circulating biomarkers/anthropometric traits
IIA
mass
Activity SBP LDL-C HDL-C TG IL6 CRP Glucose BMI C-IMT
STUDIES IN ACUTE CORONARY SYNDROME PATIENTS
CURE
FAST-MI • • • • • • •
GENDEMIP • • • • • • •
GRACE-France • • • • • •
GRACE-Scotland • • • • • • • • •
IHCS • • • • • • •
KAROLA •† • • • • • • • • •
MERLIN-TIMI 36
MIRACL • • • •
PROVE-IT TIMI 22
OTHER STUDIES
GENDER
SMART •
† Not used for analyses as measured >4 weeks after ACS event
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Table B.6: Contribution of each study to individual outcomes and primary outcome for the Mendelian randomization analysis
Study Prevalent Incident/Recurrent Contributes to
primary outcome
(MVE)
MI Stroke Coronary
Stenosis
Non-
fatal
MI
Non-
fatal
Stroke
Fatal MI
or stroke
All-
cause
mortal-
ity
STUDIES IN GENERAL POPULATION
BHF-FHS • - - - - - •
BRHS • • - • • • - •
BWHHS • • - • • • - •
CCHS • • - • • • - •
CYPRUS • • - - - - - •
EAS • • - • • • - •
EPIC-Netherlands - - - • • • - •
EPIC-Norfolk - - - • - • - •
GRAPHIC - - - - - - - -
IMPROVE • - - • • • - •
NPHS-II - - - • • • - •
PREVEND • • - • • • - •
PROCARDIS • - - - - - - •
PROSPER • • - • • • - •
Rotterdam • • - • • • - •
TPT - - - • • • - •
UCP - - - • - - - •
UDACS - - - - - - - -
Continued on next page
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Table B.6 – Continued from previous page
Study Prevalent Incident/Recurrent Contributes to
primary outcome
(MVE)
MI Stroke Coronary
Stenosis
Non-
fatal
MI
Non-
fatal
Stroke
Fatal MI
or stroke
All-
cause
mortal-
ity
Whitehall II • - - - - - - •
STUDIES IN ACUTE CORONARY SYNDROME
CURE - - - • • • - •
FAST-MI - - - • • - • •
GENDEMIP - - - - - • - •
GRACE France - - - • - - • •
GRACE Scotland - - - • • - • •
IHCS - - - • • • - •
KAROLA - - - • • • - •
MERLIN-TIMI 36 - - - • - • - •
MIRACL - - - - - - - -
PROVE-IT TIMI 22 - - - • • • - •
OTHER STUDIES
AMC-PAS • - • - - - - -
GENDER - - - - - - - -
LIFE Heart • - • - - - - -
MedStar - - • - - - - -
PennCath • - • - - - - -
SMART - - - • • • - -
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Table B.7: Meta-analysis pooled estimates of the per C allele association between PLA2G2A rs11573156 and major vascular events (including indi-
vidual components) stratified by clinical setting using random effects modelling.
Outcome Studies (Events/Total) Odds Ratio (95%CI) I2,% (95%CI)
General Population: Incident
Major vascular events 13 (8021/56359) 1.03 (0.98, 1.08) 26 (0, 51)
Nonfatal MI 13 (4208/51016) 1.05 (0.98, 1.13) 23 (0, 60)
Nonfatal Stroke 11 (2304/46790) 1.00 (0.92, 1.09) 19 (0, 59)
Fatal MI/Stroke 12 (1509/48118) 1.02 (0.90, 1.15) 41 (0, 70)
General Population: Prevalent
Major vascular events 12 (7513/55523) 1.00 (0.94, 1.06) 38 (0, 64)
MI 12 (6411/54884) 0.98 (0.91, 1.07) 52 (8, 75)
Stroke 8 (1102/37280) 1.03 (0.93, 1.15) 0 (0, 68)
Acute Coronary Syndrome: Recurrent
Major vascular events 9 (2520/15768) 0.96 (0.90, 1.03) 0 (0, 45)
Nonfatal MI 8 (1158/14152) 0.97 (0.85, 1.10) 28 (0, 68)
Nonfatal Stroke 6 (223/12283) 0.85 (0.69, 1.06) 0 (0, 75)
Fatal MI/Stroke 9 (1139/15724) 0.96 (0.87, 1.06) 0 (0, 65)
Footnotes Fatal MI/stroke includes death for some ACS studies (see Table B.6 for further details).
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B.3 Supplemental Figures
Figure B.1: Differential expression of PLA2G2A mRNA by rs10732279 genotype. P-
value corresponds to the differential expression by genotype.
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Figure B.2: Genotype frequency of PLA2G2A rs11573156 in the 34 studies.
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All information provided in this Anthera Pharmaceuticals, Inc. (Anthera) summary is provided for information 
purposes only and is subject to change without prior notice. Although every reasonable effort is made to 
present current and accurate information, Anthera makes no guarantees of any kind. 
 
 
Name of Sponsor/Company:  
Anthera Pharmaceuticals, Inc.  
Individual Study Table 
Referring to Part of the 
Dossier 
Volume: 
Page: 
(For National Authority Use 
only) 
Name of Finished Product: 
A-002 (oral) Varespladib Methyl 
Name of Active Ingredient: 
Varespladib 
SYNOPSIS 
Clinical Study Report for Study AN-CVD2233  
ABBRIVIATED REPORT 
 
TITLE OF STUDY: Evaluation of the Safety and Efficacy of Short-term A-002 Treatment in Subjects with 
Acute Coronary Syndromes 
 
INVESTIGATORS/STUDY CENTERS: 375 sites in 17 countries 
 
PUBLICATION: not applicable 
 
Study Period: 1 June 2010 to 9 March 2012  Phase of Development: Phase 3 
 
INTRODUCTION: Inflammation is associated with early recurrent cardiovascular events in subjects with 
an acute coronary syndrome. The Vascular Inflammation Suppression to Treat Acute Coronary Syndrome 
for 16 Weeks (VISTA-16, NCT01130246) study tested the hypothesis that varespladib methyl, an inhibitor 
of sPLA2 would reduce cardiovascular risk among patients with acute coronary syndromes. 
 
OBJECTIVES: 
 
 Primary:  
To determine whether 16 weeks of treatment with A-002 plus atorvastatin and standard of care is 
superior to placebo plus atorvastatin and standard of care for reducing the hazard of the first 
occurrence of the combined endpoint of cardiovascular death, non-fatal myocardial infarction, 
non-fatal stroke or documented unstable angina with objective evidence of ischemia requiring 
hospitalization. 
 Secondary:  
To determine whether A-002 plus atorvastatin and standard of care is superior to placebo plus 
atorvastatin and standard of care for reducing the occurrence of the hazard of the combined endpoint 
of all-cause mortality, non-fatal myocardial infarction, non-fatal stroke, or documented unstable 
angina with objective evidence of ischemia requiring hospitalization, or multiple occurrences of the 
non-fatal components of the composite primary endpoint. 
 Exploratory: 
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Anthera Pharmaceuticals, Inc   
  
 
To determine if A-002 plus atorvastatin and standard of care is superior to placebo plus atorvastatin 
and standard of care on the change (or % change) from baseline in biomarkers of cardiovascular risk 
(e.g., LDL-C, hs-CRP, IL-6, sPLA2). 
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METHODOLOGY:  This was a double-blind, randomized, parallel group, placebo controlled study in 
subjects presenting with an ACS.  Up to 8500 subjects were to be randomized to receive either A-002 
500 mg once daily (QD) or placebo tablets in addition to atorvastatin QD and standard of care.  Treatment 
was 16 weeks in duration.  The dose of atorvastatin could be adjusted after 8 weeks if subject’s LDL-C is 
≥100 mg/dL, but otherwise was to remain stable throughout the 16-week duration of study.  The survival 
status for all enrolled subjects was to be ascertained 6 months after they completed the study; however, 
due to early termination of the study, this information was not collected for all subjects. 
Randomization occurred within ≤96 hours of hospitalization for the index ACS event, or if already 
hospitalized, within ≤96 hours of index event diagnosis.  Follow-up visits were to occur at Hours 24, 48, 
72, and 96 and Weeks 1, 2, 4, 8, and 16.  Due to the early termination of the study, some subjects did not 
complete the 16 weeks of therapy.   
Randomization was stratified by the presence or absence of lipid-altering therapy prior to the index event 
as well as the type of index event (admission diagnosis of unstable angina, NSTEMI or STEMI).  The 
number of subjects who underwent PCI following the index event and prior to randomization was limited 
to no more than 55% of the total study population. 
 
NUMBER OF SUBJECTS (Planned and Analyzed):  Planned:  up to 8500.  Analyzed:  5189 
 
DIAGNOSIS AND MAIN CRITERIA FOR INCLUSION: 
 
Men and women ≥40 years of age  
A diagnosis of unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), or 
ST-segment elevation myocardial infarction (STEMI) 
All subjects (unstable angina, NSTEMI, or STEMI) must have had the presence of at least one of the 
following risk factors: 
 
i. Diabetes Mellitus* or 
ii. Presence of any 3 of the following characteristics of metabolic syndrome  
 Waist circumference >102 cm in males, >88 cm in females 
 Serum triglycerides ≥150 mg/dL (≥1.7 mmol/L) 
 HDL-C <40 mg/dL (<1 mmol/L) in males, <50 mg/dL (<1.3 mmol/L) in females 
 Blood pressure ≥130/85 mmHg 
 Plasma glucose ≥110 mg/dL (≥6.1 mmol/L) or 
iii. history of cerebrovascular disease (stroke or TIA) or 
iv. history of peripheral vascular disease or 
v. previous CABG or 
vi. previous documented myocardial infarction or 
vii. previous coronary revascularization 
Subjects must be randomized within ≤96 hours of hospital admission for the index event, or if already 
hospitalized, within ≤96 hours of index event diagnosis 
Revascularization, if required or planned, must occur prior to randomization 
* Defined as previously documented fasting plasma glucose level of at least 126 mg/dL (7.0 mmol/L) or a  
2-hour plasma glucose level of at least 200 mg/dL (11.1 mmol/L) during a 75 g oral glucose tolerance test. 
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TEST PRODUCT, DOSE AND MODE OF ADMINISTRATION, BATCH NUMBER: Oral A-002: 500 mg 
QD, as two 250 mg tablets.  Batch Numbers:  1004001, 1011001, 1101001, 1108001, 1109001 
 
DURATION OF TREATMENT:  All subjects were followed on treatment for 16 weeks.  Survival status 
was to be ascertained 6 months after the subject withdrew from, or completed, the study.  Due to early 
termination of the study, this information was not collected for all subjects. 
 
REFERENCE THERAPY, DOSE, AND MODE OF ADMINISTRATION, BATCH NUMBER:   
 
Comparator: placebo 
In addition to study drug (A-002 or placebo) atorvastatin ≥20 mg/day was to be given to all study subjects. 
Placebo Batch Numbers:  1004001, 1011001, 1101001, 1108001, 1109001 
 
CRITERIA FOR EVALUATION: 
 
Efficacy:  Efficacy was assessed in the intent-to-treat (ITT) population defined as all randomized 
subjects.   
Safety:  Safety was assessed in all subjects who receive any amount of study therapy by monitoring for 
the occurrence of treatment-emergent adverse events (TEAEs), including possible allergic reactions and 
the collection of conventional laboratory data (chemistry panel and complete blood count [CBC] with 
differential).   
Six months following their participation in the study, the survival status for all subjects who had not 
withdrawn consent was to be ascertained; however, due to early termination of the study, this information 
was not collected for all subjects. 
 
STATISTICAL METHODS:  The primary efficacy endpoint was the time to first occurrence of the 
combined endpoint of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, or 
documented unstable angina with objective evidence of ischemia requiring hospitalization.  All events that 
were suspected components of the primary efficacy endpoint were adjudicated in a blinded fashion by an 
independent event committee. 
An interim analysis for determining early stopping for efficacy or futility was performed by the DSMB on 
9 March 2012 when approximately 50% of the primary endpoint events had occurred.  Monitoring for 
early stopping at the 50% point was based on analysis of the primary endpoint.  Specifically, this analysis 
compared the incidence of the combined endpoint of cardiovascular death, non-fatal myocardial 
infarction, non-fatal stroke, or documented unstable angina with objective evidence of ischemia requiring 
hospitalization between the treatment groups.  A total of 383 potential endpoint events were reviewed and 
247 were determined to be positive endpoints as defined by the protocol; 212 were the first occurrence of 
an endpoint and thus, primary efficacy endpoints.  The Kaplan Meier (KM) method was used to estimate 
event rates.  The hazard ratios and 95% confidence intervals were estimated by a Cox proportional 
hazards regression model with factors for treatment, use of a lipid-altering therapy prior to the index event 
(yes/no) and type of index event (unstable angina, NSTEMI, STEMI). 
 
SUMMARY OF RESULTS: 
 
Efficacy Results:  At the time of study termination the hazard ratio for the primary endpoint was 1.244 
(p=0.155).  The hazard ratio for the combination of cardiovascular death, non-fatal myocardial infarction 
and stroke was statistically significant: HR 1.436 p=0.025.  This is primarily driven by the increased 
occurrence of non-fatal myocardial infarction: HR 1.686 p=0.009. 
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PK Results: Due to the early termination of the study, PK analysis was not performed. 
 
Safety Results:  Adverse event data are available from 5102 subjects.  Cardiac disorders (17.5%) was the 
most frequently reported organ system affected, followed by gastrointestinal disorders (11.2%), general 
disorders (7.3%), investigations (9.5%), nervous system disorders (7.2%), respiratory disorders (7.0%) 
and vascular disorders (4.4%).  
A total of 528 (10.3%) subjects reported a treatment-emergent serious adverse event.  The majority were 
cardiac disorders and also related to the primary efficacy endpoint as reported by 328 (6.4%) subjects 
(Table 14.3.12).  Amongst the cardiac disorders, unstable angina was reported by 109 subjects (2.1%), 
and acute myocardial infarction combined with myocardial infarction by 56 subjects.  All other SAEs were 
reported at frequency of ≤0.5%.  
No new or otherwise unexpected trends were observed in the AE, SAE, laboratory, hemodynamic or ECG 
data. 
 
CONCLUSIONS:   
 
The study was prematurely terminated by the DSMB because of the inability of VISTA-16 to detect a 
statistically significant benefit of the drug on the prespecified primary and secondary endpoints even if the 
trial continued to its scheduled termination with the proposed expanded sample size.  
No obvious clinical or scientific reason has been found for the increased hazard for non-fatal myocardial 
infarction amongst subjects treated with A-002 despite positive treatment-related changes in LDL-C and 
CRP. 
 
 
Appendix C
Supplemental Information for
ADH1B, alcohol and
cardiovascular disease
C.1 Studies included in the ADH1B collaboration
Atherosclerosis Risk In Communities Study The Atherosclerosis Risk In Com-
munities (ARIC) Study is a population-based prospective cohort study of car-
diovascular disease sponsored by the National Heart, Lung, and Blood Institute
(NHLBI). ARIC originally included 15,792 individuals aged 45-64 years at base-
line (1987-89), chosen by probability sampling from four US communities. Cohort
members completed four clinic examinations each spread over about three years,
conducted approximately three years apart between 1987 and 1998. The data used
in this study are from the first visit in 1987-1989. A detailed study protocol is
available on the ARIC study website (http://www.cscc.unc.edu/aric). For this
study the sample was restricted to individuals of European descent by self-report
and principal component analysis using genome-wide genotypes.
Avon Longitudinal Study of Parents and Children The Avon Longitudinal Study
of Parents and Children (ALSPAC) was established to understand how genetic
and environmental characteristics influence health and development in parents and
children (http://www.bristol.ac.uk/alspac/researchers/resources-available).1,2 All
pregnant women resident in a defined area in the South West of England, with
an expected date of delivery between 1st April 1991 and 31st December 1992,
were eligible and 13 761women (contributing 13 867 pregnancies) were recruited.
These women have been followed over the last 1922 years and have completed up
240
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to 20 questionnaires, including those providing information about their alcohol
consumption before and during the index pregnancy, which was used in this study
to define abstainers, binge drinkers and drinking levels (before pregnancy). Ab-
stainers were defined as women not drinking at either of the following time points:
before pregnancy, during pregnancy, and at 5 time points postnatally (when child
is 8, 21, 33, 61 months old). Binge drinkers were women consuming 4+ alcoholic
drinks per occasion at least once either around 18 weeks or around 32 weeks of
gestation. Weekly alcohol units derived from the questionnaire at 18 weeks gesta-
tion were used for the genotype-alcohol analysis, and so were the variables defining
abstainers and binge drinkers. Baseline questionnaires completed around the time
of the index pregnancy also provided information on education, social class, and
smoking habits. A follow-up assessment was completed 1718 years postnatal at
which anthropometry (weight, height, waist circumference), blood pressure (from
both arms, then averaged to derive SBP and DBP used in analyses), carotid intima
media thickness were assessed, and a fasting blood sample taken, from which the
following were assayed: total and HDL cholesterol, triglycerides, CRP, insulin and
glucose. DNA has been extracted from saliva or blood samples collected at various
time points. The sample used for this study included only women of self-reported
white ethnic origin, or, where this information was missing, those predicted to be
of European origin based on 5 ancestry-informative markers. Additionally, women
of self-declared Jewish faith were excluded (n=4) because the prevalence of the
rare allele is much higher in most Jewish populations. Ten principal components
variables derived from GWA panel data were available for sensitivity analyses.
British Womens Heart and Health Study British Womens Heart and Health Study
is a study comprising 4,286 women aged 60-79 years who were randomly selected
from 23 British towns between 1999 and 2001. Of the 4,278 participants who gave
consent for genetic testing, 15 were defined by the examining nurse as being non-
white and were excluded from further analysis. Of the remaining 4,263 women,
3,800 (89%) had DNA available for genotyping.
British Regional Heart Study From 1978 to 1980, 7735 men aged 40-59 were re-
cruited from general practices across the UK. A wide range of phenotypic mea-
sures is available for established risk markers such as lipids, blood pressure and
inflammatory and haemostatic markers. Most of these measures were taken both at
recruitment and re-examination, which occurred in 1998-2000 when men were aged
60-79. At this re-examination 4252 participants attended and DNA was extracted
for 3945. Data on important behavioural variables such as cigarette and alcohol
consumption, as well as physical activity, have been regularly collected through
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follow up. Well validated outcome variables including major coronary heart dis-
ease and stroke, as well as cause-specific mortality, continue to be collected from
medical records 30 years after recruitment.
Caerphilly Prospective Study The Caerphilly Prospective Study (CAPS) to exam-
ine the importance of lipids, haemostatic factors, and hormones such as testos-
terone, cortisol and insulin (Lichtenstein et al 1987) in the development of ischemic
heart disease (IHD). The initial design attempted to contact all men aged 45 to 59
years from the town of Caerphilly and adjoining villages. 2512 subjects (response
rate 89%) identified from the electoral register and general practice lists were ex-
amined between July 1979 until September 1983 (phase I). Men were initially seen
at an evening clinic, where they completed a questionnaire, had anthropometric
measures and an ECG taken. They also completed a food frequency questionnaire
at home. They subsequently re-attended an early morning clinic to have fasting
blood samples for a wide variety of tests. Quality control was examined by the
use of both ”blind” split samples as well as a second repeat measure on a random
sub-sample to examine intra-individual variation.
Cardiovascular Health Study The Cardiovascular Health Study (CHS) is a population-
based cohort study of risk factors for cardiovascular disease in adults 65 years of
age or older conducted across four field centres. The original predominantly white
cohort of 5,201 persons was recruited in 1989-1990 from random samples of the
Medicare eligibility lists and an additional 687 African-Americans were enrolled in
1992-93 for a total sample of 5,888.
Cleveland Family Study The Cleveland Family Study (CFS) is the largest family-
based study of sleep apnea world-wide, consisting of 2284 individuals (46% African
American) from 361 families studied on up to 4 occasions over a period of 16
years. NIH renewals provided expansion of the original cohort (including increased
minority recruitment) and longitudinal follow-up, with the last exam occurring in
February 2006. Index probands (n=275) were recruited from 3 area hospital sleep
labs if they had a confirmed diagnosis of sleep apnea and at least 2 first-degree
relatives available to be studied. In the first 5 years of the study, neighbourhood
control probands (n=87) with at least 2 living relatives available for study were
selected at random from a list provided by the index family and also studied.
All available first degree relatives and spouses of the case and control probands
also were recruited. Second-degree relatives, including half-sibs, aunts, uncles and
grandparents, were also included if they lived near the first degree relatives (cases
or controls), or if the family had been found to have two or more relatives with
sleep apnea. Blood was sampled and DNA isolated for participants seen in the last
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two exam cycles (n=1447). The sample, which is enriched with individuals with
sleep apnea, also contains a high prevalence of individuals with sleep apnea-related
traits, including: obesity, impaired glucose tolerance, and hypertension.
Copenhagen City Heart Study The Copenhagen City Heart Study (CCHS) is a
prospective study of 10 388 individuals randomly selected from the population of
Copenhagen, followed from blood sampling in 19911994 through 2007. Individuals
were invited based on their Central Person Registration number, the participation
rate was 55% and follow-up was 100% complete, that is, no individual was lost to
follow-up. Data on all-cause mortality were from the national Danish Civil Reg-
istration System, whereas information on cause-specific mortality was from the
national Danish Causes of Death Registry.
Copenhagen General Population Study The Copenhagen General Population Study
(CGPS) is a large general population cohort study that aims to eventually recruit
100,000 participants and collect genotypic and phenotypic data of relevance to a
wide range of health related problems. Individuals are randomly selected from the
national Danish Civil Registration System and have to be aged 20 years or older
and resident in greater Copenhagen; they also have to be white and of Danish
decent. Recruitment began in 2003 and is still on-going.
Coronary Artery Risk Development in Young Adults The Coronary Artery Risk
Development in Young Adults (CARDIA) Study is a study examining the devel-
opment and determinants of clinical and subclinical cardiovascular disease and its
risk factors. It began in 1985 with a group of 5115 black and white men and
women aged 18-30 years. The participants were selected so that there would be
approximately the same number of people in subgroups of race, gender, education
(high school or less and more than high school) and age (18-24 and 25-30) in each
of 4 centers: Birmingham, AL; Chicago, IL; Minneapolis, MN; and Oakland, CA.
These same participants were asked to participate in follow-up examinations dur-
ing 1987-1988 (Year 2), 1990-1991 (Year 5), 1992-1993 (Year 7), 1995-1996 (Year
10), 2000-2001 (Year 15), and 2005-2006 (Year 20). A majority of the group has
been examined at each of the follow-up examinations (90%, 86%, 81%, 79%, 74%,
and 72%, respectively).
Cyprus Study The Cyprus Study is a population-based cohort study of cardiovascular
disease in 1106 individuals aged 40 years or more from two areas in Cyprus. Base-
line data have been collected from Pedoulas, a village in the Troodos Mountains
of Cyprus their relatives who live in any one of the main towns and from a section
of Nissou, a village in the Mesaoria plain 10 km south of the capital, Nicosia,
between 2003-2008. These sites were randomly selected by having a blindfolded
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person throw darts at a map of Cyprus. All inhabitants were identified through
the population list held at the Mayors office and all those over the age of 40 years
were invited to participate. This was done by setting up an open public meeting
as arranged through the districts Mayor and Local Council Committee and the
local Greek Orthodox Priest. The overall participation rate of those invited was
95%.
Danish Cancer and Health The Danish Diet, Cancer, and Health (DCH) Study is a
prospective cohort study with the primary aim of studying the role of diet in cancer
risk but with a potential for studying other diseases as well. From December 1993
through May 1997, 80 996 men and 79 729 women aged 50 to 64 y were invited
to participate in the study; 27 177 men and 29 876 women accepted the invita-
tion. Eligible cohort members were born in Denmark, living in the Copenhagen
and Aarhus areas, and had no previous cancer diagnosis in the Danish Cancer
Registry. The baseline data were linked to the Danish Cancer Registry and other
population-based registries, including the Danish National Registry of Patients,
and the Danish Civil Registration System, using the civil registry number, which
is a unique number given to everyone with an address living in Denmark since
1968. The Civil Registration System has electronic records of all changes in vital
status for the Danish population since 1968, including date of death. The Danish
National Registry of Patients was established in 1977, and has records for 99.4%
of all discharges from non-psychiatric hospitals in Denmark. The Danish Diet,
Cancer, and Health Study and the present study were approved by the Regional
Ethics Committees in Copenhagen and Aarhus and by The Danish Data Protection
Agency.
Edinburgh Artery Study The Edinburgh Artery Study (EAS) is an age-stratified
random sample of men and women, aged 55-74 years, which was selected between
August 1987 and September 1988 from the age-sex registers of ten general practices
with a geographical and socio-economical catchment population spread throughout
the city of Edinburgh, UK. Subjects were excluded if they were unfit to participate
(e.g., due to severe mental illness or terminal disease); excluded individuals were
replaced by other randomly sampled subjects.
English Longitudinal Study of Ageing The English Longitudinal Study of Ageing
(ELSA) is a national cohort of participants (48% men) aged over 50 years recruited
from the Health Surveys for England in 1998, 1999, and 2001. Genetic data were
collected at wave 2 of the study (2004/5); the phenotype measurements taken at
wave 2 were used for this study.
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The EPIC-InterAct Case-Cohort Study Individuals with T2D in European Prospec-
tive Investigation into Cancer and Nutrition (EPIC) cohorts between 1991 and
2007 from eight of the ten countries participating in EPIC (26 centres) were iden-
tified. Prevalent diabetes was identified on the basis of baseline self-report of a
history of diabetes, doctor-diagnosed diabetes, diabetes drug use, or evidence of
diabetes after baseline with a date of diagnosis earlier than the baseline recruit-
ment date. All ascertained cases with any evidence of diabetes at baseline were
excluded. Ascertainment of incident T2D involved a review of the existing EPIC
datasets at each centre using multiple sources of evidence including self-report,
linkage to primary-care registers, secondary-care registers, medication use (drug
registers), hospital admissions and mortality data. Information from any follow-up
visit or external evidence with a date later than the baseline visit was used. To
increase the specificity of the case definition, further evidence for all cases with
information on incident T2D was sought from fewer than two independent sources
at a minimum, which included individual medical records review in some centres.
Cases in Denmark and Sweden were not ascertained by self-report, but identified
via local and national diabetes and pharmaceutical registers, and hence all ascer-
tained cases were considered to be verified. Follow-up was censored at the date of
diagnosis, 31 December 2007, or the date of death, whichever occurred first.
European Prospective Investigation of Cancer: Netherlands The European Prospec-
tive Investigation of Cancer (EPIC) study in The Netherlands is based in two cen-
tres, Bilthoven and Utrecht. The population in the two cohorts has been recruited
from two regions, from the general population (Bilthoven) and from those attend-
ing for breast cancer screening (Utrecht). Recruitment was carried out between
1993 and 1997. In 2006-2007, the two Dutch cohorts have been merged into one
cohort (www.epicnl.eu) to gain efficiency and sample size and to optimise the use
of the data locally. The separate cohorts, however, will co-exist besides the merged
cohort.
European Prospective Investigation of Cancer: Norfolk The European Prospec-
tive Investigation of Cancer (EPIC) Norfolk is a population-based cohort study of
25,663 European men and women aged 39-79 years recruited in Norfolk, UK be-
tween 1993 and 1997. 2,100 randomly selected control subjects were chosen from
a BMI study in which genome-wide genotyping data had been obtained.
European Prospective Investigation of Cancer: Potsdam The European Prospec-
tive Investigation into Cancer and Nutrition (EPIC)-Potsdam study is part of the
large-scale EPIC cohort and includes 10,904 male and 16,644 female participants
recruited from the general population of Potsdam and surrounding areas. The
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preferred age range for recruitment was 3565 years. Baseline examination was
conducted from 1994 through 1998 and included blood sampling, measurements of
blood pressure and anthropometric parameters, self-administered questionnaires
on diet and lifestyle, and personal computer-assisted interviews.
European Prospective Investigation of Cancer: Turin The European Prospective
Investigation of Cancer (EPIC) Turin study, part of the large-scale EPIC cohort,
and includes a longitudinal cohort of 10,603 volunteers, aged 35-64 years at base-
line, from the Turin area, Italy.
Framingham Heart Study The Framingham Heart Study began in 1948 with the
recruitment of an original cohort of 5,209 men and women (mean age 44 years; 55
percent women). In 1971 a second generation of study participants was enrolled;
this cohort consisted of 5,124 children and spouses of children of the original cohort.
The mean age of the offspring cohort was 37 years; 52 percent were women. A
third generation cohort of 4,095 children of offspring cohort participants (mean
age 40 years; 53 percent women) was enrolled beginning in 2002. Details of study
designs for the three cohorts are summarized elsewhere25-27. At each clinic visit,
a medical history was obtained with a focus on cardiovascular content.
Health, Alcohol and Psychosocial factors In Eastern Europe The multi-centre
study Health, Alcohol and Psychosocial factors In Eastern Europe (HAPIEE)
study assessing the effects of dietary factors, alcohol consumption and psychoso-
cial factors on health is being conducted in random samples of men and women
aged 45-64 selected in Russia (city of Novosibirsk), Poland (2 districts of Krakow),
Lithuania (city of Kaunas) and the Czech Republic (2 cities)
Health In Men Study The Health In Men Study (HIMS) arose out of a population-
based randomized trial of screening for abdominal aortic aneurysms (AAAs) con-
ducted in Perth, Western Australia in 199699. Only men aged 65 years and over
were recruited into the trial as AAAs are uncommon below this age and are six
times more common in men than women. The aim of the trial was to assess
whether screening reduced mortality from AAA. Secondary outcomes included as-
sessments of the impact of screening on all-cause mortality and quality of life3 and
a study of the rates of expansion of screen-detected AAAs
Health Professionals Follow-up Study The Health Professionals Follow-up Study
(HPFS) is a prospective cohort study of 51,529 US male health professionals aged
4075 years in 1986, who completed detailed questionnaires assessing dietary intake,
lifestyle factors and medical history at baseline. Follow-up questionnaires were
mailed to participants every 2 years to update baseline information and to ascertain
Appendix C. Alcohol and cardiovascular disease 247
newly diagnosed disease. Participants included in this collaboration were from a
nested case-control study of MI.
IMPROVE study The IMPROVE study is a multicentre, longitudinal, observational
study, which involves seven recruiting centres in five European countries: Finland,
France, Italy, the Netherlands, and Sweden. Recruitment of a total of 3598 pa-
tients (514 per centre) was targeted. Men and women, aged from 55 to 79 years,
with at least three vascular risk factors, asymptomatic for cardiovascular diseases
and free of any conditions that might limit longevity or IMT visualization were
considered as eligible for the study. The primary objective of the IMPROVE study
was to evaluate the association between C-IMT progression at 15 months and fu-
ture vascular events (myocardial infarction, cardiovascular death, stroke, or any
intervention in the carotid, coronary, or peripheral arterial districts occurring from
the 15th to the 36th month of follow-up).
Inter99 study The Inter99 study is a population-based randomized controlled trial,
investigating the effect of lifestyle intervention (smoking cessation, increased phys-
ical activity, and healthier dietary habits) on CVD. Data were collected with self-
administered questionnaires, a physical examination, a 2 hour oral glucose toler-
ance test and various blood tests. The Inter99 study population were residents in
the southern part of the former Copenhagen County. An age- and sex-stratified
random sample of 13,016 men and women born in 193940, 194445, 194950, 195455,
195960, 196465, and 196970 was drawn from the Danish Civil Registration System
and invited to participate in a health examination during 19992001, so that they
were aged 30, 35, 40, 45, 50, 55, 60, and 65 years on the day of the examination.
A total of 12,934 were eligible for invitation. The baseline participation rate was
52.5% (n = 6,784).
Ischemic Stroke Genetic Study/Siblings with Ischemic Stroke Study The Is-
chemic Stroke Genetic Study (ISGS) is a multicenter cohort study. Cases were
recruited from inpatient stroke services at five United States academic medical
centers. Cases are adult men and women over the age of 18 years diagnosed with
first-ever ischemic stroke confirmed by a study neurologist on the basis of history,
physical examination and CT or MR imaging of the brain. Cases had to be en-
rolled within 30 days of onset of stroke symptoms. The Siblings with Ischemic
Stroke Study (SWISS) is a multicenter affected sibling pair study. Probands with
ischemic stroke were enrolled at 66 US medical centers and 4 Canadian medical
centers. Probands are adult men and women over the age of 18 years diagnosed
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with ischemic stroke confirmed by a study neurologist on the basis of history, phys-
ical examination and CT or MR imaging of the brain. Probands were required to
have a history of at least one living sibling with a history of stroke.
Izhevsk Family study The Izhevsk Family study is a population-based case-control
study, conducted between 2003-2005 to investigate the causes of working age male
mortality. The case-control study used proxy informants (usually wife or part-
ner) to find out about the circumstances and behaviours of the deceased men.
The participants contributing towards the ADH1B project are controls who were
followed-up as a cohort.
Malmo Diet and Cancer The Malmo Diet and Cancer (MDC) study is set in Malm,
Sweden’s third largest city. The background population consisted of all men born
between 1923 and 1945 and all women born between 1923 and 1950 who were
living in Malm during the screening period 1991 to 1996 (n = 74,138). This popu-
lation was identified through the Swedish national population registries. The final
cohort consisted of 28,098 individuals (participation rate 40.8%). The subjects
were recruited through advertisements in local media and through invitation by
mail. The only exclusion criteria were inadequate Swedish language skills and
mental incapacity. The Ethics Committee at Lund University approved the design
of the MDC study (LU 5190). Written informed consent was obtained from the
participants.
Medical Research Council 1958 Birth Cohort The 1958 birth cohort or the Na-
tional Child Development Study (NCDS) was designed to examine how develop-
mental, lifestyle, and environmental factors act throughout the lifespan to influence
current ill health, and physiological and psychological function in early middle age.
Participants are survivors from an original sample of over 17 000 births, all born in
England, Wales, and Scotland, during 1 week in 1958, and followed-up by parental
interview and examination at ages 7, 11, and 16 yr and by cohort member in-
terview at 23, 33, and 42 yr. The first biomedical assessment in adulthood was
conducted by a research nurse visiting the home at 4445 yr. During childhood,
cohort members were traced through schools and immigrants born in the reference
week were added to the sample. The cohort is flagged for mortality and cancer
registration.
Medical Research Council National Survey of Health and Development The
Medical Research Council (MRC) National Survey of Health and Development
(NSHD) is an ongoing prospective birth cohort study consisting of a sample of
all singleton births, born to married mothers, in England, Scotland and Wales in
one week in March 1946. The sample includes all births whose fathers were in
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non-manual or agricultural occupations and a randomly selected one in four of all
others, whose fathers were in manual occupations. The original cohort comprised
2,547 women and 2,815 men who have been followed up over 20 times since their
birth. The data collected to date include cognitive function, physical, lifestyle
and anthropomorphic measures as well as blood analytes and other measures.
Through MRC Unit funding, a particularly intensive clinical assessment, with bio-
logical sampling, blood and urine sampling and analysis, and cardiac and vascular
imaging has recently been completed when the cohort were aged 60-64 years.
Multi-Ethnic Study of Atherosclerosis The Multi-Ethnic Study of Atherosclerosis
(MESA) investigation is a population-based study of 6,814 men and women age
45 to 85 years, without clinical cardiovascular disease, recruited from six United
States communities (Baltimore, MD; Chicago, IL; Forsyth County, NC; Los Ange-
les County, CA; northern Manhattan, NY; and St. Paul, MN). The main objective
of MESA is to determine the characteristics of subclinical cardiovascular disease
and its progression. Sampling and recruitment procedures have been previously
described in detail57. Adults with symptoms or history of medical or surgical
treatment for cardiovascular disease were excluded. During the recruitment pro-
cess, potential participants were asked about their race/ethnicity. Self-reported
ethnicity was used to classify participants into groups58.Additional individuals
were derived from the MESA Family Study, an ancillary study to MESA whose
goal is to identify genes contributing to the risk for cardiovascular disease, by look-
ing at the early manifestations of atherosclerosis within families, mainly siblings.
MESA Family studied siblings of index subjects from the MESA study and sib-
pairs in new families ascertained through index subjects meeting MESA enrollment
criteria. In a small proportion of subjects, parents of MESA index subjects partici-
pating in MESA Family were studied but only to have blood drawn for genotyping.
The MESA Family cohort was recruited from the six MESA Field Centers during
May 2004 - May 2007. The number of non-classic MESA family members recruited
was 1,633 (950 African-Americans and 683 Hispanic-Americans) from 594 families,
yielding 3,026 sib-pairs. Participants underwent the same examination as MESA
participants.
Multinational monitoring of trends and determinants in cardiovascular diseases: Czech
The Multinational monitoring of trends and determinants in cardiovascular dis-
eases (MONICA) was established in the early 1980s in many Centres around the
world to monitor trends in cardiovascular diseases, and to relate these to risk factor
changes in the population over a ten year period. All suspected coronary events in
the study populations were monitored continuously from mid 1980s to mid 1990s.
MONICA Czech represents the component of MONICA set in Czech Republic.
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The cohort used for analysis continued after the official international MONICA
collaboration, and is termed “Czech post-MONICA”.
National Health and Nutrition Examination Survey III The National Health and
Nutrition Examination Survey (NHANES) is an ongoing series of surveys that have
been conducted by the National Center for Health Statistics since the early 1960s
to assess the health and nutritional status of the US civilian non-institutionalized
population using a complex, stratified, multistage survey design. NHANES has
been reviewed and approved by the Institutional Review Board at the National
Center for Health Statistics. DNA Specimens were available for 7,159 individu-
als who participated in the second phase of NHANES III (1991-1994), were 12
years of age or older, and who consented to having specimens of their blood stored
for future research. Household interview data provided information on age, sex,
race/ethnicity, alcohol intake, smoking status, educational attainment, physical
activity, and history of heart attack and diabetes. Physical examination data pro-
vided information on body mass index, waist circumference, and blood pressure.
Serum samples provided information on cotinine, cholesterol, triglycerides, and
glucose. Individuals who self-reported their race/ethnicity as non-Hispanic white
were eligible to be included in the current analysis. Binge drinking was defined
as drinking five or more drinks of alcohol on one or more days in the past year.
Hypertension was defined as SBP 140 mmHg and/or diastolic blood 90. Fasting
glucose levels were available in a subset of participants (n=1108) who had fasting
blood samples drawn in the morning.
Nordic Diltiazem Study The Nordic Diltiazem intervention study (NORDIL) was
started in September 1992. This trial was a prospective randomized open blinded-
endpoint multicenter, parallel-group study conducted in Norway and Sweden. The
study was designed to evaluate the potential preventive effects of diltiazem com-
pared with conventional antihypertensive drug treatment. Primary endpoints were
cardiovascular mortality defined as fatal acute myocardial infarction, fatal acute
cerebrovascular disease (stroke), sudden death and other fatal cardiovascular dis-
ease as well as cardiovascular morbidity defined as myocardial infarction and cere-
brovascular disease (stroke). Secondary endpoints are total mortality, the devel-
opment or deterioration of ischemic heart disease, congestive heart failure, atrial
fibrillation, transient ischemic attacks, diabetes mellitus and renal insufficiency.
Male and female patients, aged 50-69, with primary hypertension were randomly
allocated to therapy starting with either diltiazem (180-360 mg daily) or conven-
tional treatment (diuretics or beta-adrenergic blockers). Add-on therapy in the
conventional treatment group excluded all types of calcium antagonists. The goal
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of treatment was a target diastolic blood pressure of 90 mmHg or a 10% diastolic
blood pressure reduction.
Northwick Park Heart Study II The Northwick Park Heart Study II is a prospec-
tive study of 3,012 healthy middle-aged men aged 50-64 years at recruitment,
sampled from nine UK general practices between 1989 and 1994. Full details of
recruitment, measurements, follow-up and definitions of incident disease have been
reported elsewhere64. Exclusion criteria were: history of unstable angina or acute
myocardial infarction, a major Q wave on the ECG, regular anti-platelet or antico-
agulant therapy, cerebrovascular disease, and life-threatening malignancy. Blood
pressure was recorded with a random-zero sphygmomanometer (average of 2 mea-
surements) at baseline and on five following annual visits. Baseline measures were
used for these analyses.
Nurses Health Study I The Nurses Health Study I (NHS), established in 1976, is a
prospective cohort study of 121,701 US female registered nurses aged 30-55 years
at baseline, who completed detailed questionnaires assessing diet, lifestyle and
medical history. Follow-up questionnaires were mailed to participants every 2
years to update baseline information and to ascertain newly diagnosed disease.
Participants included in this collaboration were from a nested case-control study
of MI.
Portuguese stroke study The Portuguese stroke study consisted of five-hundred sixty-
five unrelated patients with a clinical diagnosis of ischemic stroke, who were under
the age of 65 at stroke onset, recruited through Neurology and Internal Medicine
Departments throughout Portugal. Stroke was defined by the presence of a new
focal neurological deficit, with an acute onset and with symptoms and signs per-
sisting for more than 24 h. The stroke was confirmed in all patients by a computed
tomography scan in 97% of cases and/or magnetic resonance imaging in 25% of
patients. All patients were seen, and all neuroradiology tests were reviewed by
study neurologists. Trauma, tumors, infection, and other causes of neurological
deficit were excluded. Data collection forms were developed for this study that
included extensive clinical information such as stroke characteristics, general clini-
cal observation, neurological symptoms and signs, complications and interventions
during hospitalization, and situation at discharge. Data were also collected on
relevant lifestyle aspects and previous clinical risk factors. Five-hundred seventeen
unrelated healthy individuals were included in this study as a control sample pop-
ulation. Control individuals were verified to be free of stroke by direct interview
before recruitment, but no brain imaging studies were performed. The interview
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also included questions on established clinical and lifestyle risk factors for stroke.
All participants were adults of Portuguese Caucasian origin.
Prevention of REnal and Vascular ENd stage Disease The Prevention of REnal
and Vascular ENd stage Disease (PREVEND) study is an ongoing prospective
study investigating the natural course of increased levels of urinary albumin ex-
cretion and its relation to renal and cardiovascular disease65,66. Inhabitants 28 to
75 years of age (N=85,421) in the city of Groningen, The Netherlands, were asked
to complete a short questionnaire, 47% responded, and individuals were then se-
lected with a urinary albumin concentration of at least 10 mg/L (N= 7,768) and
a randomly selected control group with a urinary albumin concentration less than
10 mg.
PRrecOcious Coronary ARtery DIsease Study The Precocious Coronary Artery
Disease study (PROCARDIS) is a European consortium investigating the genetics
of coronary artery disease (CAD) in German, Italian, Swedish, and British CAD
patients and controls. Controls in this study had no personal history of CAD, hy-
pertension, or diabetes. Ascertainment criteria for PROCARDIS probands were
MI or symptomatic ACS (SACS), on the assumption that the latter represents
a similar pathological process according to modified World Health Organisation
diagnostic criteria before the age of 66 y. Diagnosis of MI required documentation
of two or more of: (a) typical ischemic chest pain, pulmonary oedema, syncope
or shock; (b) development of pathological Q-waves and/or appearance or disap-
pearance of localized ST-elevation followed by T-wave inversion in two or more
standard electrocardiograph leads; (c) increase in concentration of serum enzymes
consistent with MI (e.g. creatine kinase more than twice the upper limit of nor-
mal). Diagnosis of SACS required documentation of hospitalization for one of the
following indications: (a) unstable angina diagnosed by typical ischemic chest pain
at rest associated with reversible ST-depression in two or more standard electro-
cardiograph leads; (b) thrombolysis for suspected MI (as indicated by localized
ST-elevation in two or more standard electrocardiograph leads) even without later
development of T-wave inversion, Q-waves, or a significant enzyme rise; or (c)
emergency revascularization (i.e. during same admission) following presentation
with typical ischemic chest pain at rest. Probands completed questionnaires in
order to recruit affected siblings with a range of CAD diagnoses at age ¡66 y (MI,
SACS, chronic stable angina, or intervention for coronary revascularization), who
were then invited to participate in the study if their diagnoses were confirmed.
Parents and up to four unaffected siblings per family were recruited wherever pos-
sible to augment the recovery of linkage phase information. Informative families
were recruited in Germany, Italy, Sweden, and the United Kingdom; 99.5% of
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the study participants reported having a white European ancestry. The protocol
was approved by the Ethics Committees of the participating institutions and all
participants gave written, informed consent.
Prospective Study of Pravastatin in the Elderly at Risk The Prospective Study
of Pravastatin in the Elderly at Risk (PROSPER) trial was designed to determine
whether pravastatin 40 mg/day has primary and secondary roles in reducing coro-
nary and cerebral events in older patients with preexisting vascular disease or who
are at high risk for vascular disease and stroke. The double-blinded, random-
ized, controlled trial initially screened 23,770 patients, and the patient population
was subsequently narrowed (due to ineligibility or refusal to participate) to 5804
patients who were then randomized to either placebo (n = 2913) or 40 mg of
pravastatin (n = 2891). Patients were recruited if they had either preexisting
vascular disease (coronary, cerebral, or peripheral) or were at increased risk for
vascular disease due to such factors as smoking, hypertension, or diabetes. Inclu-
sion criteria called for men and women between the ages of 70 and 82 years with a
total plasma cholesterol of 155-350 mg/dL (4-9/mmol/L) and triglyceride levels ¡
200 mg/dL (6 mmol/L) . Patients were excluded if they showed signs of cognitive
decline, which was assessed by a Mini Mental State Examination and a series of
psychometric tests. The study population was distributed evenly between those
with existing vascular disease and those with qualifying risk factors. Patients were
followed every 3 months for an average of 3.2 years.
Rotterdam Study The Rotterdam Study is an ongoing, prospective, population-based
cohort study on determinants of a number of chronic diseases. All inhabitants of
Ommoord, a district of Rotterdam in the Netherlands, who were 55 years or over,
were invited to participate in this study. Of all 10275 eligible individuals, 7983
agreed to participate (78%). Written informed consent was obtained from all
participants and the Medical Ethics Committee of the Erasmus Medical Center
approved the study.
Second Manifestations of Arterial disease The Second Manifestations of ARTe-
rial disease (SMART) study is an ongoing, prospective, single-center cohort study
in patients with clinically manifest vascular disease or cardiovascular risk factors.
The main inclusion criteria are coronary artery disease, cardiovascular disease, pe-
ripheral arterial disease, abdominal aortic aneurysm, or any or all of the following
risk factors for atherosclerosis: hyperlipidemia, diabetes mellitus (type 1 and 2),
or hypertension. Patients with a terminal malignancy, patients not able to live
independently (Rankin scale >3), or patients who are not sufficiently fluent in
Dutch were excluded.
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Thrombosis Prevention Trial The Thrombosis Prevention Trial (TPT) was a fac-
torial -designed trail of aspirin and warfarin in prevention of CHD. The trial was
done through 108 General practices representing all parts of the UK in men aged
between 45 years and 69 years. Those excluded were current or recent history
of possible peptic ulceration, a history of possible or definite MI or stroke, and
other medication incompatible with trial treatment. Men in the top 20% of the
risk score distribution, or in the top 25% in regions with particularly high IHD
mortality rates, were considered to be at increased risk and eligible for the trial
(n=10,557). Participants who decided to take part in the trial (n=5499) visited
their doctor for a medical examination, including an electrocardiogram (ECG), to
confirm eligibility.
Uppsala Longitudinal Study of Adult Men Uppsala Longitudinal Study of Adult
Men (ULSAM)is a longitudinal, epidemiologic study based on all available men,
born between 1920 and 1924, in Uppsala County, Sweden. The men were inves-
tigated at the ages of 50, 60, 70, 77, 82 and 88 years. Full screening and official
registry data are available.
Utrecht Cardiovascular Pharmacogenetics study The Utrecht Cardiovascular PHar-
macogenetics (UCP) study enrolled participants from the population-based Pharmaco-
Morbidity Record Linkage System (PHARMO, www.pharmo.nl). PHARMO links
drug dispensing histories from a representative sample of Dutch community phar-
macies to the national registration of hospital discharges (Dutch National Medical
Registry). First, patients who received a prescription for an antihypertensive drug,
and/or had hypercholesterolemia (prescription for a cholesterol-lowering drug or
total cholesterol>5.0mmol/l), were selected from the PHARMO database for phar-
macogenetic studies on antihypertensive drugs and statins, respectively. From this
cohort, a nested casecontrol study was designed using hospital discharge records.
Patients hospitalized for MI [International Classification of Diseases 9 code 410]
were included as cases if they were registered in PHARMO for at least 1 year and
were older than 18 years. The index date was defined as the date of hospitalization
for the first MI. Controls met the same eligibility criteria as the cases, but had
not developed MI. Controls were matched with cases on age, sex, and region, and
assigned the same index.
Whitehall II The Whitehall II Study recruited 10,308 participants (70% men) between
1985 and 1989 and involved 20 London based civil service departments. In this
longitudinal study blood pressure was recorded at phase 1 (1985-1988), phase
3 (1991-1993), phase 5 (1997-1999) and phase 7 (2003-2004). DNA was stored
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from phase 7 from over 6,000 participants. The study participants are all highly
phenotyped for cardiovascular and other ageing related health outcomes.
Women’s Health Initiative The Women’s Health Initiative (WHI) was initiated in
1992 as a major disease-prevention research program among postmenopausal women.
The program includes a randomized controlled intervention trial involving 68,132
women and four distinct interventions: conjugated equine estrogens, alone or in
combination with medroxyprogesterone acetate, for coronary heart disease preven-
tion with breast cancer as an anticipated adverse effect; a low-fat eating pattern
for breast and colorectal cancer prevention; and calcium and vitamin D supple-
mentation for hip fracture prevention
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Table C.1: Design and genotyping characteristics of the studies included in the collaboration
Study Study design Sampling Frame N with DNA in
this analysis
Year of
blood
sampling
used for
DNA
extraction
Genotyping
method
Country Contributes
to obser-
vational
analysis
HWE P
value (exact
significance
probability)
Call rate
(%)
ALSPAC Cohort Pregnant women
(Avon County)
2557 1991-2010 KASPar UK N 0.41 97.7
ARIC Cohort Community 9557 1987-89 IBC 50k
CardioChip
USA Y 0.705 97.8
BRHS Cohort General practices 3843 1998-2000 KASPar UK Y 0.42 100
BWHHS Cohort General practices 3412 1999-2001 Illumina
HumanCVD
array
UK Y 0.912 99.7
CaPS Cohort Electoral register
& General
practices
1102 1993-1994 KASPar UK Y 0.46 98.4
CARDIA Cohort Community 1433 1995-1996 IBC 50k
CardioChip
USA Y 0.0005 97.3
CCHS Cohort Population 9081 1991-94 Nanogen Denmark Y 0.522 99.6
CFS Cohort Family 134 2001-2006 IBC 50k
CardioChip
USA N 0.462 98
CGPS Cohort Population 57041 2003-
ongoing
TaqMan Denmark N 0.473 NA
CHS Cohort Community 3936 19921993 IBC 50k
CardioChip
USA Y 0.001 97.9
CYPRUS Cohort Community 730 2003-2008 TaqMan Cyprus Y 0.081 99.9
Czech post-MONICA Cohort Administrative
districts
2558 2000-2001 PCR-RFLP Czech
Republic
Y 0.801 97.9
DCH Case cohort General population
(born in Denmark)
2736 1993-97 TaqMan Denmark Y 0.203 91.8
EAS Cohort General practices 873 2004 TaqMan UK Y 0.693 95.6
ELSA Cohort Respondents of
HSE
5450 2004 KASPar UK Y 0.263 98.8
EPIC InterAct Nested case control Population 9427 1991-1998 Metabochip
plus
Denmark,
France,
Germany,
Italy,
Netherlands,
Spain,
Sweden, UK
N 0.0013 99.6
Continued on next page
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Table C.1 – Continued from previous page
Study Study design Sampling Frame N with DNA in
this analysis
Year of
blood
sampling
used for
DNA
extraction
Genotyping
method
Country Contributes
to obser-
vational
analysis
HWE P
value (exact
significance
probability)
Call rate
(%)
EPIC Netherlands Nested case control Population
(Bilthoven &
Utrecht)
5186 1993 and
1997
IBC 50k
CardioChip
The
Netherlands
N 0.095 99.9
EPIC Norfolk Nested case control Population
(Norwich & E
Anglia)
20195 1997-2000 TaqMan UK Y 0.091 99
EPIC Potsdam Case cohort Population
(Potsdam
(Germany)
2253 2007 TaqMan Germany N 0.454 98.8
EPIC Turin Cohort Population (Torino
area)
4526 2008 TaqMan Italy Y 0.362 99
FHS Cohort Community 1082 1948-present IBC 50k
CardioChip
USA Y 0.002 99
HAPIEE Czech Cohort City districts 6678 2003-2005 KASPar Czech
Republic
Y 0.745 98.6
HAPIEE Lithuania Cohort City districts 6936 2006-2008 KASPar Lithuania Y 0.149 98.6
HAPIEE Poland Cohort City districts 8779 2003-2005 KASPar Poland Y 0.238 97
HAPIEE Russia Cohort City districts
(Novosibirsk City)
7083 2003-2005 KASPar Russia Y 0.041 98.8
HIMS Cohort City population 4191 2001-04 TaqMan Australia Y 4.06E-08 98.7
HPFS Nested case control Health
Professionals
1264 1994 IBC 50k
CardioChip
USA N 0.45 93
IMPROVE Groningen Cohort Clinic 421 2004-2005 TaqMan Netherlands N 0.109 >99
IMPROVE Kuopio 1 Cohort Clinic 481 2004-2005 TaqMan Finland N 0.927 >99
IMPROVE Kuopio 2 Cohort Clinic 440 2004-2005 TaqMan Finland N 0.943 >99
IMPROVE Milan Cohort Clinic 514 2004-2005 TaqMan Italy N 0.574 >99
IMPROVE Paris Cohort Clinic 436 2004-2005 TaqMan France N 0.008 >99
IMPROVE Perugia Cohort Clinic 464 2004-2005 TaqMan Italy N 0.347 >99
IMPROVE Stockholm Cohort Clinic 480 2004-2005 TaqMan Sweden N 3.43E-09 >99
Inter99 RCT Population 6332 1999-2001 KASPar Denmark Y 6.16E-27 97.6
ISGS-SWISS Case control Clinic 1124 2002-2008 TaqMan USA N 1 >99
Izhevsk Case control Population-based
controls from CC
653 2008-2009 PCR + elec-
trophoresis
Russia Y 0.192 >99
MDC Cohort Population 1937 1991-1996 IBC 50k
CardioChip
Sweden N 0.537 >99
MESA Cohort Population 2293 2000-2002 IBC 50k
CardioChip
USA Y 0.012 97
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Table C.1 – Continued from previous page
Study Study design Sampling Frame N with DNA in
this analysis
Year of
blood
sampling
used for
DNA
extraction
Genotyping
method
Country Contributes
to obser-
vational
analysis
HWE P
value (exact
significance
probability)
Call rate
(%)
MRC NSHD Cohort Population (Born
3-9 March 1946)
2696 1999 KASPar UK N 0.222 >99
MRC 1958BC Cohort Population 2587 2002-2004 Illumina
1.2M
UK N 0.2609 95.4
NHANES III Cross-sectional General population 2388 1991-1994 TaqMan USA N 1 98
NHS Nested case control Nurses (Boston) 1322 1990 IBC 50k
CardioChip
USA N <2.2E-16 97
NORDIL RCT Clinic 1921 1992-1999 IBC 50k
CardioChip
Norway and
Sweden
N 1 >99
NPHS II Cohort General practices 2659 2000 TaqMan UK Y 0.874 96.1
Portuguese Stroke Study Case control Clinic 1002 1995 and
1998
TaqMan Portugal N 0.006 99.4
PREVEND Cohort Mixed population
(Groningen City)
7729 1997-1998 KASPar Netherlands N 3.05E-09 >95
PROCARDIS Case control Hospital 6440 1998-200? IBC 50k
CardioChip
Germany,
Italy,
Sweden, UK
N 1 >99
PROSPER RCT Elderly; cholesterol
4-9 mmol/l
5504 1997 to 1999 TaqMan Scotland,
Ireland, The
Netherlands
N 0.008 95.5
Rotterdam Cohort Administrative
district
5827 1992 TaqMan Netherlands Y 0.341 90
SMART Cohort Atherosclerosis
hospital referrals
7917 1996-2006 KASPAR Netherlands N 3.85E-24 97
TPT RCT Acute coronary
syndrome
3175 1984-1989 TaqMan UK N 0.68 86.2
UCP Nested case control Hospital patients 1615 2007 IBC 50k
CardioChip
Netherlands N 1 100
ULSAM Cohort General population
(Uppsala County)
453 2004 Illumina
Golden Gate
Sweden Y 0.775 98.91
Whitehall II Cohort Workplace (civil
servants)
5029 2002-2004 IBC 50k
CardioChip
UK Y 0.106 99.3
WHI Nested case control Community 7882 1993-1998 IBC 50k
CardioChip
USA Y 3.15E-25 99.2
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Table C.2: Characteristics of the alcohol questionnaires used in the collaborating studies
STUDY Questionnaire
beverage specific
Binge drinker Alcohol Abstainer
ALSPAC Y ≥4 drinks / occasion Not drinking at 5
waves, before and
after pregnancy
ARIC Y >70g/ day Self-declared
abstainer at first
wave
BRHS Y >6 drinks / occasion Never consumed
alcoholic drinks
BWHHS Y > 6 drinks/ day Never drink at
baseline
CaPS Y ≥ 5 drinks/ normal
occasion
Not drinking at 5
waves
CARDIA Y > 5 drinks on day
drank most in past
month
Not drinking at 4
waves
CCHS Y N/A N/A
CFS N/A N/A Never drink alcohol
CGPS Y N/A N/A
CHS Y ≥ 5 drinks per day N/A
Cyprus Y N/A N/A
Czech
post-MONICA
Y N/A No drinking in past
six months
DCH Y N/A Answering never
drink to all
beverages
EAS Y N/A N/A
ELSA Y > 10 units on
heaviest day in last
7
Always an abstainer
EPIC-InterAct Y N/A N/A
EPIC Netherlands Y N/A Never drink alcohol
EPIC Norfolk Y N/A Never drunk alcohol
in the past
EPIC-Potsdam Y N/A Never drunk alcohol
in the past
EPIC Turin Y N/A Never drunk beer/
wine/ spirits
FHS Y ≥5 beverage specific
drinks at one time
N/A
HAPIEE Czech N ≥5 drinks/ day Answering never
drink to all
beverages
Continued on next page
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Table C.2 – Continued from previous page
STUDY Questionnaire
beverage specific
Binge drinker Alcohol Abstainer
HAPIEE Lithuania N ≥5 drinks/ day Answering never
drink to all
beverages
HAPIEE Poland N ≥5 drinks/ day Answering never
drink to all
beverages
HAPIEE Russia N ≥5 drinks/ day Answering never
drink to all
beverages
HIMS N ≥5 drinks on usual
drinking day
Never drunk alcohol
HPFS N >6 drinks on largest
day in typical month
Self-declared
abstainer (in 1994)
IMPROVE Y N/A No
beer/wine/spirits
(time period not
specified
Inter99 Y ≥5 drinks at least
once/ week
Self-declared
abstainer in past
year
ISGS-SWISS N N/A Self-declared
abstainer/rare
drinker in past year
Izhevsk Y ≥5 drinks on one
occasion
Never drunk in life
other than few
occasions
MDC Y N/A N/A
MESA Y > 5 drinks on day
drank most
Not drinking at 4
waves
MRC NHSD Y N/A N/A
MRC 1956BC N/A N/A N/A
NHANES III N ≥5 drinks on any
day in the past 12
months
Less than 12 drinks
in entire life
NORDIL N/A N/A N/A
NPHS II Y N/A N/A
NHS N N/A Self-declared
abstainer (in 1990)
Portuguese Stroke
Study
N/A N/A N/A
PREVEND N N/A Almost never drink
PROCARDIS N/A N/A N/A
PROSPER N N/A N/A
Continued on next page
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Table C.2 – Continued from previous page
STUDY Questionnaire
beverage specific
Binge drinker Alcohol Abstainer
Rotterdam Y >6 alcoholic
beverages on one
day during the last
year
Self-declared
abstainer in past
year
SMART N/A N/A N/A
TPT N/A N/A N/A
UCP Y N/A Self-declared never
used alcohol
ULSAM Y N/A Self-declared
abstainer(age 60)
WHITEHALL II N >5 beers or wine /
spirits in one sitting
Non drinker at 3
waves
WHI Y N/A Less than 12 drinks
in entire life
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Table C.3: Event definitions in the studies included in the collaboration
Coronary heart disease Stroke (combined subtypes) Diabetes
Fatal Non-fatal
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ALSPAC
ARIC • • • • • • • •
BRHS • • • • • • •
BWHHS • • • • • • • • • •
CaPS • • • • • • • • • • •
CARDIA • • • • •
CCHS • • • • • • •
CFS • • •
CGPS
CHS • • • • • • • • • •
Cyprus • • • • • • •
Czech
post-MONICA
• • • • • •
DCH • • • • • • •
EAS • • • • • • • • • •
ELSA • • • • • • •
EPIC InterAct • •
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Table C.3 – Continued from previous page
Non-fatal Fatal Non-fatal Fatal Non-fatal
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EPIC Norfolk • • • • • • • •
EPIC
Netherlands
• • • • • • • •
EPIC Potsdam • • • • •
EPIC Turin • • • • • • • • • •
FHS • • • • •
HAPIEE Czech • • • • • • • • • • •
HAPIEE
Lithuania
• • • • • • • • • • •
HAPIEE
Poland
• • • • • • • • • • •
HAPIEE Russia • • • • • • • • • • •
HIMS • • • • • • • • • • •
HPFS • • • • • • •
IMPROVE • • • • • • • • •
Inter99 • • • •
ISGS-SWISS • • •
Izhevsk •
MDC • • • • • • • • • • •
MESA • • •
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Table C.3 – Continued from previous page
Non-fatal Fatal Non-fatal Fatal Non-fatal
Study S
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MRC 1958BC • •
MRC NSHD • • •
NHANES III • • •
NHS • • • • • • •
NORDIL • • • • • • • • • • •
NPHS-II • • • • • • • • • •
Portuguese
Stroke Study
• •
PREVEND • • • • • • •
PROCARDIS • •
PROSPER • • • • • • • • • •
Rotterdam • • • • • •
SMART
TPT • • • • •
UCP •
ULSAM • • • • • • • • •
Whitehall II • • • • • •
WHI • • •
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Table C.4: General and alcohol characteristics of studies included in the collaboration
Study Name Age (yrs) Gender
(male)
Median Alcohol
(units/wk)
Ln units/week Binge drinking
(5 drinks in
one setting)
Self-declared
non-drinker
Ln GGT (IU/L)
N mean
(SD)
Propor-
tion
(%)
Men Women N mean
(SD)
Proportion (%) Proportion (%) N mean
(SD)
ALSPAC 2557 47.75
(4.31)
0 NA NA NA NA NA NA NA NA
ARIC 9557 54.28
(5.69)
46.46 2 0 9532 0.98
(1.26)
0.62 18.15 NA NA
BRHS 3843 68.74
(5.51)
100 8 NA 3789 1.94
(1.28)
7.32 3.35 3790 3.35
(0.60)
BWHHS 3412 68.86
(5.51)
0 NA 0 3407 0.99
(1.19)
0.28 16.24 3334 3.12
(0.63)
CaPS 1102 51.71
(4.37)
100 14 NA 1061 2.40
(1.23)
40.2 2.12 NA NA
CARDIA 1433 25.58
(3.37)
46.34 11 5 1433 1.89
(1.22)
38.03 4.4 1427 1.86
(0.60)
CCHS 9081 58.38
(15.09)
44.49 15 5 8985 2.03
(1.31)
NA NA 8254 3.59
(0.64)
CFS 134 53.2
(14.75)
57.46 NA NA NA NA NA 46.97 NA NA
CGPS 57041 56.10
(13.30)
43.63 18 9 56970 2.37
(1.10)
15.96 9.73 56997 3.45
(0.57)
CHS 3936 72.78
(5.60)
43.83 1 0 3919 0.83
(1.18)
9.16 NA NA NA
Continued on next page
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Table C.4 – Continued from previous page
Study Name Age (yrs) Gender
(male)
Median Alcohol
(units/wk)
Ln units/week Binge drinking
(5 drinks in
one setting)
Self-declared
non-drinker
Ln GGT (IU/L)
N mean
(SD)
Propor-
tion
(%)
Men Women N mean
(SD)
Proportion (%) Proportion (%) N mean
(SD)
Cyprus 730 60.48
(10.21)
46.85 2 0 729 0.64
(0.92)
NA NA NA NA
Czech
post-MONICA
2558 48.76
(10.73)
46.44 11 0 2558 1.38(1.34) NA 38.58 NA NA
DCH 2736 56.71
(4.47)
62.02 17 7 2735 2.47
(1.11)
NA 2.96 NA NA
EAS 873 64.34
(5.62)
49.37 7 1 873 1.44
(1.19)
2.87 NA 872 3.21
(0.61)
ELSA 5450 67.51
(9.80)
45.56 10 3 5450 1.76
(1.24)
6.39 3.66 NA NA
EPIC InterAct 9427 54.00
(9.70)
38 10 2 6090 1.66
(1.26)
NA NA NA NA
EPIC
Netherlands
5186 54.06
(10.11)
21.89 11 3 5164 1.58
(1.26)
NA 13.03 4339 3.23
(0.52)
EPIC Norfolk 20195 59.29
(9.23)
47.15 7 3 20005 1.59
(1.03)
NA 85.78 NA NA
EPIC-Potsdam 2253
50.64(9.01)
40.26 7 4 2253 2.05
(1.11)
NA NA 2253 2.93(0.84)
EPIC Turin 4526 49.09
(7.62)
62.62 24 3 4314 2.29(1.39) NA 9.43 NA NA
Continued on next page
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Table C.4 – Continued from previous page
Study Name Age (yrs) Gender
(male)
Median Alcohol
(units/wk)
Ln units/week Binge drinking
(5 drinks in
one setting)
Self-declared
non-drinker
Ln GGT (IU/L)
N mean
(SD)
Propor-
tion
(%)
Men Women N mean
(SD)
Proportion (%) Proportion (%) N mean
(SD)
FHS 1082 45.7
(10.10)
49.35 5 0 312 1.25(1.33) 5.05 NA 725 4.87
(0.62)
HAPIEE
Czech
6678 58.32
(7.13)
45.91 15 1 6553 1.77
(1.44)
22.15 11.68 900 3.24(0.62)
HAPIEE
Lithuania
6936 60.96
(7.58)
45.73 5 1 6899 1.14
(1.15)
25.63 6.68 NA NA
HAPIEE
Poland
8779 57.69
(6.98)
49.09 3 0 8668 1.00
(1.47)
10.62 33.71 906 3.26
(0.59)
HAPIEE
Russia
7083 58.85
(7.09)
43.1 3 0 7082 0.69
(1.18)
25.87 16.29 7080 3.30(0.54)
HIMS 4191 71.11
(4.22)
100 6 NA 4191 1.67(1.36) 6.16 5.81 NA NA
HPFS 1264 64.35
(8.57)
100 5 NA 1263 1.73(1.3) 6.01 14.64 NA NA
IMPROVE
Groeningen
421 63.85
(6.05)
49.64 7 0 421 1.31(1.58) NA NA NA NA
IMPROVE
Kuopio 1
481 63.93
(5.44)
60.91 6 0 481 1.28(1.36) NA NA NA NA
IMPROVE
Kuopio 2
440 64.43
(5.52)
53.86 7 0 440 1.31(1.34) NA NA NA NA
Continued on next page
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Table C.4 – Continued from previous page
Study Name Age (yrs) Gender
(male)
Median Alcohol
(units/wk)
Ln units/week Binge drinking
(5 drinks in
one setting)
Self-declared
non-drinker
Ln GGT (IU/L)
N mean
(SD)
Propor-
tion
(%)
Men Women N mean
(SD)
Proportion (%) Proportion (%) N mean
(SD)
IMPROVE
Milan
514 65.28
(5.75)
48.44 18 0 514 2.00
(1.72)
NA NA NA NA
IMPROVE
Paris
436 64.34
(6.34)
50.23 14 0 436 1.58
(1.70)
NA NA NA NA
IMPROVE
Perugia
464 60.63
(4.15)
24.14 27 0 464 1.67
(1.60)
NA NA NA NA
IMPROVE
Stockholm
480 66.79
(0.38)
51.46 11 5 480 1.71
(1.42)
NA NA NA NA
Inter99 6332 46.02
(7.91)
48.89 15 4 6025 2.25
(1.14)
36.65 9.83 NA NA
ISGS-SWISS 780 72.06
(14.99)
28.9 NA NA NA NA NA 59.57 NA NA
Izhevsk 653 48.21
(8.20)
100 10 NA 642 2.21
(1.27)
55.44 0.46 653 3.50
(0.76)
MDC 1937 57.78
(5.84)
57.61 10 5 1466 1.80
(1.13)
NA NA NA NA
MESA 2293 62.7
(10.24)
52.25 7 2 2054 1.63
(1.29)
12.09 22.99 NA NA
MRC 1958BC 2585 NA 51.87 2 1 2580 0.93
(0.39)
NA NA NA NA
Continued on next page
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Table C.4 – Continued from previous page
Study Name Age (yrs) Gender
(male)
Median Alcohol
(units/wk)
Ln units/week Binge drinking
(5 drinks in
one setting)
Self-declared
non-drinker
Ln GGT (IU/L)
N mean
(SD)
Propor-
tion
(%)
Men Women N mean
(SD)
Proportion (%) Proportion (%) N mean
(SD)
MRC NSHD 2696 53 (NA) 49.89 8 3 2696 1.64
(1.15)
NA NA NA NA
NHANES III 2388 53.10
(20.60)
40 1 0 NA NA 50 19.98 NA NA
NHS 1322 59.95
(6.45)
0 NA 1 1322 1.08
(1.11)
3.33 37.9 NA NA
NORDIL 1921 56.00
(3.98)
51.17 NA NA NA NA NA NA NA NA
NPHS II 2659 56.10
(3.42)
100 6 NA 2659 1.85
(1.23)
NA NA NA NA
Portuguese
Stroke Study
1002 62.9 (6.8) 0 NA NA NA NA NA NA NA NA
PREVEND 7729 49.56
(12.74)
49.24 5 1 7729 1.49
(1.19)
NA 24.53 NA NA
PROCARDIS 6440 60.72
(9.04)
58.94 NA NA NA NA NA NA NA NA
PROSPER 5504 75.33
(3.36)
48.27 4 0 5504 1.08
(1.16)
NA NA NA
Rotterdam 5827 69.12
(8.93)
41.07 9 1 4688 1.52 (1.3) 6.59 20.44 4187 3.22
(0.52)
Continued on next page
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Table C.4 – Continued from previous page
Study Name Age (yrs) Gender
(male)
Median Alcohol
(units/wk)
Ln units/week Binge drinking
(5 drinks in
one setting)
Self-declared
non-drinker
Ln GGT (IU/L)
N mean
(SD)
Propor-
tion
(%)
Men Women N mean
(SD)
Proportion (%) Proportion (%) N mean
(SD)
SMART 8068 56.51
(12.40)
57.61 NA NA NA NA NA NA NA NA
TPT 3175 57.30
(6.76)
100 NA NA NA NA NA NA NA NA
UCP 1615 62.78
(9.65)
74.37 10 0 1323 1.75
(1.33)
NA 12.3 NA NA
ULSAM 453 71.29
(0.44)
100 4 NA 421 1.58
(1.06)
NA 15.65 NA NA
Whitehall II 5029
43.87(5.94)
73.53 9 4 4990 2.01(1.08) 37.99 2.57 NA NA
WHI 7882 67.98
(6.58)
0 NA 0.5 7620 0.97
(1.14)
NA 11.33 NA NA
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Table C.5: Number and proportion of outcomes in studies included in the collaboration
Study Coronary heart
disease
Stroke (combined
sub-types)
Diabetes Hypertension
N Propor-
tion
(%)
N Propor-
tion
(%)
N Propor-
tion
(%)
N Propor-
tion
(%)
ALSPAC NA NA NA NA NA NA 145 5.81
ARIC 1308 13.77 520 5.44 1182 12.37 1195 12.51
BRHS 532 13.8 307 8 59 1.54 2551 66.38
BWHHS 303 13.7 290 8 338 9.91 2104 61.66
CaPS 193 28.47 NA NA 10 0.91 685 62.16
CARDIA 10 0.7 4 0.28 99 6.91 26 1.81
CCCHS 993 10.94 NA NA 303 3.34 4786 52.76
CFS 10 20.83 12 9.09 17 42.5 37 27.61
CGPS NA NA NA NA NA NA 30456 53.48
CHS 110 2.94 547 13.9 573 14.61 1527 38.85
Cyprus 41 5.48 4 0.55 98 13.42 450 61.64
Czech post-MONICA 58 2.27 52 2.03 100 3.97 715 27.95
DCH 135 NA* 66 NA* 105 3.84 1633 59.69
EAS 144 16.53 73 8.38 25 2.86 452 51.78
ELSA 184 3.38 155 2.84 360 6.61 3352 61.5
EPIC InterAct NA NA NA NA 3535 NA* NA NA
EPIC Netherlands 1221 NA* 443 NA* 369 8.26 1906 36.79
EPIC Norfolk 613 NA* 300 NA* 449 2.22 8218 40.77
EPIC Potsdam 224 NA* 30 NA* 106 4.7 812 36.04
EPIC Turin 32 0.74 9 0.21 63 1.46 1920 42.42
FHS 28 2.77 37 3.42 110 14.29 64 53.78
Continued on next page
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Table C.5 – Continued from previous page
Study Coronary heart
disease
Stroke (combined
sub-types)
Diabetes Hypertension
N Propor-
tion
(%)
N Propor-
tion
(%)
N Propor-
tion
(%)
N Propor-
tion
(%)
HAPIEE Czech 401 6.12 293 4.47 350 5.26 3630 54.49
HAPIEE Lithuania 652 9.4 311 4.48 392 5.68 3824 55.35
HAPIEE Poland 673 7.67 207 2.36 656 7.49 4236 48.48
HAPIEE Russia 630 8.89 461 6.51 256 3.61 4038 57.03
HIMS 540 13.47 224 5.59 339 8.09 3410 81.36
HPFS 424 NA* NA NA 69 5.46 404 31.96
IMPROVE Groeningen 59 14.05 13 3.09 234 56.52 277 66.27
IMPROVE Kuopio 1 38 7.9 7 1.46 84 17.57 295 61.46
IMPROVE Kuopio 2 67 14.77 11 2.5 201 46.1 364 82.73
IMPROVE Milan 16 3.11 3 0.58 65 11.95 205 39.88
IMPROVE Paris 29 6.65 7 1.61 107 25.12 99 22.71
IMPROVE Perugia 47 10.13 8 1.72 69 15 231 49.78
IMPROVE Stockholm 38 7.92 13 2.71 97 20.77 367 76.46
Inter99 45 0.74 59 0.97 364 6.03 2341 36.97
ISGS-SWISS NA NA 794 NA * NA NA NA NA
Izhevsk NA NA NA NA 11 1.7 383 58.65
MDC 57 2.94 47 2.43 35 1.81 4 0.21
MESA 47 2.05 32 1.4 220 9.59 483 21.08
MRC 1958BC NA NA NA NA 78 3.1 609 23.64
MRC NSHD 42 1.56 20 0.74 77 2.86 1194 44.92
NHANES III 239 10.01 NA NA 239 10.01 716 29.98
NHS 442 NA* NA NA 120 9.08 466 35.25
Continued on next page
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Table C.5 – Continued from previous page
Study Coronary heart
disease
Stroke (combined
sub-types)
Diabetes Hypertension
N Propor-
tion
(%)
N Propor-
tion
(%)
N Propor-
tion
(%)
N Propor-
tion
(%)
NORDIL 23 1.2 26 1.35 131 6.82 1921 100
NPHSII 179 6.73 84 3.16 67 2.52 1362 51.22
Portuguese Stroke Study NA NA 569 NA* NA NA NA NA
PREVEND 451 5.95 197 2.59 274 3.56 2111 27.31
PROCARDIS 3116 NA * NA NA NA NA NA NA
PROSPER 731 13.28 617 11.21 592 10.76 4326 78.6
Rotterdam 1094 18.84 835 14.33 608 10.44 2672 47.26
TPT 36 1.13 NA NA NA NA 1604 50.52
UCP 622 NA * NA NA 323 20.15 NA NA
ULSAM 85 18.76 92 20.31 48 10.6 331 73.07
Whitehall II 212 4.22 116 2.31 183 3.64 765 15.21
WHI 2943 NA* 2126 NA* NA NA 2736 34.71
Footnote: * for case control, nested case-cohort or nested case-control studies, the proportion was not estimated
A
p
p
en
d
ix
C
.
A
lco
h
o
l
a
n
d
ca
rd
io
va
scu
la
r
d
isea
se
275
Table C.6: Lifestyle characteristics of the studies included in the collaboration
Study Ever smoker Smoking frequency (cigs/day) ln Cotinine (nmol/l) Pack years Physical exercise
(hours/week)
Education (years)
Proportion
(%)
N mean (SD) N mean (SD) N mean (SD) N mean (SD) N mean (SD)
ALSPAC 38.96 522 15.21 (8.72) NA NA 919 16.43 (14.00) NA NA NA NA
ARIC 59.75 1950 20.23 (12.18) NA NA 9382 17.02 (21.78) NA NA NA NA
BRHS 67.45 399 13.87 (9.09) 3666 -0.41 (2.9) NA NA NA NA 3325 11.35 (2.79)
BWHHS 43.9 353 12.25 (6.59) 3352 0.61 (2.61) 867 18.95 (16.98) 3275 2.74 (5.55) 3183 11.21 (2.60)
CaPS 81.59 447 27.27 (13.84) NA NA NA NA 1079 0.69 (0.46) NA NA
CARDIA 23.7 582 14.92 (10.72) NA NA 580 6.19 (6.77) NA NA 1433 14.76 (2.29)
CCHS 77.49 9010 8.13 (10.54) NA NA NA NA 8992 2.26 (0.71) 9011 9.16 (2.15)
CFS 57.5 NA NA NA NA 127 16.83 (22.12) NA NA NA NA
CGPS 58.03 NA NA NA NA NA NA 57041 2.47 (0.72) NA NA
CHS 54.18 NA NA NA NA 3830 18.83 (27.59) NA NA 3927 14.00 (4.58)
Cyprus 38.63 282 24.21 (17.55) NA NA 730 13.56 (27.97) 729 2.67 (1.81) NA NA
Czech post-
MONICA
47.15 1164 14.23 (9.44) NA NA 1206 16.89 (15.03) NA NA 2555 12.53 (2.66)
DCH 72.54 NA NA NA NA NA NA 2710 1.24 (2.10) NA NA
EAS 60.58 518 15.96 (8.02) NA NA 502 25.08 (18.05) 873 .59(1.84) NA NA
ELSA 70.28 5403 2.67 (7.00) NA NA 5395 5.37 (14.34) NA NA NA NA
EPIC
InterAct
NA NA NA NA NA NA NA NA NA NA NA
EPIC
Netherlands
63.85 1487 15.44 (9.03) NA NA 1471 25.54 (16.73) 5186 2.81(1.03) NA NA
EPIC
Norfolk
54.43 2048 14.33 (8.21) NA NA 20185 9.88 (15.35) 20195 2.3 (1.09) 20185 1.31 (1.09)
EPIC
Potsdam
54.68 2253 3.12 (7.24) NA NA NA NA 2253 0.99 (1.71) NA NA
EPIC Turin 59.7 1049 13.41 (9.07) NA NA 1048 19.27 (14.81) 4313 327.89
(275.32)
4305 11.97 (4.53)
FHS 61.15 NA NA NA NA 112 13.16 (19.05) NA NA 768 14.35 (2.77)
HAPIEE
Czech
55.32 4043 12.21 (9.81) NA NA 3462 20.97 (16.88) 6496 4.32 (5.32) NA NA
HAPIEE
Lithuania
37.3 2487 15.00 (9.81) NA NA 2479 22.82 (18.36) 6894 3.25 (5.91) NA NA
HAPIEE
Poland
59.34 6174 15.27 (12.23) NA NA 5069 28.15 (20.14) 8329 5.39 (6.06) NA NA
HAPIEE
Russia
40 2793 16.06 (9.56) NA NA 2792 28.08 (20.44) 7076 2.41 (5.86) NA NA
HPFS 41.61 111 2.00 (0.97) NA NA 1232 15.18 (20.37) 1264 3.49 (5.01) NA NA
HIMS 66.45 4176 14.56 (17.11) NA NA 2740 37.75 (34.10) 4186 5.52(5.63) 4189 3.53 (0.99)
Continued on next page
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Table C.6 – Continued from previous page
Study Ever smoker Smoking frequency (cigs/day) ln Cotinine (nmol/l) Pack years Physical exercise
(hours/week)
Education (years)
Proportion
(%)
N mean (SD) N mean (SD) N mean (SD) N mean (SD) N mean (SD)
IMPROVE
Groeningen
69.83 292 14.61 (8.46) NA NA 419 15.38 (17.50) NA NA NA NA
IMPROVE
Kuopio 1
53.01 248 14.18 (8.52) NA NA 462 9.79 (16.02) NA NA NA NA
IMPROVE
Kuopio 2
47.05 195 15.41 (10.12) NA NA 428 8.93(14.58) NA NA NA NA
IMPROVE
Milan
51.75 262 17.53 (13.43) NA NA 510 13.91 (23.08) NA NA NA NA
IMPROVE
Paris
47.25 203 16.31 (10.29) NA NA 431 9.61 (15.39) NA NA NA NA
IMPROVE
Perugia
40.09 186 16.38 (7.10) NA NA 464 8.51 (15.08) NA NA NA NA
IMPROVE
Stockholm
55.83 249 14.1(7.68) NA NA 461 11.25 (15.18) NA NA NA NA
Inter99 64.34 2207 16.81 (8.65) NA NA 2418 15.14 (13.80) 5889 4.86 (2.70) 6081 12.16 (3.17)
ISGS-SWISS N/A NA NA NA NA NA NA NA NA NA NA
Izhevsk 81.6 NA NA NA NA NA NA NA NA NA NA
MDC 66.75 522 13.83 (8.15) NA NA 516 24.31 (16.65) NA NA NA NA
MESA 55.88 NA NA NA NA 2264 15.35 (28.33) NA NA NA NA
MRC
1958BC
53.64 NA NA NA NA NA NA NA NA NA NA
MRC NSHD 71.28 597 16.88 (9.76) NA NA 2169 11.42 (14.52) NA NA 2696 2.86 (2.63)
NHANES III 50 494 21.10 (12.30) 2360 1.58 (3.36) 488 16(19.80) 2383 5.5 (6.10) 2382 12.4(2.90)
NHS 64.52 346 1.95 (0.90) NA NA 1304 18.8(22.67) 1322 1.87 (2.89) NA NA
NORDIL 25.82 NA NA NA NA NA NA NA NA NA NA
NPHSII 68.45 1883 18.04 (14.38) NA NA 1665 29.65 (23.35) NA NA NA NA
Portuguese
Stroke Study
48.3 NA NA NA NA NA NA NA NA NA NA
PREVEND 71.37 NA NA NA NA NA NA NA NA 7729 0.86 (0.35)
PRO-
CARDIS
NA NA NA NA NA NA NA NA NA NA NA
PROSPER 26.84 NA NA NA NA NA NA NA NA 5504 15.12 (2.03)
Rotterdam 64.62 1198 14.56 (8.68) NA NA 3328 28.03 (24.34) 3893 42.08 (19.15) 5827 3.4 (1.94)
SMART NA NA NA NA NA NA NA NA NA NA NA
TPT N/A NA NA NA NA NA NA NA NA NA NA
UCP 69.36 690 18.15 (11.95) NA NA 660 31.85 (26.55) NA NA NA NA
ULSAM 66.67 NA NA NA NA 300 39.92 (35.54) NA NA NA NA
Whitehall II 41.63 709 14.88 (10.21) NA NA 655 19.62 (14.67) 4899 3.01 (3.38) 3700 14.46 (3.59)
WHI 49.94 NA NA NA NA NA NA NA NA NA NA
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Table C.7: Cardiovascular traits characteristics of the studies included in the collaboration (1)
Study SBP (mmHg) HDL-C (mmol/l) non-HDL-C
(mmol/l)
ln triglycerides
(mmol/l)
Apolipoprotein A
(g/l)
Apolipoprotein B
(g/l)
ln lipoprotein(a)
(mg/dl)
Fasting glucose
(mmol/l)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
ALSPAC 2496 117.70
(12.14)
2395 1.47
(0.39)
2395 3.42
(0.89)
2395 -0.08
(0.44)
NA NA NA NA NA NA NA NA
ARIC 9554 118.35
(17.00)
9540 1.31
(0.43)
9538 4.24
(1.12)
9540 0.29
(0.52)
NA NA NA NA NA NA 7717 5.91
(1.69)
BRHS 3827 149.29
(24.22)
3763 1.32
(0.34)
3763 4.67
(1.08)
3788 0.49
(0.48)
NA NA NA NA NA NA 3823 5.55
(1.24)
BWHHS 3401 147.03
(25.12)
3367 1.66
(0.45)
3367 4.98
(1.25)
3373 0.51
(0.46)
NA NA NA NA NA NA 3357 6.06
(1.64)
CaPS 1076 145.73
(22.4)
1067 1.39
(0.38)
1067 4.50
(1.11)
1059 0.38
(0.57)
1036 1.26
(0.20)
1033 0.96
(0.20)
NA NA NA NA
CARDIA 1433 109.26
(10.81)
1427 1.34
(0.33)
1427 3.22
(0.86)
1426 -0.27
(0.51)
1425 1.36
(0.19)
1425 0.91
(0.23)
1321 1.86
(1.33)
1321 4.74
(0.97)
CCHS 9072 138.89
(22.52)
9066 1.58
(0.50)
9066 4.58
(1.34)
9053 0.47
(0.54)
NA NA NA NA NA NA NA NA
CFS 134 128.92
(17.05)
40 1.06
(0.34)
40 3.49
(1.09)
40 0.48
(0.48)
NA NA NA NA NA NA 40 6.00
(2.24)
CGPS 56948 140.31
(21.32)
57012 1.64
(0.52)
57012 4.03
(1.11)
57010 0.37
(0.55)
NA NA NA NA NA NA NA NA
CHS 3930 135.48
(21.45)
3922 1.38
(0.40)
3922 4.09
(1.00)
3927 0.38
(0.43)
NA NA NA NA 3921 1.09
(1.24)
3922 6.04
(1.82)
Cyprus 713 138.97
(17.06)
711 711 711 0.41
(0.48)
711 1.44
(0.24)
710 1.20
(0.24)
688 2.01
(0.92)
710 5.77
(1.59)
Czech post-
MONICA
2526 127.38
(17.14)
2518 1.39
(0.36)
2518 4.27
(1.22)
2523 0.39
(0.56)
NA NA NA NA NA NA 2548 5.30
(1.18)
DCH 2735 143.47
(21.08)
NA NA NA NA NA NA NA NA NA NA NA NA NA NA
EAS 872 143.24
(23.63)
867 1.45
(0.38)
867 5.63
(1.31)
872 0.32
(0.45)
NA NA NA NA 568 -1.09
(1.40)
871 5.80
(1.49)
ELSA 4027 140.13
(19.22)
2019 1.45
(0.43)
2019 5419 0.45
(0.51)
NA NA NA NA NA NA 3235 5.02
(0.93)
EPIC
InterAct
NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
EPIC
Nether-
lands
5164 133.07
(21.17)
3580 1.40
(0.41)
3060 4.23
(1.25)
4321 0.44
(0.56)
NA NA NA NA NA NA 3456 5.41
(2.21)
EPIC
Norfolk
20158 135.46
(18.19)
18958 1.42
(0.43)
18958 4.73
(1.17)
19635 0.46
(0.53)
15602 1.55
(0.33)
15520 0.97
(0.25)
15782 2.57
(0.97)
NA NA
Continued on next page
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Table C.7 – Continued from previous page
Study SBP (mmHg) HDL-C (mmol/l) non-HDL-C
(mmol/l)
ln triglycerides
(mmol/l)
Apolipoprotein A
(g/l)
Apolipoprotein B
(g/l)
ln lipoprotein(a)
(mg/dl)
Fasting glucose
(mmol/l)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
EPIC
Potsdam
2253 130.12
(18.04)
2253 1.35
(0.37)
2253 3.19
(0.91)
2253 0.19
(0.59)
NA NA NA NA NA NA 325 5.56
(1.54)
EPIC
Turin
4526 132.39
(15.74)
NA NA NA NA NA NA NA NA NA NA NA NA NA NA
FHS 119 135.61
(20.4)
756 1.32
(0.40)
756 3.8
(1.09)
757 1.05
(0.67)
704 1.44
(0.30)
704 1.00
(0.25)
506 1.93
(1.37)
740 5.60
(0.60)
HAPIEE
Czech
6662 139.14
(19.66)
6502 1.39
(0.39)
6501 4.33
(1.07)
6522 0.49
(0.53)
NA NA NA NA NA NA 901 5.77
(1.63)
HAPIEE
Lithuania
6909 139.65
(21.65)
6776 1.49
(0.38)
6776 4.46
(1.16)
6894 0.26
(0.48)
NA NA NA NA NA NA 6764 5.83
(1.25)
HAPIEE
Poland
8738 138.27
(21.15)
8772 1.44
(0.38)
8772 4.4
(1.10)
8768 0.38
(0.49)
NA NA NA NA NA NA 8761 5.37
(1.40)
HAPIEE
Russia
7080 143.1
(25.05)
7081 1.54
(0.41)
7081 4.85
(1.29)
7079 0.34
(0.44)
NA NA NA NA NA NA 1045 5.97
(1.97)
HIMS 4191 155.84
(20.42)
3835 1.39
(0.36)
3835 3.51
(0.92)
3834 NA NA NA NA NA NA 3835 5.71
(1.45)
HPFS NA NA 1264 1.16
(0.32)
1264 4.16
(0.96)
1264 0.37
(0.55)
NA NA 1264 0.93
(0.22)
750 -0.76
(1.28)
NA NA
IMPROVE
Groeningen
418 147.08
(18.14)
419 1.12
(0.32)
419 3.97
(1.03)
419 0.47
(0.55)
NA NA NA NA NA NA 417 6.52
(2.31)
IMPROVE
Kuopio 1
480 144.87
(17.58)
479 1.30
(0.34)
479 3.75
(0.92)
479 0.15
(0.48)
NA NA NA NA NA NA 480 5.85
(1.06)
IMPROVE
Kuopio 2
440 153.10
(17.35)
440 1.27
(0.37)
440 4.03
(1.04)
440 0.33
(0.55)
NA NA NA NA NA NA 439 7.08
(2.12)
IMPROVE
Milan
514 131.49
(14.38)
512 1.21
(0.34)
512 4.68
(0.98)
512
0.34(0.49)
NA NA NA NA NA NA 514 5.41
(0.99)
IMPROVE
Paris
436 128.17
(14.35)
436 1.35
(0.40)
436 4.31
(1.16)
436 0.36
(0.60)
NA NA NA NA NA NA 436 5.42
(1.18)
IMPROVE
Perugia
464 139.48
(13.43)
464 1.29
(0.33)
464 464 0.35
(0.53)
NA NA NA NA NA NA 464 5.26
(1.23)
IMPROVE
Stockholm
480 149.45
(18.57)
480 1.28
(0.38)
480 4.16
(1.00)
480 NA NA NA NA NA NA 480 6.03
(1.45)
Inter99 6331 130.20
(17.50)
6328 1.43
(0.40)
6327 4.09
(1.12)
6328 0.12
(0.54)
629 4.49
(2.84)
715 12.24
(22.59)
NA NA 6326 5.60
(1.13)
ISGS-
SWISS
NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
Izhevsk 652 144.86
(22.39)
623 623 4.02
(1.02)
611 0.28
(0.52)
621 1.47
(0.31)
621 0.90
(0.26)
NA NA NA NA
MDC 1937 115.70
(6.15)
NA NA NA NA NA NA NA NA NA NA NA NA NA NA
Continued on next page
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Table C.7 – Continued from previous page
Study SBP (mmHg) HDL-C (mmol/l) non-HDL-C
(mmol/l)
ln triglycerides
(mmol/l)
Apolipoprotein A
(g/l)
Apolipoprotein B
(g/l)
ln lipoprotein(a)
(mg/dl)
Fasting glucose
(mmol/l)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
MESA 2291 123.53
(20.68)
2286 1.35
(0.41)
2286 3.71
(0.93)
2288
0.26(0.54)
NA NA NA NA NA NA 2288 5.04
(1.23)
MRC
1958BC
2576 126.70
(16.82)
2544 1.56
(0.40)
2544 4.32
(1.10)
2543 0.54
(0.60)
NA NA NA NA NA NA NA NA
MRC
NSHD
2658 136.11
(19.96)
2333 2333 4.36
(1.13)
2506 0.58
(0.58)
NA NA NA NA NA NA NA NA
NHANES
III
2383 126.80
(20.2)
2364 1.3
(0.40)
2362 4.10
(1.20)
2379 0.37
(0.57)
NA NA NA NA NA NA 1108 5.70
(1.7)
NHS NA NA 1322 1.48
(0.43)
1321 4.44
(1.07)
1227 0.23
(0.51)
183 1.73
(0.33)
1322 1.09
(0.32)
683 -0.97
(1.27)
NA NA
NORDIL 1921 177.23
(14.53)
1820 1.37
(0.46)
1819 1889 0.47
(0.51)
NA NA NA NA NA NA 1892 5.26
(1.54)
NPHS II 2658 138.54
(19.08)
1771 0.84
(0.25)
1759 4.90
(1.04)
2641
0.59(0.53)
2266 1.63
(0.32)
2266 0.90
(0.26)
2206 -1.07
(1.36)
NA NA
Portuguese
Stroke
Study
NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
PREVEND 7726
129.20(20.31)
7607 1.32
(0.40)
7575 4.33
(1.21)
7280 0.19
(0.52)
7405 1.39
(0.30)
7406 1.03
(0.31)
7405 -2.76
(1.02)
6946 4.90
(1.10)
PRO-
CARDIS
NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
PROSPER 5504 154.62
(21.87)
5504
1.28(0.35)
5504 4.41
(0.90)
5504
0.35(0.41)
5444 1.32
(0.24)
5444 1.15
(0.22)
5444 2.61
(1.25)
5482 5.47
(1.45)
Rotterdam 5654 139.32
(22.34)
5738 1.34
(0.36)
5737 5.26
(1.23)
3355 0.33
(0.43)
NA NA NA NA NA NA 3400 5.96
(1.57)
SMART NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
TPT 3175 138.49
(17.88)
NA NA NA NA NA NA NA NA NA NA NA NA NA NA
UCP NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
ULSAM 452
149.18(18.88)
452 1.29
(0.34)
452 4.49
(0.95)
453 0.24
(0.46)
313 1.27
(0.23)
315 1.03
(0.22)
314 -0.49
(1.18)
453 5.73
(1.36)
Whitehall
II
5022 122.23
(13.93)
826 1.47
(0.40)
826 4.80
(1.18)
857 0.56
(0.56)
3834 1.55
(0.26)
3834 1.02
(0.25)
4737 -
0.3(0.89)
4541 5.22
(0.59)
WHI 7877 132.96
(18.69)
4248 4175 4.54
(1.08)
3314 0.50
(0.48)
NA NA NA NA NA NA NA NA
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Table C.8: Cardiovascular traits characteristics of the studies included in the collaboration (2)
Study ln Fibrinogen
(g/l)
von Willebrand
factor (IU/dl)
ln CRP (mg/l) ln IL6 (pg/ml) BMI (kg/m2) Waist circumfer-
ence (cm)
ln CIMT (mm) ln BNP (ng/l)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
ALSPAC NA NA NA NA 2395 0.10
(1.13)
NA NA 2554 26.54
(5.21)
2554 84.37
(12.19)
2543 -0.59
(0.11)
NA NA
ARIC 9464 1.07
(0.20)
NA NA 7559 0.81
(1.08)
297
0.69(0.68)
9549 26.98
(4.85)
9547 96.11
(13.33)
NA NA NA NA
BRHS 3835 1.16
(0.22)
3837 140.08
(46.3)
3811 0.57
(1.11)
3807
0.90(0.67)
3824 26.90
(3.70)
3818 97.17
(10.44)
NA NA NA NA
BWHHS 3341 1.22
(0.20)
3348
148.26(47.55)
3244 0.62
(1.11)
3341
0.85(0.69)
3383 27.56
(4.94)
3368 86.17
(12.09)
NA NA 1200 5.07
(0.95)
CaPS 1092 1.30
(0.22)
NA NA 741 0.51
(1.00)
NA NA 1084 26.3
(3.47)
1077 94.13
(10.31)
NA NA NA NA
CARDIA 675 0.69
(0.22)
675
90.77(33.84)
1308 -0.03
(1.20)
224
0.01(0.65)
1427 23.63
(3.99)
1426 76.96
(10.45)
84 -0.68
(0.18)
NA NA
CCHS 8818 1.09
(0.27)
NA NA 8251 0.79
(0.78)
NA NA 9051 25.62
(4.34)
NA NA NA NA NA NA
CFS 37 1.19
(0.22)
NA NA 40 0.79
(0.94)
40
1.05(0.65)
134 32.35
(8.04)
45 103.36
(19.48)
NA NA NA NA
CGPS 56859 1.32
(0.24)
NA NA NA NA NA NA 56742 26.15
(4.29)
NA NA NA NA NA NA
CHS 3902 1.14
(0.20)
NA NA 3908 0.63
(1.01)
3620
0.57(0.62)
3924 26.38
(4.50)
3907 93.81
(12.83)
3918 -0.18
(0.22)
NA NA
Cyprus 704 0.97
(0.20)
NA NA 697 0.79
(1.27)
216
0.62(1.09)
716 28.08
(4.59)
65 97.12
(19.91)
730 -0.33
(0.21)
NA NA
Czech post-
MONICA
NA NA NA NA 2346 0.00
(1.01)
NA NA 2524 27.20
(4.71)
2525 89.67
(13.03)
NA NA NA NA
DCH NA NA NA NA NA NA NA NA 2736 26.53
(4.00)
2736 91.67
(12.7)
NA NA NA NA
EAS 854 0.96
(0.25)
790
111.74(43.7)
640 0.66
(1.09)
619
0.80(0.74)
873 25.53
(3.84)
NA NA 825 -0.33
(0.32)
NA NA
ELSA 1823 1.01
(0.24)
NA NA 5416 0.72
(1.11)
NA NA 5144 27.46
(4.37)
4415 92.68
(12.71)
NA NA NA NA
EPIC
InterAct
NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
EPIC
Nether-
lands
NA NA NA NA 4338 0.83
(1.69)
NA NA 5184 26.77
(4.45)
5180 88.47
(12.49)
NA NA NA NA
EPIC
Norfolk
18654 1.05
(0.28)
NA NA 15709 0.49
(1.06)
NA NA 20169 26.30
(3.81)
20182 88.42
(12.32)
NA NA NA NA
Continued on next page
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Table C.8 – Continued from previous page
Study ln Fibrinogen
(g/l)
von Willebrand
factor (IU/dl)
ln CRP (mg/l) ln IL6 (pg/ml) BMI (kg/m2) Waist circumfer-
ence (cm)
ln CIMT (mm) ln BNP (ng/l)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
EPIC-
Potsdam
NA NA NA NA 2253 -0.25
(1.39)
NA NA 2249 26.19
(4.29)
2252 86.41
(12.96)
NA NA NA NA
EPIC
Turin
NA NA NA NA NA NA NA NA 4467 25.85
(3.59)
4296 89.02
(11.55)
NA NA NA NA
FHS 308 1.26
(0.21)
689
131.77(47.23)
312 0.41
(1.26)
693
1.11(0.72)
312 27.72
(5.73)
728 90.04
(14.55)
671 -0.53
(0.26)
NA NA
HAPIEE
Czech
NA NA NA NA 6540 0.30
(1.03)
NA NA 6673 28.20
(4.56)
6671 93.32
(12.73)
NA NA NA NA
HAPIEE
Lithuania
NA NA NA NA 926 0.42
(1.11)
NA NA 6930 29.36
(5.29)
6903 92.61
(13.49)
NA NA NA NA
HAPIEE
Poland
NA NA NA NA 906 0.47
(1.06)
NA NA 8767 28.15
(4.58)
8772 92.65
(12.38)
NA NA NA NA
HAPIEE
Russia
NA NA NA NA 1045 0.49
(1.2)
NA NA 7082 28.61
(5.45)
7080 92.89
(12.84)
NA NA NA NA
HIMS NA NA NA NA 3834 0.70
(1.04)
NA NA 4188 26.77
(3.41)
4191 98.65
(9.81)
NA NA NA NA
HPFS 756 1.37
(0.20)
NA NA 1262 0.16
(1.11)
755
0.66(0.94)
1264 25.78
(3.31)
1170 98.29
(10.01)
NA NA NA NA
IMPROVE
Groeningen
NA NA NA NA 420 0.88
(1.12)
NA NA 420 29.40
(4.76)
415 101.71
(12.28)
421 -0.13
(0.24)
NA NA
IMPROVE
Kuopio 1
NA NA NA NA 480 0.14
(1.29)
NA NA 481 27.72
(4.02)
481 93.19
(11.06)
480 -0.07
(0.21)
NA NA
IMPROVE
Kuopio 2
NA NA NA NA 440 0.32
(1.25)
NA NA 440 29.12
(4.62)
439 99.17
(13.43)
439 -0.07
(0.20)
NA NA
IMPROVE
Milan
NA NA NA NA 514 0.35
(1.17)
NA NA 514 25.24
(3.28)
512 88.07
(10.49)
514 -0.15
(0.20)
NA NA
IMPROVE
Paris
NA NA NA NA 436 0.27
(1.26)
NA NA 436 26.34
(3.83)
435 93.08
(12.79)
436 -0.22
(0.18)
NA NA
IMPROVE
Perugia
NA NA NA NA 464 0.66
(1.07)
NA NA 464 26.27
(3.51)
464 88.34
(10.30)
464 -0.24
(0.18)
NA NA
IMPROVE
Stockholm
NA NA NA NA 480 0.43
(1.27)
NA NA 480 26.82
(4.13)
480 95.27
(11.77)
480 -0.09
(0.19)
NA NA
Inter99 718 0.55
(0.72)
NA NA 5629 -0.12
(1.29)
621 1.08
(1.02)
6328 26.31
(4.62)
6318 86.55
(13.34)
NA NA NA NA
ISGS-
SWISS
NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
Izhevsk NA NA NA NA NA NA NA NA 649 26.71
(4.97)
653 94.79
(11.79)
NA NA NA NA
MDC NA NA NA NA NA BA NA NA 1936 24.39
(3.31)
1936 81.24
(14.46)
NA NA NA NA
Continued on next page
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Table C.8 – Continued from previous page
Study ln Fibrinogen
(g/l)
von Willebrand
factor (IU/dl)
ln CRP (mg/l) ln IL6 (pg/ml) BMI (kg/m2) Waist circumfer-
ence (cm)
ln CIMT (mm) ln BNP (ng/l)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
N mean
(SD)
MESA 2283 1.19
(0.20)
415 134.55
(54.34)
2284 0.58
(1.15)
2251 0.15
(0.66)
2293 27.75
(5.06)
2293 97.97
(14.53)
2269 -0.34
(0.26)
NA NA
MRC
1958BC
2512 1.07
(0.20)
2513 124.32
(41.74)
2513 0.02
(1.20)
NA NA 2585 27.26
(4.82)
2580 92.00
(13.58)
NA NA NA NA
MRC
NSHD
NA NA NA NA NA NA NA NA 2671 27.34
(4.65)
2682 91.62
(13.06)
NA NA NA NA
NHANES
III
NA NA NA NA NA NA NA NA 2388 26.60
(5.60)
2300 92.90
(14.70)
NA NA NA NA
NHS 707 1.23
(0.27)
NA NA 1322 0.72
(1.15)
675
0.63(0.68)
1321 25.66
(4.75)
942 80.06
(11.10)
NA NA NA NA
NORDIL NA NA NA NA NA NA NA NA 1883 28.27
(4.57)
NA NA NA NA NA NA
NPHSII 2646 1.00
(0.19)
170 110.46
(34.61)
2205 0.92
(1.00)
NA NA 2656 26.45
(3.5)
NA NA NA NA NA NA
Portuguese
Stroke
Study
NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
PREVEND NA NA NA NA 7327 0.25
(1.13)
NA NA 7653 26.08
(4.21)
7654 0.88
(0.10)
712 -0.28
(0.23)
NA NA
PRO-
CARDIS
NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA NA
PROSPER 5357 1.26
(0.21)
5327 140.79
(45.9)
5400 1.13
(1.12)
5374 0.98
(0.66)
5504 26.84
(4.19)
NA NA NA NA NA NA
Rotterdam 2354 0.99
(0.24)
3380 137.20
(63.63)
5458 0.62
(1.04)
NA NA 5635 26.29
(3.68)
5341 90.62
(11.12)
4745 0.00
(0.19)
3355 4.74
(1.06)
SMART NA NA NA NA NA NA NA NA NA NA NA NA 7917 -0.17
(0.28)
2700 2.47
(0.98)
TPT 3109 1.09
(0.19)
NA NA NA NA NA NA 3162 27.47
(3.56)
NA NA NA NA NA NA
UCP NA NA NA NA NA NA NA NA 1480 27.14
(4.15)
NA NA NA NA NA NA
ULSAM 319 1.27
(0.27)
NA NA 435 0.64
(1.01)
405 1.39
(0.84)
452 26.02
(3.24)
445 94.59
(9.21)
NA NA 444 4.83
(1.15)
Whitehall
II
1456 0.98
(0.20)
4306 104.80
(38.84)
4488 -0.16
(1.16)
4466 0.37
(0.59)
5022 24.35
(3.30)
4691 84.78
(11.35)
3249 -0.26
(0.19)
NA NA
WHI 2453 1.08
(0.25)
NA NA 4681 0.69
(1.36)
3546 0.81
(0.74)
7814 28.35
(6.26)
NA NA NA NA NA NA
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Table C.9: Meta-analysis pooled linear and quadratic coefficients of the association be-
tween alcohol and traits on observational analysis, adjusted for age and gender
Trait Number Linear beta (95%CI) P-value Quadratic beta
(95%CI)
P-value
BMI 130909 -0.14(-0.16,-0.13) 1.5E-92 0.03(0.03,0.03) 8.6E-54
SBP 129573 -0.10(-0.12,-0.09) 1.1E-51 0.04(0.03,0.04) 5.4E-84
DBP 129557 -0.06(-0.08,-0.05) 6.5E-20 0.03(0.03,0.03) 3E-52
ln TG 112496 -0.12(-0.14,-0.11) 1.7E-58 0.03(0.02,0.03) 3.3E-43
HDL-C 109998 0.11(0.09,0.12) 3E-48 0.02(0.01,0.02) 8.9E-21
Non-HDL 109910 -0.05(-0.06,-0.03) 1E-09 0.01(0.00,0.01) 0.000033
Waist
circumference
108381 -0.14(-0.15,-0.12) 2.7E-82 0.04(0.03,0.04) 5.6E-79
ln CRP 90131 -0.15(-0.16,-0.13) 4E-66 0.04(0.03,0.04) 3.9E-56
Physical
activity
88630 0.07(0.05,0.09) 6.6E-16 -0.01(-0.02,-0.01) 9.5E-09
Pack years 69727 -0.16(-0.18,-0.15) 1.4E-69 0.07(0.06,0.07) 7E-150
Education 66022 0.25(0.23,0.27) 2E-140 -0.04(-0.05,-0.04) 3.7E-63
Glucose 65571 -0.07(-0.09,-0.05) 1E-12 0.02(0.01,0.02) 7.1E-11
ln Fibrinogen 64288 -0.12(-0.14,-0.10) 1E-29 0.01(0.00,0.01) 0.0053
Cigarettes/day 48323 -0.19(-0.21,-0.17) 4.8E-72 0.07(0.06,0.07) 2E-127
ln GGT 31588 -0.15(-0.18,-0.13) 9.5E-30 0.09(0.08,0.09) 3E-118
ln Lp(a) 29319 0.01(-0.02,0.04) 0.57 -0.01(-0.01,0.00) 0.28
ApoA-1 26153 0.04(0.00,0.07) 0.024 0.04(0.03,0.05) 1.7E-15
ApoB 26146 -0.08(-0.11,-0.04) 0.000015 0.02(0.01,0.03) 1.2E-06
lnIL6 23535 -0.20(-0.23,-0.17) 1.4E-31 0.05(0.04,0.06) 2.3E-24
Von
Willebrand
factor
17983 -0.11(-0.15,-0.07) 2.4E-08 0.02(0.01,0.03) 0.00065
Factor VII 17305 -0.05(-0.09,-0.01) 0.016 0.01(0.00,0.03) 0.012
ln CIMT 14797 -0.08(-0.12,-0.04) 0.000045 0.02(0.01,0.03) 0.000028
ln Cotinine 6960 -0.27(-0.33,-0.21) 8E-18 0.09(0.07,0.11) 8.4E-23
ln NT-proBNP 4553 -0.06(-0.14,0.01) 0.092 0.02(-0.00,0.04) 0.056
Footnote: traits were standardized prior to analysis thus beta coefficients represent the difference in
standard deviation for each trait
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Table C.10: Linkage disequilibrium between rs1229984 and SNPs on chromosome 4 that
are associated with cardiometabolic traits from previous GWAs and gene-centric array
analyses
SNP Platform Primary phenotype Base pair
position
Distance
from
rs1229984
R2 with
rs1229984
rs1458038 GWAS Systolic BP 81164723 -19074596 N/A
rs16998073 GWAS Diastolic BP 81184341 -19054978 N/A
rs871606 GWAS BP 54799245 -45440074 N/A
rs442177 GWAS Triglycerides 88030261 -12209058 N/A
rs1878406 GWAS Carotid intima media
thickness
148000000 48154345 N/A
rs2200733 GWAS Stroke (ischemic) 112000000 11470850 0.00119
rs4688985 Gene
Centric
Type 2 diabetes 6285715 -93953604 0.00188
rs4689388 GWAS Type 2 diabetes and
other traits
6270056 -93969263 0.0000387
rs7659604 GWAS Type 2 diabetes 123000000 22426195 0.0000246
Footnote: The analysis was conducted in Whitehall II, restricted to Europeans using PLINK. N/A: not
available as SNP on Metabochip and not IBC 50K CardioChip. BP: blood pressure. For those SNPs
with R2 annotated as NA, the distance from the rs1229984 makes it unlikely that LD value between the
SNP with rs1229984 would be high. GWAs: genome wide association study
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C.3 Supplemental Figures
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Figure C.1: ADH1B rs1229984 A-allele frequency in the 56 collaborating studies, arranged by geographical region
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Figure C.2: Subgroup analysis of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and alcohol traits.
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Figure C.3: Subgroup analysis of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and alcohol traits.
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Figure C.4: Subgroup analysis of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and alcohol traits.
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Figure C.5: Subgroup analysis of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and cardiovascular traits.
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Figure C.6: Subgroup analysis of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and cardiovascular traits.
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Figure C.7: Subgroup analysis of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and cardiovascular traits.
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Figure C.8: Subgroup analysis of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and cardiovascular traits.
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Figure C.9: Subgroup analysis of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and cardiovascular traits.
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Figure C.10: Subgroup analysis of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and cardiovascular traits.
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Figure C.11: Subgroup analysis of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and cardiovascular traits.
A
p
p
en
d
ix
C
.
A
lco
h
o
l
a
n
d
ca
rd
io
va
scu
la
r
d
isea
se
297
Geographical region
W Europe/Australia
USA
Gender
Women
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Age (mean)
<60yrs
 60yrs
Year of DNA Extraction
DNA 1990-1999
DNA 2000-2009
Genotyping platform
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Individuals)
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P
lower  higher 
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ADH1B rs1229984 A-carriers vs GG subjects (reference)
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Genotyping platform
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HWE P 0.001
Contributes to Observational Analysis
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No contribution
Meta-analysis Model
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Random
Subgroup
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(9, 13383)
(6, 8902)
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(2, 4560)
(9, 17355)
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(10, 20509)
(10, 20509)
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0.789
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P
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Figure C.12: Subgroup analysis of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and cardiovascular traits.
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Geographical region
N Europe
W Europe/Australia
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USA
Gender
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Age (mean)
<60yrs
 60yrs
Year of DNA Extraction
DNA 1980-1989
DNA 1990-1999
DNA 2000-2009
Genotyping platform
Individual
Array/Chip
Hardy Weinberg Equilibrium
HWE P>0.001
HWE P 0.001
Contributes to Observational Analysis
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No contribution
Meta-analysis Model
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Random
Subgroup
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(10, 22196)
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(15, 108666)
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(15, 106062)
(12, 30585)
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P
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Figure C.13: Subgroup analysis of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and cardiovascular traits.
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(1, 2555)
(1, 4305)
(4, 8510)
(11, 22856)
(11, 23318)
(8, 30235)
(4, 15939)
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Figure C.14: Subgroup analysis of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and lifestyle traits.
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Figure C.15: Subgroup analysis of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and lifestyle traits.
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Hardy Weinberg Equilibrium
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Contributes to Observational Analysis
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No contribution
Meta-analysis Model
Fixed
Random
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Figure C.16: Subgroup analysis of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and lifestyle traits.
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Figure C.17: Subgroup analysis of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and cardiometabolic disorders.
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<60yrs
 60yrs
Year of DNA Extraction
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Figure C.18: Subgroup analysis of the association between ADH1B rs1229984 (A-allele carriers vs. GG-subjects) and cardiometabolic disorders.
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ADH1B	  
rs1229984	  
Alcohol	   CVD	  
U	  (A)	  
(B)	  
In	  the	  classical	  Mendelian	  randomiza?on	  analysis,	  the	  intermediate	  phenotype	  (in	  this	  case	  Alcohol)	  is	  a	  collider*	  between	  unmeasured	  
confounders	  (U)	  and	  the	  gene?c	  instrument	  (ADH1B	  rs1229984).	  This	  means	  that	  no	  pathway	  exists	  from	  ADH1B	  via	  alcohol	  that	  goes	  
through	  U	  to	  CVD	  (shown	  by	  the	  direc?onality	  of	  the	  green	  arrows).	  Thus	  the	  pathway	  from	  ADH1B	  rs1229984	  through	  alcohol	  to	  CVD	  
should	  be	  free	  from	  confounding.	  	  
*	  A	  collider	  is	  a	  variable	  that	  is	  the	  outcome	  of	  two	  or	  more	  variables	  
If	  we	  stra?fy	  on	  the	  intermediate	  phenotype	  (e.g.	  by	  subgroups	  of	  alcohol,	  indicated	  by	  the	  box	  with	  the	  black	  border)	  this	  breaks	  the	  
collider	  status.	  A	  pathway	  is	  now	  induced	  	  between	  ADH1B	  rs1229984	  and	  CVD	  that	  runs	  through	  unmeasured	  confounder(s)	  (U),	  	  shown	  
by	  the	  dashed	  arrow.	  The	  implica?on	  is	  that	  an	  analysis	  stra?ﬁed	  by	  the	  intermediate	  phenotype	  may	  introduce	  confounding.	  
ADH1B	  
rs1229984	  
Alcohol	   CVD	  
U	  
(condi?oned)	  
Figure C.19: Directed acyclic graphs to illustrate potential collider bias in Mendelian randomization analysis of alcohol and CVD using the ADH1B
rs1229984 variant.
Footnote: Collider bias is the principle that adjusting or stratifying for a trait that is a collider may introduce bias by opening a new pathway through the confounder.
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ADH1B (rs1229984) Alcohol & Cardiovascular Disease  
 
Analysis Plan 
 
 
Overview 
 
The collaboration will utilise the ADH1B-rs1229984 variant as an instrument to investigate the effect of 
alcohol consumption on cardiovascular traits and disease. To accomplish this, we will conduct the following 
steps:  
 
i. First, to confirm the association between ADH1B variant (rs1229984) and the multiple alcohol 
phenotypes.  
 
ii. The association between ADH1B-rs1229984 variant and cardiovascular biomarkers and prevalent 
disease will be meta-analysed across studies. 
 
iii. To perform instrumental variable (IV) analysis to estimate the unbiased effect of alcohol 
consumption on cardiovascular biomarker and prevalent disease, by combining the pooled gene-
alcohol and gene-biomarker estimates.  
 
Background 
 
The detrimental effects of alcohol consumption are wide and varied, with consumption linked to over 60 
conditions and diseases.11 Despite this, there is great interest about the potential cardio-protective effect 
of moderate drinking, which is thought to operate, at least in part, via a favourable impact on lipid profiles 
most notably raised HDL-C.1 Other proposed mechanisms include lower levels of LDL-C, lower plasma 
apolipoprotein A concentration, prevention of clot formation and reduction in platelet aggregation.1-5  
 
The potential for alcohol metabolising genes to act as instruments, or proxy measures of alcohol 
consumption, has been previously described.15 A significant association has been found between variants of 
alcohol metabolising genes and several alcohol-related conditions including hypertension, oesophageal 
cancer and head & neck cancer.16-18 To date, Mendelian randomization studies have most successfully used 
ALDH2*2 as the instrument for lifetime alcohol exposure. ALDH2*2 is common in Asian populations but 
absent in populations of European descent.19 ALDH2*2 is an inactive variant of the alcohol-metabolizing 
enzyme aldehyde dehydrogenase (ALDH) which is responsible for oxidising acetaldehyde to acetate and 
water. Acetaldehyde is a toxic and volatile compound that can cause considerable damage if not quickly 
converted and eliminated from the body. But because acetaldehyde also causes uncomfortable physical 
symptoms such as facial flushing, palpitations and hangovers, individuals predisposed to high 
concentrations are protected from excessive drinking.  
 
The other major enzyme of the alcohol metabolizing pathway is alcohol dehydrogenase (ADH) which 
oxidizes alcohol to acetaldehyde. Seven genes coding for ADH are found in a tight cluster on chromosome 4 
and some are polymorphic in white European populations.20 More active variants of ADH cause higher 
concentrations of acetaldehyde in the body following alcohol consumption and are therefore protective 
against drinking. Functional variants in both ADH1B and ADH1C have been associated with alcohol 
consumption or alcohol dependence.21-25 The ADH1B variant (rs1229984) has emerged as the strongest 
ADH1B SNP to associate with alcohol phenotypes and is therefore the most suitable instrument for 
Mendelian randomization studies in Europeans.22 The protective A allele has an allele frequency of 
approximately 2-5% in Europeans.26-27  
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Objectives 
 
1. To confirm the association between rs1229984 variant and multiple alcohol phenotypes  
 
2. To investigate if the ADH1B (rs1229984) variant is associated with potential confounders (e.g. 
smoking, education, socio-economic status and physical activity). 
 
3.  To investigate the association between rs1229984 variant and cardiovascular biomarkers and 
disease 
 
Data 
 
The final analysis will be based on meta-analysis of individual-participant data and summary genetic data 
provided by individual studies (See Table). Designated members from each study will be responsible for 
arranging analysis of their data according to this plan, and for reporting agreed summaries to the meta-
analysis co-ordinating group. 
 
Investigators are asked to provide basic information about their study including sampling details and 
genotyping procedure. A spreadsheet detailing all the information required is provided with this analysis 
plan (appendix A). Please note that automatic genotype coding using standard coding algorithms is 
preferred to manual coding. 
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Table. List of studies currently involved in the collaboration 
 
Cohort Name Number of 
participants 
ALSPAC 6108 
ARIC 9557 
BRHS 3843 
BWHHS 3412 
CARDIA 1433 
CCHS 9081 
CFS 134 
CHS 3936 
CYPRUS 730 
CaPS 1102 
DCH 2736 
EAS 873 
ELSA 5450 
EPIC Potsdam 2253 
EPIC Netherlands 5186 
EPIC Norfolk 20195 
FHS 1082 
HIMS 4191 
HAPIEE Czech 6678 
HAPIEE Lithuania 6936 
HAPIEE Poland 8779 
HAPIEE Russia 7083 
Health Professional’s Study 1264 
IMPROVE Groeningen 421 
IMPROVE Kuopio 1 481 
IMPROVE Kuopio 2 440 
IMPROVE Milan 514 
IMPROVE Paris 436 
IMPROVE Perugia 464 
IMPROVE Stockholm 480 
ISGS 1124 
Inter99 6332 
Izhevsk 653 
MESA 2293 
MONICA 2558 
MRC 1946 2696 
NHANESII 2388 
NPHSII 2659 
Nurse’s Health 1322 
PREVEND 7729 
PROSPER 5504 
Portugese Stroke Study 1002 
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Rotterdam 5827 
SMART 7917 
TPT 3175 
Turin 4526 
UCP 1615 
ULSAM 453 
WH2 5029 
WHI 7882 
TOTAL 187,962 
 
 
 
 
Statistical analysis plan 
 
NB: For specific details of the analysis please see the Stata do-file document that is attached to this 
invitation.    
 
Data preparation (please note that almost all of these steps are undertaken in the Stata do-file with the 
exception of selection of ‘wave’ in studies with multiple waves [repeated measures]) 
 
 Repeated measures: Whenever phenotypes are available at more than one time-point, analyses 
should be undertaken on the wave that maximises inclusion of subjects for key variables (usually 
the baseline). 
 
 Coding of genotypes: According to the dominant model (carriers of the rare allele to be compared 
to non-carriers). Rare homozygotes should be grouped together with heterozygotes. 
 
 All alcohol units refer to British units equivalent to 7.9g of ethanol. Units of alcohol can be 
calculated by multiplying the volume of alcohol in litres by the alcohol beverage percentage.  
 
 Treatment of missing data: All analyses should be limited to subjects who have complete data for 
sex, age, gene-variant and any one of the cardiovascular biomarkers of interest (e.g. blood 
pressure, lipid profile, apolipoproteins, fibrinogen). It is understood that analyses of other 
phenotypes including alcohol consumption might be limited to a smaller group of people because 
of further missing data in the specific phenotype analysed. 
 
 Ethnicity: analysis is limited to individuals of white European ancestry  
 
 Family members: where individuals are related, please limit analysis to the oldest person in the 
relation and discard the younger relative(s) 
 
 
Analyses: 
Analyses are performed automatically by the Stata do-file. For a comprehensive list of traits that are used, 
please refer to “ADH1B project variables.xls” excel sheet, in which the units for each traits are documented. 
Conversion factors for traits are provided in the Stata do-file. 
 
Wherever possible analyses should be undertaken using the standardised do file provided. 
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Meta analysis 
 
Meta-analysis (forest plots etc.) of individual study regression coefficients is conducted by the analysis 
coordinating group at LSTHM/UCL after submission and preparation of the data. 
 
Observational analysis 
 
A pooled dataset is being created to establish the comparable observational effects of weekly units of 
alcohol consumption on CVD biomarkers. 
 
Instrumental variable analysis 
 
The instrumental variable analysis will take 2 forms: 
 
(1) Assuming that the curvilinear relationship is entirely due to confounding, the standard two-state 
least squared IV regress will be performed using summary data from each collaborating study 
(2) A non-linear Mendelian randomization model has been developed by Professor Frank Dudbidge at 
LSHTM. This requires an additional analysis, and the analysis files are in development and will be 
distributed shortly. 
 
 
 
 
 
 
 
The ADH1B-CVD collaboration 
LSTHM/UCL co-ordinating centre: Michael Holmes, Caroline Dale, Richard Silverwood, Aroon Hingorani, 
Dave Leon, Frank Dudbridge, Juan P Casas 
Email inquiries: m.holmes@ucl.ac.uk or Caroline.Dale@lshtm.ac.uk 
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